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Chapter 1
Introduction
1.1. This document
For the purposes of this document, ‘club drugs’ is a short-hand term used for 
convenience to refer to a group of psychoactive substances typically used in dance 
venues, house parties, music festivals and sometimes in a sexual context. The term 
therefore describes a diverse group of substances with different actions. They include 
substances with primarily stimulant effects, those with primarily hallucinogenic effects, 
as well as some central nervous system depressants and synthetic cannabinoids. 
Club drugs include substances well established in the UK such as MDMA (ecstasy), 
as well as the rapidly expanding range of novel psychoactive substances (NPS) such 
as synthetic cannabinoids, synthetic cathinones and a range of other amphetamine-
type stimulants. Some club drugs are sold on the illicit market, whilst others are sold 
as so-called ‘legal highs’.
This document provides guidance on the clinical management of harms resulting 
from acute intoxication and from the harmful and dependent use of club drugs and 
NPS. It categorises club drugs broadly according to their clinical effects: 
•	depressant;
•	stimulant;
•	hallucinogenic.
In addition, the synthetic cannabinoids are treated as a separate category, largely for 
reasons relating to their clinical management but also because they do not fit neatly 
into that threefold categorisation. 
The guidance is based on available evidence and clinical consensus. It is a response 
to the current gap in knowledge and experience in the management of these drugs 
across the UK and beyond.
Guidance is aimed in particular at clinicians in a range of settings, specifically: 
•	specialist drug treatment services
•	hospital emergency departments (EDs)
•	general practice/ primary care
•	sexual health clinics
This document provides guidance, not guidelines. Together with the recommenda-
tions of its reviews, technical appraisals and standards, national guidelines produced 
by the National Institute for Health and Care Excellence (NICE) determine the wider 
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principles within which treatment and care should be provided within drug services, 
EDs, primary care, sexual health and mental health services. However, these guidelines 
do not relate specifically to NPS. NEPTUNE guidance must be used within the wider 
principles of these national guidelines.
This guidance does not aim to replace the role and resources of the National 
Poisons Information Service (NPIS) and its online toxicology database and telephone 
enquiry service TOXBASE® for advice on the clinical assessment and management 
of acute toxicity within hospital EDs, primary care and other healthcare facilities 
(Box 1.1). Clinicians should consult TOXBASE®, and where necessary call the NPIS for 
up-to-date information. It is highly recommended that clinicians and departments be 
registered to be able to use these facilities. Readers should also consult TOXBASE® 
for information provided by the UK Teratology Information Service (UKTIS) on all 
aspects of the toxicity of drugs and chemicals in pregnancy.
Non-UK readers of this document should contact their local, regional or national 
poisons information service for up–to-date advice and guidance on the management 
of acute club drug intoxication and withdrawal. 
NEPTUNE guidance is time-limited (provisionally to end 2017), not least because 
new compounds continue to emerge and the evidence is continuing to grow. 
Box 1.1. TOXBASE®
For up-to-date guidance on the management of acute toxicity, it is recommended that 
information be sought from the National Poisons Information Service (NPIS), specifically the 
NPIS 24-hour telephone service and the poisons information database TOXBASE®.  
The database (http://www.toxbase.org) contains information on approximately 17,000 
products, together with generic advice on the management of poisoning. It is available free of 
charge to registered NHS users and it is highly recommended that clinicians and departments 
be registered to be able to use these facilities. By using TOXBASE®, clinical staff can obtain key 
clinical information rapidly, including advice on potentially hazardous doses and appropriate 
management. 
The NPIS 24-hour telephone helpline (in the UK 0844 892 0111 and Ireland NPIC (01) 809 2566) 
is available for discussion of more complex cases. When appropriate, senior medical staff can 
discuss their cases directly with an NPIS consultant clinical toxicologist.
Non-UK readers should consult their local or national guidelines.
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1.2. Novel Psychoactive Treatment 
UK Network (NEPTUNE): project aims 
and guidance development
1.2.1. Objectives of the NEPTUNE Project 
This guidance has been developed by NEPTUNE (Novel Psychoactive Treatment UK 
Network), a project funded by the Health Foundation’s* Shine Innovation Programme 
2012† and led by Central and North West London NHS Foundation Trust. 
The objectives of the NEPTUNE project were as follows:
•	Convene a multidisciplinary group of UK experts in the treatment of harms resulting 
from the use of club drugs, including experts by experience (patients).‡ 
•	Review the national and international evidence on club drugs, and most 
particularly the evidence on the harms and the management of harms linked to 
acute intoxication and acute poisoning, as well as those associated with long-term 
harmful use and/or dependence.
•	Develop treatment guidance based on the best available research evidence. Where 
this is lacking, the guidance is based on the expert group’s’ clinical consensus and 
patient experience. 
•	Develop guidance specifically for the following clinical settings:
(1) drug treatment services;
(2) emergency departments;
(3) general practice; 
(4) sexual health clinics.
The group convened comprises UK experts in the management of acute and chronic 
problems associated with club drugs. It is a collaboration between individuals from a 
number of different NHS and voluntary organisations, with observers from relevant 
government departments (for the full list see pp. ii–iii). The expert group includes psy-
chiatrists, psycho-pharmacologists, psychologists, clinical and analytical toxicologists, 
emergency physicians, genitourinary medicine (GUM) physicians and HIV physicians, 
general practitioners, urologists, nurses, senior managers and experts in club drugs 
among lesbian, gay, bisexual and transgender (LGBT) populations.
1.2.2. Aims of the NEPTUNE clinical guidance
The aim of the guidance is to improve confidence and competence, and increase 
the skills of clinicians in the detection, assessment and management of the harms 
* The Health Foundation is an independent charity working to improve the quality of health care in the 
UK. http://www.health.org.uk/
† http://www.health.org.uk/areas-of-work/programmes/shine-twelve/
‡ Henceforth referred to as ‘expert group’.
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associated with the use of club drugs, across all target settings. Specific areas 
addressed include:
•	Detection/identification. Recognising the significant psychological, physical and 
social risks which can be associated with club drugs, and equipping professionals to 
be able to recognise problematic use, associated harms and dependence, and to be 
able to use screening tools where indicated. 
•	Assessment. Assessment of the problems related to the use of club drugs, including 
the assessment of both direct and indirect harms. 
•	Management. Clinical management of acute and chronic harms related to the use 
of club drugs- in the target clinical settings, based on the best available evidence, 
or on clinical consensus where evidence is lacking. 
•	Harm reduction. Interventions aimed at preventing morbidity and mortality 
among individuals presenting to clinical settings, including measures to reduce the 
harms of club drugs for individuals and communities and to help patients achieve 
and sustain recovery and well-being.
The underlying principles of good clinical practice in relation to the users of club 
drugs are applicable to all problematic psychoactive drug use and form the basis of 
national UK guidelines aimed at the drug treatment and recovery field. However, 
good assessment and management of the harms of club drugs (including NPS) must 
also take into account the particular challenges posed by these drugs and address 
them directly. These include challenges posed by:
•	new drugs (rapidly changing profile and ever increasing numbers of substances, 
with poorly understood harms);
•	new populations in treatment (including new patterns of drug use and contexts of 
harm);
•	new harms (some club drugs are associated with harms not previously linked to 
illicit drug use, for example ketamine-related ulcerative cystitis).
NEPTUNE therefore aims to improve clinicians’ knowledge of the specific issues 
relating to club drugs and to support evidence-based practice at local levels. It also 
aims to help improve clinicians’ confidence in working with patients who use club 
drugs, by providing the following:
•	‘technical’ knowledge (what the drugs are and how they work).
•	‘cultural’ knowledge (who is using them, and how).
•	‘clinical’ knowledge (how to clinical manage both acute and chronic presentations).
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1.3. Target audience for the guidance
1.3.1. Primary audience
This guidance is aimed primarily at a clinical audience. The target clinical settings 
have been chosen because they offer specialist treatment for acute or chronic 
problems (EDs and specialist drug services) or because they provide an untapped 
access to populations at risk of drug-related harms (sexual health clinics and general 
practice, which are potentially clinical areas with a high prevalence of patients using 
club drugs). 
The stepped care approach used in this guidance document, as well as the phased and 
layer framework of drug treatment (see Chapter 2), takes into account the different 
roles and competencies of clinicians in each of the target settings in delivering inter-
ventions aimed at those who use club drugs. 
1.3.2. Other audiences
The guidance is also a resource for commissioners and policy-makers in developing 
local and national services. It also provides patients and carers with information on 
what interventions should be available.
1.4. The process of developing the guidance: 
method for the literature review
A comprehensive review of the English language literature on the harms and the 
clinical management of a range of club drugs was carried out, using systematic 
methods. 
Studies, including case reports, were identified using electronic searches of Medline, 
Medline Plus, the Cochrane Library, CINAHL, Current Content, Embase, PUBMED, 
PsychINFO, Google Scholar and the Science Citation Index. In addition, bibliographies 
of articles were screened for additional relevant studies. 
Box 1.2. Search terms included in combination with drug names
Addiction; Adverse effects; Subjective effects; Craving; Chronic; Clinical features; Cognitive; 
Detoxification; Dependence; Harms; Ingestion; Intoxication; Pharmacology; Poisoning; Psycho-
logical interventions; Psychological treatment; Brief interventions; Drug management; Clinical 
features; Harms; Toxicity; Motivational; Chronic use; Withdrawal; Craving; Cue exposure; Detox-
ification; Dependence; Addiction; Managed care; Pharmacotherapy; Intoxication; Prevention; 
Health outcomes; Clinical outcomes; Recreational use; Toxicology; Prescribing; Relapse 
prevention; Relapse management; Motivational interviewing; CBT; Behavioural therapies; Cue 
exposure treatment; Community reinforcement approach; Motivational enhancement therapy; 
Relapse prevention; Relapse management; Psycho-sexual counselling; Care plan; Gay men; Men 
who have sex with men; LGBT; Clubbers; Party circuit; Drug use in clubs; Drug-facilitated sex; 
Injecting; Insufflation; Clinical; Guidelines; A&E; Substance misuse treatment; General practice; 
Sexual health; Urology; Dentistry; Ophthalmology; Pregnancy; HIV; Hepatitis C.
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Search terms included the drugs names alone, or in combination with the terms listed 
in Box 1.2. Terms specific to one of the substances reviewed were also included where 
relevant (e.g. ulcerative cystitis for ketamine). 
The outputs of searches were considered against sets of inclusion and exclusion criteria 
(see section 1.4.1). The citations produced by these searches were then screened via 
their abstract. Those considered relevant were identified and subjected to critical 
assessment by the core NEPTUNE team and other members of the NEPTUNE expert 
group.
The critical assessment of the evidence was based on the framework developed by 
the British Association for Psychopharmacology for the development of guidelines 
for the management of substance misuse.1 This classifies the strength of evidence as 
follows:
•	Strong research evidence (e.g. Cochrane reviews, meta-analyses, high-quality 
randomised controlled trials);
•	Research evidence (e.g. controlled studies or semi-experimental studies);
•	Emerging research evidence (e.g. descriptive or comparative studies, correlation 
studies, evaluations or surveys and non-analytic studies, for example case reports, 
case series);
•	Expert panel evidence/consensus;
•	Expert by experience evidence (service users/patients);
•	Lack of evidence (no evidence, for or against);
•	Conflicting evidence.
In order to assess the applicability and relevance of the international literature to a 
UK context, considerations of population, setting, intervention and outcomes have 
been taken into account for statements in the guidance.
It was clear from the onset of the literature review that the evidence base is relatively 
small. In particular, studies on the toxicity of NPS, and risks associated with long-term 
use and dependence liability, are few, partly because most NPS have limited or 
no medical use,2 and partly because some of these substances have only recently 
emerged. 
Overall, there is a lack of robust evidence, in particular from meta-analyses or 
high-quality randomised controlled trials, and even controlled and semi-experimental 
studies are few. The bulk of the research available provides what is referred to as 
emerging research evidence, as it is based principally on non-experimental descriptive 
studies, consisting mainly of case reports and series and a small number of prospective 
observational studies, retrospective cohort studies and analysis of patient records. 
The literature review also identified clinical questions that were not addressed by 
the research evidence. Where evidence was lacking, consensus was sought from the 
multidisciplinary NEPTUNE expert group, based on a process of open discussion, with 
a view to producing guidance that is of practical use to clinicians.
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This document therefore does not give definitive answers on the clinical 
management of club drugs and NPS, but broad guidance based on the current 
best available evidence and clinical consensus. 
1.4.1. General inclusions and exclusions in the guidance
•	The guidance focuses on acute and chronic harms linked to the use of club drugs, 
and their management. 
•	The guidance is aimed at the management of adults (18 years and older). The 
development of similar guidance for children and adolescents is recommended.
•	The guidance does not address interventions in non-clinical or pre-hospital 
settings, such as nightclubs, schools and universities, or festivals, some of which 
are discussed elsewhere.3 
•	Issues specifically pertaining to prisons and corrective facilities have also been 
excluded, although much of the clinical guidance is equally applicable to clinical 
management within the prison service. The 2013–14 annual report of HM 
Inspectorate of Prisons mentions the increased availability of NPS, and most 
particularly synthetic cannabinoids, in prisons and the association of these drugs 
with debt and bullying, as well as their effects on health.4 
1.4.2. Substances and drug groups covered by this guidance 
Cocaine is the most commonly used substance in the UK that can be described as 
a club drug, despite some reduction in its use since its peak in 2008/09 in England 
and Wales. However, this document does not address the management of long-term 
harms and dependence of cocaine specifically. This is because substance misuse 
treatment professionals already have access to an extensive and robust body of 
evidence on the long-term harmful and dependent use of cocaine, and Cochrane 
reviews have been published. There is also good clinical experience in drug treatment 
services in the UK in the management of cocaine-related harms and evidence that 
people with primary cocaine problems are accessing treatment and recovery services 
(for more details see Chapter 2). This document does, however, address briefly acute 
cocaine intoxication, which is a significant clinical problem in the UK. Studies from 
the UK have shown under-recognition of acute cocaine toxicity in patients presenting 
with chest pain. There are aspects of acute cocaine toxicity that are different to the 
toxicity associated with other stimulants, in particular myocardial ischaemia/chest 
pain (related to vasospasm) and arrhythmias (related to ion channel effects). These 
are discussed briefly in Chapter 6.
Not all NPS meet the loose definition of a ‘club drug’ and some NPS have been 
excluded from this guidance document, such as the newly developed opioids receptor 
agonists and benzodiazepines that have recently been on sale on the internet.
Because of the potentially very large number of club drugs and NPS that can currently 
be bought on the illicit and ‘legal’ markets and those that will emerge in the future, it 
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is not possible to cover them all in any detail within the confines of this work. In order 
to address this issue, a two-pronged approach has been adopted:
First, the structure of the guidance provided by this document – and within which 
individual drugs are discussed – is based on the following broad classifications:
•	predominantly depressant drugs;
•	predominantly stimulant drugs;
•	hallucinogens drugs;
•	synthetic cannabinoids.
Although these classifications provide a useful framework for this guidance, it is 
important to note that they are not rigid categories. In reality, many club drugs have 
a combination of effects, for example stimulant and hallucinogenic effects.5 
The second part of our approach was to focus in more detail on the drugs (as well as 
their derivatives and related compounds) most used in the UK and those that cause 
most harm. 
Where a particular drug is not discussed in this document (either because it was 
infrequently used in the UK or because it was not developed at the time of writing), 
clinicians can refer to the broad groups to which it belongs and can extrapolate 
information on the management of its acute and chronic harms, while taking into 
account potential differences in potency, toxicity, half-life, length of effect and so 
forth.
1.5. An overview of club drugs
1.5.1. Old drugs, new drugs and ‘legal highs’ 
‘Club drugs’ include a wide rage of substances. Some, such as ecstasy, are well 
established substances, that have been subject to legal control for many years. 
Others are new psychoactive substances (NPS), which are emerging at a fast pace on 
the drugs market, many supposedly as non-illicit alternatives to controlled drugs.2 At 
the time of writing, many of these NPS were controlled, whilst others were sold as 
so-called ‘legal highs’.
An increasing number of NPS can be found globally. The United Nations Office on 
Drugs and Crime has identified six main groups: synthetic cannabinoids, synthetic 
cathinones, ketamine, phenethylamines, piperazines and plant-based substances; 
there is also a seventh group, of miscellaneous substances – recently identified NPS 
which do not fit into the groups mentioned.2
The World Drug Report 2014 indicated that the number of NPS on the global market 
more than doubled over the period 2009–13. By December 2013, the number of NPS 
reported to UNODC reached 348, up from 251 in July 2012 and 166 substances in 
2009. This means that, now, the number of NPS exceeds the number of psychoactive 
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substances controlled at the international level (234 substances).6 The overall increase 
over the period August 2012–December 2013 was mostly due to new synthetic 
cannabinoids (50% of newly identified psychoactive substances), followed by new 
phenethylamines (17%), other substances (14%) and new synthetic cathinones (8%). 
The use of NPS is thus emerging as a truly global phenomenon. NPS are now found in 
most of Europe and North America, as well as Oceania, Asia and South America, and 
in a number of African countries. To some extent, however, NPS are a North American 
and European phenomenon, with the UK accounting for 23% of the European total 
of NPS users.7
The number of NPS is increasing at a fast pace in Europe, as shown in Figure 1.1.8
In recent years, these newly emerging ‘legal highs’ in Europe have been dominated 
by new synthetic cannabinoid receptor agonists, with phenethylamines, tryptamines 
and cathinones reflecting other popular illicit drugs. Of the 81 new psychoactive 
substances reported for the first time within the EU in 2013, 29 were synthetic 
cannabinoids, 14 phenethylamines, 7 synthetic cathinones, 7 arylalkylamines, 5 
opioids, 2 benzodiazepines, 1 tryptamine, 1 aminoindane, 1 arylcyclohexylamine, 1 
piperidines/ pyrrolinde, 1 piperazine, and 12 were substances that do not conform 
to any of these groups. Of particular concern are new synthetic opioids – such as 
AH-7921, MT-45, carfentanil and ocfentanil – reported as emerging in the past two 
years but which are already controlled under the Misuse of Drugs Act.8 These are, 
however, outside the remit of this document, because they cannot be considered club 
drugs, as defined in section 1.1.
Most of these NPS are thought to be manufactured to mimic the effects of controlled 
drugs, usually in China or India, or in clandestine laboratories in Europe. There is no 
doubt that the producers of novel NPS and ‘legal highs’ are well aware of the legal 
framework surrounding illicit substances and are continuously replacing controlled 
compounds with an array of compounds which are modified to avoid legal control. 
Figure 1.1. Number of psychoactive substances with use reported for the first time 
within the European Union
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Given the very numerous possibilities for altering the structure of chemicals, the list 
of substances produced is likely to grow continuously.2
New substances are produced very quickly to replace those that are placed under 
legal control by various states. A well known example is from Germany, where a 
second generation of synthetic cannabinoid products (JWH-073) were available on 
the market just four weeks following the ban of JWH-018.9 In the UK, and although 
JWH-018 continued to be found in 60% of ‘spice’ products after the ban, products 
containing JWH-073 increased from 6.5% to 70% of products tested.10 Similarly, it 
was noted that online discussions on MDAI in drug user fora became more frequent 
after May 2010, following the UK ban on methcathinones the previous month. MDAI 
was then advertised as a ‘legal’ alternative to mephedrone.11
However, despite the fact that the manufacturers of so-called ‘legal highs’ often 
try to circumvent the law by developing compounds slightly different from those 
banned, there is evidence that some of these products sold online or in ‘head shops’ 
do contain classified compounds and are therefore illegal under UK law.10 Reports of 
the Forensic Early Warning System (FEWS) confirm that this continues to be the case: 
products advertised as legal alternatives to illicit substances are not always legal.12,13 
In addition, the report showed that 81% of the approximately 2000 products that 
contained new psychoactive substances collected during 2012–13 were a mixture of 
two or three different active compounds.12,13 Products with the same name brands 
also sometimes contained different mixtures of active compounds, even those from 
the same supplier.12
In 2013–14, 19.2% of NPS samples collected by FEWS contained controlled drugs. 
There a difference by setting, whereby a low proportion of controlled drugs was 
detected in NPS samples from headshops (4.3%) and the internet (3.0%), but a high 
proportion of controlled drugs was detected in NPS samples from festivals (88.1%). 
In addition, approximately 91% of the samples analysed that contained NPS were 
identified as mixtures of either two (61%) or three (30%) different active components; 
1% of samples were identified as containing six different active components. 
Furthermore, products with the same brand name, such as ‘Black Mamba’, ‘Critical 
Haze’ and ‘Sparklee’, including those from the same suppliers, were observed to 
contain mixtures of different components.13
UK and other research has also shown that there is significant variation in the content 
of ‘legal high’ products bought over the internet.14–19 One study found that six out 
of the seven products it analysed did not contain the advertised active ingredients 
but, rather, some controlled products.19 Moreover, the actual components of products 
sold as ‘legal highs’ are subject to variation even between batches, and change over 
time and in different places. For example, ‘Ivory Wave’ was identified in 2009 as a 
mixture of MDPV and lidocaine,20 but further toxicological analyses of other ‘Ivory 
Wave’ batches also revealed the presence of 2-DPMP21 and D2PM.22 It has also been 
reported that caffeine has been detected in legal high products and some products 
tested were shown to contain caffeine only.14
Therefore, although the term ‘legal high’ is used for a number of NPS, it is a confusing 
and unhelpful one. It has been argued that these substances are not ‘legal’ but are 
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instead ‘not prohibited’. Their ‘legal’ status does not reflect their safety but rather the 
lack of regulation over their production, distribution and use.23,24 Many are untested 
and have unknown psychological and toxicological effects.25,26 
Moreover, not all NPS are ‘novel’. ‘New’ does not always mean a new invention but 
could refer to substances that have recently been made available for recreational 
use. For example, mephedrone was reportedly first synthesised in 1929, but emerged 
as a recreational substance of misuse as late as 2007.2 Other ‘new’ substances were 
synthesised and patented in the 1970s or earlier, but recently their chemistry has been 
modified slightly to produce psychoactive effects similar to those of well established 
illicit substances, as is discussed in the chapters below.
It is also important to note that new drugs may appear on the illicit market and then 
disappear, usually as a result of little demand. NPS may be popular at first and then 
fall in and out of favour, as users try them and move away from them; for example, 
pipradrols such as D2PM, desoxypipradrol and bromo-dragonfly are currently used 
less than previously. 
There is some evidence that the appeal of some NPS is sometimes linked to the 
poor quality of more established illcit substances available on the black market. In 
particular, a reduction in the purity of ecstasy and cocaine was linked to an increased 
use of mephedrone in the UK27 and 2C-B in Spain.28
1.5.2. New markets and user communication about drugs
Club drugs are sold through a variety of channels, including street-level drug dealers 
and through web sites; such outlets often sell controlled substances as well as ‘legal 
highs’ (see below for details). Some users will access a mixed economy; for example, 
there is anecdotal evidence from clinical practice that some GHB/GBL users will buy a 
small amount from street dealers as well as purchasing in bulk via the internet.
‘Legal highs’ are sold online, in ‘head-shops’ or sometimes alongside controlled 
substances on the illicit market. Anecdotal reports from the UK also suggest that 
some legal high products (such synthetic cannabinoid products) are being sold in a 
wide range of outlets,29 including corner shops, pubs and petrol stations. Legal highs 
are marketed as ‘plant food’, ‘bath salts’, ‘research chemicals’, ‘incense’ or ‘herbal highs’ 
and are typically labelled as ‘not for human consumption’ in an apparent attempt to 
evade legal sanction. 
One of the attractions of NPS to users is the inability of standard drug tests to 
identify them. There are currently no accurate field testing devices for most of the 
NPS, despite continued developments in the area of chemical standards, analytical 
capability and forensic detection of compounds.
The ‘market’ for club drugs and NPS appears to have gradually become more sophisti-
cated. For example, a Spanish study of 2C-B has reported that whereas in 2006/07 the 
majority of 2C-B samples collected appeared to be in poorly elaborated forms such as 
powder or capsules, in 2008 and 2009 the most frequent form of presentation was 
tablets.28
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As compounds are controlled and substances banned, their new illegal status does 
not always deter use. Some drugs, like mephedrone, quickly made the cross-over in 
the UK from being a so-called ‘legal high’ to becoming a relatively commonly used 
Class B substance.30 Most sales were then transferred to street dealers, with users 
reporting paying a higher price than they did before the substance was controlled, for 
what was perceived to be a lower-quality product.31,32
The rise in the use of club drugs and NPS coincided with the ability to purchase drugs 
online. Although mostly bought through street-level dealers, illicit substances are 
also sometimes bought on the internet (some with next-day delivery to consumers8), 
specifically from websites operating from outside the UK, or on the ‘dark web’ – that 
part of the internet which is not indexed by standard search engines and is accessible 
only through anonymising browsers such as Tor. A number of websites sell a wide 
variety of so-called ‘legal high’ products, as well as controlled substances, using this 
method.6 Information about new psychoactive products is often now provided via 
‘alerts’ in the form of text messages, instant messaging or emails (‘email this product 
to a friend’).33,34
There has been a steep rise in the number of online ‘shops’ selling both ‘legal’ and 
illegal products to European customers. The targeted internet (snapshot) study 
carried out by the European Monitoring Centre for Drugs and Drug Abuse (EMCDDA) 
looked at the rise in the number of internet NPS ‘shops’ over the period 2010–13.35 
The results are shown in Figure 1.2.36
The internet is also facilitating communication for people who use NPS and providing 
access to knowledge, expertise and logistics about these drugs. There are a number 
of sites and moderated discussion fora and blogs that are used to share information 
about newer compounds, feedback on the effects of drugs and harm reduction advice 
developed through experience.36 User sites, such as Drugs Forum, Bluelight and 
Erowid, among others, have also provided researchers with some understanding of 
these drugs when scientific evidence was not available. 
Figure 1.2. Number of internet NPS shopping sites in Europe per year identified by 
the EMCDDA’s targeted internet study (snapshot)8
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1.6. Club drug use in the UK 
1.6.1. Overall drug use 
Based on combined data from the Crime Survey of England and Wales (CSEW; 
formerly the British Crime Survey), with similar population data from Scotland and 
Northern Ireland for 2010/11, the UK Focal Point Report estimated that 35.6% of 
the adult population in the UK, between the ages of 16 and 59 years, had used drugs 
sometime in their lifetime.37
The most complete time series data available come from England and Wales through 
the CSEW. In 2013/14, approximately 1 in 11 (8.8%) adults aged 16–59 had taken 
an illicit drug in the last year. This proportion more than doubles when looking at 
those aged 16–24 years (18.9%).38 Overall, data from the CSEW show that cannabis 
continued to be the most commonly used drug in 2013/14, with 6.6% of all adults 
between the ages of 16 and 59 years using it in the past year, followed by cocaine 
powder (2.4%) and ecstasy (1.6%).38
In the Scottish Crime and Justice Survey (SCJS) 2012/13,39 23% of respondents 
reported lifetime use of drugs, which was a statistically significant decrease from 
2008/09, where 25.6% of adults reported drug use. Drug use in the last year also 
decreased, with 6.2% of adults reporting having used one or more illicit drugs in 
2012/13, in comparison with 7.6% of adults in the 2008/09 SCJS.
1.6.2. Club drug and NPS use 
As with drugs in general, subsequent CSEW data have consistently shown that adults 
between the ages of 16 and 24 years are more likely to use club drugs than adults in 
general. The data for 2013/14, for example, are shown in Table 1.1.38
Table 1.1. Percentage of adults using drugs in the last year (CSEW, 2013/14)
Drugs used in past year by age group, 2013/14 Adults aged 16–24 
years
All adults aged 
16–59 years
Ecstasy 3.9% 1.6%
Mephedrone 1.9% 0.6%
Ketamine 1.8% 0.6%
LSD 0.9% 0.3%
Magic mushrooms 0.8% 0.4%
Methamphetamine 0.1% 0.1%
Salvia 1.8% 0.5%
Nitrous oxide 7.6% 2.3%
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The 2012/13 Scottish Crime and Justice Survey also showed variations, with men, and 
young people, most likely to have used any of five drugs from a group of new drugs 
(benzylpiperazine, GBL, synthetic cannabinoids, khat or Salvia divinorum) as well as 
mephedrone.39
Some club drugs and NPS can be injected. In England, the 2014 Public Health England 
(PHE) report on infections among people who inject drugs mentions a recent increase 
in the injecting of amphetamines and amphetamine-type substances, including 
mephedrone and methamphetamine. The injecting of these drugs is associated with 
high risks of infection and lower levels of intervention uptake.40
Among people presenting for treatment of their drug misuse in England and who 
have used mephedrone, methamphetamine, ketamine and GHB/GBL, the proportion 
of those who reported injecting doubled, to 10%, between 2011/12 and 2012/13.40 
In Wales, the proportion of those using needle and syringe exchanges and reporting 
injection of amphetamine and/or other amphetamine-type substances (ATS) as 
their main drugs increased from 7% in 2011/12 to 10% in 2013/14.41 In Scotland, 
there is no evidence of an increase in presentations for treatment of people using 
amphetamines, ecstasy or mephedrone, and numbers remain small.40
1.6.3. Drug-using repertoires and poly-drug use
There are also are reports of indiscriminate use of substances by some, with users 
reporting taking unidentified synthetic white powders with no knowledge of their 
chemical content, as shown by a survey of participants in the night-time economy.42 
This was supported by the results of the Global Drug Survey, which found that 15% 
of all respondents and a fifth of those aged between 18 and 25 years had in the past 
12 months used an ‘unknown white powder’.*
Thus, the users of club drugs will typically use a wide repertoire of substances. The 
co-ingestion of more than one substance (simultaneous use), including alcohol, is also 
relatively common and increases the risk of adverse effects, as is discussed in greater 
detail in the chapters within Parts II to V of this document.
1.6.4. Club drug users and contexts of use
There is evidence that levels of drug use are higher among particular populations and 
that club drugs are a popular aspect of socialisation.43 These include the following:
1.6.4.1. Clubbers and night-time economy
There is evidence that people who use the night-time economy, and dance clubs 
or nightclubs in particular, are more likely to use club drugs than the general 
population.44,45 Data from the CSEW consistently show that the levels of drug use 
* The Global Drug Survey is independent research organisation. See http://globaldrugsurvey.com/about. 
The results of a 2012 survey sponsored by the Guardian were reported in that newspaper: see http://
www.guardian.co.uk/society/2012/mar/15/guardian-mixmag-drug-survey-drugs and http://www.
guardian.co.uk/society/datablog/2012/mar/15/global-drug-survey-us-uk.
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increase with frequency of visits to nightclubs and pubs. For example, the 2013/14 
CSEW reported that 10.9% of respondents who had been to a nightclub four or more 
times in the last month were frequent users of drugs, in comparison with 2.3% of 
users who had not visited a nightclub in the past month. Similarly, 9.2% of adults who 
had visited a pub nine or more times in the last month had taken any drug in the last 
year, compared with 2.4% of those who had not visited a pub.38 
Other targeted surveys have also shown variations by user of different types of venues 
in the night-time economy, for example with those attending nightclubs reporting 
significantly higher levels of drug use than bar/pub attenders.44 Drug use is also 
higher in certain music or stylistic ‘scenes’, such as among club-goers attending dance 
events playing ‘hard dance’ music compared with the same venues when playing 
other genres of dance music.44 There are reports of particularly high levels of lifetime 
use among ‘clubbers’ who attend electronic dance music clubs, ranging from 79% to 
94%.46,47 Clubbing and club drug use, as part of a socially active lifestyle, has been 
associated with elevated sexual health risks.48
1.6.4.2. Lesbian, gay, bisexual and transgender populations
There is UK and international evidence that levels of club drug use among LGBT 
people, and men who have sex with men (MSM) in particular, is higher than in the 
general population. The European Men-Who-Have-Sex-With-Men Internet Survey, 
carried out in 38 countries in 2013,49 showed, for example, that UK has higher levels 
of the use of some drugs than do other parts of Europe.
Robust UK prevalence data on drug use among LGBT populations, and comparisons 
with the heterosexual population, are limited. The 2013/14 CSEW and its predecessor, 
the British Crime Survey (BCS), have provided data over a number of years, but these 
must be treated with caution because of the small numbers in the survey. In 2011/12 
and 2013/14, respondents who identified themselves as lesbian, gay and bisexual 
(LGB) were approximately three times more likely to have reported taking any illicit 
substances in the last year in comparison with heterosexual respondents (28.4% 
versus 8.1%), with differences remaining when age-standardised data were analysed. 
LGB respondents were also much more more likely to report the use of stimulant 
drugs* (14.4% versus 2.9%). A higher level of use was reported by LGB respondents 
for most individual substances, including powder cocaine, ecstasy, hallucinogenic 
drugs, amphetamine, cannabis, tranquillisers, ketamine and amyl nitrite.38
There are increasing concerns over associations between club drug use and high-risk 
sexual behaviours among a minority of MSM. This includes concern over ‘chemsex’, 
a term used to describe sex between men that occurs under the influence of drugs 
immediately preceding and/or during the sexual session,50 with methamphetamine, 
GHB/GBL and mephedrone the drugs most often used. A combination of factors, 
including high-risk sexual practices and injection, have been described as ‘a perfect 
storm for transmission of both HIV and HCV, as well as a catalogue of ensuing mental 
health problems’.51 
* The stimulant drugs surveyed were powder cocaine, crack cocaine, ecstasy, amphetamines and amyl 
nitrite.
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1.6.4.3. ‘Psychonauts’
‘Psychonauts’ is a term given to a group of people who explore their own psyche, 
especially by taking psychedelic or hallucinogenic substances. The emphasis of use is 
on seeking novelty and extremes of experience. Psychonauts may experiment with 
newly emerging psychoactive substances, including obscure hallucinogens, and may 
experiment with drug combinations or push boundaries in terms of dose, for example. 
The internet plays an important role and provides a platform for sharing experience 
and information.52
1.7. Overview of the effects 
and harms of club drugs
1.7.1. How drugs work
Drugs can be classified in various ways – according to chemical structure, pharma-
cological activity or psychological effects.53,54 One approach is to consider a drug’s 
primary effects along the dimensions of sedation–stimulation, although account 
needs to be taken of the fact that in some people sedatives can be disinhibiting in 
the early rising phase of drug entry into the brain, or at low doses, and so can mimic 
the effects of stimulants. For example, although GHB/GBL is a sedative, it has, at low 
doses, a stimulant effect.
A separate axis is in terms of alterations of perceptions and feelings. For example, 
MDMA, as well as being a moderate stimulant, is also an empathogen (empathy-
enhancing), whereas magic mushrooms and LSD alter consciousness to cause novel 
phenomena such as hallucinations and a disordered sense of time and being (hallu-
cinogens or psychedelics). Ketamine and related drugs are dissociative anaesthetics, 
producing a state of altered consciousness. Opioids dampen pain but also promote 
sleep and visions during it, and produce a profound sense of pleasure. Stimulants tend 
to activate a person.
The proximal mechanisms of most of these effects (as far as they are known) are 
shown in Table 1.2. Most NPS are designed to provide legal alternatives to controlled 
substances, and have harms similar to those associated with the controlled drugs 
they have been manufactured to mimic.
1.7.2. Toxicity and other harms
Club drugs and NPS are associated with a range of harms.55 The harm associated 
with any drug of potential misuse may include: the physical harm to the individual 
user caused by the drug; the dependence-inducing potential of the drug; and the 
effects of drug use on families, communities and society.56 All three aspects need to 
be considered when assessing the impact of a drug. 
‘Toxicity’ generally refers to the extent to which a substance causes functional or 
anatomical damage to a living organism.57,58 There are wide variations in the toxicity 
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of the various club drugs and NPS, including their single-dose lethal toxicity.57 In 
addition, individuals vary greatly with respect to metabolism and psycho-physical 
vulnerability. 
A number of other factors are also linked to acute toxicity:
•	The co-use of more than one substance will increase the chances of acute toxicity, 
particularly when drugs with similar physiological effects are combined (e.g. 
sedatives such as GHB and alcohol or stimulants such as cocaine and amphetamine)
•	The risk of overdose is increased by repeated administration of the drug.
•	The safety ratio of drugs does not reflect the metabolic or functional tolerance 
that a user may have developed.
•	Non-drug variables can alter toxic reactions significantly (e.g. the psychological 
effects of the environment, diet, stress, expectation etc.).58
Table 1.2. The proximal mechanisms of drug effects
Drug Primary (proximal) target Brain effects 
Alcohol Agonist at GABA and antagonist at 
glutamate receptors 
Increases GABA 
Blocks NMDA glutamate 
receptors 
Benzodiazepines Agonists at benzodiazepine site on 
GABA-A receptor 
Increase GABA 
GHB GHB and GABA-B receptor agonist Mimics GABA 
Inhibits dopamine release 
Ketamine NMDA glutamate receptor antagonist Blocks glutamate 
Caffeine Antagonist at adenosine A2 receptor Reduces sedation 
Increases noradrenaline 
Khat Releases ephedrine, a dopamine 
releaser
Mild increase in noradrenaline 
and dopamine
Cannabis Cannabis CB1 receptor agonist Stimulates endo-cannabinoid 
signalling, leading to a change in 
cortical and memory functions
Cocaine Blocks dopamine reuptake site Greatly increases dopamine 
Amphetamines 
(dexamphetamine and 
methyl)
Release dopamine and block reuptake Greatly increase dopamine and 
noradrenaline 
Nicotine Agonist at (nicotinic) acetylcholine 
receptors 
Slightly increases dopamine 
MDMA Blocks serotonin and dopamine 
reuptake 
Increases serotonin and 
dopamine function
Mephedrone Release dopamine and block reuptake Increase dopamine, and 
serotonin 
Hallucinogens Agonists at serotonin 5-HT2A receptors Change across-cortex signalling
Heroin and other 
opioids
Agonists at endorphin receptors Produce euphoria, reduce pain 
Agonist = drug that activates or stimulates a receptor; Antagonist = drug that blocks a receptor.
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•	The mode of administration, with injecting not only exposing the user to the risk 
of bacterial infections but also increasing the risk of overdose and dependence.55
•	Drug purity and adulterants can affect toxicity.
Club drugs and NPS pose a particular challenge to clinicians and may constitute a 
public health challenge, for the following reasons:33 
•	these substances are not approved for human consumption;
•	they are possibly associated with a number of unknown adverse effects;
•	insufficient information on them is available in peer-reviewed scientific journals;
•	they appear in increasingly sophisticated (i.e. non-powder) forms and remain 
unregulated for long periods of time;
•	they are often synthesised in underground laboratories by modifying the molecular 
structure of controlled drugs, raising concerns over the presence of contaminating 
agents;
•	they are largely available online to everyone, ‘just a click away’;
•	they are increasingly accepted as part of a ‘trendy’ lifestyle.
Whereas, all users of club drugs face the risk of acute toxicity, the harms caused by 
club drugs encompass a wide range of different patterns. Club drugs are associated 
with harmful use, defined by the World Health Organization (WHO) as a pattern of 
psychoactive substance use that is causing damage to health, which can be physical 
(e.g. ketamine can lead to bladder damage and ulcerative cystitis) or mental (e.g. 
psychosis associated with synthetic cannabinoids).59 Some club drugs have also been 
shown to have a liability to produce dependence and some have been associated with 
a withdrawal syndrome, which can be severe, for example in the case of GHB/GBL. 
1.7.3. Mortality related to the use of club drugs 
Data on drug-related mortalities have been provided for a number of years by the 
National Programme for Substance Abuse Death (NPSAD). Deaths involving NPS 
(including ‘legal highs’) have increased in recent years,60 although the rates remain 
much lower than deaths from heroin/morphine. 
Overall, the limitations of data on drug-related mortality must be used with caution 
and as indicative, rather than robust.61 The Office for National Statistics’ report Deaths 
Related to Drug Poisoning in England and Wales 2012 indicates a sharp increase in 
the number of deaths involving NPS, from 29 in 2011 to 52 in 2012.62 This rose to 60 
in 2013. There were 26 deaths in 2013 involving cathinones (including mephedrone). 
This was a rise of 44% from the 18 deaths in 2012, and was over four times greater 
than the 6 deaths in 2011.63 Deaths in 2013 where other NPS were implicated include 
those listed in Table 1.3. 
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Table 1.3. Number of deaths related to drug poisoning with a mention of a novel 
psychoactive substance, by specific substance, England and Wales, 2013
Substance Sole drug mentioned 
in coroner’s report
Any drug mentioned 
in coroner’s report
1-(benzofuran-6-yl)-propan-2-amine 0 2
2-(1H-indol-5-yl)-1-methylethylamine 0 1
4-fluoroephedrine 0 0
4-fluoromethcathinone 1 1
4-methylamphetamine 0 1
4-methylethcathinone 1 3
Alpha-methyltryptamine 4 7
BZP 0 1
Cathinonea 0 1
Desoxypipradrol 0 0
Fluoromethcathinone 0 0
Gamma-hydroxybutyrate (GHB)/ 
gamma-butyrolactone (GBL)
10 18
Khat 0 0
Legal high 0 0
Mephedrone 1 18
Methiopropamine 1 4
Methoxetamine 1 2
Methylenedioxypyrovalerone 1 2
Methylone 1 4
Synthetic cannabinoid 0 0
TFMPP 0 0
1-(benzofuran-5-yl)-propan-2-amine 0 3
1-(benzofuran-5-yl)-N-methylpropan-2-amine 0 1
APB 2 3
2-diphenylmethylpyrrolidine 0 1
4-Methoxymethcathinone 0 1
N-Methyl-3-phenyl-norbornan-2-amine 1 1
Fluoromethamphetamine 0 1
MDDA 0 1
a Where cathinone was found in the text of the coroner’s report and no further derivative breakdown 
was available. This does not represent the total number of deaths relating to the group ‘cathinones’.
Source: Deaths related to drug poisoning with a mention of NPS in the coroner’s report, by specific 
substance, England and Wales, deaths registered in 2013.63 
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1.8. Response to club drug use
1.8.1. Policy response to club drug and NPS use
The question of how to respond to the challenges posed by the emergence of new 
drugs has now become a major concern within the EU and at the international 
level.8 In the UK, the need to tackle the problematic use of NPS and club drugs and 
actions to do so featured prominently in the government’s 2010 drug strategy64 and 
the subsequent reviews of that strategy.65 The issue of NPS was also addressed by 
devolved administrations in Scotland, Northern Ireland and in Wales, which supported 
the expansion of the WEDINOS (Welsh Emergency Doctor Illicit Novel Substances).
In December 2013, the Home Office convened an expert panel to look at NPS66 and 
provide recommendations.67 The government in its response endorsed the dissemina-
tion of effective practice and specifically highlighted the role of the NEPTUNE project 
in doing so.68 NPS and club drugs continue to be a government priority.
To date, the government has banned more than 500 new drugs, created the Forensic 
Early Warning System to identify NPS in the UK and supported law enforcement 
action with the latest intelligence on new substances. It is also taking forward a com-
prehensive action plan to further enhance the response to prevention, treatment and 
information sharing regarding NPS, for example providing a toolkit for commission-
ers which gives a broad overview of the challenges and which provides them with 
resources and advice to inform a suitable local response. A guidance document has 
also been issued to informal educators of young people (e.g. youth workers), with 
basic information on NPS and which provides signposting information for further 
advice and support.
1.8.2. NPS and drug-related  presentations 
to hospitals and treatment
Accurate data on emergency hospital admissions resulting from club drug use in the 
UK are difficult to obtain, for a variety of reasons, not least because ICD-10 codes do 
not include specific codes for NPS and because coding is generally based on clinical 
condition at presentation. In order to address this current paucity of reliable data, the 
European Drug Emergencies Network (Euro-Den) established in 2014 as a network 
of 16 sentinel centres in 10 EU and neighbouring countries. The project was set up 
to provide data on the clinical, demographic and geographical patterns of acute 
recreational use and NPS toxicity, and to act as a stimulus to ensure best practice 
in the management of acute toxicity from recreational drug and NPS in pre-hospital 
recreational settings.69
A useful indicator is provided by activity data of the NPIS, although it needs to be 
borne in mind that these do not record hospital admissions. The NPIS received 1561 
telephone enquiries and 58,469 TOXBASE® accesses related to 61 drugs of misuse 
monitored by the NPIS during 2013/14. When adjusted for overall increases in all 
NPIS enquiries, telephone enquiries for these drugs of misuse increased by 24.9% and 
TOXBASE® accesses by 0.6% compared with 2012/13.70
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Data are available on patient access to substance misuse recovery services. There is 
evidence that some individuals regularly using club drugs are developing on-going 
problems, including dependence. Data on club drug use among populations in 
treatment in England has been collected by the National Drug Treatment Monitoring 
System (NDTMS) for England since 2005/06.71,72 A ‘club drug user’ was defined as a 
person citing any of the following five substances, as either a primary or an adjunctive 
drug: GHB/GBL, ketamine, ecstasy, methamphetamine or mephedrone. The number 
of clients presenting for drug treatment in England for a club drug reported by 
NDTMS increased from 2675 in 2011/12 to 3543 in 2013/14. Increases in numbers 
presenting to treatment were observed for all five substances: the most significant 
was an 82% increase in mephedrone presentations, from 900 in 2011/12, to 1641 in 
2013/14. Numbers presenting to treatment citing methamphetamine use increased 
by 107%, from 116 in 2011/12 to 240 in 2013/14, but still made up just 0.3% of all 
presentations to drug treatment and recovery services.73 The PHE report on drug 
treatment in England in 2012/13 suggested that recovery rates for the users of club 
drugs and NPS remained good.72 
1.8.3. Principles underlying the assessment and management 
in target settings of the harms associated with the use of 
club drugs and NPS
1.8.3.1. Emergency departments 
Emergency medicine physicians and other clinicians should seek advice on the 
diagnosis, treatment and care of patients who have been – or may have been – 
poisoned with a club drug, primarily from the National Poisons Information Service 
(NPIS) through its telephone service and TOXBASE® database. This will assist in 
ensuring optimal and up-to-date information on care for patients in cases of serious 
poisoning and, where toxicity is low, offering advice to minimise unnecessary hospital 
attendances and admissions.
The use of psychoactive substances in pregnancy can lead to multiple health and social 
harms to mother and child. The NPIS provides the UK Teratology Information Service 
(UKTIS), which is the national source of information and advice about exposures to 
drugs and chemicals during pregnancy. Information is provided to health profession-
als via a telephone information service and online through TOXBASE®, which holds the 
full pregnancy review documents produced by UKTIS on maternal exposures to drugs 
and chemicals. Other guidelines on the identification and management of substance 
misuse in pregnancy are available, including recent guidelines from the WHO.74
1.8.3.2. Sexual health services
The association between substance misuse and high-risk sexual behaviours is well 
established and there is evidence of a high prevalence of drug use among patients 
attending sexual health clinics. For example, one study of patients at a London sexual 
health clinic reported significantly higher rates of past month drug use, than in 
the general adult population in England and Wales. This was particularly so among 
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MSM.75 Sexual health services may therefore provide opportunistic encounters to 
identify patterns of recreational drug use, explore motivations for use and implement 
strategies to reduce harms related to drug use.75
MSM and people who have alcohol and drug problems have also been identified as 
higher-risk groups for poor sexual health outcomes.76,77 As a result, targeted work 
has been suggested. For example, the Royal College of Physicians and the British 
Association for Sexual Health and HIV recommend that sexual health settings 
distribute information on alcohol-related harms and facilitate brief alcohol interven-
tions to reduce consumption and related sexual ill-health.78,79
NICE public health guidance (PH24)80 identifies sexual health services as a specific 
setting where alcohol use should be assessed and interventions provided and/
or referral made. Given the clear proven association (if not causation) between 
substance misuse and high risk sexual behaviour and consequent sexual ill health, 
along with some of the emerging harms associated with specific substances (e.g. 
ketamine bladder) there has been increasing recognition within the specialty for a 
need to identify those potentially at risk, and to provide either simple interventions 
or clear pathways into specialised services. Recent data81 suggest there is a low level 
of screening for either alcohol and or substance misuse within sexual health services. 
However, screening for some risk behaviour is common (e.g. injecting drug use), as it 
forms part of the risk assessment for the acquisition of blood-borne viruses (BBV).
The British Association for Sexual Health and HIV (BASHH) provides recommenda-
tions on screening for alcohol and recreational drug use in several of its specialty 
guidance documents. The ‘2013 UK national guideline for consultations requiring 
sexual history taking’82 recommends that all patients are asked about their alcohol 
intake and suggests that a recreational drug history is considered for specific at-risk 
groups, such as MSM and young people. The ‘2012 UK National Guidelines on safer 
sex advice’83 highlighted the need to identify those who may be at risk of sexual ill 
health and thus may be good candidates for advice on safer sex and other brief inter-
ventions, including those individuals with a history of alcohol or substance misuse. 
The BASHH statement on ‘club’ (recreational) drug use84 identifies MSM, young people, 
students and ‘clubbers’ as possible target groups for screening, so as to identify 
potentially problematic use, and provides some proposed screening questions. It 
recommends that clinicians give simple safety advice and information on possible 
harm, including other sources of information, and that services have agreed referral 
pathways into appropriate local services.
The British HIV Association (BHIVA), in its Standards of Care for People Living with HIV 
in 2013,79 recommends screening for drug and alcohol misuse within three months 
of diagnosis, and annually thereafter, and that services have appropriate referral 
pathways in place.
Currently, there is no systematic capture and reporting of alcohol and substance use 
by individuals accessing sexual health services in the UK. However, there are proposed 
changes to the national GUM clinical activity dataset (GUMCAD) which will include 
both alcohol and drug use data fields. If approved, this should, for the first time, permit 
some estimate of the scale of the problem within this patient group. 
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1.8.3.3. Substance misuse treatment services
Guidelines for substance misuse treatment in the UK in general is defined by the Drug 
Misuse and Dependence: UK Guidelines on Clinical Management85 (a 2007 document 
that was due to be updated in 2015). These provide the standards and quality of care 
for the appropriate treatment of drug misusers, if the performance of any clinical 
area is to be assessed. 
Guidelines for standards of care are also defined by range of relevant NICE clinical 
guidance and technology appraisals, although none currently focuses on club drugs 
and NPS. In order to deliver high-quality treatment, including for the users of club drugs 
and NPS, drug treatment services should be able to demonstrate their adherence to 
the NICE quality standards for drug use disorders (NICE Quality Standard 23)86 and 
alcohol (NICE Quality Standard 11).87 Such guidance should contribute to improving 
the effectiveness, safety and positive experience of care for people with substance 
misuse disorders. There should also be adherence to NICE psychological interventions 
guidelines on the management of drug misuse.88 NICE Clinical Guidance 52, on opiate 
detoxification,89 states that ‘all interventions for people who misuse drugs should be 
delivered by staff who are competent in delivering the intervention and who receive 
appropriate supervision’.
To increase the prospects of recovery from drug misuse, PHE recommends that 
treatment needs to be dynamic, phased and layered.90 Its publication Medications in 
Recovery suggests an approach to phasing and layering treatment which includes the 
following steps:90
•	engagement and stabilisation; 
•	preparation for change;
•	active change; 
•	completion.
1.8.4. Overview of the interventions for the screening, identifica-
tion and management of drug harms in the target settings
The different target organisations (treatment settings) of the NEPTUNE guidance 
have different roles in the detection, identification and management of chronic 
harms and/or dependence resulting from the use of club drugs. This is determined 
by the competence of clinicians to deliver substance misuse treatment and particular 
pharmacological or psychosocial and recovery interventions.
Table 1.4 provides a summary of the role of each of the target settings and the aims 
of the interventions provided in terms of the screening, identification, assessment 
and management of the harms linked to the use of club drugs. Further information 
on the level of intervention needed is also presented in Chapter 2.
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Table 1.4. The role of particular settings and the aims of interventions provided
Detection Assessment Brief 
intervention
Complex 
intervention 
(acute)
Complex 
intervention 
(chronic)
Primary care     
Emergency department     
Sexual health     
Substance misuse treatment     
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Chapter 2
Psychosocial interventions for 
club drugs and novel psychoactive 
substances
There is a large body of evidence on the effectiveness of psychosocial interven-
tions (PSIs) for the management of substance misuse problems, as well as national 
guidelines. It is therefore possible to make specific and robust recommendations.
Effective treatment for all substance misuse problems includes PSIs. These in fact 
are the primary form of treatment intervention for the misuse of, and dependence 
on, the majority of substances, as few types of substance misuse have recognised 
pharmacological inter ventions.1 Where pharmacological interventions do have a role, 
for instance in opioid dependence, PSIs are generally believed to enhance treatment 
outcomes.2 PSIs are important in helping people prepare for planned, medically 
assisted detoxification and are essential following detoxification, to sustain changes. 
Psychological interventions for substance misuse problems focus on supporting 
behaviour change to achieve desired outcomes. PSIs may aim to support people to 
achieve abstinence from use of specific or multiple substances, or a reduction in use 
to a less harmful level or using substances in a less harmful manner. Psychological 
inter ventions are also used to help with co-occurring psychological, social or physical 
problems, again with the aim of contributing to sustained change in substance misuse. 
The evidence for the effectiveness of PSIs for a range of substance use problems is very 
positive. However, in what Orford terms the ‘outcome equivalence paradox’, no single 
approach is regarded as universally superior. 3 In the UK, several specific psychosocial 
approaches reach the standard of evidence to be recommended by the National 
Institute for Health and Care Excellence (NICE; formerly the National Institute for 
Health and Clinical Excellence) and meta-analyses such as Cochrane reviews (see 
Table 2.1). Very limited research has so far been published relating specifically to PSIs 
for the treatment of NPS. Where this exists, it has been summarised in the relevant 
chapters in this publication. Given the growing use of NPS and the concerns about 
direct and associated harms, the expert group sees this as an area to be prioritised 
for high-quality research. 
In the UK, the evidence for the effectiveness of PSIs for drug misuse is described in 
the NICE guideline Drug Misuse: Psychosocial Interventions4 and further elaborated in 
the document Drug Misuse and Dependence: UK Guidelines on Clinical Management.5 
However, these publications largely relate to opioid and (crack) cocaine treatment. 
This chapter makes important recommendations on initial and lower-intensity 
responses for individuals who identify use of club drugs and NPS but focuses 
mostly on the psychosocial treatment options for their problematic use (including 
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dependence). Many NPS are stimulant in nature and this chapter therefore draws 
heavily on research for the treatment for stimulant misuse. However, it also draws 
on the broader literature on PSIs for health behaviour change in general, for which 
the evidence base is described in NICE’s public health guidance Behaviour Change: 
Individual Approaches.6 Reference is also made to commonly accepted good practice 
for effective psychological interventions in general. 
Patterns of NPS use show a close parallel to recognised patterns of alcohol use: the 
most common pattern is infrequent, non-dependent use, with lower risk of severity and 
likelihood of harm; through to a much smaller proportion of entrenched dependent 
use with the potential for more significant associated harm. The chapter therefore 
also draws on the much more extensive literature on PSIs for alcohol problems. 
These are described in NICE guidance (number 115, originally published in 2011 and 
updated in 2013) on the diagnosis, assessment and management of harmful drinking 
and alcohol dependence.7 
Table 2.1. Summary of evidence for the effectiveness of PSIs for substance misuse
Document Content and conclusions
NICE recommendations (CG51, 
2007) on drug misuse4,8
Brief interventions (motivational interviewing)
Information on self-help groups
Behavioural couples therapy
Contingency management
Evidence-based PSI for co-occurring psychological problems
Government clinical guidelines 
(2007) on drug misuse5
NICE 51 plus:
CBT-based relapse prevention
Community reinforcement approaches
Social behaviour network therapy
Family therapy
Psychodynamic therapy
NICE recommendations (CG 
115, 2011 and 2013) on alcohol 
misuse7
Motivational interviewing
Information on self-help groups
CBT-based relapse prevention
Behavioural therapies
Social network and environmental therapies
Behavioural couples therapy
Evidence-based psychosocial interventions for co-occurring 
psychological problems
Cochrane reviews:
Smedslund et al. (2011)9
Knapp et al. (2007)10 on cocaine 
and psycho-stimulants
Motivational interviewing
Contingency management
CBT
Community reinforcement approach
National Treatment Agency 
(2005)11
CBT – coping skills
Motivational interviewing
Relapse prevention
Community reinforcement
Contingency management
Supportive expressive psychotherapy
Family therapy
Social behaviour network therapy
NICE (PH 49, 2014)6 Proven behaviour change techniques:
goal setting and planning
feedback and monitoring
social support
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2.1. Stepped care
Psychosocial interventions for substance use are commonly provided following a 
stepped care model (Figure 2.1).12,13
Within stepped care models, psychosocial and psychological interventions are grouped 
according to the level of specific psychological treatment competences required to 
deliver them effectively. It is therefore common to refer to ‘lower-intensity PSIs’ and 
‘higher-intensity PSIs’.
The main principles of a stepped care approach are as follows:
•	The least intrusive intervention needed to achieve a required outcome is delivered 
first.
•	If an intervention does not achieve the desired outcome, service users should be 
offered the option of being ‘stepped up’ to a more intensive intervention.
•	Where a higher level of intensity of treatment is no longer required, ‘stepping down’ 
to a less intensive option should be offered.
•	Service users should have access to all levels of treatment within a treatment 
system.
•	Service users should have direct access to the intensity of intervention likely to be 
required to achieve their desired outcomes, and not unnecessarily proceed through 
lower levels in a stepwise order.
Figure 2.1. Stepped care PSI for problematic NPS use
Identification
of problematic
NPS use
 
Lower severity
Lower-intensity PSI  
Brief advice and information
and brief intervention
 
  
Higher severity 
and dependence 
 
Higher-intensity PSI  
Structured drug treatment
and formal psychological therapy
Residential
treatment
Mutual aid 
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2.2. Identification of NPS use and its severity
The clinical identification of individuals experiencing NPS harmful use, misuse or 
dependence, particularly those less severely affected, is not always easy when regular 
use may be linked to a clubbing-related lifestyle. Determining the need for specific 
psychosocial interventions to address behaviour change will also be influenced by 
a wide range of factors. Many people make substantial changes to their substance 
misuse without formal treatment.3 
Substance use or intoxication is not in itself an indication for treatment. Unlike the 
several robust screening tools for alcohol use, there are no recognised screening tools 
for NPS use and routine screening for NPS use in general health care settings has not 
been recommended. However, any contact with a health professional where NPS use 
is identified can be an opportunity to offer non-judgemental health advice on safety 
and, potentially, change.
Self-report, incidental or opportunistic enquiry may reveal NPS use and risk but no 
evidence of harm or need for a treatment intervention. This provides a potentially 
useful opportunity to offer information and brief advice or to signpost to sources of 
other information. Other individuals will provide clearer evidence of at least some 
degree of problematic use. Many such problematic users may well be able to change 
their risky behaviour without assistance and not require professional help. Some of 
these problematic users will benefit from the offer of information and brief advice (and/
or signposting). Brief advice and information should also be considered (in addition to 
the offer of referral to formal treatment services) where higher-severity NPS use and 
dependence are identified. This would amount to an opportunistic intervention for 
anyone who does wish to, or does not go on to, access treatment at that time. When 
information and brief advice is used in this way to help address problem use, it forms 
part of the stepped care ‘treatment’ pathway shown in Figure 2.1.
Contemporary thinking emphasises approaches based on strengths and needs, for 
example a ‘recovery capital’ model, rather than a deficits-based approach (see Marsden 
et al.14). A recovery capital model looks at the strengths and needs a service user has 
over a range of domains beyond substance use. More resources across the domains 
would suggest greater likelihood of positive outcomes, and fewer resources suggest 
an indication for broader and more intensive interventions. Four types of recovery 
capital are identified:15
•	human capital – e.g. skills, employment, mental and physical health;
•	physical capital – e.g. tangible resources, housing, money;
•	cultural capital – e.g. values, beliefs;
•	social capital – e.g. relationships with others.
Those who have more strengths and resources (recovery capital) may be more likely 
to achieve their desired outcomes with little or no professional input.16 Indicators 
for more intensive interventions include: longer problem duration, injecting drug 
use, substance dependence, unsuccessful independent attempts to change, multiple 
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substance misuse problems, multiple co-occurring problems, fewer individual 
strengths and less access to resources. An additional consideration is that people may 
have substantial substance misuse problems but at the present time are only ready 
or able to access and engage with less intensive interventions (e.g. needle exchange 
interventions for injecting drug use).
The intensity of the PSI should be more directly related to the severity of the substance 
misuse problem than to the severity of the health and other consequences of the 
substance use. For example, someone experiencing an extreme medical consequence 
of one-off use of a substance may be able to make desired changes without formal 
treatment.
It seems likely that most NPS use is infrequent, largely remains within the control of 
the individual and is associated with a low risk of harm.17 Nonetheless, some NPS are 
injected and the majority of NPS have reported incidents of serious associated acute 
and chronic harms. The repeated use of some NPS can lead to dependence and for 
some, such as GHB/ GBL, acute withdrawal can be a medical emergency. 
Box 2.1 lists the recommended as pragmatic indicators for a referral to drug treatment 
services, which will include PSIs.
Box 2.1. Indicators for a referral to drug treatment services and PSIs
•	 Current injecting of any substance;
•	 Self-report of inability to make changes to NPS use when attempted;
•	 Repeated presentation(s) with drug-related harm (psychological, social or physical);
•	 Self-identification of needing specialist help or request for referral to drug treatment 
services.
2.3. Settings for the delivery of PSIs
The intensity of the PSI delivered will vary across the settings in which they are 
offered. Some PSIs require additional or specialist competences to deliver them, 
whereas mutual aid, for instance, is a peer-led intervention and so is not dependent 
on particular settings for its delivery (and therefore is not discussed further in this 
sub-section). 
2.3.1. Settings for lower-intensity PSIs
In non-drug treatment settings, where NPS use, or problematic use, has been 
identified during a clinical interaction with a service user, the offer of brief advice 
and information may be helpful. Such non-drug treatment settings include general 
practice, emergency departments, primary and secondary care mental health services, 
sexual health clinics and HIV services, in addition to other services where people may 
present with acute problems related to NPS use.
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There is evidence that NPS use has a higher prevalence in people attending sexual 
health services18 and HIV treatment services.19 These services (and others with 
service users with known higher prevalence rates of NPS use) have an appropriate 
opportunity actively to ask about NPS use as part of their normal clinical assessment 
process. These non-drug treatment services that work with service user groups with 
a higher prevalence of NPS use, as an additional level of opportunistic intervention 
beyond offering brief advice and information, should also develop the relevant skills 
and competences and should offer brief interventions (BIs), referring individuals on 
for additional support, if needed.
Numerous studies report people living with HIV have a higher prevalence of NPS use 
(as will be discussed below) and there are concerns about the additional health and 
viral transmission risks NPS use may pose. People living with diagnosed HIV typically 
have frequent medical review appointments at HIV treatment services. These service 
contacts provide a valuable opportunity for similar appropriate questions on NPS 
use, asked routinely or targeted as appropriate; and the offer of brief advice and 
information and, if suitable, brief interventions. 
Because of high levels of presentations related to substance use, some EDs have staff 
with skills to provide a brief intervention. Similarly, because there are high levels of 
substance misuse among people accessing mental health services,20 these services 
often have staff with additional competences (‘dual-diagnosis workers’) to provide 
higher-intensity drug interventions in combination with mental health interventions.
2.3.2. Settings for higher-intensity PSIs
Higher-intensity PSIs, structured drug treatment and formal psychological therapy 
are likely to be delivered in community or residential drug treatment services.
There may be benefits in locating the delivery of higher-intensity PSIs in specific 
non-drug services where presentation with problematic NPS use is frequent and 
associated with other health or social problems. This may encourage engagement 
in drug treatment, by minimising any perceived stigma involved in attending drug 
treatment services. There may also be merit in developing specialist hybrid services 
for specific populations with co-occurring needs. For example, innovative services 
where drug treatment and psychological therapy are provided in settings such as 
sexual health services with a high level of presentation of co-occurring sexual health 
problems, problematic NPS use and in some cases psychological problems. 
These differing levels of intensity of interventions will be reflected in the increasing 
specialised competences that the health professionals delivering them will have. All 
levels of intervention must be delivered within an appropriate governance framework 
with more intensive PSIs requiring specific supervision.8
Recommendation A stepped care model of interventions for NPS use should be 
available to service users across a treatment system, with referral pathways between 
the various services where service users are likely to present. It is recommended 
that the settings listed in Table 2.2 offer a minimum level of PSI. Each intervention is 
described in greater detail below.
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All non-drug treatment services should offer referral to drug treatment services, as 
indicated in Box 2.1. 
2.4. Lower-intensity PSIs
Lower-intensity PSIs can be divided into two main interventions: provision of brief 
advice and information; and provision of brief interventions. The published evidence 
that underlies this for drug users mainly relates to the provision of brief interventions. 
However, recommending the provision of brief advice and information is a considered 
and pragmatic approach that takes account of wider evidence on brief advice and is 
based on what is considered a minimum approach to addressing the basic health needs 
of NPS users attending non-drug treatment services. Brief interventions, derived 
mainly from the principles of motivational interviewing, are NICE recommended. 
They are also opportunistic interventions used in non-drug treatment settings with 
people who have little or no contact with drug treatment services. Winstock and 
Mitcheson recommend brief interventions for the majority of NPS users, whose use 
would be in the lower severity range. Provision of brief advice and information and 
brief interventions is also commonly recommended for risky drinking and alcohol use 
problems.7,8,21
Lower-intensity PSIs (brief advice and information, and brief interventions) may be 
carried out by health professionals outside of the substance misuse treatment field 
who have identified problematic substance use in the course of a consultation for 
another problem or after routine or opportunistic screening. Lower-intensity PSIs 
may take no longer than a few minutes, perhaps forming part of a wider conversation 
about a health problem. Typically, lower-intensity PSIs for substance use involve:
•	identification of substance use (and any related problems);
•	personalised feedback;
•	the offer of information on how changes might be made if the service user decides 
to take up the advice. 
Table 2.2. Minimum recommended levels of PSI in settings dealing with NPS use
Setting Minimum level of PSI
General practice Availability of brief advice and information
Emergency department Availability of brief advice and information
Sexual health services Availability of brief advice and information plus brief intervention
HIV services Availability of brief advice and information plus brief intervention
Mental health services 
(including primary and 
secondary care psycho-
logical therapy services)
Availability of brief advice and information plus brief intervention
(Some services may have ‘dual diagnosis workers’ with additional 
competences to provide structured drug treatment)
Drug treatment services Availability of brief advice and information, brief intervention, 
struc tured drug treatment, formal psychological therapy, facilitated 
access to mutual aid. Access to assessment for residential drug 
treatment
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The information may include a short information leaflet or reference to reliable 
internet resources. Lower-intensity PSIs can be effective at reducing the risks and 
harms associated with substance use.4 The user’s desired outcome is more likely to 
be a reduction in drug-related harms than abstinence. Lower-intensity PSIs are more 
likely to be effective when users perceive they have a problem (or reason to change) 
and believe that they can make a change. 
All health professionals should already have the competences required to deliver 
brief advice and information. Clinicians could adopt a key element of motivational 
interviewing, which has a very strong evidence base for its effectiveness as substance 
use intervention, known as the ‘elicit, provide, elicit’ strategy (see Figure 2.2).22
Box 2.2. FRAMES: a framework for brief interventions
Identification of NPS use (and any related problems) followed by:
F Feedback on personal risk – from screening, medical tests or clinical interview give 
personalised feedback on the person’s current and likely substance-related problems
R Responsibility and choice – emphasise the service user’s responsibility for and choice in 
making any changes
A Advice to change – give clear advice to change substance use
M Menu of options – offer a variety of strategies or options
E Empathy – a warm, reflective and understanding style of delivering brief intervention is more 
effective
S Self-efficacy and optimism – build confidence by affirming what the service user has already 
done or some aspect of strength
Figure 2.2. A framework for brief advice and information
Identification of NPS use (and any related problems) followed by:
•Ask permission to give information 
• Explore service user's prior knowledge 
• Check if interested in possible information Elicit  
• Provide relevant information 
in a neutral manner
 Provide
• Elicit service user's view or interest
in the information provided  Elicit  
Brief interventions offer structured advice on behaviour change in the context of a 
warm, reflective, empathic and collaborative approach by the practitioner. While this, 
too, is likely to require no more than the competences expected of any healthcare 
professional, a commonly used structure for BI across the substance misuse field is 
FRAMES (Box 2.2).23
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Box 2.3. Example of a brief intervention based on the FRAMES model
Health worker (HW): All the tests we’ve run are fine and I’m happy for you to go now. I’ve got a few 
minutes; before you go, would you want to know some more about how to perhaps avoid something like 
this in the future? (Asking permission)
Service user (SU): Yes, okay, if you like.
HW: You mentioned to me earlier you were using G [GBL] pretty much every weekend of late? Did I get 
that right? (Brief history)
SU: Yeah, every weekend for a couple of months now, more often than it used to be.
HW: What would a typical weekend be like? (Open-ended question/brief history)
SU: Can vary. Depends who I’m with and what we are doing.
HW: This weekend – tell me, if you will, about this weekend. (Open-ended question)
SU: This weekend was a pretty big one: it was my friend’s birthday. We were partying then clubbing, then 
we hooked up with a few other guys and went on to another club.
HW: So you came here to A&E early this morning, Sunday. When did you start?
SU: Early Saturday night, at a friend’s place. We had a few drinks then started with a couple of cap-fulls, 
then just before we all left for the club we had a few more. I guess before we left I’d had about four or five 
cap-fulls and a few vodkas, not so much by that stage as I knew it was going to be a long night.
HW: You were thinking ahead, pacing yourself. Good for you. (Affirmation)
SU: Then at the club we were having a cap-full in water every so often; we were there till about 3am so 
probably I’d have had another four. We left there and went on to another club with these other three guys 
we met. There was a lot of it going around between us there; I don’t know really how much I had. We 
started taking their stuff as we’d run out. Then five or six of us went to this guy’s flat. I think the idea was 
… was, it would be a, you know, party. There was other stuff too like crystal meth, these guys were taking 
but I wasn’t keen – I’ve had a couple of bad times with that before.
HW: So you’ve had a bad time with crystal meth before; now you’re keeping away from it. That’s good to 
hear. (Affirmation)
SU: That’s where we had some more G and some more vodka. And then, I don’t really know, then I was 
with the ambulance crew. 
HW: So from what you’ve said it sounds like your use of G has been pretty regular over the last few 
months and maybe increasing. This weekend was a big one, as you say. It’s likely the increasing amount 
and the combination with alcohol led to you being unconscious. It’s good your friends called an 
ambulance to get you here. (Feedback)
You mentioned you are staying away from crystal meth because of some problems you’d had. Would 
you be interested to hear about the kinds of problems we see with G use like you’ve described? (Asking 
permission)
SU: Well I thought I was pretty clued up, but maybe I should.
HW: With G one of the big problems, even for experienced users, is that it can only need a very small 
amount, one or two more mils, before someone is overdosed. Even more of an issue if you’re not entirely 
sure how strong the stuff you’re taking is. Overdose is linked to vomiting, seizures, disorientation, memory 
loss, agitation, mood swings and collapse – at more severe levels being unconscious and coma. The other 
feature of G is its potential for dependence, when taking it regularly turns into not being able to go 
without, taking it daily even throughout the day. Once dependent, stopping can be pretty difficult and in 
some cases stopping suddenly can lead to serious medical emergencies. (Feedback)
It’s of course up to you what you do with this kind of information, I’m just letting you know how your 
current pattern of G use might be linked to some health risks or problems that could develop. (Responsi-
bility)
SU: I knew a fair bit of that, but some of it, like getting dependent, would concern me. I don’t think I’m 
getting there yet though.
HW: No, you’re right, it sounds like you can still keep your use to the weekends. The best way you can 
avoid something like getting dependent and some of the other problems would be to cut down or stop 
your use. (Advice)
In terms of being safer, stopping using G would be the safest option. If that doesn’t feel like something 
you could do just now, not mixing with alcohol would make problems like the ones that brought you 
here less likely. If you do use, using less and knowing how much you’re using would help. Some guys use 
something to measure their G, like a pipet. Its good that you use with friends and you take care of each 
other if needed. (Menu of options)
SU: I’m not sure stopping is what I want right now, but I’d already been a bit concerned about using so 
often.
HW: You could try having some weekends not using? It sounds like that’s something you’ve managed 
before. Plus you said how you’d made previous changes like with crystal meth. (Self-efficacy)
SU: Yes and I’ve got friends who don’t use G and stuff and I’ve not been spending much time with them 
lately, which isn’t what I want.
HW: Is there anything more you’d like me to help with? I have the details of a website that has the 
information I just spoke about if you’d like it? I’ll leave you this card with the details of a local service 
just in case you want some more expert help. I’ve heard good things about them and helping guys with 
problems with G.
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Recommendations from alcohol treatment suggest that simple BI can be enhanced 
by including goal-setting (e.g. start date and daily or weekly limits of use), written 
self-help materials for the service user to take away (this may contain more detailed 
information on consequences of substance use and tips on cutting down) and 
arrangements for follow-up monitoring.24
The World Health Organization has developed a manual on brief interventions 
in substance misuse for primary care.25 The manual draws on components of 
motivational interviewing and the FRAMES model. Although the manual was not 
developed for, or tested with, NPS specifically, it does cover a range of substances, 
including  amphetamine-type stimulants. The manual provides clear information on 
how to deliver brief interventions.
An example of a brief intervention based on the FRAMES model is given in Box 2.3. 
Recommendation It is recommended that health professionals who, in the course 
of contact with service users, identify ‘lower severity’ NPS use, offer brief advice and 
information or a brief intervention, following a recognised format, focusing on making 
changes to substance use with the aim of improving health outcomes.
2.5. Higher-intensity PSIs
2.5.1. Structured drug treatment
Structured drug treatment comprises two or more treatment sessions, each lasting 
half an hour or longer, applying a single or range of psychosocial approaches, 
commonly including motivational interviewing. Structured drug treatment may 
range from an extended form of brief intervention, sometimes known as extended 
brief intervention,21 to a more ongoing regular set of treatment sessions. Structured 
drug treatment of any duration includes the setting and evaluation of specific goal(s) 
relating to a change in substance use. 
Structured drug treatment should follow from a more comprehensive assessment 
of needs and resources that has led to intervention based on a care plan.24 More 
advanced competences, of accreditation standard, in these approaches will be 
required for effective delivery, along with supervision and an appropriate governance 
framework.8 Structured drug treatment may be delivered as individual psychological 
therapy or as group-based interventions.
There is evidence that the outcomes of drug treatment (all drug treatment, not only 
PSIs) can be enhanced with the use of mapping tools.26 Mapping tools are not in 
themselves a psychosocial intervention but a vehicle that can enhance the effective 
delivery of treatment. Mapping tools employ a structure known as ‘node link mapping’ 
to visually convey key elements for a structured conversation derived from evidence-
based PSIs. For more detailed information and examples of mapping tools for drug 
treatment see Routes to Recovery via the Community.27 
The most relevant research findings relate to PSIs for various forms of stimulant 
use. Knapp et al., in a Cochrane review, report that interventions based on cognitive 
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behavioural, contingency management and community reinforcement approaches 
appear to be the most effective.10 Knapp et al. argue that a comprehensive treatment 
package drawing on these three models may be required for better outcomes, given 
the multidimensional nature of stimulant dependence. They further argue that for 
sustained outcomes, treatment needs to support service users to make effective 
changes to their lives, including abstinence from stimulant use, the ability to work 
and the ability to maintain successful relationships. A focus on narrow, short-term 
goals such as reductions in amount or frequency of use is of little benefit in achieving 
sustained change.10
Recommendation It is recommended that structured drug treatment is offered 
to service users with ‘higher severity’ problems relating to NPS use. Structured 
drug treatment will be based on an assessment of needs and strengths and on a 
care plan which is reviewed regularly. The intervention will draw on evidence-based 
psychosocial approaches and is likely to include motivational interviewing.9 As 
a minimum, structured drug treatment should include: goal setting and planning, 
feedback and monitoring, and developing social support.6 The largest amount of 
reported evidence for structured drug treatment is for cognitive-behavioural therapy 
(CBT), contingency management (CM) and the community reinforcement approach 
(CRA).10 Specific competences to deliver such interventions, supervision and an 
appropriate governance framework are required.
2.5.2. Formal psychological treatment
Formal psychological treatment is likely to be effective for people with higher-sever-
ity and dependent NPS use. Formal psychological treatment is particularly relevant 
where a service user has a co-occurring common mental health problem4 or other 
psychological problems. Formal psychological treatment usually consists of a planned, 
time-limited series of sessions. The intervention will be grounded in a psychologi-
cal formulation, derived from a process of assessment and evaluated using formal 
or informal outcome measures. The competences required to deliver this intensity 
of intervention will be more advanced – of professional registration standard – and 
a governance and supervision structure will be needed.28 Formal psychological 
treatment may be delivered as individual therapy or as a group-based intervention. It 
is likely to draw on one or more of the evidence-based psychological therapy models 
listed below and may be combined with other evidence-based interventions for psy-
chological problems. 
The aims of formal psychological treatment are likely to be a combination of changes: 
to the substance use, to the psychological problems, but also in related domains (e.g. 
health, social functioning, criminal justice).
There are high levels of co-occurring mental health problems in drug treatment 
populations20 and it can be assumed this would be similar for dependent users of NPS. 
Some NPS users may have other co-occurring psychological difficulties; for example, 
there are reports of problematic NPS use associated with psycho-sexual problems.
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Treatment services need to be able to screen, assess and provide treatment for these 
co-occurring difficulties. 
Whilst NICE4 recommends CBT to treat co-occurring mental health problems, the 
complexity of the presenting psychological difficulties may limit the impact of these 
approaches. Other approaches may be required for psycho-sexual problems.
For patients with complex needs, formal psychological treatment may be 
complemented by a formulation-based approach.28
A psychological formulation is a hypothesis about a person’s difficulties and integrates 
a broad range of biopsychosocial causal factors which link theory with practice to 
guide the intervention. It is individually determined and may draw upon a range of 
psychological models to achieve an effective treatment plan. 
A psychological formulation can integrate both the substance use behaviour and 
the co-occurring mental distress in a way that seeks to reveal the function of the 
substance use for the service user. It can also include consideration of other psycho-
logical and behavioural factors, such as sexual behaviour.
A formulation-based approach can incorporate personal meaning and be constructed 
collaboratively with service users and their care teams. 
Some key features of a formulation are that it: 
•	summarises the service user’s core problems;
•	suggests how the service user’s difficulties may relate to one another, by drawing 
on psychological theories and principles;
•	aims to explain, on the basis of psychological theory, the development and 
maintenance of the service user’s difficulties, at this time and in these situations;
•	indicates a plan of intervention which is based in the psychological processes and 
principles identified;
•	is open to revision and reformulation.
A distinguishing characteristic of psychological formulation is its multiple-model 
perspective – it integrates theory and evidence from a range of psychological models 
as well as biological, social/societal and cultural domains. 
The incorporation of this multiple-model perspective may have particular value in 
working with service users from marginalised and stigmatised populations, as it 
explicitly incorporates culture-specific issues. 
For example, a recent report29 describes the association of NPS use and sexual 
behaviours, often referred to as ‘chemsex’. As detailed in Part III of this publication, 
contemporary research has highlighted the frequent use of NPS by men who have sex 
with men (MSM) in the context of sex. A proportion of this behaviour has also been 
linked to drug-related and sex-related harms. Sex under the influence or intoxication of 
substances with the potential for associated harm is by no means a new phenomenon, 
however. 
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Bourne et al.29 suggest some NPS offer a specific range of psychological and physical 
sex-enhancing effects. Where sex and NPS use have, over time, become powerfully 
associated for an individual who has developed problems, a combined approach 
to treatment is likely to be required. With a theoretically grounded psychological 
formulation identifying motivations, meanings and values associated with sexualised 
drug use, individualised for that service user, a psychological formulation is a basis 
for a proposed psychological intervention, drawing on evidence-based models of 
psychological therapy. A small number of studies in the US have looked at the impact 
of psychological interventions on condom-less sex among methamphetamine-using 
MSM. Combined cognitive behavioural and CM interventions have shown a positive 
impact on changing drug use and sexual behaviours among this population.30,31 
Working with the same population, however, Rajasingham et al.32 suggest that CM fails 
to address service users’ mental health needs or to develop post-intervention relapse 
prevention plans. A review of three randomised controlled trials (RCTs) examining the 
outcomes of CBT interventions and HIV risk behaviours among substance-misusing 
MSM found that while CBT did reduce unprotected anal intercourse in this group, 
it was unclear whether CBT was more effective than less intensive interventions or 
mere assessment.33
Recommendation It is recommended that formal psychological therapy is offered 
to people with higher-severity and dependent NPS use, and in particular those with 
co-occurring psychological problems. Formal psychological therapy is derived from a 
comprehensive assessment, based on a psychological formulation and informed by 
one or more evidence-based psychological therapy models.
Recommendation It is recommended that higher-intensity PSIs (structured drug 
treatment and/or formal psychological therapy) are offered to service users where 
medically assisted detoxification is part of the recommended treatment. Unless 
de toxification is undertaken as an emergency, higher-intensity PSIs, including 
motivational interviewing, should be offered before detoxification. Following de-
toxification, it is essential that higher-intensity PSIs, typically including a relapse 
prevention model, is offered. Service users completing detoxification may also benefit 
from formal psychological therapy for any co-occurring psychological problems such 
as common mental health problems or psycho-sexual problems.
2.6. Residential psychosocial treatment
Residential treatment is defined by the controlled environment where treatment takes 
place. It generally involves one or more evidence-based high-intensity psychological 
interventions and requires the same level of competence and governance as the 
higher-intensity PSIs described in section 2.5. Residential treatment may be preceded 
by medically assisted detoxification for safe withdrawal from specific substances (see 
section 1.8). 
Service users live within the treatment service (or very nearby) for the duration of 
the treatment. Residential treatment is considered a more intense form of treatment, 
often requiring several hours per day of treatment engagement over a minimum 
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period of typically 12 weeks. The location of the treatment service is generally a 
distance away from the service user’s usual home. Residential treatment is recognised 
as an important option; however, there is debate around the precise indications for 
its use and the evidence base is currently far from clear. Almost without exception, 
the explicit aim of residential treatment is long-term or lifetime abstinence from all 
substances. Residential treatment is therefore not appropriate for people who are 
not prepared for this treatment aim. 
Broadly, the indications for residential treatment are:
•	multiple co-existing psychological, physical and/or social problems;
•	poly-drug dependence;
•	optimised community treatment has not been effective
•	the service user has a treatment goal of long-term abstinence.4
Recommendation It is recommended that service users with significant physical, 
psychological and/or social problems associated with NPS dependence (or use of high 
severity), who are aiming for long-term abstinence and who have been unable to 
achieve this in effective community treatment (or who would be highly unlikely to be 
able to do so), have access to residential treatment, including, where necessary, prior 
medically assisted detoxification. On successful completion of residential treatment, 
relapse prevention support should be offered to help service users maintain changes. 
Service users who leave residential treatment before its completion should be 
promptly offered support to minimise any return to substance use and minimise the 
risk of overdose.
2.7. Mutual aid
There is a long tradition of mutual aid in the substance misuse field. Perhaps the 
best-known are Alcoholic Anonymous (AA) and Narcotic Anonymous (NA), sometimes 
known as 12-step groups. More recently other forms of mutual aid have been 
developed, including SMART groups where the approach is derived from CBT. There is 
a strong evidence base for the outcomes from mutual aid (the research has primarily 
been with 12-step groups).34 
Mutual aid is not a professionally delivered treatment. There is, though, evidence of 
the benefit of health professionals proactively supporting service users’ engagement 
with mutual aid, often referred to as facilitating access to mutual aid (FAMA); therefore 
NICE recommends that services routinely provide information on the benefits of 
mutual aid to service users with higher severity and dependent substance use 
problems.4,7 Public Health England has produced a guide to FAMA.35 In some of the 
major UK cities there are specific 12-step groups primarily attended by people with 
current or former problems with some NPS or club drugs such as methamphetamine.
Recommendation It is recommended that service users with higher-severity and 
dependent NPS use are routinely offered information about mutual aid. This includes 
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service users completing residential treatment. Where service users show an interest 
in engaging with mutual aid, it is recommended that additional support along the 
lines of facilitated access is offered. Mutual aid as a treatment option should be 
revisited periodically where desired outcomes have not been achieved.
2.8. Models for specific 
psychosocial approaches
Higher-intensity PSIs for the treatment of substance misuse problems, in the form of 
structured drug treatment, formal psychological therapy and many of the approaches 
used in residential treatment, are derived from specific psychological therapy models. 
The main evidence-based models are described only briefly here, but references are 
given to sources of more detailed information and to treatment manuals.
2.8.1. Motivational Interviewing
Ambivalence about changing substance use behaviour is common, perhaps the 
norm, even for people actively seeking treatment. Motivational interviewing as an 
approach offers a framework for helping people resolve ambivalence to changes 
to their substance use. Motivational interviewing and its more manualised variant 
motivational enhancement therapy (MET) have a robust evidence base across a wide 
range of substances.4,7 The use of motivational interviewing is likely to be a part of 
brief interventions and the early part of structured treatment. A framework for the 
delivery of competence-based motivational interviewing is described in Routes to 
Recovery: Psychosocial Interventions for Drug Misuse.13
2.8.2. Network and environmental therapies
Network and environmental therapies are a range of psychological approaches 
which seek to utilise social contextual reinforcers to promote and sustain change 
in substance use. This often involves enlisting the support of (non-using) partners, 
families or peers. Behavioural couples therapy (BCT) is recommended by NICE for 
the treatment of drug misuse.4,7 Notably, there is specific evidence for BCT with 
lesbian and gay service users in the treatment of alcohol problems.36 Network and 
environmental therapies are recommended for the treatment of alcohol problems.4,7 
The widely recognised importance of social support in achieving positive outcomes 
for drug problems is reflected in the recommendations made by NICE in Behaviour 
Change: Individual Approaches.6 
Variants of network and environmental therapies with specific recognition in the 
treatment of substance misuse are social behaviour network therapy (SBNT), the 
community reinforcement approach (CRA) and behaviour couples therapy (BCT). On 
SBNT, see Copello et al.37; on CRA see Miller et al.38; on BCT see O’Farrell and Fals-
Stewart.39
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2.8.3. CBT-based relapse prevention
Relapse prevention (RP) is a commonly used psychological approach in substance 
misuse treatment11 and is recommended for the treatment of alcohol problems.4,7 
However, CBT focused only on drug misuse was not recommended in the NICE guidance 
on drug misuse.4 RP aims to help people make and sustain changes to substance 
misuse through the identification of thinking and behavioural patterns that typically 
precede an individual’s substance use. RP is considered particularly relevant in helping 
people sustain changes to substance misuse once they have achieved them, including 
following medically assisted detoxification, a phase of treatment often referred to as 
aftercare. For a description of CBT-based RP models, see Marlatt and Donovan40 and 
Mitcheson et al.12
Inevitably, innovative developments may take time to be included in high-level 
meta-analyses. It is worth noting the current attention to what are often referred 
to as ‘third-wave CBT models’. These contemporary developments include 
 mindfulness-based interventions (MBIs), acceptance and commitment therapy (ACT) 
and dialectical behaviour therapy (DBT). In a systematic review of evidence, Chiesa 
and Serretti report that MBIs can reduce the use of a range of substances, including 
stimulant drugs.41 Zgierska and Marcus42 note that the combined findings of early 
studies of MBIs suggest these may be efficacious for substance misuse problems. Of 
note, Smout et al.43 conducted a preliminary RCT of ACT for methamphetamine use 
disorders. While it had no advantage over CBT, Smout et al. describe it as a viable 
intervention for this population. Zgierska and Marcus note the strength of positive 
evidence for MBIs with common mental health problems and conclude that they are 
therefore of value for service users with co-occurring substance misuse and mental 
health problems.42
2.8.4. Contingency management
Contingency management has a strong evidence base from numerous research 
trials, carried out primarily in the US, focusing on stimulant use. UK programmes 
are currently uncommon outside RCTs. CM is one of the psychological interventions 
recommended for the treatment of drug misuse by NICE.4 CM is used to reduce 
substance use by the provision of tangible (often monetary or material) rewards for 
the achievement of verifiable behavioural goals, such as negative biological drug 
screen tests. A framework for the delivery of CM is described in Routes to Recovery: 
Psychosocial Interventions for Drug Misuse.13
2.8.5. Psychodynamic therapy
There is no specific literature on the evidence for psychodynamic therapies for the 
treatment of NPS problems. NICE4 did not recommend psychodynamic therapy 
focused on the treatment of drug misuse for people who misuse cannabis or 
stimulants or those receiving opioid maintenance treatment. National Treatment 
Agency for Substance Misuse11 reported one study (of limited strength) where court-
enforced counselling resulted in reduced cocaine use.44
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depressants 
Depressants (also known as sedatives) are drugs that lower neurotransmission levels. 
They activate  GABA or opioid receptors, and inhibit glutamatergic or catecholamin-
ergic activity. As  central nervous system (CNS) depressants, their use can decrease 
the rate of breathing, decrease heart rate and lead to loss of consciousness, and even 
coma or death. Taking large or frequent doses can lead to dependence.
A few CNS depressants are used within a club drug context. Generally, depressant 
drugs appear to increase sociability and enhance mood. Some depressant drugs, such 
as GHB/GBL and alcohol, also release noradrenaline, so some of their effects may 
appear to be like those of a stimulant. 
Not all drugs with essentially sedative effects are easy to classify. For example, 
although ketamine is predominantly a sedative drug, inasmuch as it blocks glutamate, 
its subjective effects have been described as hallucinogenic,  as it distorts perceptions 
of time and space. Ketamine and its analogues are the subject of Chapter 4.
Sedative and depressant drugs used in a club 
drug-context: inclusions and exclusions
Part II focuses on depressant/sedative drugs most commonly used within a club-drug 
context in the UK, namely GHB and its precursor GBL, ketamine and its derivatives, 
and nitrous oxide. 
A number of other new CNS depressants are available, which can be broadly 
categorised as opiates and benzodiazepines. While these substances can be bought 
online through sites that sell club drugs and NPS, they are outside the remit of this 
document and guidance as they are not used as ‘club drugs’ and there is extensive 
experience in the UK in the management of opiate- and benzodiazepine-related acute 
and chronic harms.  The newly developed opioid receptor agonists include AH-7921, 
which has analgesic potency similar to that of morphine, and 1-phenylethylpiperi-
dylidene-2-(4-chlorophenyl)sulphonamide (W-15), a potent opiate agonist with a 
distinctive chemical structure that is not closely related to other established families 
of opioid drugs. So-called ‘designer benzodiazepines’ newly available online include 
diclazepam, phenazepam and nimetazepam (referred to as Happy 5s). Like other new 
drugs, their potency is unknown and it is not clear why they have been developed, 
given the profusion of benzodiazepines available. There is some anecdotal evidence 
from clinical practice that new benzodiazepines like diclazepam are used to help the 
‘come-down’ from stimulants in particular.
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Chapter 3
Gamma-hydroxybutyrate (GHB) and 
gamma-butyrolactone (GBL) 
Drug group: depressants
This chapter discusses GHB (gamma-hydroxybutyrate) and its precursor GBL (gamma- 
butyrolactone). Another precursor of GHB, 1,4-BD (1,4-butanediol), has not been 
widely available in recent times, but is mentioned in the literature. In the UK, GBL is 
used more than the other two. 
3.1. Street names
Street names at the time of publication include G, GHB, GBL, Gina, liquid E, liquid 
ecstasy, liquid X, Gamma-O, Blue Verve, Gobbe, Charisma. Other street names are 
used in particular localities. 
3.2. Legal status
GHB, GBL and 1,4-BD are controlled in the UK as Class C Scedule 2 drugs under the 
Misuse of Drugs Act 1971. However, GBL and 1,4-BD are controlled under that Act 
only when supplied or possessed with the intention for human consumption, but not 
when available for legitimate use in industry (see section 3.5).
3.3. Quality of the research evidence 
The international evidence on the management of the acute and chronic harms 
related to the use of GHB and GBL is limited; randomised control trials in particular are 
not available. Evidence mainly consists of case reports and series and a small number 
of prospective observational studies, retrospective cohort studies and analysis 
of patient records. Despite these limitations, data/evidence from these sources is 
relatively consistent.
3.4. Brief summary of pharmacology
GHB acts primarily as a CNS depressant but at low doses can also produce euphoric 
effects and effects that appear to be like those of stimulants. GHB is both a metabolite 
and a precursor of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) 
GHB and GBL 50
N
E
P
T
U
N
E
and acts as a neuromodulator in the GABA system, acting on both GABA-B and its 
own so-called GHB receptors. GBL and 1,4-BD are converted into GHB after they are 
absorbed.1 
A number of studies have looked at GHB pharmacokinetics in healthy volunteers.2–6 
GHB is absorbed rapidly, is extensively metabolised to carbon dioxide and rapidly 
eliminated,7 mainly through the lungs (less than 5% is excreted in the urine as GHB, 
although this may be greater in overdose). It has a half-life of only 20–30 minutes.8 
The effects of GHB usually occur 15–20 minutes after ingestion and can last for up 
to three to four hours,9 with peak effects at 30–60 minutes after ingestion.8 It is 
undetectable in urine after approximately 12 hours.10 
GBL is a precursor of GHB and is non-enzymatically converted in the body into 
GHB. GBL is absorbed more rapidly than GHB and potentially has a faster onset of 
action. Its duration of action may also be longer.10 Some users report that GBL is 
more potent than GHB. 1,4-BD is another precursor to GHB; it is converted in the 
liver through a two-step conversion, via hepatic alcohol dehydrogenase to gamma-
hydroxy butyr aldehyde followed by metabolism into GHB via hepatic acetaldehyde 
dehydrogenase.11,12 Animal studies have shown that both ethanol and fomepizole 
competitively block the metabolism of 1,4-BD to GHB.13,14 
GHB (and therefore GBL and 1,4-BD) has a steep dose–response curve and narrow 
therapeutic threshold. It can readily cross both the placenta and the blood–brain 
barrier, leading to profound CNS and respiratory depression.8,9 Daily use of GHB/GBL 
can lead to dependence and the possibility of withdrawal syndrome on cessation of 
use, which can be severe, with agitation and delirium. Acute GHB/GBL toxicity and 
acute withdrawal can be life threatening.
3.5. Clinical and other uses 
Clinical uses of GHB have included alcohol and opiate detoxification regimens, 
anti-craving medication after alcohol detoxification,9 and as an anaesthetic agent in 
some European countries (although this latter use is now declining). The sodium salt 
of GHB, sodium oxybate (Xyrem SPC), is approved for the treatment of narcolepsy 
with problematic catalepsy in specialist sleep centres the US and Europe.*
GHB was sold in US health food stores for weight control and sedation, until the 
over-the-counter sales were banned in 1990, following reports of acute intoxication.15 
It has also been sold for its antidepressant and anxiolytic effects and for its 
 cholesterol-lowering effects. It has also been used in bodybuilding, as it has been 
thought to release growth hormone; however, its anabolic effects are unproven.16 
GHB has been implicated as a facilitator in ‘date rape’, although a systematic review 
of the inter national evidence suggests that it is rarely identified in cases of drug-
facilitated sexual assaults.17 
* See http://www.medicinescomplete.com/mc/bnf/current/PHP2146-sodium-oxybate.htm;  
http://www.medicines.org.uk/emc/medicine/17364/SPC/Xyrem+500+mg+ml+oral+solution;  
http://www.ukmi.nhs.uk/NewMaterial/html/docs/SodiumOxybateNMP0603.pdf;  
as well as the manufacturer’s website, http://www.xyrem.com/images/Xyrem_Med_Guide.pdf.
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GBL and 1,4-BD are used extensively by the chemical industry as precursors for the 
synthesis of plastics and industrial solvents. They are found in floor-cleaning products, 
nail polish (previously nail polish removers) and superglue removers.
3.6. Prevalence and patterns of use
At a population level, the use of GHB/GBL in the UK is low and appears to be 
concentrated among some sub-groups, often in specific contexts. Despite low levels 
of use, its health costs are relatively high compared with other drugs,18 and other club 
drugs in particular, because of its intrinsic toxicity and potentially life-threatening 
withdrawal syndrome as discussed in section 3.12.2.
Questions regarding GHB/GBL use were added to the Crime Survey for England 
and Wales (CSEW; formerly the British Crime Survey) in October 2009 in response 
to concerns about its use. Overall, data from the CSEW show that the use of GHB/
GBL in England and Wales remains low, although there was a statistically significant 
increase in its use by adults aged between 16 and 59 years, from 0.0% in 2010/11 to 
0.1% in 2011/12. The 2010/11 survey showed that GHB/GBL was more likely to have 
been used in the past year by the 16–24-year age group (0.1%) than in the age group 
25–59 years (0.0%).19 Questions about the use of GHB/GBL were not included in the 
2012/13 or 2013/14 surveys. No data on GHB/GBL use in Scotland are available, but it 
is believed that the prevalence is low, as suggested by police seizure data for Scotland 
2010–11.20
There is evidence that GHB/GBL is often used as part of a wider poly-drug repertoire 
(see section 3.10.2). An internet survey of 189 GHB/GBL users reported that a third 
had taken GHB/GBL during the last month and two-thirds reported mixing GHB/
GBL with other drugs.21 Available data suggest that GHB/GBL users tend to be a well 
educated and well functioning group.22,23 
GHB/GBL use is concentrated among some sub-groups and in particular settings and 
geographical areas. A number of European surveys conducted in dance music venues 
and other targeted settings suggest that the lifetime prevalence of use of GHB/GBL 
ranges from 3% to 19%.18
The Global Drug Survey 2012 reported that among UK respondents (69.7% male 
and 82.7% heterosexual) ‘regular clubbers’ used GBL and GHB more than other 
respondents (Table 3.1).24
Table 3.1. Use of GBL and GHB among UK respondents in the 2012 Global Drug 
Survey
Lifetime use Use in past 12 months Use in the past 12 months by 
regular clubbers
GBL 7.7% 1.6% 2.5%
GHB 3.8% 1.5% 2.0%
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In the UK, mainland Europe, the US and Australia, GHB/GBL use is particularly 
concentrated among gay men and other MSM, particularly those who frequent night 
clubs.18,21,22,25–28 The 2007 UK Gay Men’s Survey of 6155 men suggested that almost 
13% had ever used GHB or GBL and 7% have used it in the last year.29 GHB/GBL use 
is highest among attenders of gay clubs.29 A survey carried out in 2010 in London 
gay nightclubs suggested there were higher levels of use of GHB/GBL than the study 
mentioned above, with 34% reporting lifetime GHB use (22% past-year use and 14% 
past-month use) and 27% reporting GBL lifetime use (24% past-year use and 19% 
past-month use). On the night of the survey, 7% reported having taken or planning 
to use GHB, and 14% reported already having taken or planning to take GBL on the 
night.27
Although its use has been mainly reported in cities, there is one report of a GHB-related 
hospital acute presentation in rural Wales.30
Due to its pro-sexual effects and muscle relaxant properties, GHB/GBL is often used 
by MSM in a sexual context. It is one of the drugs commonly implicated in ‘chemsex’ 
(see section 1.6.4.2.) and may be associated with high-risk sexual behaviour and thus 
with an increased risk of sexually transmitted infections. Studies in both the US and 
the UK have shown that GHB/GBL use is associated with increased sexual risk, with 
HIV-positive men more likely to use GHB/GBL and more likely to use it in a sexual 
context,28,31,32 than those not known to be infected.29
GHB/GBL is often taken with other drugs, including alcohol, cannabis, ecstasy, 
stimulants and sildenafil (Viagra).22,23 The setting for GHB/GBL use is typically 
nightclubs, circuit parties, sex parties, saunas and sex clubs,28 although some evidence 
suggests that GHB/GBL is used in private settings as well.21 The setting in which the 
drug is consumed may be linked to risk, as one study has shown that people who 
commonly use GHB/GBL in club settings are more likely to report problems than 
those who usually use it at home.21
3.7. Routes of ingestion and 
frequency of dosing 
The routes of administration of GHB/GBL include:
•	oral use (this route is the most common, when it is typically diluted in a beverage); 
•	insufflation;
•	injection (though this is rare);
•	mucosal (e.g. previously from absorption of nail polish removal pads).
GHB/GBL used for recreational purposes is most usually sold in the form of a liquid 
formulation, often in bottles or vials. Its taste is described as unpleasant and salty 
and is it therefore typically diluted in a beverage. It is more rarely used as powder, 
usually GHB sodium salt (capsules or loose) or a waxy substance to which water can 
be added.18 The ‘irritant’ nature of GHB/GBL has been described, with a case report of 
a user syringing the liquid into capsules to make it easier to swallow.33
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GBL for recreational use in the UK is usually bought from street dealers or via the 
internet in amounts ranging from 125 ml to 10 litres. The price of the substance 
differs by locality and over time, but a 2006 report by the Advisory Council on the 
Misuse of Drugs (ACMD) published in suggested that a 250 ml bottle of 99% pure 
GBL could be bought for £20, which amounts to 8p per recreational dose.1 According 
to anecdotal reports from users at the time of writing (2014), a litre costs £80–£100.
Usually, 1 ml of liquid contains 1 g of GHB, although purity and concentration may 
vary;18,34–36 data for 1,4-BD are limited. Miotto et al. suggest that single doses of GHB 
can range from 0.5 g to 5 g and those who develop tolerance and dependence will use 
in the range of more than 25 g per day.34 GBL is far more lipophilic than GHB; hence, 
typical ingested dosages of GBL (1.5 in a single dose) are lower than those of GHB 
(with an average single dose ranging from 1 g to 5 g).37,38
GHB/GBL dose is often measured by users in imprecise ‘capfuls’, teaspoons, eye 
droppers or vials. This imprecise dose measurement is one of the main suggested 
causes of the acute GHB/GBL-related harms, as users risk overdose because of its 
steep dose–response curve.
Recreational users will typically use small doses frequently, in the context of binges, 
or sometimes at night to assist with sleep. Dependent users will ingest GHB/GBL 
frequently and at regular intervals over prolonged periods. They will generally use 
multiple daily doses, including at night.34 The mean frequency of dosing in cases of 
dependence was reported by McDonough et al. to be every 4.4 hours,39 although with 
case reports and series showing a wide range, from hourly to daily.35,40,41
3.8. Desired effects of GHB/
GBL for recreational use
GHB/GBL affects people in different ways and a euphoric dose for one person may be 
a sedative dose for another.42 GHB/GBL tends to produce euphoric and pleasurable 
effects43 without hangover or other subacute adverse effects, which helps popularise 
it as a ‘club drug’.1 
The desired effects of GHB/GBL include euphoria, relaxation, increased sociability, dis-
inhibition, confidence boost, social and sexual disinhibition, enhanced libido, increased 
sexual arousal and enhancement of sexual encounters, with effects being dose-
dependent.8,18,44–46 The use of GHB/GBL for its stimulant, dissociative and sedating 
effects have also been reported.34,47,48 In addition, some individuals use GHB/GBL after 
using other drugs (generally stimulants), to help ‘come down’22 or to enhance and 
modify the effects of drugs34 such as stimulants. 
GHB/GBL is also used as self-medication for sleep problems and anxiety. There are 
reports of people using GHB/GBL in the hope that it will improve cognitive ability, 
reduce the effects of ageing, reduce depression and anxiety, or make them feel more 
energised and dance more joyously.49 
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3.9. Mortality
Acute GHB/GBL toxicity and a severe withdrawal syndrome have been associated 
with fatalities. According to the Office for National Statistics, there were 20 deaths in 
England and Wales in 2011 where GHB/GBL was mentioned on the death certificate, 
13 such deaths in 2012, and 18 in 2013.50
The National Programme on Substance Abuse Deaths (NPSAD) database from 1995 
to 2006 identified 47 cases in the UK where GHB or GBL was found post-mortem and/
or implicated in death.1 In 2012, NPSAD reported a total of 17 such deaths for the 
whole of the UK. There was a slight increase from the previous years in the number 
of GHB/GBL-related deaths in England, with 6 deaths where no substance other 
than GHB/GBL was implicated, and 11 deaths where GHB/GBL was detected with or 
without another substance.51 
In Scotland, 3 GHB/GBL-related deaths were reported with no other substances 
implicated and a total of 5 where GHB or GBL was found either on its own or with 
other drugs. The co-use of alcohol was implicated in many of these deaths.52 
3.10. Acute harms
3.10.1. Acute GHB/GBL toxicity
There are potential acute harms relating to any use of GHB/GBL, as well as dependent 
use. All GHB/GBL users risk acute toxicity and overdose; tolerance is not fully protective 
of overdose and people dependent on GHB/GBL are also at risk of acute toxicity. In 
terms of acute single-dose systemic toxicity, GHB/GBL appears to be the most physi-
ologically toxic club drug, with a safety ratio of 1053 and overdoses typically occurring 
as a concequence of using large concentrations over a short period, or when GHB/GBL 
is used in combination of other CNS depressants, such as alcohol or benzodiazepines.9
The hazard profile of GHB has been described as less favourable than that of many 
other psychoactive substances. One study concluded that GHB is the most physio-
logically hazardous drug, partly because the dosage range is narrow53 and varies 
between individuals and with whether other substances have also been used. The 
authors commented on particular harm resulting from imprecise dosing of illicit GHB 
or GBL, which cannot be easily measured.53
As mentioned above, GHB/GBL affects people in different ways and a euphoric dose for 
one person could be a sedative dose for another.42 It has been reported that adverse 
effects of GHB/GBL happen at a variety of doses, indicating the variable individual 
responses to the drug.54 GHB/GBL intoxication exists within a spectrum of severity 
and that is influenced by: dose ingested, individual variation and other substances 
ingested (discussed in more detail below). 
The effects of GHB are dose-dependent, as summarised in a recent review (Table 
3.2).8
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Table 3.2. Dose-dependent effects of GHB
Dose Effects
Below 10 mg/kg Mild clinical effects: short term anterograde amnesia, hypotonia (relaxed 
muscles) and euphoria55
20–30 mg/kg Drowsiness, sleep and myoclonus ( jerking of muscles) can happen55,56
50 mg/kg May cause coma57–59
Over 50 mg/kg May lead to the onset of coma, bradycardia (slowed hear rate) and/or 
respiratory depression and death.55,57,59
GHB/GBL has a steep dose–response curve, whereby even a small increase in dose 
can cause serious toxic effects, such as impaired consciousness and coma. This steep 
dose–response relationship differentiates GHB/GBL from other drugs. 
The usual clinical course after overdose – if other sedative hypnotics (most commonly 
alcohol) have not been used – is rapid, spontaneous awakening from drug-induced loss 
of consciousness or coma and uneventful recovery. CNS depression usually persists 
for 1 to 3 hours, with patients typically making a full recovery within 4–8 hours.54,60–62
Thus, patients with acute intoxication typically: develop signs of intoxication rapidly 
but then improve quickly.
Overdoses are common among all users – dependent users as well inexperienced, 
intermittent and regular users (tolerance and dependence do not protect against 
overdose).22 In an Australian study of 76 GHB users, half reported a history of overdose 
during which they had lost consciousness.22 In another study, 66% reported some 
degree of loss of consciousness.34 Similarly, a study of 505 consecutive GHB cases in 
emergency departments in Barcelona showed that the motive for seeking medical 
treatment in all cases was reduced consciousness.44
The use of other drugs and alcohol can increase the toxic effects of GHB and is 
discussed in section 3.10.2. In addition to the GHB-related adverse effects, the 
adulterant compounds may also have serious toxic effects.18 As with alcohol, and 
unlike with benzodiazepines, there is no antagonist or antidote.
Because of GHB’s short elimination half-life, people can progress from deep coma to 
wakefulness over about 30 minutes. A 30-month review of an Australian emergency 
department reported that if ventilation was not required, the great majority improved 
rapidly and were discharged straight from the emergency department, without a 
need for further medical treatment.63,64
In European cities, accidental GHB/GBL overdoses in night clubs account for 
a substantial proportion of drug-related emergencies that require ambulance, 
emergency or hospital services.18 A similar picture may exist in the UK, as suggested 
by a retrospective review of a clinical toxicology database of a large London inner-city 
emergency department which showed that 38% of all poisonings with drugs of 
misuse in 2006 were GHB/GBL-related. The total number of presentations was 420 
and 158 (37.6%) included the use of GHB or GBL.65
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3.10.1.1. The features of acute GHB/GBL toxicity 
The reported effects of acute GHB/GBL toxicity are summarised as follows:
•	Mild/moderate effects include nausea, hypersalivation, vomiting, diarrhoea, 
drowsiness, headache, ataxia, dizziness, confusion, amnesia, urinary incontinence, 
tremor, myoclonus, hypotonia, agitation, euphoria and hypothermia.
•	Severe effects include coma, convulsions, bradycardia, ECG abnormalities (e.g. U 
waves), hypotension (or rarely hypertension after intravenous use), Cheyne-Stokes 
respiration and respiratory depression leading to respiratory arrest. Metabolic 
acidosis has been reported. 
Laboratory investigations may also indicate hypernatraemia, hypokalaemia, hypergly-
caemia and metabolic acidosis.
GHB/GBL produces CNS and respiratory depression of relatively short duration. 
Psychotic episodes may occur. It has also been suggested that GHB/GBL intoxication 
should be considered a differential diagnosis for patients presenting to an ED with 
acute agitation.47
Box 3.1. Reported neurological and psychiatric features of GHB/GBL 
intoxication 
CNS symptoms: dose-related. Patients may therefore present with CNS symptoms ranging from 
sudden drowsiness through to unresponsive coma, depending on dose44,54–56,60,61,63–76 Common
Amnesia77,78 Common
Ataxia45,47,57,61,71,77–113 Common
Hypotonia57,66,74,79,114 Common
Disorientation44,61, 78,84,110 Common
Hyporeflexia91,100,105,109 Common
Dizziness45,68,77,92,93,94,110 Common
Tremor57,80 Common
Confusion68,78,79,93,94 Common
Myoclonus54,57,58,60,77,90,115–117 Common
Hallucination83,84,93,94 Common
Convulsions (seizures or seizure-like activity) have been reported,34,57,60,61,63–65,68,69,72,74,78,87,89,93,94,97, 
108,113,114 but most studies have shown them to be uncommon. They may occur secondary to 
hypoxia or due to other substances used8
Somnolence78,82,90,112 Common
Agitation,47 bizarre behaviour and combativeness, either at presentation or when waking44,47,55,56,60, 
61,63,66,68,71,75–78,80,81,84,85,88,92–94,96,98,101,106,108,110,114,115
Slurred speech80,83,84 Common
Miosis44,68 Common
Dysarthria44,77 Common
Less common neurological effects include bruxism,98 vertigo,57 delusion,110 extrapyramidal side-
effects,83 dystonia,83 athetoid posturing98
Confusion68,84,66 Common
Mydriasis (wide pupils)44,68,72,80,85,86,90,92,93
Headache44,85 Common
Horizontal and vertical gaze nystagmus79,80,83–85
Reduced coordination80,93 Common
Pupils may be sluggish and non-reactive66,72,94,107
Euphoria Common
One report of paroxysmal sympathetic surge118
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Box 3.2. Reported medical features of GHB/GBL intoxication 
Cardiovascular effects
Bradycardia44,57,60,61,65,68,72,76–78,80,84,89,92,93,95,96,98, 100,102,106–109,112,114,115 Common
Mild bradycardia without haemodynamic compromise is the most common cardiovascular 
effect and has been noted in recreational drug users54
Tachycardia and hypertension61,63,72,77–79,81,93,106
Hypotension44,57,63,68,74,77,84,89,98,101,102,107,112,119 Rare when GHB/GBL used on its own; generally when 
GHB/GBL co-ingested with other substances54,68
ECG abnormalities occur occasionally63
Chest tightness44,94
Palpitations44
Respiratory effects
Dose-related respiratory depression56,57,60,61,65,68,71,72,75,77,78,81,88,92,93,107 Respiratory failure is normally 
the cause of death from GHB/GBL
Tachypnoea63
Bradypnea44,63,64,66,77,84,91,92,98,100,101,104,107 Common
Pneumothorax109
Periodic (Cheyne-Stokes) respirations114,120,121
Cyanosis66,72
Pulmonary aspiration61,66–68,70,73,107
Pulmonary oedema77,88,105,122,123
Apnoea and respiratory failure54,56,93
Hypothermia
Hypothermia44,54,60,63,68,71,74,78,98,100,107,109,110 Common
Metabolic features
Hyperglycaemia61, 88, 106
Elevated creatine activity/rhabdomyolysis60, 68, 85, 112, 114,124
Gastrointestinal symptoms
Nausea and vomiting57,61,59,60,63,65,66,68,71,74,77,78,82,84,89,9–94,97,109,110,115,123 Common
Incontinence (urine and stools)68,77,78,93,94,98,109,112,113
Salivation114,125
Diarrhoea126127
Abdominal pain110
Diaphoresis56,71,77,78,81,84,112,128
Reported features of GHB/GBL intoxication are listed in Boxes 3.1 and 3.2. It is 
important to note that other additional symptoms or features may occur due to 
co-used ethanol or other recreational drugs.
The CNS symptoms of acute toxicity can vary, depending on ingested dose, from 
sudden drowsiness to unresponsiveness and profound coma. CNS depression typically 
persists for 1–3 hours, with patients making a complete recovery typically within 4–8 
hours. 
Coma accounts for a significant proportion of GHB/GBL-related presentations to EDs, 
with a reported range of 16–33%.68 For example, a third of cases in a Swiss study68 
presented to hospital with coma, 28% of cases of a US study54 and 16% of cases in a 
study conducted in Spain.60 In a case series of presentations to a London ED, approxi-
mately 16% of cases had severe coma at presentation, with a score on the Glasgow 
Coma Scale (GCS) of 3. In this study, 47% of patients had a GCS score ≤8, which is 
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the usual cut-off for intubation.65 A case series of 88 patients presenting to medical 
services after taking GHB reported a GCS score of 3 and 33% had a score of 4–8.54
Vomiting in acute intoxication is common. The London-based study mentioned 
above reported that vomiting occurred in 17% of presentations,65 while Garrison et 
al. reported vomiting in 22% of presentations.128 Other studies have reported higher 
rates: 30% of the presentations in a US ED study54 and more than half of cases of 
overdose in an Australian study.22 Vomiting in individuals with reduced consciousness 
(especially when the GCS score is less than 8 out of 15) is believed to increase the risk 
of aspiration due to the lack of protective airway reflexes in people with neurological 
depression.129 Indeed, aspiration in patients intoxicated with GHB/GBL needs to be 
considered a significant risk, particularly in those with reduced consciousness. Local 
clinical protocols should include steps to assess and reduce the likelihood of vomiting 
and subsequent aspiration.
Convulsions – or seizures or seizure-like activity – associated with GHB/GBL have 
been reported,34,60,63,65,68,72,87,93,113,130 especially in severe cases of acute intoxication, 
although studies suggest that they are uncommon.8 It has been argued that it is 
difficult to determine the true frequency of ‘seizures’, as GHB and its analogues have 
been shown to cause myoclonic jerks, which – in pre-hospital settings in particular – 
may be misinterpreted as a seizure.129
Hypothermia is usually not severe, but can be common. For example, in a series of 88 
cases of GHB/GBL overdose, 55% were assessed to have an initial temperature of 36oC 
or less and 25% an initial temperature of 35o C or less.54 Bradycardia is also common. 
In the same case series of 88 GHB overdose patients, over a third (36%) developed 
bradycardia, although only one case was severe enough to require atropine.54
Acute GHB/GBL toxicity can cause amnesia, which increases the risk of relapse 
because users do not remember the experience of acute intoxication and overdose.131 
As mentioned above, GHB can cause profound unconsciousness and the steep 
dose–response curve puts the user at risk of death. The co-ingestion of alcohol is a 
significant added risk factor, but GHB/GBL intoxication alone can cause death.1
Other reported effects of GHB/GBL use include one observational case report of 
acute central serous chorioretinopathy.132
3.10.1.2. Acute withdrawal
People who use at least daily may commonly develop tolerance and dependence. 
Withdrawal syndrome following abstinence or dose reduction after prolonged use 
can be severe and must be treated as a medical emergency. 
For more details on withdrawal see section 3.12.2.
3.10.2. Poly-drug use and drug interactions
The co-ingestion of alcohol (ethanol) and/or other recreational drugs may contribute 
to some of the other clinical features seen in patients presenting with GHB/GBL and 
or GHB/GBL toxicity.133 A number of authors have suggested that GHB users who 
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co-ingest alcohol are more likely to develop severe complications related to GHB use. 
A double-blind, placebo-controlled, cross-over volunteer study that investigated the 
potential for toxicity associated with GHB alone compared with GHB and alcohol 
co-ingestion showed that GHB plus ethanol was associated with more adverse 
effects, in particular hypotension and hypoxia; there were no differences in GHB/GBL 
concentrations between the groups.134
Co-ingestion of GHB/GBL and alcohol has been associated with increased agitation68 
and aggressive behaviour. Patients who used alcohol were also more likely to vomit.68 
There is evidence that when GHB/GBL is taken in combination with other drugs 
(including alcohol or stimulants), the duration and depth of coma are greater than 
when it is taken alone, and recovery times are longer. 44,135,68 
GHB is rapidly eliminated by metabolism to succinic semialdehyde (SSA) via the 
GHB-dehydrogenase enzyme, and then to succinic acid via the SSA-dehydrogenase 
enzyme. Several drugs (i.e. valproate, ethosuximide, salicylate, amobarbital, phenytoin, 
disulfiram, cyanide) have been shown to inhibit GHB-dehydrogenase. However, 
the clinical significance of the co-administration of such agents and GHB remains 
unknown.136,137
3.10.3. GHB and HIV antiretroviral therapy
While clearance of GHB from the systemic circulation occurs rapidly by oxidation 
to succinic acid,138 136 animal data suggest that GHB is also a substrate of first-pass 
metabolism (while not proven, this may involve the enzymes CYP2D6 and CYP3A4). 
Therefore, co-administration of GHB with CYP2D6 inhibitors (i.e. cobicistat) or 
CYP3A4 inhibitors (i.e. ritonavir, cobicistat) may lead to raised systemic exposures of 
GHB and increased toxicity.
It has been recommended that GHB/GBL should be used with caution by HIV-sero-
positive patients with predisposing seizure disorders or with opportunistic infections 
that may lower seizure threshold (i.e. toxoplasmosis, cryptococcal meningitis), as 
GHB/GBL may precipitate seizure-like activity. GHB/GBL use may also cause severe 
nausea, vomiting and gastrointestinal tract irritation, and adversely effect absorption 
of antiretroviral therapy.139 There are also concerns about compliance with HIV 
medication while intoxicated, especially during prolonged binges, which may 
complicate antiretroviral therapy and affect adherence.139
3.11. Clinical management of acute toxicity
3.11.1. Identification and assessment 
Diagnosis of acute GHB/GBL toxicity should be made on clinical assessment. There are 
no rapid urine or serum field tests, so analytical assessment should not be considered 
a component of routine diagnosis. It has been suggested by Wood et al. that the 
diagnosis of acute GHB/GBL toxicity be based on the recognition of the clinical 
toxidrome associated with the overdose of GHB/GBL.129
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Standard medical assessment is always indicated, so that other causes of the 
presentation can be excluded. The ease of making a clinical diagnosis often depends on 
understanding the circumstances in which an individual was found and the frequency 
of managing patients with acute GHB/GBL intoxication. 
Problems relating to the identification of GHB/GBL intoxication are linked to the 
similarities in clinical features to alcohol, opiate and/or benzodiazepine intoxication, 
140,8 or similarities to other clinical presentations, such as hypoglycaemia. Given the 
similarity to acute opioid toxicity, it is recommended by TOXBASE® that, where there 
is clinical uncertainty, it may be worth considering a trial of the opioid antagonist 
naloxone, although it is not effective in managing acute GHB/GBL intoxication. 
Diagnosis is also complicated by frequency of other co-intoxicants141 and by the 
diversity of clinical presentation.47 That is, some or all of clinical features of acute 
GHB/GBL toxicity may be ‘masked’ by other co-ingested substances (e.g. an individual 
may present with drowsiness and normal heart rate due to co-ingestion of GHB/GBL 
and a stimulant such as cocaine or amphetamine). 
3.11.2. Clinical management of overdose and acute toxicity
No randomised controlled trials have looked at the management of acute GHB/
GBL toxicity but there is consistency in the evidence reviewed that the treatment of 
GHB/GBL acute toxicity should consist of symptom-directed supportive care with an 
emphasis on respiratory support. Wood et al. suggest that the duration of reduced 
consciousness (particularly non-responsive coma) is generally short-lived, with the 
majority of patients recovering fully within 2–3 hours of the onset of coma.129
Overall, the evidence suggests the following:
The protection of airways and proper airway management is recommended 
because vomiting is common.61,75,109,121,142 However, it has also been suggested that 
‘prophylactic’ intubation in cases of vomiting is not indicated54 and it has been argued 
that routine intubation of patients with acute GHB/GBL toxicity is not recommended 
unless patients exhibit vomiting, seizures or other clinical indications for intubation.129 
Clinical consensus suggests that there does not appear to be a need to intubate purely 
on the basis of GCS score, as in other medical and trauma patients. 
For up-to-date guidance on the management of GHB/GBL acute toxicity, it is recommended 
that information be sought from the National Poisons Information Service (NPIS), specifically 
the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.TOXBASE.org/Chemicals/Management-Pages/GHB-overdose---features-and-
management
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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Reports in the literature indicate that intubation is needed in 3–13% of cases.54,60,63,68,124 
One study found a greater requirement for mechanical ventilation for patients who 
had ingested GHB/GBL with other drugs or alcohol, as the duration and depth of 
coma were greater than when it was taken alone.44
Gastric decontamination (e.g. activated charcoal) is not recommended, as its effects 
are uncertain. There are no antidotes for GHB/GBL poisoning.8 It may be worth giving 
naloxone to treat possible opiate poisoning where there is an uncertain presentation 
or opiate use is suspected. Pharmacological intervention is rarely required for 
bradycardia. 
Case series have shown that where mechanical ventilation has not been required, 
consciousness was recovered within 5 hours.1 Expert consensus has highlighted the 
need to fully investigate unconscious patients, particularly when the diagnosis is 
unclear. CT scanning may be indicted, particularly when convulsions occur, although 
there is no robust evidence on the routine use of CT scanning specifically for GHB/
GBL overdoses.
Some patients may have a fluctuating course on recovery, where they have periods 
of agitation alongside periods of drowsiness or coma. These patients can sometimes 
be difficult to manage, since they require appropriate sedation for their periods of 
agitation, which may worsen the degree of sedation when it occurs. Should this occur, 
there may be a need for appropriate respiratory support until the patient has fully 
recovered. Dependent users may begin to go into withdrawal on recovery from the 
overdose – see section 3.12.2.
Outside clinical settings, in night clubs for example, harm reduction information should 
stress the need to put people in the recovery position and call for an ambulance. 
GHB/GBL users should similarly be told to put people with signs of acute intoxication 
in the recovery position. 
3.11.3. Treatment outcome
Patients with GHB/GBL acute toxicity will typically develop symptoms quickly, but 
will also improve rapidly. Even in more severe cases, patients will usually make a full 
recovery, provided they are hospitalised and receive appropriate supportive care.8 
Studies have shown that patients will regain a GCS score of 15 in a short time after 
presentation (a median of 76 minutes in one study), albeit this is longer for those with 
severely reduced consciousness, typically resulting from poly-substance use.44,63 They 
also show a rapid rate of discharge from hospital,44,63 although people presenting to 
hospital with a low GCS may have a longer recovery period.65
A retrospective study of patients presenting to a large London inner-city ED with 
acute poisoning with self-reported GHB/GBL toxicity reported on the disposition of 
patients with acute GHB/GBL intoxication. The majority (92.2%) were discharged 
directly or self-discharged from ED or required only a short period of observation in 
the ED observation ward. Fewer than 1 in 10 (7.8%) required admission to hospital. 
Among those, the majority were admitted to critical care facilities, usually because 
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of significant neurological or respiratory compromise and the need for airway 
protection and intubation. The study also looked at length of stay and reported an 
overall median stay of 2.8 hours: discharged or self-discharged directly from ED 2.4 
hours (range 1.7–3); admitted to ED observation ward 5.6 hours (range 3.6–8.6); 
admitted to general medical ward 15.6 hours; admitted to a critical care facility 18.7 
hours (range 10.1–39.2).65
As amnesia is a direct effect of GHB/GBL, patients may recover with no recall of GHB/
GBL intoxication or overdose.34 In a study of 42 users, 13% had amnesia during GHB 
use and 45% after GBL use.34 As noted above, patients may be at risk of relapse or 
may delay treatment because they do not remember their experience of overdose or 
severe withdrawal.131
3.11.4. Acute withdrawal following detoxification
In GBL/GHB-dependent people, rapid improvement from acute toxicity may be 
followed by deterioration as withdrawal symptoms develop if they are dependent on 
GHB/GBL (for details on withdrawal see section 3.12.2). Withdrawal symptoms may 
manifest quickly, or up to 24–48 hours later, and the delayed onset of withdrawal 
symptoms must be considered in the management of acute toxicity.143 A vital part 
of discharge instructions to patients, friends and carers is to inform them about the 
potential for these symptoms to recur after discharge.143
In the majority of published cases of GHB/GBL withdrawal, detoxification was 
unplanned and treatment started after the patient presented in crisis, usually to an 
ED.39 Acute withdrawal is potentially life threatening and it is recommended that cases 
are considered a medical emergency. It is also recommended that all dependent users 
of GHB/GBL are advised not to stop use abruptly or to attempt self-detoxification. 
Medical assistance should always be sought.
3.12. Harms associated with chronic use
3.12.1. Dependence
The regular, prolonged use of GHB/GBL and its analogues can lead to physiological 
dependence.8 Its typical features include difficulty controlling the amount used, neglect 
of other activities and withdrawal. Part of the dependence syndrome is tolerance, in 
which larger doses are needed over time to produce the same psychoactive effects. 
Long-term users therefore typically use higher doses than naïve users.18 Users have 
reported taking larger doses in order to achieve previous effects or use just ‘to 
normalise’ themselves rather than to get high.40 Cross-tolerance between GHB/GBL 
and alcohol may exist.
At a social level, dependence has been described by patients to be the opposite to 
why they chose to use GHB/GBL in the first place: rather than enhancing sociability, 
GHB/GBL dependence leads to introversion, lack of motivation and failing to 
maintain contact with family and non-using friends; other concerns included loss of 
employment and absenteeism.23
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3.12.2. The GHB/GBL withdrawal syndrome
The potential of GHB/GBL to produce dependence is well recognised. Dependent users 
will consume GHB/GBL at regular intervals during the day and at night, sometimes as 
often as every 1–3 hours,9 in order to avoid withdrawal. 
GHB/GBL withdrawal can appear clinically similar to withdrawal from opioids, benzo-
diazepines and alcohol,8 and problems relating to the identification of GHB/GBL 
intoxication and withdrawal are linked to the similarities in clinical features.140 However, 
although the autonomic features of GHB/GBL withdrawal are less prominent than for 
alcohol withdrawal, symptoms are often more prolonged (up to 2 weeks, occasionally 
longer) and are typically more resistant to treatment with benzodiazepines.
GHB/GBL withdrawal can also have similarities to clinical presentations such hypo-
glycaemia or sympathomimetic toxicity, typically associated with stimulant use. 
3.12.2.1. Predictors of withdrawal
Dependent users will develop withdrawal symptoms on reduction or cessation of 
use, which can be severe and life threatening.39,126,144,145 GHB/GBL withdrawal is on a 
spectrum that varies in clinical severity. 
There is increasing evidence that daily use of GHB/GBL is a predictor of withdrawal. 
In their review, McDonough et al. report a minimum daily dose associated with 
withdrawal is approximately 18 g for GHB and 10 g for GBL,39 but it is possible that 
it occurs at lower daily doses. Withdrawal can be seen after as little as 2–3 months of 
use,39 or even a shorter time after high-frequency use.
3.12.2.2. Rapid onset and duration of withdrawal syndrome
One distinctive feature of GHB/GBL is the quick onset of withdrawal. It can happen 30 
minutes after the last dose, but more typically it is a few hours. GHB/GBL withdrawal 
symptoms have been reported to last from 3 to 21 days,8,39 with one review reporting 
a mean of 9 days.39
Wood et al. report that in their clinical experience, 50% of those who present to 
hospital with acute GHB/GBL withdrawal will require barbiturates and admission to 
intensive care, as they typically present with delirium.146
3.12.2.3. Individual variations and unpredictability of the withdrawal syndrome
Although there are similarities between cases of withdrawal reported in the 
literature, there are also wide variations in both the withdrawal symptoms and the 
clinical responses between and within patients.147 Withdrawal symptoms can be self-
limiting in some patients, but others can present with more severe withdrawal that 
can progress to delirium.9
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3.12.2.4. GHB/GBL withdrawal symptoms
The early symptoms of GHB/GBL withdrawal typically include insomnia, tremor, 
confusion, nausea and vomiting. Over the next 12–48 hours, tachycardia, hypertension, 
agitation, seizures and/or myoclonic jerks and hallucinations may develop.
Withdrawal symptoms reported in the literature are summarised in Box 3.3.
It is not possible to determine accurately how common these symptoms are. 
A review of 36 ED presentations reported that the early symptoms of withdrawal 
were tremor (67%), hallucinations (63%), tachycardia (63%), insomnia (58%), seizures 
(7%) and rhabdomyolysis (7%).145 
McDonough et al. in their review reported that an 8-hourly dosing was the minimum 
frequency associated with withdrawal delirium.39 There are indications that heavy, 
frequent users are most likely to progress to severe delirium. It has been proposed 
that withdrawal in cases of co-dependence on GHB/GBL and another CNS depressant 
Box 3.3. GHB withdrawal symptoms
Commonly reported symptoms
Hallucinations – visual and auditory9,15,41,126,145,148–162
Anxiety15,23,34,40,41,59,126,149,150,156,163–165
Tremors23,36,40,41,59,140,148–151,154,156,157,159–164
Paranoia9,15,40,41,126,153–156,159,162
Tachycardia15,34,41,126,145,148–151,153,156–159,163,164
Insomnia15,23,36,41,59,148,149,151,153,156,158,162
Hypertension41,126,148,149,158,159,164
Disorientation15,126,145,149,150,153,156,158,162
Sweating36,40,41,126,148,149,151,154–157,159,163
Confusion15,126,140,149,153,156,160
Agitation34,126,140,145,153,155,157,158,160,166
Aggression/combativeness40,126,150,152,159
Other reported symptoms
Depression36,41,156
Tachypnoea154
Miosis153
Nausea and vomiting126,163
Nystagmus15,157,162,164, 
Diarrhoea126,165
Cardiac palpitations35,160,164
Abdominal pain (less common)164
Dyspnoea160
Severe withdrawal
Delirium23,34,41,140,145,148,157,158,160
Seizures40,126,140,145,153 – may become life-threatening
Psychosis67,151,153,156, 159,160,161
Withdrawal mimicking schizophrenia167
Rhabdomyolysis145, 149, 161
Medical complications reported during withdrawal include sepsis, myoglobinuria, Wernicke’s 
encephalopathy without alcohol dependence
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(opiates or other sedatives) or a stimulant are likely to be more severe, but such cases 
have not been described in the literature.39
Seizures associated with GHB/GBL withdrawal appear to be less common than with 
alcohol and are reported in fewer than 10% of cases.129
3.13. Management of harms from chronic use
GBL has been described as a mild skin irritant and a strong mucous membrane irritant. 
It can penetrate the epidermis and cause rashes or eczema.1
Little is known about the long-term harms of GHB/GBL that are secondary to acute 
harms or dependence. It is recommended that more research be carried out on the 
long-term effects of GHB/GBL, including psychiatric (and cognitive), physical and 
teratogenicity-related harms. This includes the recommendation by Mitto et al. to 
study the possibility of persistent problems with memory acquisition as a result of 
GHB/GBL use.168
Among MSM in particular, GHB/GBL is often used in a sexual context and in a context 
of potential high-risk sexual behaviour. Studies have shown that GHB/GBL use is 
associated with increased sexual risk and potential transmission of HIV, as well as 
other sexually transmitted and blood-borne infections169–171 (see section 3.10.3).
3.13.1. Clinical management of dependence
3.13.1.1. Identification and assessment of GHB/GBL dependence and withdrawal 
The NEPTUNE group consensus was that the warning signs of dependence might be 
the use of GHB/GBL during the week when not out clubbing or engaging in similar 
social activities. Alert signs for dependence are the following: 
•	daily use on multiple times throughout the day;
•	waking at night to use;
•	using other drugs to prevent symptoms overnight;
•	symptoms on days not using;
•	not able to go a day without use.
There are no validated GHB/GBL withdrawal scales, but it may be reasonable to use 
alcohol or benzodiazepine withdrawal scales.9 However, in cases of emergency acute 
withdrawal, many would recommend not using scales and instead treating on the 
basis of symptomatic control, since non-GHB-specific scales do not always pick up 
the degree of neuropsychiatric symptoms, which could lead to underdosing and then 
escalation of delirium.
In specialist drug treatment clinical practice, the Clinical Institute Withdrawal 
Assess ment of Alcohol Scale (CIWA-Ar) has been used, as well as the Alcohol 
With drawal Scale (AWS). Other scales used include: the Subjective Withdrawal 
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Scale (SWS), which is based on the Subjective Opiate Withdrawal Scale, where all 
subjective criteria of the DSM-IV-TR withdrawal syndromes were added to SWS;and 
the Objective Withdrawal Scale, which is based on the Objective Opiate Withdrawal 
Scale, where nursing staff record their observations.172
There are no validated tools for the identification of or screening for harmful GHB/
GBL use in non-drug specific settings. Winstock and Mitcheson have provided helpful 
guidance for addressing substance misuse issues in general practice.173
It is worth noting that some individuals self-medicate with baclofen or ethanol or 
benzodiazepines to prevent GHB/GBL withdrawal. This can also be harmful and must 
be discouraged. Self-detoxification from GHB/GBL can be dangerous and should be 
avoided, as withdrawal symptoms can be severe and potentially life threatening. GHB/
GBL users who wish to stop should be encouraged to seek medical assistance. If they 
want to reduce GHB/GBL use on their own, they should do so in very small increments 
and with the support of health professionals. Consumption diaries may be useful. 
Attempts at self-detoxification from GHB/GBL can be ineffective. In one study of 56 
users recruited via the internet, respondents had unsuccessfully attempted to quit 
on average 4.07 times and 30% had been previously treated for GHB/GBL misuse.49
3.13.1.2. Psychosocial and pharmacological support
Chapter 2 discusses in general terms the psychosocial interventions for the use of 
club drugs. These are applicable to the management of the chronic harms of GHB use, 
as well as aftercare and support, and so are not discussed further here. The pharma-
cological interventions are discussed below.
3.13.2. Clinical management of withdrawal
No randomised controlled trials or robust prospective clinical trials have investigated 
GHB/GBL withdrawal. The research evidence on the management of GHB/GBL 
withdrawal is instead based mainly on case reports and series and it is therefore not 
possible to draw robust recommendations. 
For up-to-date guidance on the management of GHB/GBL withdrawal, it is recommended that 
information be sought from the National Poisons Information Service (NPIS), specifically the 
NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Chemicals/Management-Pages/GHB-withdrawal---features-and-
management1
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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It is, though, consistently suggested that symptomatic treatment is indicated for GHB/
GBL withdrawal syndrome. The review of the evidence shows that benzodiazepines are 
most typically used for this purpose.15,126,149,153,154,158,163,165 Combined evidence suggests 
that benzodiazepines are the first line of treatment, but adjuncts may be helpful to 
control symptoms.149 Baclofen and barbiturates have been described as second-line 
adjuncts.39,41,55,126,129,145 TOXBASE® recommends that withdrawal symptoms can be 
effectively treated with a combination of diazepam and baclofen and this has been 
used successfully in clinical practice, as part of medically assisted detoxification.23 
However, clinicians must be aware of the risks of patients taking the baclofen on top 
of their use of GHB/GBL and this leading to coma and respiratory distress.174 There is 
anecdotal evidence that some GHB/GBL users are also buying baclofen online.
A wide range of medications have been used and described as potentially helpful in 
GHB/GBL withdrawal management. However, supporting evidence for any of these 
medications is mainly based on a small number of case reports and case series. The 
decision on which additional agent to use depends on the clinical presentation. Anti-
psychotics should be used with caution due to the risk of neuroleptic malignant 
syndrome and seizure.
Medications which have been used to manage acute withdrawal are listed in Box 3.4. 
Box 3.4. Medications used to manage acute GHB/GBL withdrawal 
Diazepam126,143,165,175
Baclofen23,140,156
Barbiturates41, 59, 157, 159, 161 
Benzodiazepines are safe and effective in managing most cases
Barbiturates can be used in benzodiazepine refractory cases39
Carbamazepine156
Gabapentin156
Chloral hydrate151,156
Clonidine35,156
Paroxetine35
Beta blockers35,127
Bromocriptine145
Trazadone41,150,156
Fentanyl148
Propofol77, 48,161
Antipsychotics15,126,150,151,153,155,159,160,161,162,166
Antipsychotics, including haloperidol, should be administered with caution151,157,160,176
Typical antipsychotics should be avoided due to the risk of developing NMS type syndromes156 
Intramuscular typical antipsychotics in GHB withdrawal should be used with caution161
Antipsychotic not indicated unless delirium is present167
Lorazepam and/or droperiol for the management of agitation47
Olanzapine160
Pentobarbital in an inpatient setting. 41
Propranol35
Pharmaceutical GHB.35 Gradual dose tapering can be an effective way to achieve withdrawal 
from dependent GHB use. However, this requires high motivation and careful monitoring in an 
in-patient setting
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3.13.2.1 Medical complications reported during withdrawal
A 2004 review by Mc Donough et al.39 of 38 cases reported the following complications 
during withdrawal: sepsis, rhabdomyolysis and Wernicke’s encephalopathy – without 
alcohol dependence. No frank withdrawal seizures were  Seen. Rosenberg et al. suggest 
that all cases of GHB withdrawal delirium be considered medical emergencies and be 
managed in critical care settings, rather than psychiatric settings. The involvement of 
both disciplines, however, may be required.161
3.13.3. Medically assisted elective or planned 
withdrawal and detoxification
There is limited evidence on the provision of medically assisted withdrawal, as most 
case reports and series are concerned with acute withdrawal. There are, though, a 
few reports of elective medically-assisted withdrawal23 and it has been argued that it 
is best if detoxification is carried out on a elective basis,23 planned in advance so that 
withdrawal symptoms can be identified and treated early, as most patients presenting 
symptomatically following enforced abstinence have presented with more severe 
symptoms and increased risk of delirium.41 This approach also enables planning of 
post-withdrawal support and recovery.
There seems to be no consensus on the best clinical settings for the detoxification 
of patients with GHB/GBL dependence. Intensive care, hospital inpatient basis or in 
outpatient specialist drug treatment centres have all been suggested. Some have 
recommended that withdrawal be monitored in an intensive care unit (ICU) along 
with continuous monitoring of vital parameters because of the severity of associated 
symptoms.8,177,178 Others have described successful outpatient detoxification.23
There have been some attempts to identify the parameters and to develop algorithms 
for the management of GHB/GBL detoxification in specialist drug treatment or acute 
centres on an inpatient or outpatient basis,39 as well as to define the medication and 
monitoring required.23,39
3.13.4. Aftercare and supporting recovery
There are few studies of the longer-term outcomes of detoxification. It is recommended 
that research be funded and carried out. Relapse to further use following GHB/GBL 
detoxification may be high, as suggested by some case series and case reports.30,156
In elective, medically assisted detoxification, aftercare is an integral part of treatment 
and should be planned at the onset of the intervention. The risk of relapse is addressed 
through psychological interventions, as well as through peer support groups such as 
Narcotics Anonymous or Alcoholics Anonymous (for more information see Chapter 2). 
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3.14. Public health and safety
GHB/GBL use can have a negative impact on public health and safety. Studies have 
shown that it is associated with increased sexual risk and potential transmission of HIV, 
as well as other sexually transmitted infections and blood-borne infections.169,170,171 
The links between GHB/GBL use and increased aggression (especially in combination 
with alcohol) should also be kept in mind, as should the possibility that GHB/GBL is 
used in drug-facilitated sexual assaults. 
GHB/GBL is associated with the abrupt onset of sleep, which can have dangerous 
consequences if driving or operating heavy machinery.9 However, the lack of hangover 
or sub-acute effects may encourage some to drive under the influence. 
One study also noted that re-arrests for driving under the influence of GHB/GBL were 
not uncommon.179
3.15. Harm reduction
3.15.1. Supporting patients undergoing outpatient 
medically assisted GHB/GBL withdrawal
Patients undergoing outpatient medically assisted GHB/GBL withdrawal should 
be provided with a pro-forma letter describing their detoxification and medication 
regime, to be presented to ED in case of severe withdrawal. 
3.15.2. Advice for users S-T-A-Y-I-N-G S-A-F-E on GHB/GBL
S Seek medical attention immediately if you have taken too much GHB/GBL. Do not 
use other drugs in the hope of reversing the effects.
T Two or more substances used at the same time increase the risk of overdose sig-
nificantly (especially sedatives e.g. alcohol, ketamine).
A Always measure GHB/GBL doses accurately (use for example syringes or pipettes). 
Wait until the effects are felt and do not re-dose for at least 2 hours.
Y You should avoid using GBL on your own and always use in a safe place and with 
someone who has not taken it, as it is common to become unconscious.
I If you have used and are going to sleep, sleep on your side in case you are sick. 
Place sleeping or unconscious friends in the recovery position.
N Never drink GHB/GBL straight out of a bottle or pour a dose straight out of a 
bottle. Always dilute in water and add food colouring to avoid accidental drinking. 
Never keep GBL in drinks bottles, especially in public venues, where it might be 
drunk by others not aware of the content.
G GHB/GBL is physically addictive and dependence can happen quickly. Avoid 
frequent use, especially daily use. 
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S Severe and potentially serious GHB/GBL withdrawal symptoms occur if you are 
dependent and you miss a dose or reduce amounts taken abruptly. 
A Acute withdrawal symptoms and have no GHB/GBL? Seek medical help immediately 
in an emergency department. It can be a very serious medical emergency.
F Find a medical support for planned GHB/GBL detoxification. Do not attempt to 
stop abruptly on your own. If you want to reduce your dose, do so in very small 
doses until you find medical support.
E Employ methods to stabilise your use; consumption diaries can be very helpful. 
Keep a GHB/GBL diary and record of your doses and times you use.
Users should also be reminded of safe sexual practices, given the association between 
GHB/GBL and chemsex and other forms of high-risk sexual behaviour.
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Chapter 4
Ketamine and methoxetamine
Drug type: depressant/dissociative
4.1. ‘Dissociative’ drugs
‘Dissociative’ drugs can distort perceptions of sight and sound and create feelings 
of detachment or dissociation from the self and the environment; however, these 
mind-altering effects are not hallucinations. Dissociative drugs, such as ketamine and 
phencyclidine, were initially developed as anaesthetics for surgery, but then became 
used for recreational purposes.
Ketamine hydrochloride is one of the dissociative drugs most commonly used 
for recreational purposes in the UK. The recreational use of ketamine analogues 
has also been reported; these include methoxetamine ((RS)-2-(ethylamino)-2-(3-
methoxy phenyl) cyclohexanone) and 3-MeO-PCE (N-ethyl-1-(3-methoxyphenyl)
cyclo hexanamine. Methoxet amine is the ketamine analogue that is most extensively 
discussed here, because the evidence suggests it is more widely used for recreational 
purposes than other analogues and because the evidence base is large than it is for other 
analogues. Other dissociatives include, but are not limited to, phencyclidine (PCP or 
‘Angel Dust’), the 3- and 4-methoxy analogues of phencyclidine – namely 1-[1-(3-meth-
oxyphenyl) cyclohexyl]piperidine and 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine – 
N-ethyl norketamine, N-ethylketamine, tiletamine, dextromethorphan – and nitrous 
oxide (discussed in Chapter 5). N-ethyl norketamine, currently a so-called legal high, 
has effects similar to ketamine is sold mainly on the internet. More recently, new 
substances have appeared on the market: diphenidine, which is 1-(1,2-Diphenyl ethyl) 
piperidine, and methoxphenidine, which is 1-[1-(2-methoxyphenyl)-2-phenylethyl-
piperidine; these, like ketamine and its analogues, are all NMDA receptor antagonists.
Methoxetamine was at a point one of the more popular ketamine analogues. As it is 
not included in the Crime Survey for England and Wales (CSEW), it is not possible to 
determine how prevalent its use is in the UK. There is anecdotal evidence, however, 
that it is limited and that it has decreased in recent years. There was also a reduction 
in National Poisons Information Service (NPIS) activity relating to methoxetamine, 
following it becoming subject to a temporary class drug order in April 2012, with 
calls and TOXBASE® enquiries becoming infrequent.1 It is likely that these reductions 
resulted from ‘market forces’, reflecting the fact that users may not like the effect of 
these drugs.
Ketamine and methoxetamine 79
N
E
P
T
U
N
E
4.2. Street names
Street names for ketamine at the time of publication include: K, Ket, Special K, Kit-Kat, 
Cat Valium, Super K, Vitamin K. Cornflakes, Cereal and Level.  
Street names for methoxetamine at time of publication include: M-ket, K-max, Mexxy, 
MXE powder, Special M and METH-O. 
Other names for both may be used locally. 
4.3. Legal status
Ketamine is currently a Class B drug under the Misuse of Drugs Act 1971 and is placed 
in Schedule 2 of the Misuse of Drugs Regulations 2001. 
Methoxetamine was the first drug to be subject to a temporary class drug order 
(TCDO), in April 2012. It is now a Class B drug under the Misuse of Drugs Act 1971 
(Schedule 1).
4.4. Quality of the research evidence
In comparison with other club drugs, the international evidence on the management 
of the acute and chronic harms related to the use of ketamine is relatively wide and 
includes studies of healthy volunteers and animal studies. 
The evidence on ketamine analogues is very limited, in contrast. Evidence on the 
management of methoxetamine’s acute and chronic harms, especially where there 
was analytic confirmation of its use, is very limited and confined to a few case reports.
4.5. Brief summary of pharmacology
Ketamine is a predominantly sedative drug, but its complex neurochemical profile 
reflects its actions as a dissociative, anaesthetic, psychostimulant and analgesic 
substance.2 
Ketamine is part of the arylcyclohexylamine group of compounds, which act primarily 
as non-competitive antagonists at glutamate receptors of the N-methyl-D-aspartate 
(NMDA) sub-type. It also acts at dopamine D2 and 5-HT2A receptors and the activation 
of 5-HT2A receptors is thought to be related to perceptual disorders and hallucina-
tions. Ketamine also shows affinity for mu, delta, and sigma opioid receptors and 
affects monoamine transporters.2
Ketamine is a non-competitive NMDA receptor antagonist that acts as a dissociative 
anaesthetic with analgesic and amnestic properties. It is a derivative of phencyclidine 
(PCP), and both are arylcyclohexylamines. Like PCP, ketamine stimulates the vital 
functions of heartbeat and respiration, though it is less toxic and shorter acting than 
PCP, which is a Class A drug.3
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The term ‘dissociative’ suggests that sensory loss and analgesia, as well as amnesia, 
are not accompanied by actual loss of consciousness.4 As a dissociative anaesthetic, 
ketamine has the capacity to induce narcosis and narcosis-like states in which con-
sciousness appears to be separated from the body.5 Its use can lead to a trance-like 
cataleptic state, unconsciousness, amnesia and deep analgesia, but with intact ocular, 
laryngeal and pharyngeal reflexes.6 Ketamine impairs psychomotor performance in a 
dose-dependent fashion.
Ketamine has a plasma half-life of 2–4 hours.7 Peak plasma concentrations are reached 
within a minute when ketamine is injected intravenously, 5–15 minutes when injected 
intramuscularly or snorted,and 4–6 hours when taken orally.8,9 
Enzyme kinetic studies have shown that for ketamine the initial metabolic steps in 
humans (N-de-ethylation) are catalysed by CYP2B6 and CYP3A4. Therefore, caution 
should be addressed when co-administered orally with CYP3A4 and CYP2B6 inhibitors 
(such as ritonavir and cobicistat).10,11 
Methoxetamine, which is 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone, or 
3- MeO- 2-Oxo-PCE, is an analogue of ketamine. Its analogues are 1-[1-(3-methoxy-
phenyl)cyclo hexyl]-piperidine (methoxyphencyclidine; 3-MeO-PCP) and N-ethyl-1-
phenylcyclo hexylamine (eticyclidine).
Methoxetamine first appeared in 2010 and was synthesised as a close structural 
analogue of ketamine in order to elude the classification of ketamine while retaining its 
psychoactive properties.12 Because of its structural similarities to PCP and ketamine, 
it has been assumed that the effects of methoxetamine are similar.13
Methoxetamine is both a dopamine reuptake inhibitor and an NMDA receptor blocker; 
its affinity for the NMDA receptor is comparable to or higher than that of ketamine. 
In addition, methoxetamine (in addition to PCP and its analogues) has affinity for the 
serotonin transporters.14
Methoxetamine has been marketed to drug users as much more powerful and as 
having longer-lasting effects than ketamine (these characteristics derive from its 
N-ethyl group). It has also been claimed that it is a ‘bladder-friendly’ alternative 
to ketamine, although there is no evidence to support this (or indeed to refute it). 
There are also indications that methoxetamine has a shorter half-life than PCP, but 
longer than ketamine, and that the psychoactive effects should be anticipated to 
last longer than would be expected for ketamine.13 Although the group modification, 
from 2-chloro to 3-methoxy, seems to give methoxetamine lower levels of analgesic 
and anaesthetic properties than ketamine, it may be responsible for a half-life that is 
longer than that of ketamine.4
4.6. Medical uses of ketamine
Ketamine is used as an anaesthetic and a powerful analgesic, particularly in paediatric, 
emergency medicine and veterinary medicine, and is considered as a safe battlefield 
anaesthetic due to its pharmacological profile. It also has a medical role in the 
management of pain in both humans and animals. 
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A number of studies have investigated the role of ketamine in treatment-resistant 
depression and major depressive disorders.15–17 Experimental studies are being 
conducted on the use of ketamine as a pharmacological agent for modelling psychosis. 
The Advisory Council on the Misuse of Drugs (ACMD)has recommended the need 
for further research into the role of ketamine as an analgesic in chronic cancer pain 
(palliative care) and non-cancer pain.1
There are currently no clinical or non-clinical uses of methoxetamine. However, as an 
analogue of ketamine, it could be of pharmaceutical interest for treatment- resistant 
depression if it were to show rapid antidepressant properties similar to those of 
ketamine.14,18 
4.7. Prevalence and patterns of use
4.7.1. Prevalence of use in the UK
The recreational use of ketamine has been characterised by the EMCDDA as having 
‘potential for more widespread diffusion’,19 although currently its use in Europe is 
still relatively low, lower than that of ecstasy,19 and is concentrated among particular 
sub-groups. In the UK, ketamine use escalated in the 1990s on the ‘rave scene’, first as 
an adulterant of ecstasy, before becoming increasingly mainstream.20 
Measurement of the use of ketamine by the British Crime Survey (BCS; which is 
now the Crime Survey for England and Wales, CSEW) started in 2006/07, when it 
was suggested that it had been used in the past year by 0.3% of 16–59-year-olds. In 
2013/14, ketamine use in the past year was reported by 0.6% of the adult population 
(aged 16–59 years), a statistically significant increase from 0.4% in 2012/13.21
The CSEW in 2013/14 estimated that 1.8% of people between the ages of 16 and 
24 years (a total of around 100,000) had used ketamine in the previous year. In the 
16–59 age group, it was estimated that 200,000 people had used done so (0.6%), 
with ketamine being the sixth most commonly used substance (Table 4.1).
Table 4.1. Prevalence of ketamine use as found in the Crime Survey for England and 
Wales, 2013/14
Age group and use Prevalence
16–24-year-olds reporting ketamine use in past year, 2013/14 1.8%
16–59-year-olds reporting ketamine use in past year, 2012/13 0.6%
There was a statistically significant increase in past-year use of ketamine among all 
adults from 2012/13, when it was used by 0.4% of adults, to 2013/14. This was also 
the case among the 16–24-year age group, with an increase from 0.8%.
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Ketamine use is higher among some sub-cultures, lifestyles and occupations.22 These 
include clubbers,20,23–30 ‘travellers’, ‘free party scene’,31,32 gay men and MSM27,28,33–35 
young injectors, self-exploratory people28 and workers in the medical field.36,37 In 
a 2011 survey in a gay-friendly club, 10% reported it as their favourite drug and 
intended to use it on the night of the survey.38
Ketamine is associated with ‘clubbing’, as well as post-club ‘chill-out’, when it is used 
for extending clubbing experience and as part of the drugs repertoire or stages in 
clubbing.39 Of the respondents to the Global Drug Survey 2013 survey (2012/13 data) 
50.6% reported lifetime use of ketamine and 31.5% use in the past month.40 
However, despite the association of ketamine with clubbing and post-clubbing use, 
a study has reported that the most commonly endorsed settings were home or a 
friend’s house or somewhere else familiar.41 In addition, there is some evidence that 
its use in clubs varies significantly within the different dance ‘scenes’ and regions. In 
surveys of the users of the night-time economy and clubs, it was shown that ketamine 
use was highest use in gay-friendly clubs, dance clubs playing ‘hard dance’ music, 
‘funky house’ and ‘trance’ music and lowest in ‘straight’ (heterosexual) bars and those 
playing ‘drum and bass’ music.42
The 2011/12 CSEW reported that ketamine users generally have high rates of 
simultaneous poly-use, with 48% using another drug the last time they used ketamine 
(third highest after methadone users, at 58% and ecstasy users, at 49%). Ketamine 
users were also more likely, compared with the users of any other illicit substance, to 
have used (concurrently) other drugs in the past year and past month.43
There is some evidence from the UK that initiation in ketamine use may take place at 
a slightly older age than for other substances, and that it is possible more experienced 
users add ketamine to their poly-use repertoire.39 
Research carried out in the US, England and Australia suggests that ketamine users 
tend to be white, male, under 30 years old, urban and moderately well educated.20,28,33,44 
In the UK, the CSEW also indicates that ketamine users are more likely to be male, 
single, in the 20–24-year age group, unemployed or a student. Differences between 
the various sub-groups have been shown. For instance, Morgan et al.45 found that 
frequent and daily users had spent significantly fewer years in education than 
infrequent or non-users. 
Ketamine is typically used intranasally, by insufflation. It is rarely injected. A study 
conducted in Scotland, for example, found that ketamine was injected by only 0.9% 
of users.46 
No population data are available on the use of methoxetamine in the UK, but a 2012 
ACMD report stated that there was some evidence of its use in England, Scotland 
and Wales. It is not clear how much it is used or whether geographic differences 
exist.47 However, and as mentioned above, there is anecdotal evidence that the use of 
methoxet amine has become negligible. 
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4.7.2. Ketamine use and high-risk sexual and injecting behaviours
Like other club drugs, ketamine is used as part of a socially active lifestyle and is 
associated with elevated, even pronounced, sexual health risks.48 The Global Drug 
Survey showed that, compared with the general population, clubbers are more 
socially active, have more concurrent partners, use condoms less consistently and 
have higher rates of sexually transmitted infections.48
Ketamine is associated with an increased incidence of unsafe sex among gay 
men.49,50–52 A US study of gay and bisexual men attending ‘circuit parties’ in three cities 
found that over 60% had used ketamine at parties in the past year and unsafe sexual 
behaviour was associated with frequent ketamine use.51 One study suggested that 
ketamine use (as well as GHB use) was associated with unprotected anal intercourse 
with regular partners, whereas methamphetamine was associated with unprotected 
anal intercourse with casual partners.35
Ketamine is rarely injected (typically being taken intranasally) but some use by 
injection has been reported. Laukenau et al. studied young ketamine injectors in US 
cities and described two types of ketamine injectors, with different demographic 
profiles: experienced injecting drug users (IDUs), who injected a number of drugs 
and who tended to be homeless youth and homeless travellers;53,54 and new IDUs, 
who initiated injecting with ketamine and tended to have stable housing and who 
associated with others who used ketamine.54
The injecting of ketamine in the UK has not been systematically documented. There is 
some anecdotal evidence from the few UK treatment centres that provide treatment 
pathways to ketamine users that a minority of users inject this drug (intravenously 
and/or intramuscularly). There is also some anecdotal evidence which suggests that it 
is possible that a minority of older injecting opiate drug users also inject ketamine.55
US studies have found ‘hidden’ populations of ketamine injectors in US cities but it is 
not possible to determine whether those findings are relevant to the UK. A 2002 study 
among ketamine injectors found that a slight majority had injected other substances 
prior to injecting ketamine for the first time (56%) but a large minority (44%) began 
their injecting career with ketamine. The median age at first injecting ketamine (18 
years) was slightly older than injecting other drugs (17 years). Most ketamine injectors 
were poly-users: 56% had used one or more additional drug before, during or after 
their last ketamine injection, while 44% had not.54 
In interviews with ketamine injectors, subjects reported the advantages of injecting 
over snorting: sniffing aggravated the nasal passage and injecting produced a 
‘cleaner’ high. Those who developed tolerance from sniffing found that injecting 
was a more potent and reliable mode of ingestion.54 Most reported that the main 
reason for injecting was to achieve the ‘k-hole’ (where the user experiences feelings 
of detachment and perceptions appear divorced from reality), which was more 
reliably achieved and intensely experienced by injecting.54 Among those who injected 
ketamine only, intramuscular injecting was more common than intravenous injecting.
Injecting ketamine was shown to be associated with high-risk behaviours. Multiple 
injections were typical, for example 8 to 10 injections over several hours.54 Multiple 
injecting of any substance has health implications.54
Ketamine and methoxetamine 84
N
E
P
T
U
N
E
4.8. Routes of ingestion, dosing 
and frequency of dosing
4.8.1. Ketamine
Illicit ketamine in the UK is mainly in powder form, typically sold in gram doses. It is 
less frequently available as a liquid, in which form it is possibly diverted from pharma-
ceutical supplies. Illicit ketamine for recreational use is often sold as a powder of fine 
crystal and is crushed for insufflation. It is usually white or transparent but can also 
be off-white or brown. Doses for recreational use are known as ‘bumps’ and are often 
measured as the quantity of powder that fits on the tip of a domestic key, a method 
therefore known as ‘keying’. Ketamine is sometimes sold in tablet form (in which form 
it is on occasion falsely sold to users as ecstasy). Ketamine is sometimes dissolved for 
injecting and then has a faster and more potent effect. 
Ketamine is rarely taken orally, as it will then be metabolised into norketamine, which 
produces a sedative effect rather than the desired psychedelic effect. It can also be 
smoked, used rectally56,57 or swallowed in a wrap of paper. 
The onset of the effects of ketamine is likely to occur approximately 5 minutes (but 
up to 30 minutes) after insufflation, the most common form of use. Effects occur 
in a matter of seconds or minutes after injection, smoking and smoke inhalation. 
This rapid onset of effect is thought to increase its potential for misuse. The effects 
themselves are generally short-lived, typically lasting 1–4 hours,58 depending on 
dose, tolerance, individual factors and other drugs ingested. This short duration of 
effect may promote bingeing; ketamine users in a session will typically self-administer 
several doses in order to maintain psychotropic effects over time,59 until supplies are 
exhausted.60,61 On the other hand, the short duration of effects may also increase its 
appeal over longer-lasting hallucinogens.39
A typical recreational dose is approximately 10–25% of the effective general 
anaesthetic dose.6 Single doses for intranasal use vary widely.6,61,62 A follow-up of the 
Mixmag survey looked at both typical amounts used in a ‘session’ and the number 
of days of consecutive use. It reported that just under a third of respondents (31%) 
used less than 0.125 g; just over a third (35%) used between 0.25 g and 0.50 g, and 
34% used more than 1 g per session. Five per cent reported using more than 5 g in a 
typical session. The mean number of maximum days of consecutive use was 3.5 days, 
with 11% reporting using ketamine on seven or more consecutive days. Seventy per 
cent used ketamine 1–4 days per month, 16% 5–8 days and 13% 9 or more days per 
month.63 
The small number of specialist treatment services offering specific treatment to 
ketamine users report that most of their patients use ketamine most days or every 
day and use up to several grams per day.1 The highest dose noted in a series of 60 
patients attending three clinical urology centres for a ketamine-related urological 
syndrome was 20 g per day.64 
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4.8.2. Methoxetamine
Methoxetamine is generally sold as a white crystal powder, but can be found in 
tablet form. It is generally used by insufflation, but can be used rectally, by sublingual 
application and by injection (intramuscular mainly, but also intravenous).13,65 It is also 
used orally, usually swallowed in a cigarette paper, or as tablets. 
The range of doses reported is 20–100 mg for oral administration and 10-50 mg 
for intramuscular injection.4,13,65 The effects of methoxetamine were described as 
lasting 1–3 hours65 by one report, but drug user websites investigated by Corazza 
et al. stated that the duration of action of methoxetamine ranges from 5 to 7 hours 
when insufflated, less (approximately 1 hour) when administered by intramuscu-
lar injection.58 The onset of the effects of methoxetamine have been described to 
start 10–20 minutes after ingestion,65 but can be delayed by 30–90 minutes after 
insufflation.4 This could have serious implications, as users may ingest a second dose 
thinking that the first dose was inadequate. The effects after intramuscular injection 
are faster, with onset after approximately 5 minutes.58 Compulsive re-dosing has also 
been described.58
Powders and tablets sold as methoxetamine have been found typically to include 
a range of other compounds and adulterants, including mephedrone, caffeine and 
cocaine.47
4.9. Desired effects for recreational use
4.9.1. Ketamine
The mind-altering effects of ketamine make it attractive to some drug users, along 
with its lack of hangover, short duration and relatively low cost. One of the earliest 
studies on the recreational use of ketamine found that users perceived it as a safe and 
potent hallucinogen with short duration of action and an equal balance of positive 
and negative effects.66
According to Teltzrow et al., ketamine has characteristic subjective effects which 
differ according to individual and setting of use.67 Overall, however, it can produce a 
range of experiences, depending on dose:68
•	At low doses, ketamine produces distortion of time and space, visual and auditory 
hallucinations and mild dissociative effects.69 It also has stimulant-type properties.70
•	At high doses, it produces more severe dissociation, known by some users as the ‘k–
hole’, where the user experiences feelings of intense detachment and perceptions 
appear completely divorced from reality.69
Ketamine has been described as able to induce a ‘raft’ of intense experiences, including 
some that can be characterised as positive and negative psychotic-like features.71 
Ketamine can act like a stimulant at low doses and can cause potent psychedelic 
experiences in moderate or high doses. It is dissociative inasmuch as it causes users 
to feel both sedated and separate from their bodies.54 Ketamine exhibits features of 
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a hallucinogenic drug and its use leads to alterations in mood and thought content. 
The combination of effects of ketamine has been described by some as ‘alcohol-like 
intoxication, cocaine-like stimulation, opiate-like calming, and cannabis-like imagery’.72
Moore et al. referred to the ‘playful’ effect of ketamine, in that it leads to improved 
moods and a child-like state. The intensity of ketamine was also emphasised.39 Its 
effects include euphoria, depersonalisation and derealisation, feelings of universal 
empathy and experiencing synaesthesia (combinations of sense experiences such as 
sound and colour).73 Ketamine users also report that it enhances creativity and that it 
is used to manage the ‘come-down’ from other drugs, such as stimulants. 
Ketamine users often experience floating sensations, sensory distortions and 
transcendental phenomena, such as mystical insight, spiritual trips, revelations or 
alternative realities.69 Ketamine is sought by some because it induces a ‘separate 
reality’, ‘near death’, ‘lack of fear of death’ and out-of-body experiences.74 States 
similar to those reported as near-death experiences have been described and include 
altered perceptions of time, a strong sense of detachment from the physical body and 
a sense of peace and joy.75
There are individual variations in motivations to use ketamine, as well as in what 
constitutes desired or unwanted effects. These have been described by a study as 
revolving around axes of sociability and intensity, with control over effect being 
an important concept. The voluntary versus involuntary entry into the k-hole39 is a 
salient example: for some it is too intense; for others it is a desired journey or place. 
Interviews with users suggest that the dose is a key point of control, which users 
associate with the possibility of negative or positive consequences of ketamine use. 
It has been reported that some users ‘test’ doses of ketamine to assess the strength 
of batches39 and then adjust doses for desired effects. Self-administration of titrated 
ketamine is attempted by users to achieve the desired amount of dissociative 
sensation, hallucination and transcendental experience.66
In addition to dose, frequency of use and past exposure have been self-reported as 
influencing the experience. In a study of recreational users, 58% interviewed said they 
had experienced the k-hole and that this was related to increased exposure to the 
drug (more than 20 times).28
Ketamine is also used for self-medication for depression and studies are currently 
being conducted to examine its possible antidepressant action. There is also anecdotal 
evidence that it is also used as self-medication for sleep and anxiety. Anecdotal 
evidence also suggests that it is commonly used by MSM for some forms of anal sex 
(‘fisting’) because of its anaesthetic and muscle-relaxing effects.
4.9.2. Methoxetamine
Reports from users suggest that methoxetamine produces ketamine-like effects. It 
has been marketed as much more powerful and longer-lasting than ketamine (but 
less so than PCP).4,13 Although the effects have been described as broadly similar to, 
albeit more intense than, those of ketamine, there may be individual variations. One 
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patient implied that the clinical effects of methoxetamine were subjectively very 
different from his previous ketamine use.76
The effects and dosage of methoxetamine are linked to mode of ingestion. Typically, 
it works as a short-acting mood enhancer, with powerful visual hallucinogenic and 
dissociative properties. The desired effects include euphoria, empathy, ‘cosiness’, 
intensification of sensory experiences, especially while listening to music, a mild to 
strong sense of dissociation, distortion of the sense of reality, vivid hallucinations, 
introspection and brief antidepressant effects.4 There is one report of the use of 
methoxetamine as an analgesic for self-medication for chronic foot pain.77
An ‘m-hole’ has been described by users, typically referring to a subjective state of 
dissociation, which mimics the out-of-body experiences of near-death experiences,75,78 
and is often accompanied by feelings of derealisation, depersonalisation and disorien-
tation, as well as vivid hallucinations.4
4.10. Mortality 
No deaths have been reported associated with the medical use of ketamine. In terms 
of recreational use, fatalities solely linked to ketamine toxicity are relatively rare. 
Ketamine-related deaths have been reported in adults after intravenous doses of 
500–1000 mg.79,80
A study by the National Programme for Substance Abuse Deaths (NPSAD) identified 
23 deaths in the UK from 1993 to 2006 where ketamine was mentioned in the death 
certificate or coroner’s report. However, ketamine was used on its own in only four 
of these cases, suggesting the particular risk is posed by poly-drug use and drug 
interaction. Nonetheless, the four fatalities associated with ketamine on its own have 
led some to question the high safety profile often attributed to ketamine.78
One of the limitations of the data on drug-related mortality was highlighted by the 
authors of the NPSAD study: the fact that even if ketamine was recorded in the 
post-mortem examination, this did not necessarily mean that it had contributed 
directly to the death. The four deaths from ketamine alone could, for instance, have 
been associated with the increased likelihood of accidents caused by the drug’s 
dissociative effects.78 The effects of ketamine, notably a reduced awareness of risk, 
a reduced perception of pain, a lack of coordination, a temporary paralysis and an 
inability to speak, would indeed put users at significant risk of injury or accidents. 
Although it has been argued that the highest risk of mortality from ketamine is 
through accidental death when intoxicated,57,81 there is little scientific evidence to 
support this at present.82 
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4.11. Acute ketamine toxicity*
In comparison with other drugs, ketamine in itself has a wide margin of safety,82 but it 
is often co-ingested with other substances, which increases both its associated harms 
and those of other substances. It is also gives rise to a greater risk of accidents (see 
section 4.11.3) and chronic use can lead to urological problems, which can be severe 
(see section 4.14.4).
Ketamine is characterised by its ability to cause unconsciousness, amnesia and 
analgesia, while sparing airway reflexes and maintaining haemodynamic stability.6 
Coughing and swallowing reflexes are maintained with minor suppression of the gag 
reflex, even when a user is very intoxicated, thus reducing the potential risk for users, 
if ketamine is used on its own.82
The Morgan and Curran review suggests the lack of severe acute physical health 
consequences, with no adverse outcome reported from large overdose, where no other 
substances are co-ingested.82 The main features of acute intoxication associated with 
ketamine are related to its psychedelic, dissociative and hallucinogenic properties.
In humans, a single dose of ketamine induces dose-dependent impairments in 
working and episodic memory, which can have a profound effect on the user’s ability 
to function.83 Ketamine is associated with direct neurotoxicity and can cause acute 
neuropsychiatric effects, such as agitation or ketamine-related psychotic states. 
Generally, clinical features are related to physical harm (e.g. agitation or accidents, 
and behaviours resulting from dissociative effects), but systemic toxicity with cardio-
vascular effects can occur and can be severe. 
Ketamine stimulates the cardiovascular system, leading to increased heart rate, cardiac 
output and blood pressure,82 and this will present a risk for people with hypertension 
or severe cardiac disease, and people at risk of stroke and raised intracranial pressure. 
Risks are increased with co-ingestion of stimulants82 and should be emphasised in 
harm reduction messages (section 4.16). 
4.11.1. Features of acute ketamine toxicity
The reported acute effects of ketamine use are summarised in Box 4.1.
Case reports provide some insight into how common these ketamine-related 
effects are. In a study by Ng et al.92 which reviewed 233 cases of presentations to 
an emergency department, the most common presenting symptoms were: impaired 
consciousness (45%), abdominal pain (21%), lower urinary tract symptoms (12%) and 
dizziness (12%). The most common physical symptoms included high blood pressure 
(40%), tachycardia (39%), abdominal tenderness (18%) and chest discomfort and 
palpitations (11%). However, no patient had serious cardiovascular complications 
(e.g. myocardial infarction or significant arrhythmias). In that study, 46% of patients 
* SPC data ketamine hydrochloride for injection can be found (for Ketalar) at http://www.medicines.
org.uk/emc/medicine/12939/SPC/Ketalar+Injection/#PRODUCTINFO. SPC states that respiratory 
depression may occur with overdosage.
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had a period of altered consciousness at some point after ketamine ingestion. This 
effect of ketamine was short-lived, however; only 14% of the patients had a score on 
the Glasgow Coma Scale of less than 15 when examined in hospital. Among patients 
who had blood tests performed, leukocytosis (in 36%) and a raised creatinine kinase 
level (in 32%) were the most common abnormalities, whereas 16% had abnormal 
liver function test results and 3% had abnormal renal function test results. Most of 
the patients were managed solely in the emergency department (72%) and 85% had 
no or only minor complaints.92
Box 4.1. The reported acute effects of ketamine use 
Dermatological 
Transient rash, predominantly in face and neck 
Gastrointestinal
Nausea 
Vomiting 
Neurobehavioural effects/psychiatric effects66,83,84
Hallucinations (visual and auditory)
Slurred speech 
Dizziness 
Numbness 
Confusion
Blurred vision 
Insomnia
Decreased sexual motivation 
Cognitive impairment
Aggression
Paranoia and display of dissociative-type symptoms 
Ataxia 
Acute dystonia (one report) 
Agitation (agitated patients are at risk of other effects including hyperthermia, rhabdomyolysis, 
self-injury, enhanced perception, depersonalisation, movement disorders and confusion)
Paralysis and muscle rigidity 
Ketamine-related psychotic states (typically short-lived with complete resolution).71,85 Among 
patients with schizophrenia stabilised on an antipsychotic, however, ketamine can cause a 
relapse of psychotic symptoms,86 which are idiosyncratic to those each individual exhibited 
during the acute phase of their illness87,88
Delirium
Polyneuropathy
Seizures 
Convulsions 
Cardiovascular and respirator89–91
Self-resolving sinus tachycardia (most commonly reported)
Hypertension (common) 
Chest pain 
Palpitation
Transient major Brugada ECG patterns (one case report) 
Raised intracranial pressure 
Pulmonary oedema 
Respiratory depression 
Cardiac and respiratory arrest Increased muscle tone and activity may produce hyperpyrexia
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There are few reports (albeit they are increasing in number) of methoxetamine use 
with analytical confirmation of the use of the substance.13,93 The effects of methoxet-
amine are dose dependent and include mild euphoria, hallucinations, disorientation, 
confusion, vertigo, analgesia, numbness, anxiety, tachycardia, hypertension, nausea, 
vomiting, diarrhoea, insomnia, agitation, sweating, catatonia and hypertonia; as well 
as elevated creatine kinase.13 Opiate-like effects have been described by a user (quoted 
by Rosenbaum et al.65), as well as respiratory depression, antidepressant effects and 
amelioration of phantom limb pain. Cognitive impairment has also been reported.47 
Partial amnesia to preceding events was noted in one report.77
Methoxetamine can cause rapid-onset neurological impairment; reversible cerebellar 
impairement has also been reported.94 A case series on the effects associated with 
methoxetamine use reported cerebellar ataxia, incoordination, dysarthria and 
nystagmus.76 Cerebellar signs were reversible in all cases observed, but recovery could 
extend over several days.76 Nystagmus and tremor have been reported.13,93,95
A report of three presentations with confirmed methoxetamine consumption at an 
emergency department shows that acute effects include ketamine-like dissociative/
catatonic symptoms, as well as features of sympathomimetic activation, with marked 
tachycardia and hypertension and agitation or aggression.93,96
Methoxetamine seems to have more severe side-effects than ketamine.58 It has greater 
effects than ketamine in terms of hypertension and other stimulant-like effects, 
including agitation, tachycardia and cerebellar features, such as ataxia.47 People have 
presented at hospital with methoxetamine intoxication with impaired consciousness. 
One report of three cases mentioned a patient presenting to hospital with a score on 
the GCS of 13, another 10 and the third 7.76
Corazza et al. cite a report of a fatality following an unconfirmed intravenous injection 
of both methoxetamine (8–100 mg) in addition to 400 mg of 5,6-methylenedioxy-
2-aminoindane (MDAI).58
4.11.2. Acute withdrawal
For withdrawal see section 4.13.2.
4.11.3. Poly-drug use: complicating factors for acute toxicity
Acute ketamine toxicity is often complicated by poly-drug use, which is common. In one 
study of attenders at an emergency department, 89% of self-reported ketamine users 
stated that they had used another drug and/or alcohol.89 It is therefore recommended 
that when people present with acute toxicity after ketamine use, clinicians consider 
the possible impact of other drugs ingested.6 Poly-drug use has also been implicated 
in death (section 4.10). 
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4.12. Management of ketamine-
related acute harms
4.12.1. Identification and assessment of acute toxicity
Diagnosis of acute ketamine intoxication in an ED setting should be made on clinical 
assessment and the recognition of the clinical effects of ketamine, also taking into 
account the common co-ingestion of a number of substances, including alcohol.
A case series of US ED presentations suggested that the diagnosis of ketamine 
should be considered when people (especially young people) present with agitation, 
tachycardia and either visual hallucinations or nystagmus, although the absence 
of the latter two findings does not rule out the possibility of ketamine misuse. The 
authors also recommend that if symptoms are not improving, they should investigate 
other drugs co-ingested or another differential diagnosis.90
Because the onset of the effects of ketamine intoxication are rapid and are generally 
short-lived, people will typically develop the adverse effects in the setting where the 
drug was ingested, in night clubs for example, and symptoms may resolve before they 
reach hospital. Indeed, some clubs provide a room or area where unwell users of club 
drugs are initially assessed and managed prior to transfer to hospital, if required.97 
Wood et al. analysed the patient presentations, one such facility over a five-month 
period in 2008/09. Of the 173 presentations for recreational drug toxicity, 37.9% 
were for ketamine, which was the second most frequently mentioned drug, after 
GHB/GBL. However, the authors stated that ketamine was not as commonly seen in 
the emergency department where they worked.98
Information on presentation to the hospital EDs resulting from ketamine toxicity is 
limited. In the UK, ketamine was the seventh most frequently searched for drug in 
TOXBASE® enquiries in 2012/13, at 2933 enquiries, but this was a 14.2% reduction 
from the previous year. A reduction was also noted in telephone enquiries over the 
same period.99 
4.12.2. Clinical management of acute toxicity
No antidote exists for ketamine overdose. The effects of ketamine are not reversed 
by naloxone and no other agents are available to reverse the effect on humans.7 
Activated charcoal is not necessary after ketamine acute intoxication, unless there is 
evidence that a co-ingestant may be contributing to the patient’s symptoms or, in the 
case of a large ingestion, if the patient presents very early.
Most patients will improve rapidly following acute ketamine toxicity.6 Although 
randomised controlled trials and other robust studies are not available, there is 
consistency in case reports and series that patients are best managed with: 
•	standard supportive care, with special attention to cardiac and respiratory functions, 
as the effects of the drug are usually short-lived;6,90,100
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•	benzodiazepines, where the patient is agitated;
•	consideration of other causes for clinical presentation, for example co-ingestion of 
other psychoactive drugs, head injury, hypoglycaemia etc.
•	removal of the person from auditory and visual stimulation until symptoms resolve 
has been recommended. A quiet environment, with minimum of external stimuli, 
may prevent excessive agitation.6
Observation of the patient until vital signs and mental state have normalised is 
also recommended. If symptoms fail to improve within an hour of presentation, the 
diagnosis and the management should be reviewed. 6,90
Profoundly obtunded (altered level of consciousness) patients may require airway 
support, intravenous fluids and titrated benzodiazepine therapy if they are agitated, 
hyperthermic or show overt sympathomimetic signs.92
As for ketamine, in the management of acute methoxetamine intoxication observation 
and symptom-directed supportive care13 are recommended; cardiovascular and 
respiratory support is sometimes needed. Oral diazepam and midazolam have been 
prescribed.
For up-to-date guidance on the management of ketamine acute toxicity, it is recommended 
that information be sought from the National Poisons Information Service (NPIS), specifically 
the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://TOXBASE.org/Poisons-Index-A-Z/K-Products/Ketamine/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
For up-to-date guidance on the management of methoxetamine acute toxicity, it is recom-
mended that information be sought from the National Poisons Information Service (NPIS), 
specifically the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/K-Products/Methoxetamine/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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4.12.3. Outcome of treatment for acute toxicity
A study of presentations at a Hong Kong ED92 reported that most of the patients 
(197/233; 85%) developed no, or only minor, complications. The majority (168/233; 
72%) were safely managed in the emergency department with supportive measures, 
including intravenous fluid and benzodiazepines for agitation. The five patients 
requiring management in an intensive care setting had all co-ingested other drugs 
that could have contributed to their clinical status.92
4.13. Harms associated with 
chronic ketamine use
4.13.1. Ketamine dependence
There is evidence that the administration of NMDA receptor agonists, such as 
ketamine, increases the release of dopamine in the nucleus accumbens, which is 
typically associated with addiction liability.101 There are case reports of ketamine 
dependence,37,68,102,103 but a lack of large studies, so the incidence is not known. It can 
be argued that the ICD-10 criteria for ‘dependence syndrome’ can be applied in some 
cases of chronic ketamine use.
Frequent ketamine use is associated with tolerance. Animal studies104,105 and human 
studies (children undergoing anaesthesia106) have shown a rapid development of 
tolerance with repeated ketamine dosing. A study of Australian recreational ketamine 
users found that 22% reported physical tolerance to ketamine.28 Frequent users 
of recreational ketamine report escalating dose, with one case report of a 600% 
increase from dose at first use61 and another a reported 760% increase from the 
initiation dose.41 Also of concern among frequent users are the compulsive patterns 
of behaviour: bingeing or using without stopping until supplies run out.41
There are no reports of methoxetamine dependence, but withdrawal has been 
described by users. Corazza et al. investigated through their analysis of drug user 
websites the effects of the chronic methoxetamine use. Withdrawal symptoms were 
described and included low mood and depressive thoughts, cognitive impairment for 
many hours, as well as insomnia and suicide attempts.4 
4.13.2. Ketamine withdrawal 
There is conflicting evidence on the existence of a specific ketamine withdrawal 
syndrome following cessation of ketamine use but a specific ketamine withdrawal 
syndrome has not yet been described.82 In a study of 30 daily users, 28 reported 
having tried to stop taking ketamine but failing; all reported ketamine cravings as 
the reason for failure. The study also found that 12 of the 30 daily users reported 
withdrawal symptoms – anxiety, shaking, sweating and palpitations.61 Other studies 
also reported craving and somatic and psychological symptoms (e.g. anxiety) of 
ketamine withdrawal.73,107,108
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Clinical experience suggests that ketamine withdrawal does exist. Although ketamine 
rarely produces serious withdrawal symptoms, the marked drug tolerance and psy-
chological dependence might contribute to the difficulty in abstaining.109 
It has been argued that in cases of sustained and heavy use, the existence of a ketamine 
withdrawal syndrome must be considered. 73 Although ketamine has a short half-life, 
metabolites are present for some hours and may be responsible for continuing 
symptoms.73 In addition, the symptoms of acute withdrawal may be short-lived 
and therefore not identified.110 However, case reports have described somatic and 
psychological aspects of anxiety as withdrawal symptoms.73,107,108 One case report 
mentioned withdrawal symptoms such as ‘chills’, autonomic arousal, lacrimation, 
restlessness, nightmares and psychological craving, with further ketamine use to 
relieve these symptoms.108 Another described in detail the effects of discontinuation 
of use on one patient, which included craving and drug hunting, anxiety, shaking, 
sweating, palpitations, tiredness, low appetite and low mood.73
4.13.3. Other harms of chronic use of ketamine
4.13.3.1. Ketamine-induced damage to the urinary tract
Ketamine use is associated with damage to the urinary system, which can be in the 
form of severe and in some cases irreversible bladder damage. This has been referred 
to as ketamine-induced ulcerative cystitis,82 although some have argued that it would 
be more appropriate and concise to describe it as ketamine-induced uropathy.111 The 
mechanism of damage from ketamine is not yet clear but the effects, which are not 
specific to the bladder, are most likely to result from direct toxicity of ketamine or its 
metabolites. Damage can affect the entire urinary tract.64 
The urological syndrome associated with ketamine use can lead to severe clinical 
symptoms:64 a small, very painful bladder, dysuria, painful haematuria, urge 
incontinence, frequent and urgent urination, nocturia, obstruction of the upper 
urinary tract, papillary necrosis,and hepatic dysfunction.64,111–113 Auxiliary examination 
showed cases of patients with symptoms including the following: sterile pyuria, 
contracted bladder (involving chronic inflammation with ulceration), erythematous 
swelling, necrotic mucosa, thin epithelium with neutrophilic and lymphoplasma cell 
infiltration in bladder mucosa, collagen and adipose tissue and bladder wall fibrosis 
with or without vesico-ureteric reflux and involvement of the upper urinary tract.111 
Cystoscopic inspection of the bladder also often shows a denuded urothelium, which, 
in the most severe cases, may slough off as intact sheets of cells. There are reports 
of young patients at an end-stage of the disease process who required cystectomy 
(bladder removal) and reconstruction, 64 with a serious impact on life expectancy.
It has been reported that 20–30% of ketamine users suffer from lower urinary tract 
symptoms.41,112 A study assessing the prevalence of urinary symptoms in a large cohort 
of non-treatment-seeking ketamine users found that harms to the urinary tract are 
dose related and are particularly common among regular and dependent users. 
Urinary symptoms are associated with an increased frequency of use and increased 
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amount used per session.1 However, the duration and/or amount of ketamine used to 
induce lower urinary tract symptoms is not known. 
The time of onset of lower urinary tract symptoms following ketamine misuse varies 
from a few days to a few years following the onset of use, with the severity being 
in part determined by the chronicity of use. Up to 100% of those using more than 
5 g per day report urinary symptoms.114 Because of the severe bladder pain, users 
frequently self-medicate for severe pain with ketamine, as the only effective means of 
pain relief they know, thus perpetuating the damage to their urinary tract.64
Studies of patients in chronic pain and palliative care receiving ketamine suggest 
individual variations, with some individuals are more susceptible than others to 
ketamine-related urological damage.64 Some series have reported a slight male 
predominance, but this is insignificant and not universally reported.115 At the present 
time, it would seem that ketamine-induced vesicopathy does not exhibit any gender 
bias.112
There is also a link between chronic ketamine use and kidney dysfunction. Hydro-
nephrosis secondary to stenosis (narrowing) of the ureter seems to be an emerging 
health problem associated with frequent and high-dose ketamine use.82 Chu et al.112 
reported in their study of ketamine-induced ulcerative cystitis that 51% of patients 
presented with unilateral or bilateral hydronephrosis. Four patients also showed 
papillary necrosis and this led to renal failure in one. Patients presenting with a history 
of ketamine use and urological symptoms need to have their kidneys imaged to rule 
out ureteric strictures.
Methoxetamine was marketed as more ‘bladder friendly’ than ketamine. However, 
there is emerging evidence from an animal study that exposure to methoxetamine 
can induce changes in the kidney and bladder after daily use, suggesting that chronic 
use of methoxetamine in humans may be associated with similar lower urinary tract 
symptoms, as those described for chronic ketamine use.116 
4.13.3.2. Gastrointestinal toxicity
People with prolonged and heavy use of ketamine have reported intense abdominal 
pain, referred to by users as ‘k-cramps’.41 The Ng study of presentations to EDs 
reported that 21% of ketamine patients presented with abdominal pain and 15% had 
abnormal liver function.92
Little is currently known about ketamine-induced abdominal pain. A small number 
of case reports113,117,118 have reported colic-like, upper gastric pain in young ketamine 
users who also presented with abnormal liver function. CT scans showed dilation of 
the common bile duct, mimicking cholecystitis. These symptoms appear to resolve 
once the patient stops using ketamine. In one UK case, a person had a dilated common 
bile duct that regressed with abstinence but recurred following a return to ketamine 
use.117 It has been postulated that biliary tree dilation might be related to dysfunction 
of the sphincter of Oddi, but the exact pathophysiology remains unknown.92,113,117,118
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4.13.3.3. Diabetic ketoacidosis (DKA) 
Ketamine can precipitate DKA in type 1 diabetes. The metabolic acidosis can be severe 
and has, in some cases, been associated with rhabdomyolysis.119–138
4.13.3.4. Drug interaction in HIV treatment
The use of ketamine raises general issues of adherence to antiretroviral regimens. 
As a substrate of the CYP450 system (specifically 3A4), ketamine may interact with 
certain antiretroviral medications, particularly the protease inhibitors with CYP450 
inhibitive properties.139 Also, its cardiovascular effects may be deleterious among any 
patients with underlying heart disease or lipid abnormalities.
4.13.3.5. Neurobehavioural, psychiatric and psychological effects
4.13.3.5.1. Cognitive impairment and memory impairment
Overall, studies have shown that infrequent ketamine users do not appear to 
experience long-term cognitive impairment. However, there is evidence that frequent 
ketamine users do have profound impairments of their short-term and long-term 
memory, although many studies have been cross-sectional and hence unable to 
address causation.82 
Neuropsychological harms appear to be related to frequency and quantity of dosing. 
Cognitive impairment and long-term psychological effects can result from prolonged 
use.45 Ketamine is associated with direct neurotoxicity and can cause acute neuro-
psychiatric effects. One longitudinal study showed that frequent ketamine use 
impaired visual recognition and spatial working memory; the degree of impairment 
was correlated with changes in the level of ketamine use over 12 months.81 Acute and 
acute-on-chronic use has been associated with impaired information handling within 
working memory and episodic memory, as well as deficits in semantic processing,83,140 
with men more affected than women.141
A case control study found that frequent ketamine use is associated with impairment 
of working memory, episodic memory, executive function and psychological well-
being.142 One-year follow-up with the same group showed the frequent users on 
increasing doses were more likely to have cognitive deficits, especially with spatial 
working memory and pattern recognition memory tasks, with both short-term and 
long-term memory affected.45
One study has shown that delusional thinking was positively correlated with the 
amount used by frequent users and persisted despite abstinence.142 A dose- dependent 
relationship was found at one-year follow-up, with frequent users more delusional 
than infrequent, abstinent and non-users.45 
Taking ketamine regularly has detrimental effects on memory function which last 
beyond the acute effects of the drug. Research suggests frequent use of ketamine 
produces long-lasting impairments in episodic memory and aspects of retrieval from 
semantic memory, which goes beyond ingestion.59
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A three-year longitudinal study of people who had ceased or reduced ketamine use 
reported that some may continue to experience drug-related symptoms three years 
later. This is particularly in relation to impairment of episodic memory which was 
still present three years later and possibly also attentional functioning. Schizotypal 
symptoms and perceptual distortion may also continue after ketamine cessation.143
Research on infrequent users (defined as taking ketamine more than once a month 
but less than three times per week) and daily ketamine users found that scores on 
measures for delusion, dissociation and schizotypy were higher in the daily users.20,45 
Morgan et al. found that daily ketamine users had patterns of symptoms similar to 
individuals in the prodromal phase of schizophrenia.45 Long-term ketamine users have 
more pronounced and persistent neuropsychiatric symptoms, generally characterised 
as schizophrenia-like symptoms. However, there is no evidence of clinically significant 
positive or negative psychotic symptoms among infrequent users.144 There is also 
little evidence of a link between chronic heavy use of ketamine and diagnosis of a 
psychotic disorder.82
4.13.3.5.2. Depression 
Frequent use of ketamine is typified by increased dissociative and depressive 
symptoms45 (as well as subtle visual anomalies103). Morgan et al.’s longitudinal study45 
found increased levels of depression in both daily users and ex-ketamine users over 
the course of one year, but not among infrequent users. However, the depression was 
not at clinical levels and the increase was not correlated with changes in ketamine 
use.82 
In contrast, there is some evidence that ketamine may be of therapeutic use for the 
management of treatment-resistant depression,15,16,145 as well as post-traumatic stress 
disorder.146 A recent large clinical trial testing the efficacy of intravenous ketamine in 
mood disorders reported that it was associated with a rapid and large antidepressant 
effect at 24 hours, significantly superior to midazolam. Ketamine appears to possess 
rapid antidepressant effects independent of its transient psychoactive effects.147
4.13.3.5.3. Neurological effects
Animal studies have shown that ketamine is directly neurotoxic. Abnormalities were 
also found in ketamine-dependent patients in bilateral frontal (including corpus 
callosum and anterior cingulate cortex) and left temporoparietal whiter matter. A 
recent human study of 41 ketamine-dependent users and 44 drug-free volunteers 
showed bilateral degeneration of frontal and left temporoparietal white matter 
in ketamine users.148 The study also reported that fractional anisotropy* values 
negatively correlated with the total lifetime ketamine consumption.148 
A case report has also demonstrated a reduction of frontal grey matter volume 
in ketamine-dependent patients. This reduction was correlated with duration of 
* White matter integrity can be studied by examining the degree of fractional anisotropy; this is a 
measure that quantifies the restriction (anisotropy) of water diffusion by tissue microstructure in each 
image voxel.
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ketamine use; reduction in the left superior frontal gyrus correlated with estimated 
total lifetime consumption.149
4.13.3.6. Social harms
A study of 100 recreational users of ketamine found that while one in five stated 
that they had ever experienced severe side-effects, more than a third (38%) reported 
having to deal with someone else who had suffered badly following ketamine use. The 
most common reported problems were in the areas of employment (20%), relation-
ships (5%), financial (5%) and legal (1%).28 The authors suggest that the problems 
were likely linked to the neurochemical consequences of ketamine use and the toxicity 
that might result.28
4.14. Management of harms related 
to chronic ketamine use
4.14.1. Numbers in specialist drug treatment for 
ketamine-related harms and dependence
Presentations among adults (18 years and over) in England for treatment for ketamine 
have risen year on year between 2005–06 and 2010–11 from 114 to 845 patients, 
falling to 751 in 2011–12. This rise followed by a reduction in presentation was also 
reported for young people under the age of 18, whereby numbers rose from 25 in 
2005–05 to 405 in 2010–11 then falling to 387 in 2011–12.150
4.14.2. Identification and assessment 
The first step for the identification of ketamine use and harms by specialist treatment 
services is to include questions relating to ketamine in routine care. The modification 
of existing national data collection tools is indicated, such as the Treatment Outcome 
Profile (TOP) forms. Assessment of ketamine use is similar to assessment for other 
drug use, with the addition of screening questions on urological and gastrointestinal 
symptoms and questions on the direct consequences of dissociation (e.g. cognitive 
impairment, sexual behaviours).
4.14.3. Psychosocial and pharmacological support
4.14.3.1. Psychological support
Information on psychosocial support is presented in Chapter 2 and is relevant for 
ketamine users. 
A small number of ketamine-specific studies have also been conducted. Copeland et 
al. suggest that the harms that require further investigation are the association of 
ketamine use with unsafe sex and injecting behaviours and its neurotoxic effects. 
They also argue that effective brief and early interventions are needed for those who 
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are at risk of harm because of ketamine intoxication and/or excessive and regular 
consumption. Interventions should address ketamine use in situations where there is 
a heightened risk of accidental death because cognition is impaired.7
Critchlow described the treatment of a person with dependence on ketamine that 
involved three motivational interviewing sessions in the first instance.73 Jansen and 
Maxwell suggest an abstinence-oriented approach be used for ketamine, similar to 
that used for psychostimulants.151 They suggest following the model used for cocaine 
and amphetamine dependence, with abstinence from all drugs from day 1. This may 
require the therapist to avoid being confrontational to prevent treatment drop-out; 
relapse prevention is also indicated.60
4.14.3.2. Pharmacological interventions for dependence and withdrawal
Ketamine withdrawal is described in section 4.13.2. Only one case report is available 
and that describes medically assisted detoxification carried out in conjunction with 
three sessions of motivational interviewing. Detoxification was carried out using 
a reducing regimen of diazepam over three days. The regimen was successful and 
eliminated the majority of withdrawal symptoms.73
Others have also suggested that, in cases of sustained heavy use and where acute 
withdrawal syndrome is a possibility, a benzodiazepine detoxification regimen 
modified from alcohol detoxification regimens may lessen the symptoms arising 
from discontinuation.152 It has been suggested that symptomatic management of 
withdrawal is indicated in some cases, with low-dose benzodiazepine as a starting 
point. There are no studies to support the use of other pharmaceutical agents, so any 
prescribing must be carried out based on clinical assessment. 
4.14.3.3. Aftercare and support
Chapter 2 presents information on aftercare. A few ketamine-specific studies have 
been conducted, with some suggesting that ketamine users’ ability and willingness to 
abstain from using the drug may be low, even when (and perhaps because) experiencing 
significant urological problems. Chu et al. showed that 9 out of 24 ketamine users 
with bladder problems were able to abstain from the drug and complete the Pelvic 
Pain and Urgency/Frequency questionnaire.112 Another study found that only 3 out of 
10 patients stayed ketamine free for more than one year.109
4.14.4. Management of urinary tract problems
It is recommended that patients with recurrent urological problems, or patients 
with unexplained urinary symptoms, are assessed by a urologist to exclude other 
causes and evaluate any damage. Any patients with unexplained symptoms should 
be screened for ketamine use.64 Appropriate support to stop ketamine use must be 
available, as well as advice regarding appropriate medical pain relief.
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The most effective treatment for ketamine-related urological problems is cessation of 
use and it is essential that use of ketamine is stopped upon recognition of symptoms. 
Strategies are limited when use continues.153 If drug cessation is achieved, the 
syndrome may be partially or completely reversed, but if ketamine use persists, so 
do symptoms. In a few patients, however, symptoms persist despite stopping drug 
use.63 Patients should also be referred to specialist drug services. 64 A survey of UK 
urologists suggested that approximately a third of urological problems resolved after 
drug cessation, a third remain static and a third progressed.153
Treatment for urinary tract symptoms is either symptomatic (analgesia, urinary 
diversion) or the treatment of complications (e.g. percutaneous nephrostomy 
insertion).153 Early stages of the urological syndrome may present in casual or 
weekend users as episodes of cystitis, which can be treated empirically64 (based on 
practical experience and observation). More frequent users may have irreversible 
damage and scarring. The most affected patients may require major surgery, in the 
form of cystectomy and bladder reconstruction.64
Where ketamine is identified as a factor, it has been recommended that renal function 
be assessed; a CT urogram can also be an important investigation to reveal the extent 
of the disease. A urine culture is mandatory. A routine evaluation of the upper tracts 
with a CT urogram can rule out ureteric stricture and cystoscopy can be used to assess 
bladder capacity.64 In patients with normal renal function and with an ultrasound that 
shows no hydronephrosis, a CT scan may not be necessary.154
A strategy for the treatment of ketamine-related urological problems has been 
suggested by Wood et al.64 Central to this is the requirement for patients to stop their 
ketamine use. However, this may be complicated by a need for pain control in those with 
ulcerative cystitis. This will require the treating team to develop an alternative pain 
management plan with the patient. There may also be a lack of motivation to abstain 
and non-compliance with urological investigation and treatment appointments.64
Winstock et al. recommended a multidisciplinary approach promoting harm reduction, 
cessation and early referral, to avoid progression to severe and irreversible urological 
pathologies.63 Similarly, Wood et al. suggest a need for liaison between specialist 
drug services and local urology services.63 Some drug agencies have developed 
proactive models.64 However, this is not always possible, as patients can see urology 
departments outside their residential area. In this case, support is best organised by 
the general practitioner.64
4.15. Public health and public safety 
4.15.1. Viral and bacterial infections
Studies have reported that ketamine injecting is associated with high-risk behaviours 
like the sharing of injecting equipment and paraphernalia,155,156 poly-drug use156,157 
and multiple injections. Ketamine injecting puts the user at risk of viral and bacterial 
infections and hence the potential risk of their transmission to others.
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4.15.2. Accidents and assaults
Ketamine impairs psychomotor functioning dose dependently and higher doses 
increase the risk of accidents.158 Ketamine use has been associated with driving 
accidents in Hong Kong: 9% of fatal drug and alcohol-related single-car collisions 
during 1996–2000 involved ketamine.159 New regulation (coming into force in March 
2015) has identified ketamine as one of the specified controlled drugs for the purposes 
of section 5A of the Road Traffic Act 1988.160
Ketamine use can place the user at risk of sexual assault, although studies have 
suggested that ketamine is not implicated in drug-facilitated assault.161,162
4.16. Harm reduction
It has been recommended that all ketamine users are given the standard harm 
reduction advice, which includes not using the drug when alone, avoiding poly-use 
and co-ingestion of other substances, including alcohol, and information on a safe 
environment and safer injecting techniques.7,59
The following more specific harm reduction advice should be given to ketamine users:
•	Users should be advised to measure dose carefully and start with a small test dose. 
They should also be advised to measure intervals between doses accurately.
•	The use of ketamine with other drugs including alcohol should be avoided.7
•	Users should minimise the risk of accidental injury by ensuring that intoxicated 
friends are always accompanied by others who are not.82 The dissociative effects 
of ketamine puts users at risk: drowning in shallow waters, including a bath, and 
hypothermia from long walks have been highlighted as risks.
•	Users should be made aware of the link to urological problems, and other ketamine-
related harms.
•	Users who develop tolerance and who find themselves needing to use increasingly 
higher doses, and who are using more frequently than intended, should be advised 
to monitor their intake. Diaries and electronic tools can be very useful.
•	Advice should be given to users that those acutely intoxicated should not be left 
alone in case of accidents and should have with them someone who has not used 
the substance.82 
•	Users should be made aware of the potential neurological and cognitive changes 
following frequent use of ketamine, which can result in poor performance at school, 
college or work.82
•	Ketamine users who feel depressed and anxious when stopping or reducing ketamine 
should be encouraged to seek professional help to manage their symptoms during 
a gradual reduction or detoxification. 
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•	Users should be made aware that the anaesthetic topical effects of ketamine mean 
that they may not feel pain from tissue trauma and extra caution must be exercised 
with any sexual activity which risks tissue damage (e.g. ‘fisting’).
•	Daily use of ketamine should be avoided, due to the urological risks.
•	Ketamine users with urological problems should be strongly encouraged to cease 
using the drug.
•	Advice should be given to users with urological problems not to deliberately 
dehydrate and to seek medical help and referral to a specialist to reduce the risk of 
permanent harm.
Corazza et al. in their analysis of internet sites found that users themselves suggested 
that dosages should increase only gradually. Users recommended that doses of 50 mg 
should not be exceeded on the first occasion of use, or when the drug was taken orally. 
The websites also advised users not to use methoxetamine with alcohol, tetrahydro-
cannabinol, selective serotonin reuptake inhibitors or monoamine oxidase inhibitors. 
Users were advised to try a test dose of a few milligrams and to wait 2 hours before 
re-dosing.
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Chapter 5
Nitrous oxide
Drug group: depressant/dissociative/inhalant
5.1. Street names
Street names at the time of publication include: Laughing Gas, Hippie Crack, Whippets 
(cartridges of nitrous oxide), Chargers, Bulbs. 
Other names may be used locally. 
5.2. Legal status
In the UK it is legal to sell nitrous oxide to people aged over 18 but not under if 
may be assumed that they are likely to be inhaling it. The sale of nitrous oxide for 
catering and other legitimate reasons is legal, although its sale in gas-filled balloons 
or canisters intended for human recreational use violates the Medicines Act.1
5.3. Quality of the research evidence
The evidence on the management of the acute and chronic harms associated with 
the recreational use of nitrous oxide is limited, consists mainly of case reports, with 
occasional experimental studies into acute effects. There are few findings on acute 
harms and interventions relating to the use of the drug, but consistent findings on 
the chronic effects of prolonged nitrous oxide use.
5.4. Brief summary of pharmacology
Nitrous oxide is a gas whose pharmacology is not well studied and existing evidence 
is not conclusive. It has been suggested, however, that opioid receptors may be 
responsible for its analgesic properties2 and a study has shown that naloxone inhibits 
its analgesic effects.3 Furthermore, nitrous oxide may act as an N-methyl-D-aspartate 
(NMDA) antagonist, similar in nature to ketamine, another anaesthetic (Chapter 4).2 
It works primarily via the opiate system, mediating the release of beta-endorphins 
and directly binding to mu, delta and kappa opiate receptors.4 Nitrous oxide is used 
clinically as an anaesthetic gas with pain-relieving properties. 
It is also a ‘dissociative’ drug. Although the effects of the drug on the brain are not 
fully understood, its dissociative effects are probably caused by preventing the normal 
action of the NMDA receptor.
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Nitrous oxide is rapidly absorbed via pulmonary circulation.4 Due to high lipid solubility 
it passes easily through the blood–brain barrier and has a rapid onset of action; it is 
cleared from the body within a few hours.5 
The use of nitrous oxide leads to vitamin B12 depletion, which is believed to be due to 
its effect on cobalt in vitamin B12, whereby the vitamin is converted from an active, 
monovalent form to an inactive, bivalent form.6
5.5. Clinical and other legitimate 
uses of nitrous oxide
Nitrous oxide has been used as a medical anaesthetic for over 150 years and 
continues to be widely used for medical, dental and veterinary purposes. It is also 
used for analgesia and can help relieve anxiety. It is used in various settings, including 
ambulances, emergency departments, relief for women in labour and in dentistry, 
where its short duration of action is an advantage.1 The use of nitrous oxide in 
anaesthesia, however, has long been challenged because of the hazards posed to 
both clinicians through unintended occupational exposure and patients by its haema-
tological, neurological, myocardial and immunological effects, and because it can lead 
to postoperative nausea and vomiting and expansion of air-filled spaces.7
Nitrous oxide has been shown to ameliorate craving and withdrawal symptoms from 
alcohol, opioid, nicotine, cocaine and cannabis.8–13 
Outside of human and animal applications, nitrous oxide is used as a fuel additive, 
as an oxidising agent to increase the power of cars, as a component of rocket fuel, 
as an aerosol dispersant and in the catering industry in the dispensing of whipped 
cream. This forms the basis of its legal sale on websites in the form of small canisters 
or larger tanks, which are labelled with ‘approved for food use’ and not intended for 
recreational use.1
5.6. Prevalence and patterns of use
The use of nitrous oxide for recreational purposes is not new, as ‘laughing gas parties’ 
were popular in Victorian times, mostly in the context of variety performances in 
music halls, theatres and carnivals. There is anecdotal evidence that nitrous oxide 
is currently popular for use in some clubs and music festivals, where it is bought as 
gas-filled balloons. This has led to moves by the Medicines and Healthcare Products 
Regulatory Agency (MHRA) to control the drug’s supply under section 52 of the 1968 
Medicines Act.14
The use of nitrous oxide for recreational use was recorded in the Crime Survey for 
England and Wales (CSEW; formerly the British Crime Survey) for the first time in 
2012/13. The 2013/14 CSEW found that:
•	2.3% of adults aged 16–59 had taken nitrous oxide in the last year; 
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•	7.6% aged 16–24 had taken nitrous oxide in the last year. 
This prevalence was not significantly different from that in the previous year. 
The 2011/12 MixMag Global Drug Survey reported lifetime recreational use by 49.6% 
of UK respondents and past-year use by 27.2%, and past-year use by 43% of UK 
regular clubbers.15 The 2011 report from the UK Advisory Council on the Misuse of 
Drugs (ACMD) on novel psychoactive substances presented anecdotal evidence of 
widespread use at the Glastonbury Festival in 2010.1
Wood et al. investigated the use of nitrous oxide among 330 men who have sex with 
men (MSM) in gay-friendly London clubs. Levels of use reported were lower than those 
reported in the Global Drug Survey, with 28.1% reporting lifetime use and 11.9% use 
in the previous year.16
5.7. Routes of ingestion and 
frequency of dosing 
Nitrous oxide is used for its euphoric effects. The onset of the effects is immediate 
and they last for approximately two minutes; users may take many ‘hits’ over a few 
hours.
Nitrous oxide is a colourless gas that is slightly sweet smelling and tasting. It is 
typically inhaled, sometimes referred to as ‘nagging’, commonly from balloons or steel 
bulbs. The latter (sometimes called chargers) are small cartridges containing highly 
pressurised nitrous oxide that are available from catering suppliers and used for 
whipped cream. These containers or cylinders are sometimes referred to as whippet/
whippit. Cylinders vary by brand, but are approximately 6 cm long, 1.8 cm wide and 
have a wall approximately 2 mm thick to withstand the pressure of the gas. Most 
contain approximately 8 g of nitrous oxide under pressure and are non-refillable. 
These ‘bulbs’ are supplied with a dispenser into which, when fitted, they release their 
compressed gas. If the dispenser is not filled with cream, the nozzle simply releases 
the gas only. A balloon can be placed over the nozzle to capture the nitrous oxide.14 
Alternatively, ‘whippets’ can be opened with the ‘cracker’ on the cream dispenser and 
the nitrous oxide again released into a balloon, from which it then can be inhaled. 
Both whippets and crackers can be obtained from online suppliers and in ‘head shops’. 
The quality (purity) of the nitrous oxide depends on its source. Products intended for 
food use are of higher quality, especially if they originate from the UK. Products for 
industrial use may be adulterated or impure. Regular and long-term users of nitrous 
oxide in particular should be aware of impurity. The typical cost at the time of writing 
is £3 for a balloon-full, but it seems to be common to buy in bulk, for parties, at 
around 24 chargers for £10, which is less than 50p a balloon.*
* This was ascertained by searching a listing of small advertisements for the London area (http://www.
gumtree.com/other-kitchen-appliances/london/nitrous+oxide).
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Nitrous oxide is also available in much larger gas cylinders intended for medical 
or industrial use. The use of these, for purposes other than those intended, can be 
dangerous. Unsafe methods include breathing directly from a cylinder using a face 
mask, opening a cylinder tank in a car or small room or filling a bag with the gas and 
putting it over the head. Cylinder tanks of nitrous oxide intended for cars can contain 
harmful contaminants like sulphur dioxide. 
Case studies have shown that the average number of containers/whippets inhaled in 
a session is usually fewer than 5;17 for example, a survey of students in Auckland found 
that recreational use typically amounted to 2–5 containers in a session.18 However, 
other studies report a range of 10–100 bulbs used in one session.17–28 Recreational 
users will typically inhale a number of small, imprecise doses from small containers 
and consequently it may be difficult to assess the quantity of nitrous oxide. 
An experimental study testing the effects of nitrous oxide in 12 volunteers found that 
the primary effects were found only at the inhalation of 20% to 40% concentrations.29 
At the inhalation of 40% nitrous oxide (the highest concentration tested), subjects 
were confused, sedated, high, dysphoric and stimulated, but fatigue and depression 
were observed once the effects had worn off.
As nitrous oxide is used as an anaesthetic, official advice has been issued on the 
short-term occupational exposure limit, to avoid harms. The advice on this ranges 
from 25 parts per million (ppm) to 100 ppm,7 and may provide an indication of the 
level at which harms can occur in recreational users. The harms resulting from nitrous 
oxide are largely determined by its mode of use rather than its direct physiological 
effects. Inhalation through balloons or canisters is relatively safe, whereas the use of 
airtight bags, masks or respirators carries a high risk of asphyxiation.14
5.8. Desired effects of nitrous 
oxide for recreational use
Nitrous oxide is used recreationally to induce euphoria. Its effects are very short-lasting 
and typically include a rush of dizziness, relaxation, laughing fits, auditory distortions 
and sometimes hallucinations. As an anaesthetic gas, it affects coordination and 
awareness. It is reported that some people use it to self-manage pain and anxiety. 
Nitrous oxide consumption also reduces psychomotor performance.30
There is variability in the subjective effects of the drug. In one study, 12 individuals 
(under controlled, blinded conditions) were given a choice between oxygen and nitrous 
oxide after a sampling period for both. There was significant individual variability in 
the reported effects of the drug. Those who reported feelings of ‘tingling’, ‘drunk’, 
‘dreamy’, ‘coasting’, ‘floating’ and ‘having pleasant bodily sensations’ during the nitrous 
oxide sampling period chose nitrous oxide more often during the choice period.30
There is disagreement in the literature as to whether there are gender differences in 
the effects of nitrous oxide.29,31
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5.9. Mortality
A number of cases of death by asphyxiation are reported among individuals who 
were using nitrous oxide at the time. Although nitrous oxide does not depress the 
respiratory drive significantly, the normal physiological response to hypoxia is blunted 
when 50% nitrous oxide is given and deaths are often in relation to bags put over the 
head in order to facilitate inhalation32 or inhalation in cars. 
5.10. Acute harms 
5.10.1. Acute toxicity
The 2011 ACMD report on novel psychoactive substances suggested that nitrous 
oxide typically has few short-term adverse effects, other than headache for some.1 
Harms are likely to result from disorientation and unsteadiness caused by inhalation 
(e.g. falling down29). There are also isolated instances in the literature of hypothermic 
skin trauma resulting from contact with chilled canisters.33 
Nonetheless, acute exposure to nitrous oxide may irritate the respiratory tract and 
acute use of inhalants in general can result in sneezing, coughing, excess salivation 
and conjunctival erythema.4 It can also cause asphyxia, headache, nausea, vomiting, 
Box 5.1. Features of acute intoxication with nitrous oxide
Respiratory effects
Asphyxia
Hypoxia
Neurological and psychiatric effects
CNS depression
Convulsions
Psychiatric symptoms
Headache
Myeloneuropathy
Polyneuropathy
Dizziness
Excitement
Paraesthesias
Paralysis
Psychosis
Cardiovascular effects
Hypertension
Cardiac dysrhythmias
Megaloblastic anaemia
Leukopenia
Anoxia
Metabolic features
Thrombocytopenia
Gastrointestinal symptoms
Nausea and vomiting
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dizziness and excitement, and to central nervous system (CNS) depression, convulsions 
and death. Hypertension and cardiac dysrhythmias are possible. Patients can present 
with altered mental state, paraesthesias, ataxia and weakness or spasticity of the 
legs.7 Nausea, cyanosis and fainting have been reported as a result of nitrous oxide.34 
The features are summarised in Box 5.1.
When nitrous oxide is inhaled from a balloon it displaces the air in the lungs, thus 
temporarily preventing oxygen from entering the bloodstream and potentially 
causing tachycardia and transient peripheral neurological symptoms. There have 
been reports of fatalities after acute exposure, due to asphyxiation.35,36
Nitrous oxide is insoluble in blood, and therefore rapidly clears into the alveoli from 
the blood once inhalation has ceased.37 At the high concentrations (e.g. >70%) used in 
anaesthesia there is the potential for hypoxia if a high concentration of oxygen is not 
then provided. Nitrous oxide may have effects on immune function, but the evidence 
is unclear on this issue.7
There is a risk that users may confuse the much more toxic or potent gases or volatile 
substances, such as butane, with nitrous oxide. If a patient requires admission to an 
emergency department, there is a chance that he or she has used butane, which does 
not only have different effects but also different harms. The use of nitrous oxide is not 
as life-threatening as the use of butane, which can cause arrhythmia and increases 
the risk of sudden cardiac arrest. Life-threatening risks of nitrous oxide are linked to 
mode of use, which may lead to hypoxia or anoxia.
5.10.2. Acute withdrawal
For withdrawal see section 5.12.1.1.
5.10.3. Poly-drug use and drug interactions 
There may be some increase in the effects of nitrous oxide when it is combined with 
alcohol.38 It is possible that nitrous oxide ingested at the same time as stimulants has 
a greater effect on blood pressure and heart rate. There is anecdotal evidence that 
nitrous oxide can briefly enhance the effects of psychedelics like LSD, or bring the 
effects back strongly when the drug is wearing off, which could be very frightening if 
unexpected. 
As it is not metabolised by the liver, the potential for drug interactions with other 
agents, including antiretrovirals, is very low.
5.11. Clinical management of acute toxicity
5.11.1. Identification and assessment of acute toxicity
The diagnosis of acute nitrous oxide toxicity should be made by clinical assessment. 
There are no rapid urine or serum field tests, so analytical assessment should not be 
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considered a component of routine diagnosis. Assessment should be based on the 
recognition of the clinical toxidrome associated with nitrous oxide and the potentially 
harmful modes of use.
5.11.2. Clinical management of acute toxicity
The management of acute harms resulting from nitrous oxide include removal 
from exposure and providing symptomatic treatment for any resultant problems. 
TOXBASE® recommends observation for at least one hour after exposure and a need 
to perform a 12-lead ECG and a full blood count in symptomatic patients. Where 
there is chronic use of nitrous oxide, it is recommended that B12 concentration is 
checked in symptomatic patients (see section 5.12.2).
5.12. Harms associated with 
chronic use and dependence
5.12.1. Dependence
There are currently no reported instances of nitrous oxide dependence in the 
literature, and it has been suggested that its addictive potential is low as it is only 
a partial opiate agonist and its euphoric effects fade rapidly. 20 However, as the 
effects are short-lasting and pleasurable, people may use it re-dose frequently. There 
is anecdotal evidence of psychological dependence, and daily use of nitrous oxide 
should be avoided in particular by people with mental health problems or other 
psycho logical vulnerability. 39
5.12.1.1. Withdrawal
Nitrous oxide is sometimes used in a compulsive way by some individuals, possibly 
explaining one of its street names, ‘hippie crack’. There are no significant withdrawal 
symptoms aside from the desire to use more nitrous oxide.
For up-to-date guidance on the management of nitrous oxide acute toxicity, it is recommended 
that information be sought from the National Poisons Information Service (NPIS), specifically 
the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/N-Products/Nitrous-oxide/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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5.12.2. Other harms – vitamin B12 deficiency
The harms caused by nitrous oxide tend to stem from heavy usage and specifically 
the depletion of vitamin B12 by oxidising the cobalt moiety of the vitamin.23,40,41 By 
inactivating vitamin B12, a critical cofactor in haematopoiesis and lipid membrane 
formation, nitrous oxide can cause anaemia and neuropathy; severe myelo neuropathy 
is one complication of nitrous oxide use.23
Regular or long-term use of nitrous oxide has been associated with leukopenia, 
thrombocytopenia, myeloneuropathy23 and vitamin B12 deficiency leading to severe 
megaloblastic anaemia.42 It can also lead to neurological complications and psychiatric 
symptoms, including psychosis, paralysis, paraesthesiae and sensory loss, though these 
can respond to vitamin B12 replacement. One case report has described peripheral 
neuropathy43 and a number of others have given details of myelopathy5,17,23,24,26,44–49 
and polyneuropathy43 as a result of sustained nitrous oxide misuse and associated 
vitamin B12 deficiency. This has been seen to present with paralysis21 and ataxia,23 
and may be confused with Guillain–Barré syndrome.26 A case report of cardiac arrest 
has been published.21
Although the evidence is limited, it is possible that nitrous oxide can worsen some 
mental health problems, and its use has been linked to manic relapse.50 One case report 
describes a psychotic episode occurring in a patient with no history of psychosis who 
had been regularly using nitrous oxide.42
There is a growing body of evidence, mainly from animal studies, that nitrous oxide 
may have some neurotoxic effects. Rat studies suggest long-term developmental 
issues such as memory impairment, but the long-term cognitive outcomes in humans 
remain unknown.2
5.13. Management of harms 
related to chronic use
Suggested treatment for the chronic harms related to the use of nitrous oxide 
resulting from vitamin B deficiency include parenteral folinic acid,23,44 intramuscular 
vitamin B12 injection17,23,43,45,47 and intravenous methylprednisolone.5 A number of 
studies have shown that stopping exposure and introducing vitamin B supplementa-
tion may result in either partial or complete recovery, although this can take months.45 
A case report suggests that where symptoms persist, methionine treatment has been 
successful where B12 treatment alone has failed.51
One case report has highlighted the need to consider vitamin B12 deficiency in 
patients who arrive at a hospital with psychiatric manifestations who report a history 
of nitrous oxide exposure or misuse in the recent or remote past.42
5.13.1. Psychosocial and pharmacological support
There is no relevant pharmacological support. For psychosocial support, see Chapter 2.
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5.14. Harm reduction and public health
The inhalation of nitrous oxide through the balloon method may carry less risk than 
other methods and minimises the risk of anoxia. Users will drop the balloon if they are 
getting too hypoxic or lose consciousness. Other methods may carry more risk, in that 
the user may become unconscious through anoxia and continue to have insufficient 
access to oxygen.
The following harm reduction measures have been identified:14
•	Users should always inhale nitrous oxide from a balloon – never from a tube or 
mask, or directly from a dispenser or compressed air tank.
•	Users must be careful not to confuse nitrous oxide with other gases and volatile 
substances, which have far greater risks.
•	Users should avoid inhaling while standing up and should be aware of their 
immediate surroundings (e.g. steep drops, fires, rivers).
•	The use of nitrous oxide should be avoided in particular by people with problems 
with low blood pressure or any mental health issues.
•	Users should stop inhaling if they feel any physical discomfort, such as ‘pins and 
needles’ or numbness.
•	Regular and long-term users of nitrous oxide in particular should be aware of the 
purity of the products they use and of the impact of any impurities.
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A wide range of substances are used recreationally for their stimulant effect, notably 
of course caffeine and nicotine. Illicit substances so used include cocaine,  the range 
of amphetamine-type substances (ATS) and pipradrols. Substances with a stimulant 
effect have been used by successive generations, and psychostimulants form a large 
proportion of club drugs and novel psycho-active substances . The toxic effects of the 
latter have not been well studied,  but are expected to be similar to those of better-
understood stimulants.
The patterns of effects of the various stimulant agents vary, but stimulant drugs 
overall stimulate the brain and central nervous system by increasing the  activity of key 
neurotransmitters, such as noradrenaline, dopamine and serotonin. This  takes place 
through a number of mechanisms, including increasing release of and/or inhibiting 
reuptake of these chemicals. 
The extent to which a specific drug elevates these levels will determine the effect. 
Drugs that elevate dopamine significantly will induce greater reward and pleasure 
or even euphoria, but are also more likely to increase a desire to re-dose. Those that 
elevate noradrenaline will be less euphoric, but may increase alertness and cause 
anxiety. They also increase strain on the heart and circulatory system. 
There are other new stimulant-type drugs (NPS) that are not used for their psycho-
active effects, but as appetite suppressants and ‘fat burners’. These include appetite 
suppressants and ‘fat-burners’ which can have adverse effects, but which fall outside 
the remit of this document.
Part III begins with a chapter on non-amphetamine-type stimulants, cocaine and 
synthetic cocaine derivatives, as well as piperazines (the last only briefly because their 
use has faded away in the UK since 1-benzylpiperazine became a controlled substance 
in 2009). Chapter 7 then gives an overview of the wide range of amphetamines that 
are currently used recreationally in the UK, before Chapters 8–11 give further details 
on more specific groups. 
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Chapter 6 
Cocaine, synthetic cocaine 
derivatives and piperazines
This chapter reviews the literature on recreationally used stimulants which are not 
phenethylamines. These include cocaine as well as synthetic cocaine derivatives, and 
piperazine. Crack cocaine is not recreationally used as a ‘club drug’ and is therefore 
excluded from this review, which focuses on powder cocaine only.
6.1. Cocaine: an overview
Powder cocaine has been used in the UK for a number of decades and remains the 
second most commonly used drug in the country, after cannabis. It is the drug that is 
most commonly used in a ‘club drug’ context (unlike crack cocaine). 
Generally speaking, clinicians in the UK have experience in managing the harms of 
powder cocaine and there is a body of evidence relating to its acute toxicity and to 
dependence in particular. This document will therefore not cover cocaine to the same 
extent and level of detail as for the other novel substances. In particular, this chapter 
will not address the management of chronic harms of (powder) cocaine and cocaine 
dependence. Cocaine-related disorders are clearly identified in ICD-10* and there is a 
large body of evidence on cocaine-related harm and its management, including the 
management of dependence and withdrawal.1–6 This includes a number of Cochrane 
reviews.† 
This chapter will, though, address the most common acute health problems associated 
with cocaine. In addition, it ends with a brief section on piperazines, which, like 
cocaine, are sympathomimetic stimulants but not phenethylamines, as are the other 
stimulant drugs discussed in Part III (Chapters 7–11). 
There are no Cochrane reviews relating to cocaine acute intoxication and the evi-
dence-base is not as substantial as it is for dependence. Acute cocaine intoxication 
is a common reason for presentation to emergency departments in the UK and 
elsewhere in Europe,7 but the data show that there is there is an under-recognition of 
acute cocaine toxicity in patients presenting with chest pain.89 
There are aspects of acute cocaine toxicity that are different from the acute toxicity 
associated with the stimulants to be covered in the other chapters in Part III of this 
document, in particular myocardial ischaemia and chest pain (related to vasospasm) 
and arrhythmias (related to ion channel effects). Cocaine-induced psychosis (CIP) is 
* See http://www.icd10data.com/ICD10CM/Codes/F01-F99/F10-F19/F14.
† Further examples can be accessed at ttp://www.thecochranelibrary.com/details/browseReviews/ 
579489/ Cocaine.html.
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also a recognised cause of presentation to emergency departments. This chapter 
therefore focuses on cardiovascular disorders and psychosis.
6.2. Legal status and pharmacology
Cocaine is a Class A Schedule 1 drug under the Misuse of Drugs Act 1971.
Cocaine increases the activity of monoamine neurotransmitters in the central and 
peripheral nervous system by blocking reuptake transporters of dopamine, nor-
adrenaline and serotonin. In addition, cocaine modulates preprodynorphin and the 
mu and kappa receptors of the endogenous opiate system.10 Cocaine stimulates the 
sympathetic nervous system.
6.3. Prevalence, patterns of use, desired and 
unwanted effects and routes of ingestion
The 2013 report from the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) indicated that approximately 2.5 million young adults (aged 15–34) in 
the European Union had used the drug in the previous year, with high levels of use 
concentrated in the UK, Denmark, Spain, Ireland and Italy.11 However, these countries 
with high levels of use have reported in recent years a declining trend in cocaine use, 
as well as in treatment demand.11
The use of cocaine powder continues to be relatively high in the UK, in comparison 
with most other European countries. The 2013/14 report from the Crime Survey for 
England and Wales (CSEW) indicated that cocaine was the second most commonly 
used drug after cannabis by all adults in the UK between the ages of 16 and 59 years: 
2.4% had used it in the previous year. This was significantly higher than in 2012/13, 
when it was used by 1.9% of adults. It was also significantly higher than in 1996 
(0.6%), although it was lower than during the peak of its use, in 2008/09 (3%).
After a period of decline in the purity of cocaine powder sold on the illicit market in 
the UK, the mean purity of the drug increased in 2011,12 as it did in other countries 
with sizeable consumer markets, such as France and Germany.13 The impact of this on 
recreational use remains to be seen.
The desired effects of cocaine use are feelings of increased energy, alertness and 
intense euphoria, as well as a decrease in tiredness, appetite and sleep. Unwanted 
effects include fear, irritation, panic attacks, paranoia, impaired judgement, delusions 
and disturbance of sleep. Weight loss and hallucinations occur with increased doses 
or a more efficient route of administration.14 Following binges in particular, a user is 
often anhedonic, irritable and anxious, and has low mood.15–17 
Cocaine intoxication has been associated with anorexia, insomnia, anxiety and motor 
hyperactivity. It is linked with increased adrenergic tonus, manifested by diaphoresis, 
dilated but reactive pupils, hyper-reflexia and tachycardia. Stereotypical movements 
of face, mouth and extremities and even grand mal seizures may be present.18 
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Cocaine can be smoked, snorted or used intravenously. It is absorbed readily through 
all mucosae. The peak effect occurs 1–90 minutes after administration, depending on 
the route. The half-life varies between a few seconds and 20 minutes, depending again 
on the mode of administration (inhalation, intravenous administration or snorting, 
respectively ). After oral use, the half-life is longest, at approximately 3 hours.19
6.4. Mortality
Figure 6.1 shows the mortality associated with cocaine use in the UK (data from the 
Office for National Statistics).20
Cocaine users have an increased mortality compared with the general population.21–23 
Cardiac disease is a common cause of cocaine-related sudden death and a number of 
post-mortem studies have demonstrated an extremely wide range of serum cocaine 
concentrations in individuals who died following its use, suggesting that no blood con-
centration is always safe.24 Cocaine users often smoke and have a high use of alcohol, 
which will also have an impact on risk. The combination of cocaine and cigarette use 
results in greater increases in heart rate and vasoconstriction than either cocaine use 
or cigarette smoking alone.25 Similarly, cocaine and alcohol combine to be metabolised 
to a reinforcing compound, cocaethylene, and the combination is substantially more 
toxic than either substance on its own. Cocaethylene is a cocaine metabolite, formed 
in the liver only in the presence of ethanol; it depresses the myocardium, causing 
cardiotoxicity.26 
A study by Lucena et al., of a consecutive series of 686 sudden deaths, found that 
myocardial infarction was the most common cardiac condition responsible for 
sudden death following cocaine use, with some patients having occlusive coronary 
thrombosis with acute infarction and others having organised, recanalised thrombus 
and remote infarction.27
Figure 6.1. Number of drug-related deaths where cocaine was mentioned in the 
death certificate, England and Wales, death registered between 1993 and 2012
 
11 
24 22 
13 
27 
65 
88 83 
97 
128 
129 
154 
176 
190 196 
235 
202 
144 
112 
139 
0
50
100
150
200
250
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
 
Cocaine, synthetic cocaine derivatives and piperazines 124
N
E
P
T
U
N
E
6.5. Acute harms
Problems relating to acute cocaine intoxication are relatively common, although 
many users will not experience any. Cocaine can cause a range of acute health-related 
problems and even sudden death (section 6.4). 
Cocaine use has been associated with a number of medical complications, which result 
from acute and chronic use and may differ according to the route of administration. 
Medical complications may involve all of the body’s major organs and systems.28 
The harms related to acute cocaine intoxication and to chronic use have been 
summarised as follows:7
•	cardiovascular disorders (including ischaemia, acute coronary syndrome, 
arrhythmia);
•	cerebrovascular disorders and neurological impairment (cerebrovascular accident 
or stroke, and status epilepticus);
•	psychiatric disorders (euphoria, dysphoria, agitation, anxiety, suicidal thoughts, 
paranoid psychosis and depression);
•	respiratory disorders, either acute (pulmonary oedema, pulmonary infarction, 
haemoptysis) or chronic (e.g. pulmonary hypertension);
•	genitourinary and obstetric disorders, either acute (acute renal failure, mediated 
by rhabdomyolysis or direct toxicity, testicular infarction, placental abruption, 
spontaneous abortion) or chronic (premature birth, growth retardation);
•	gastrointestinal complications (mesenteric ischaemia or infarction);
•	musculoskeletal and dermatological disorders.
Chronic cocaine use has also been associated with hepatocellular damage.28
6.5.1. Acute toxicity
TOXBASE® (accessed 6 January 2015) has identified the features of cocaine-related 
toxicity, which include euphoria, agitation, tachycardia, tachypnoea, sweating, ataxia, 
dilated pupils, nausea, vomiting, headache, delirium and hallucinations. Complications 
related to cocaine toxicity include hypertension, chest pain (often non-ischaemic), 
myocardial ischaemia and infarction, as well as cardiac dysrhythmias, coronary 
artery dissection,29 aortic dissection, convulsions, subarachnoid and intracerebral 
haemorrhage, cerebral infarction and gastrointestinal (gut) ischaemia. There may also 
be hyperpyrexia, rhabdomyolysis, renal failure, hypokalaemic paralysis,30, metabolic 
acidosis and cardiorespiratory arrest. Choreoathetoid movements have also been 
reported.31 Serotonin syndrome may occur (for more information see Chapter 7).
 The most common acute health problems associated with cocaine include 
neurological impairments and cardiovascular and cerebrovascular effects. These are 
associated with both acute intoxication and chronic use.32 Common non-cardiac 
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features of acute cocaine toxicity include seizures, hyperthermia and intracerebral 
haemorrhage or infarction. Hyperthermia is possible and can be life-threatening.28 
Agitation, anxiety, aggression and cocaine-induced psychosis are also common33 and 
psychiatric symptoms can include suicidal thoughts.28
A Spanish study of 720 regular cocaine users aged 18–20 who were not regular heroin 
users found that 27% had experienced acute cocaine intoxication during the previous 
year. Of these, 35% presented symptoms of psychosis (hallucinations or delirium) and 
more than 50% reported chest pain.34
6.5.1.1. Cardiovascular disorders
There are many cardiovascular consequences of cocaine use and these can be severe. 
Cocaine has unique mechanisms of cardiotoxicity, which include sympathomimetic 
effects, blockade of sodium and potassium channels, oxidative stress and mitochon-
drial damage, and disruption of excitation–contraction coupling. In combination, 
these effects increase myocardial oxygen demand while simultaneously decreasing 
oxygen supply.35
Cocaine has multiple cardiovascular and haematological effects that likely contribute 
to the development of myocardial ischaemia and/or myocardial infarction (MI). It 
blocks the reuptake of noradrenaline and dopamine at the presynaptic adrenergic 
terminals, causing an accumulation of catecholamines at the postsynaptic receptor 
and thus acting as a powerful sympathomimetic agent.36 Indeed, cocaine use has been 
associated with myocardial ischaemia and/or acute coronary syndrome (ACS).37,38 US 
survey data have suggested that cocaine use is the cause of approximately a quarter 
of all fatal myocardial infarctions in patients who are 45 years or younger.39 
A common symptom of people presenting to emergency departments is non- 
traumatic chest pain.40 Chest pain and other complaints suggestive of coronary 
ischaemia are among the most common complaints of patients presenting to 
emergency departments following cocaine use.41–45 Cocaine-associated chest pain 
has been described as having a pressure-like quality.46
However, the presence of chest pain is not universal in cases of cocaine-associated MI. 
The American Heart Association’s guidelines on the management of cocaine-related 
chest pain and MI suggested that chest pain may have little value in distinguishing 
an ischaemic from a non-ischaemic cause in these patients.36 In one study, only 44% 
of 91 patients with cocaine-associated MI reported antecedent chest pain.44 Another 
study showed that in 130 patients with cocaine-associated MI, there was equal 
distribution between anterior (45%) and inferior (44%) MI, and most were non-Q 
wave (61%).47 Cocaine-associated chest pain may be caused not only by MI but also 
by aortic dissection, and the American Heart Association’s guidance suggests that 
this must be considered in the differential diagnosis.36
It has been shown that, in persons who are otherwise at relatively low risk, the risk 
of acute MI is increased by a factor of 24 during the 60 minutes after the use of 
cocaine,37 when the blood cocaine concentration is highest.37,46,48 However, this is not 
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always the case, as the onset of symptoms was also reported several hours after the 
administration of the drug, when the blood concentration of cocaine is low or even 
undetectable.37,49
The risk is unrelated to the amount ingested, the route of administration and the 
frequency of use; it has been reported with doses ranging from very small amounts 
to 2000 mg, after ingestion by all routes, and in habitual as well as first-time users.24,40 
There is also evidence that cocaine-related MI occurs in individuals who use the drug 
infrequently (e.g. less than once a month).27,37 It has been suggested that cocaine 
users with atherosclerotic coronary artery disease are probably at greater risk of an 
ischaemic event after cocaine use than are cocaine users without coronary artery 
disease.50,51
The accurate identification of patients with cocaine-related MI may be difficult, for a 
number of reasons.40 The electrocardiogram may be abnormal in many patients with 
chest pain after cocaine use, even in the absence of MI. In addition, serum creatine 
kinase concentrations are not a reliable indicator of myocardial injury, since they are 
elevated in about half of cocaine users who do not have MI.40 It has been suggested 
that this elevation of serum creatine kinase may be due to rhabdomyolysis.50,51 
There is very little information on the prevalence of recent cocaine use in individuals 
presenting to the emergency department (ED) with chest pain and/or suspected acute 
coronary syndrome (ACS) in the UK or elsewhere. A 12-month retrospective review 
of all suspected myocardial ischaemia/ACS presentations to a London ED (1 January 
to 31 December 2008) found 54 cases (1.9% of the 2810 presentations) with self-
reported cocaine use before the onset of symptoms. Among the self-reporting 
cocaine users, 20 individuals (37.0%) had one or more features of potential cocaine 
sympathomimetic toxicity at presentation to the ED. Agitation/anxiety was most 
commonly observed (in 14 cases), followed by tachycardia (10), systolic hypertension 
(6), diastolic hypertension (2) and hyperpyrexia (1).38
US studies have shown that approximately 6% of patients who come to the ED with 
cocaine-associated chest pain have enzymatic evidence of MI.46,52
There are potential cardiovascular complications resulting from cocaine-related 
MI.36,40,48 A study of 130 such patients found that 38% had additional cardiac com-
plications; heart failure occurred in 7% and arrhythmias in up to 43%. Notably, 90% 
of these complications occurred within the first 12 hours of presentation to the 
hospital.48 It has been reported that patients who continue to use cocaine after their 
initial hospitalisation and have a higher cumulative risk of MI and associated compli-
cations.36
Cocaine use also causes increased endothelial production of endothelin, a potent 
vasoconstrictor,53 and decreased production of nitric oxide, a potent vasodilator,54 
effects that may promote vasoconstriction.40 Cocaine use has been associated with 
accelerated coronary atherosclerosis in individuals who do not have other athero-
sclerotic risk factors. In Lucena et al.’s study, this was present in 76% of the sudden 
cocaine-related deaths.27
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In addition to being a nidus for plaque rupture and subsequent platelet aggregation and 
thrombus formation, sites of atherosclerotic narrowing manifest enhanced coronary 
arterial vasoconstriction in response to cocaine.55 Post-mortem studies of long-term 
cocaine users have shown premature atherosclerotic coronary artery disease, which 
may be associated with a nidus for such thrombus formation56 and cocaine may induce 
thrombus formation in the coronary arteries.57 It has been suggested that thrombus 
formation may be promoted by the fact that cocaine use is associated with enhanced 
platelet activation and aggregability58–60 as well as increases in the concentration of 
plasminogen-activator inhibitor,61 which may promote thrombus formation. 
Long-term use of cocaine is also associated with cocaine-induced myocardial 
dysfunction and can cause left ventricular hypertrophy62 and systolic40 and diastolic 
dysfunction.63 This may be caused in some cases by the metabolic disturbances and 
acid–base disturbances (or both) that accompany cocaine intoxication. In other cases 
it may be caused by a direct toxic effect of the drug.40 There is also some evidence 
that repeated exposure to cocaine may induce left ventricular systolic dysfunction.40 
Dysrhythmias are also associated with the drug. The sodium-channel-blocking 
properties of cocaine and its ability to induce an enhanced sympathetic state are likely 
to produce or exacerbate cardiac arrhythmias.40 Cocaine can produce arrhythmias 
either through the production of myocardial ischaemia or as a direct result of ion 
channel alterations. It can cause arrhythmias in the absence of any myocardial 
ischaemia.64–66 It has been suggested that this is due to the actions of cocaine and 
its major metabolites on cardiac ion channel function and alteration of the ‘normal’ 
cardiac action potential.67
Cocaine-related life-threatening arrhythmias and sudden death caused by arrhythmia 
occur most often in patients with myocardial ischaemia or infarction or in those 
with non-ischaemic myocellular damage.40 Long-term cocaine use is associated with 
increased left ventricular mass and wall thickness, which is known to be a risk factor for 
ventricular dysrhythmias. It has been suggested that this may provide the substrate 
that facilitates the development of arrhythmias in some cocaine users.40
Cocaine use can cause both acute and chronic dissection of the aorta,68 a potentially 
life-threatening condition in which there is bleeding into and along the wall of the 
aorta. This probably results from the severe transient increase in systemic arterial 
blood pressure caused by the drug.7
In addition to MI and aortic dissection, cocaine use may lead to pulmonary hypertension 
and associated chest pain and dyspnoea.69
The intravenous injection of all drugs is associated with endocarditis, but a study has 
suggested that the use of cocaine appears to be a greater independent risk factor 
than the use of other drugs.70 In addition to endocarditis, is thought that the increases 
in heart rate and blood pressure that result from cocaine use may lead to valvular and 
vascular injury that predisposes to bacterial invasion; the immunosuppressive effects 
of cocaine may further increase the risk of infection.32,71
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6.5.1.2. Cerebrovascular disorders 
The acute and chronic use of cocaine may cause haemorrhagic or ischaemic stroke and 
the association between cocaine use and stroke has been observed for many years.72–75 
although some studies have contested these findings.39 Recently, a systematic review 
has reported that epidemiological evidence suggests that cocaine use increases the 
risk of stroke, but that more research is needed to quantify this risk; such research 
should consider stroke type, hypertension variation, frequency and length of cocaine 
use, as well as amphetamine co-use.76
A number of factors may be involved, including vasospasm, cerebral vasculitis, 
enhanced platelet aggregation, cardio-embolism and hypertensive surges associated 
with altered cerebral auto-regulation.77
Seizures associated with cocaine typically occur after chronic use, but may also result 
after the initial use of cocaine, through any route of administration.7 Most cocaine-
related seizures occur within minutes and almost always within 90 minutes, when 
there is peak concentration of cocaine in the blood.78
Cocaine-induced seizures are usually single, generalised seizures. However, status 
epilepticus can also occur after cocaine use. Seizures can occur in patients with or 
without a history of seizure disorder, but the prevalence of cocaine-induced seizures 
is twice as high in people with a history of non-cocaine-related seizures as in those 
without a history of seizure disorder. Seizures caused by cocaine may be lethal, 
primarily because of associated cocaine-induced hyperthermia, systemic acidosis, 
cardiac dysrhythmias and cardiac arrest.7
6.5.1.3. Cocaine-induced psychosis
Cocaine-induced psychosis has been recognised for decades, especially in emergency 
departments.79 Cocaine has a wide range of neuropsychiatric effects, including 
transient psychotic symptoms. These symptoms include paranoia and hallucina-
tions,80–82 violence and aggression,4,83,84,85,86,87,88,89 repetitive or stereotyped simple 
behaviours and repetitive complex behaviours such as drawing and writing. The term 
‘cocaine-induced psychosis’ (CIP) has been used to describe this syndrome. These 
symptoms typically disappear with abstinence.90–92
As with other psychostimulants, cocaine can produce psychotic syndromes in healthy 
individuals. Among the majority of those with schizophrenia, cocaine use – at doses 
which would not be psychogenic in healthy individuals – will exacerbate psychotic 
symptoms.18 Compliance with antipsychotic medication in those diagnosed by schiz-
ophrenia will not prevent a relapse or worsening of psychotic symptoms if stimulants, 
including cocaine, are used.93
It is difficult to estimate the prevalence of CIP among cocaine users; different studies 
have reported prevalence ranging from 48% to 88%.94–96 CIP is common in cocaine-
dependent patients who seek treatment.79 The factors found to increase the risk CIP 
include the amount of cocaine ingested79,97–99 and early onset of cocaine use.82,95,98 
There are reports that the early onset of cocaine dependence, or onset in vulnerable 
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periods of brain development, may increase the severity of CIP.98,100 However, one 
study found that the number of years of cocaine use was not linked to CIP.101 In 
comparison with nasal insufflation (snorting), the smoking99 or injecting102 of cocaine 
may increase the risk of CIP. A history of cannabis dependence was associated in a 
study with CIP79 and another study found that adolescent onset of cannabis use 
increased the risk of CIP in cocaine-dependent individuals.95
It has also been reported that the severity of the substance use disorder is associated 
with the prevalence of psychotic symptoms, and that the prevalence of CIP is higher 
in dependent individuals than in other users of cocaine,94 and in the most severely 
dependent patients.94,95 Some studies have observed that drug-dependent individuals 
with cocaine-induced paranoia are at higher risk of developing a psychotic disorder. 
15,103 CIP has been linked to hostile behaviours and antisocial personality disorder 
(ASPD).79 Studies have suggested a pattern in which stimulants generate hostility 
through psychotic symptoms. For example, the use of cocaine may lead to a perception 
of the environment as a hostile and threatening place, and increase impulsivity. Thus 
CIP can trigger hostile behaviours.104,105
6.6. Management of cocaine-
related acute harms 
6.6.1. Hospital presentation with acute cocaine intoxication
Cocaine is the illicit drug that leads to the most ED visits in the US, with 138 per 
100,000 population in 2009.106 In the European Union, a study was carried looking at 
cocaine-related emergency admissions; data were obtained from 17 of the member 
states at that time. In the most recent year for which data were available, the UK 
reported the most cocaine-related emergency episodes, followed by Spain, Italy and 
the Netherlands. 107
In the UK in 2010/11, 2247 hospital inpatient discharges recorded cocaine poisoning 
and 4209 inpatient discharges recorded mental and behavioural cocaine-related 
disorders.7 It is widely acknowledged that these figures grossly underestimate the 
overall prevalence of patients presenting with acute cocaine-related toxicity, as 
coding is often based on presenting symptoms (e.g. chest pain) rather than cause 
(e.g. cocaine use).33 In addition, there is under-recognition of acute cocaine toxicity in 
patients presenting with chest pain and a study has shown, for example, that although 
junior medical staff in a London hospital were aware that cocaine is a risk factor for 
ACS and acute MI, they were not likely to ask about it in routine clinical practice or to 
record its use/non-use in the case notes.8
6.6.2. Management of cocaine-induced cardiovascular disorders
It has been argued that it is essential that patients presenting with chest pain or 
suspected ACS are asked about cocaine use,8,38 as the management of these patients 
is different from the management of those with ACS secondary to ‘classical’ cardio-
vascular risk factors.36,40,45,108
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Some guidance is available on the management of cardiovascular disorders induced by 
cocaine use, from the American Heart Association36 and others.40,45,108 The evidence on 
the management of other cocaine-related disorders has also been reviewed, including 
the treatment of patients with cocaine-induced arrhythmias109 and the management 
of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction.67
The management of cocaine-induced cardiovascular harms can be complex and 
readers should seek up-to-date guidance from TOXBASE®.
It has been argued that as cocaine toxicity is a dynamic process, patients are best 
served by close observation until stability has been assured.109 Overall, however, in 
most instances treatment of cocaine intoxication is supportive.
The evidence base on the management of cocaine-related cardiovascular harms 
reflects some of the controversies regarding therapeutic strategies. This includes the 
disagreement on the use of beta-blockers in the management of cocaine-induced 
chest pains and MI. Cardiology guidelines, for instance from the American Heart 
Association, mentioned above, recommend against their use36,110,111 because of the 
potential lethality of an interaction between cocaine and a beta-adrenergic receptor 
antagonist, as shown by a recent care report, for example.112
However, some have argued recently that there may be a role for certain beta-block-
ers in ameliorating the cardiovascular, as well as central nervous system, effects of 
cocaine.113 A retrospective study of consecutive patients admitted to San Francisco 
General Hospital between 2001 and 2006 with chest pain and urine toxicological test 
results positive for cocaine found that beta-blockers did not appear to be associated 
with adverse events in patients with chest pain and recent cocaine use.114 
Similarly, there is controversy over the management of cocaine-associated cardiac 
arrhythmias, including the use of sodium bicarbonate and lidocaine.67
6.6.3. Management of cocaine-induced psychosis
A systematic review has concluded that, in the absence of better evidence, treatment 
of stimulant-induced psychosis, including CIP, should involve efforts to encourage 
abstinence from stimulants and treatment with antipsychotic drugs until the acute 
For up-to-date guidance on the management of cocaine acute toxicity, it is recommended that 
information be sought from the National Poisons Information Service (NPIS), specifically the 
NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/C-Products/Cocaine/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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symptoms settle. It is also argued that this should be followed by regular low doses of 
antipsychotics for those who have experienced more than one episode of psychosis.93
Treatment for CIP includes providing a safe environment, managing agitation, and 
addressing the underlying substance use disorder. It has been argued by Nunes et al. 
that because schizophrenia and cocaine use are multifaceted conditions, no simple 
solution exists for their clinical management. While reliance on established treatment 
guidelines and best practices is the optimal modus operandi, clinicians must assess 
patient presentation to institute the proper individually tailored management 
strategy.18
6.6.4. Discharge and onward referral
It has been argued that when the patient is ready for discharge, referral to a drug 
treatment programme is likely to be the most important intervention to help prevent 
a recurrence of an emergency presentation.109 However, there is some evidence that 
ED visits for cocaine-related chest pain represent missed opportunities to link patients 
to drug treatment, and interventions are needed to motivate patients to seek care.115 
6.7. Chronic use and dependence 
and their clinical management
6.7.1. Cocaine dependence and its management
Cocaine use is associated with dependence. This is a major public health problem that 
is characterised by recidivism and a host of medical and psychosocial complications.116
There is a large body of evidence on the management of cocaine dependence and 
associated harms,1–6 including a number of Cochrane reviews.* There is still no phar-
macological treatment of proven efficacy. In the last two decades, a number of trials 
have been conducted using antidepressants, antipsychotics, anticonvulsants and 
dopaminergic medications. The potential usefulness of disulfiram has been reported 
and there is an interest in assessing the efficacy of psychostimulants for use as 
replacement therapy.117 Work is currently being undertaken on a cocaine vaccine that 
could lead the immune system to generate specific antibodies that would bind the 
drug while it is still in the bloodstream and prevent it from entering the brain.118
Psychosocial interventions remain the cornerstone of treatment. Although there are 
important differences in the neuropsychiatric and medical consequences of cocaine 
when compared with amphetamine use disorders, there is currently no evidence for 
a differential treatment effect of any psychosocial treatment in the management 
of these disorders.119 For detailed information on the psychosocial interventions 
relevant to cocaine users, see Chapter 2.
* See for further examples http://www.thecochranelibrary.com/details/browseReviews/579489/
Cocaine.html (accessed 31 October 2013).
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6.7.2. Access to cocaine-dependence treatment in the UK
The UK National Drug Treatment Monitoring System (NDTMS) reports that 5% 
of all adults in drug treatment in England in 2013/14 had a primary problem with 
powder cocaine (10,610 individuals). This group had a median age of 30, lower 
than the median age of those using opiates only (38 years) but older than those in 
treatment for cannabis misuse (median age 26 years). Data provided through the 
Treatment Outcome Profile (TOP) suggest that people treated for powder cocaine 
misuse typically have better outcomes at six-month review than people who use 
opiates, with 76% of people in treatment for cocaine misuse classified as abstinent 
or improved at review. An analysis of new treatment presentation over 9 years (from 
2005/06 to 2013/14) found that cocaine users were most likely to have completed 
treatment than those with another primary problem drug, with 55% having done so 
without subsequently returning.120 
These data reflect those reported in an in-depth analysis of NDTMS data pertaining 
to users of powder cocaine over a period of 6 months in 2008-09 and which reported: 
‘Effective treatment is available for people who have a powder-cocaine problem – 
seven in ten of those who come into treatment either stop using or reduce their use 
substantially within six months’. The report showed that within 6 months of entering 
treatment, 61% had abstained from using cocaine for at least 28 days and a further 
11% had cut their use significantly.121 
6.8. Synthetic cocaine derivatives
‘Synthetic cocaine’ is the slang term sometimes used for substances that are sold on 
online as a legal alternative to cocaine.122 A small number of synthetic cocaine sub-
stitutes are available and include the relatively recently reported RTI 111 (dichloro-
pane ((-)-2β-carbomethoxy-3β-(3,4-dichlorophenyl)tropane, RTI-111, O-401), RTI 
121 ((-)-2β-carbo isopropoxy-3β-(4-iodophenyl)tropane, RTI-121, IPCIT) and RTI-126 
((-)-2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane). 
Fluorotropacocaine (pFBT), with a structure closely related to that of cocaine, was 
first reported in the European Union by Finland in 2008. Its adverse effects were first 
reported in Ireland in 2010, where it was identified in two products sold by ‘head 
shop’ (shops where drug paraphernalia and/or so-called legal highs are sold). Both 
3-(p-fluorobenzoyloxy)tropane (pFBT) and dimethocaine have been sold from retail 
websites as ‘research chemicals’ or have been identified in ‘legal highs’.123,124
There are reports of the use of some synthetic cocaine in the UK and in a survey 
conducted in London gay nightclubs in July 2011 9.9% of respondents reported 
lifetime use of ‘synthetic cocaine’ and 3.5% reported using it in the past month.125 No 
information was available on which synthetic cocaine this was.
Little is known about the detailed pharmacokinetics and pharmacodynamics of pFBT 
in humans.123 However, the drug has close structural similarities to cocaine and is likely 
to have similar pharmacology.124 Animal studies have shown that it is associated with 
a longer half-life than cocaine, suggesting that its effects are likely to last longer.124 In 
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animals, dimethocaine has stimulant effects and inhibits dopamine uptake almost as 
effectively as cocaine. Animal studies demonstrate a lower potency of dimethocaine 
compared with cocaine.126 User accounts on the internet note that dimethocaine 
produces a mild stimulant effect.123 
As with cocaine, pFBT is anecdotally reported to cause hypertension, tachycardia, 
anxiety and temporary psychosis in humans.127 The symptoms of acute intoxication 
include increased heart rate, increased breathing rates and raised blood pressure. 
Patients experience differing levels of anxiety and a small number of cases of psychotic 
episodes have been reported.127 One case report described a patient presenting 
with excitement, xerostomia (dry mouth), chest pain, dyspnoea, tachycardia and 
hypertension. Blood glucose and creatine kinase were elevated.122
At the time of writing, neither of these substances are under international control, 
and apart from Denmark (pFBT) and Romania (dimethocaine) there are no national 
controls in the European Union. 
6.9. Piperazines
Other stimulants which are not phenethylamines include the piperazines. Piperazines, 
notably 1-benzylpiperazine (BZP), is a stimulant with similar action to amphetamine 
sulphate and with effects similar to dextroamphetamine (but with approximately 
one-tenth of the potency) and other sympathomimetics. 
To a large extent, the use of BZP in the UK has faded away since its control in 2009. It 
was often sold as hydrochloride salt, usually white powder in capsules or pressed into 
tablets. A typical dose is 100–250 mg. Tablets have often been passed off as ecstasy, 
although they are also sold as BZP. In a survey carried out in gay nightclubs in London, 
9.3% of respondents reported using BZP and 1.6% had done so in the last month.125
High doses of BZP are associated with a sympathomimetic toxidrome.128 The most 
common reported adverse effects associated with BZP are palpitations, agitation, 
vomiting, anxiety, confusion and seizures.129,130 The most serious effects are metabolic 
acidosis, seizures, prolongation of ventricular repolarisation and possibly also toxic 
paranoid psychosis and hyponatraemia. Two severe cases of BZP poisoning associated 
with multi-organ failure have been reported.128
It has been reported that many of the formulations sold in tablets as BZP also 
contain other drugs, including 1-(3-trifluoromethylphenyl) piperazine (TFMPP). 
This combination has been reported to produce subjective effects similar to those 
observed with MDMA (ecstasy – see Chapter 10), although human studies are 
limited.124 Inducible clonus, dissociative symptoms, bruxism (excessive grinding of 
teeth) and nausea have been reported as resulting from this combination.131
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Chapter 7
Amphetamine-type substances 
(ATS): an overview
Drug group: stimulant
The use of amphetamine-type substances (ATS) for their psychoactive effects is a 
global and growing phenomenon and, in recent years, there has been a significant 
increase in the production and use of ATS worldwide, both legal and illicit. The 
2013 report of the United Nations Office on Drugs and Crime (UNODC) on the 
challenges of new psychoactive substances reported that the ATS market has 
always been characterised by a large variety of substances, but, in recent years, new 
psychoactive substances (NPS) have rapidly emerged in this market, purportedly as 
‘legal’ alternatives to controlled drugs, causing similar effects to the latter, with the 
potential to pose serious risks to public health and safety.1
The term ‘amphetamine-type stimulants (ATS)’ is used to refer to the following 
groups of substances or amphetamine analogues with stimulant effects: including 
phenethylamines; methcathinone and other synthetic cathinones; and benzofurans.
Phenethylamines are a broad range of compounds that share a common phenyl-
ethan-2-amine structure and include stimulants (e.g. amphetamine itself), 
entactogens (e.g. MDMA, considered in Chapter 10), and hallucinogens (e.g. 2C-E). 
Amphetamine, methamphetamine and MDMA are the most commonly used. The 
phenethylamines also include ring-substituted substances such as the ‘2C series’, ring-
substituted amphetamines such as the ‘D series’ (e.g. DOI, DOC), benzodifurans (e.g. 
Bromo-Dragonfly, 2C-B-Fly) and others (e.g. p-methoxymethamphetamine, PMMA). 
Phenethylamines in the ‘D series’ are described as longer lasting, more potent and 
more liable to induce vasoconstriction than other members of the phenethylamine 
family.2 PMA, PMMA and 4-methylthioamphetamine have been more often associated 
with incidental deaths than other phenethylamines. PMA and PMMA are known to 
have a particularly high toxicity.3 A number of amphetamine derivatives have also 
appeared on the market in recent years, including various aminoindanes, 2-amino-
tetralins and benzofurans, 2-aminoindane, 5-IAI, AMMI, DFMDA, MMAI, MDMAI and 
MDAT. Methiopropamine – a thiophene ring-based structural analogue of metham-
phetamine – is also sold as a ‘legal high’ alternative to cocaine; brands include Charlie 
Sheen and China White.
Studies have shown that phenethylamines have three different principal effects,: 
central stimulant action; hallucinogenic action; and ‘other’ psychoactive action.4 
Some produce more than one of these effects.5 
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Some substances, such as MDMA, also have entactogenic/empathogenic effects and 
cause unusual changes in consciousness, leading to euphoria and an intense love of 
self and others.6
Methcathinone and other synthetic cathinones, which include mephedrone, are 
closely related to the phenethylamine family. They are characterised by the presence 
of a beta-keto group on the side chain of the phenethylamines. Typically, synthetic 
cathinones have an amphetamine-type analogue; mephedrone and methylone 
(discussed in Chapter 9) are structurally related to amphetamine, methamphetamine 
and MDMA.7 
Benzofurans, specifically 5- and 6-APB, are ring-substituted amphetamine derivatives. 
These have appeared on the market in recent years. They are related to methylenedi-
oxyphenethylamines, such as MDMA and MDA. For pragmatic reasons, these will be 
discussed at the end of the Chapter 10, on ecstasy (MDMA).
7.1. Pharmacology 
While amphetamines are classed as stimulants, their pharmacological effects appear 
to be different from other stimulants; for example, cocaine prevents dopamine 
reuptake while amphetamines increase its release. The effects of amphetamines (and 
especially of methamphetamine, discussed in Chapter 8), also last longer than those 
of cocaine.8 It is generally believed that dopamine reuptake blockade – in particular 
in the nucleus accumbens – is the most important action of cocaine. On the other 
hand, enhancing the release of dopamine in the nucleus accumbens appears to be 
the mediating effect of amphetamines8,9 and amphetamines increase the release of 
newly synthesised noradrenaline and dopamine.8,10 ATS can reverse the action of the 
transporters facilitating neurotransmitter efflux* into the synaptic cleft and displace 
newly synthesised neurotransmitters from the vesicle stores. They also inhibit 
monoamine oxidase (the enzyme responsible of the metabolism of the neurotrans-
mitters).11 
Amphetamine itself, as well as the ATS, are derivatives of a beta-phenylethylamine 
core structure and are kinetically and dynamically characterised by: easily crossing 
the blood–brain barrier; resistance to brain biotransformation; and the release of 
monoamine neurotransmitters from nerve endings. All the structural features that 
enable these physiological characteristics are present in the simplest derivative, 
amphetamine, as well as other ATS.12
Pharmacokinetically, amphetamines are a homogeneous group of drugs, with a high 
oral bioavailability and low plasma protein binding (typically less than 20%). Their 
elimination half-lives range from 6 to 12 hours and renal and hepatic elimination 
occurs. Many amphetamines are extensively metabolised by the liver, but a significant 
proportion of several of these drugs is usually excreted without prior biotrans-
formation.12,13 Chemically, amphetamines are weak basic drugs (with pKa value of 
* Active efflux is a mechanism also responsible for the moving of toxic substances and antibiotics out of 
the cell.
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approximately 9.9); they also have low molecular weight. This means that they can 
cross cellular membranes and lipidic layers easily, reaching high levels in tissues and 
biological fluids with a pH lower than blood, including saliva and sweat.12,14
ATS share common properties, but their effects must not be seen as homogeneous. 
Some stimulants, such as MDMA, have distinct social and emotional effects, leading 
some to propose that they should be classed as ‘entactogens’. ATS sit on a continuum 
of stimulant, hallucinogenic and euphoriant effects and, indeed, many have a 
combination of such effects. Methamphetamine is the only ATS compound that is 
smoked. 
7.2. Medical and other legitimate 
uses of amphetamines
The clinical uses of amphetamines are currently limited. Dexedrine (dexamphetamine 
sulphate) is used in the treatment of narcolepsy and attention deficit hyperactivity 
disorder (ADHD). Methylphenidate (Ritalin) has a similar chemical structure and has 
effects to amphetamine and is also used for the treatment of ADHD Ethylphenidate 
is currently a commonly used so-called ‘legal high’.
Chapters 8–10 describe in greater detail the clinical and other legitimate uses of the 
specific substances. 
7.3. Prevalence and patterns of use
Globally, ATS are the second most commonly recreationally used psychoactive drugs 
after cannabis. Recent global estimates suggest that the use of ATS now exceeds that 
of heroin and cocaine combined.15 The 2013 World Drug Report stated that there are 
signs that the market for ATS is expanding. The use of ATS, excluding ecstasy, remains 
widespread and appears to be expanding in most regions. Seizures of methampheta-
mine constituted 71% of the global ATS seizures.16 In 2011, an estimated 0.7% of the 
world population aged 15–64 (or 33.8 million people) had used ATS in the preceding 
year (excluding ecstasy).16 
The recreational use of illicit stimulants and amphetamines has been well established 
in the UK for a number of decades now. Amphetamine sulphate use assumed what 
was described as ‘epidemic proportions’ among young people in the 1960s17 and, 
although there was a decline in the scale of its use in the 1970s, its continued use was 
described by Klee in the late 1990s to represent ‘the love of speed’ or the ‘enduring 
attraction of amphetamine sulphate for British youth’.17
In the UK, amphetamine sulphate continues to be the most commonly used stimulant, 
with a reported lifetime use by 10.4% of adults between the ages of 16 and 59 years 
in 2012/13. It is the second most common drug ever used, after cannabis (30% of 
adults) in 2012/13. The use of amphetamines nonetheless decreased among all adults 
as well as young adults (16–24 years) between 1996 and 2003, although there was no 
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change to 2012/13 and to 2013/14 from the previous year (2011/12).18 
NEPTUNE will not cover guidance specific to the harms associated with amphetamine 
sulphate because there is extensive experience in the management of this drug, 
spanning many decades. Instead, the guidance will focus on substances that have 
become available on the UK recreational drug scene more recently, in particular 
methamphetamine (Chapter 8) and mephedrone (Chapter 9), around which clinical 
experience is limited.
The WHO suggested that there is no typical profile for ATS users and there is a wide 
range of desired effects from ATS. ATS are used by students and drivers to stay awake 
and concentrate, used by athletes to enhance performance, and used at parties and 
clubs to increase sociability.19 ATS are also used to increase confidence and lift mood, 
lose weight and increase sex drive. A WHO 1997 report on ATS classified the patterns 
of use in the following way:20
1 Instrumental use. Amphetamines are exploited by the users to achieve desired 
goals, such as improve concentration and ward off fatigue.
2 Sub-cultural/recreational use. Their stimulant properties are exploited to allow 
the user to remain active for longer periods in social and recreational settings, such 
as at music and dance events and all-night drinking venues.
3 Chronic use. For several reasons, including craving, tolerance and withdrawal, some 
amphetamine users develop chronic patterns of consumption to relieve unwanted 
effects of abstinence or in the context of dependence.
7.4. Routes of ingestion and dosing
The purity of street drugs varies widely. Depending on the substance, ATS can be 
taken orally, by insufflation or injected; methamphetamine is the only stimulant which 
can be smoked. The association between route of administration and risks associated 
with use has been well documented. Smoked and injected ATS are more likely to lead 
to dependence than oral use,12 while injecting increases the risks of transmission of 
blood-borne viruses.21
The effects of ATS generally appear 30–40 minutes after ingestion and can last for 
4–8 hours, but there are variations, depending on the ATS used, the dose, the potency 
and the length of the effects, as well as tolerance. Some ATS, such as the 2 desoxy 
form (2-DPMP, found in Ivory Wave) have particularly long-lasting effects and have 
longer half-lives.22–24 There are also wide differences in physiological effects, with para-
methoxyamphetamine (PMA) for example, having a much steeper dose–response 
curve than MDMA.
Although more robust evidence is required, there is some anecdotal evidence of an 
increase in the UK of injecting of ATS, such as mephedrone and meth amphetamine. 
Among populations in treatment, figures from the National Drug Treatment 
Monitoring System (NDTMS) suggest that injecting may be a growing issue, up in four 
years from 6% to 8% in 2011/12. This is particularly so among methamphetamine 
users, with 24% reported injecting in 2011/12.25 
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There is anecdotal evidence of the injecting of ethylphenidate (sometimes known 
as ‘Ching’ or ‘Mr White’) in Scotland in particular. Anecdotally, this has been linked 
to repeated injecting and is associated with severe vein damage and other injection 
injury. Research is needed into this potentially high-risk pattern. 
This increase of injecting among people who use ATS as their main drug was also 
reported by the 2012 Unlinked Anonymous Monitoring (UAM) survey of people who 
inject drugs (PWID): from 4.5% (81/1796) in 2002 to 12% (173/1438) in 2012.26,27 
This was reiterated in November 2014 by Public Health England, which reported a 
rise in the injecting of amphetamine and ATS in England, Wales and Northern Ireland, 
from 3.5% in 2003 to 11% in 2013, although this remains less common than the 
injecting of opiates.28 In Scotland, the proportion of people who had injected in the 
past six months and who reported amphetamine as their main drug of injection was 
low (1.3% in 2011/12) and less than 1% of respondents reported the injecting of 
ATS.29
There is evidence that injection of ATS is associated with high levels of infection risk.26 
ATS are injected more frequently than other substances (such as heroin).26 The UAM 
survey also reported that those who injected amphetamine and ATS as their main 
drug were more likely to report the sharing of injecting equipment than those who 
reported using other main drugs.26 Those who reported injecting ATS alone as their 
main drug were also significantly less likely to have ever had an HIV test or a hepatitis 
C test than those who reported other main drugs.26
7.5. Desired and unwanted 
subjective effects of ATS
Overall, ATS are used for their stimulant, euphoric, anorectic and, in the case of 
some substances, empathogenic, entactogenic and hallucinogenic properties. ATS 
produce feelings of euphoria and relief from fatigue; they may improve performance 
on simple tasks and increase activity levels.8 It is thought that the misuse liability of 
amphetamines is related to their euphorigenic effects.8,30
Unwanted subjective effects of amphetamines include increased anxiety, insomnia, 
irritability, aggression, restlessness and paranoia, and in some cases violent behaviour. 
Psychotic symptoms can occur when using amphetamines and can last for days or 
weeks. The ‘come-down’ from ATS, which is distinct from the physiological withdrawal 
observed in many dependent users, can last up to a few days; users may feel tired, 
anxious, depressed and some may experience restlessness, insomnia, muscle ache and 
fasciculation. Its intensity will depend on the substance, the dose consumed and the 
individual. Serotonin syndrome or toxicity is a potential risk (see section 7.7.2 for 
details on the serotonin syndrome).
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7.6. Mortality
Mortality data relating to stimulant use from the Office for National Statistics from 
2003 to 2012 are plotted in Figure 7.1. 
Mortality among amphetamine users is relatively low in comparison with other 
‘problem drugs’. It is is associated with longer drug careers and with injecting.31 Deaths 
are often caused by blood-borne viruses and infectious diseases or damage to the 
cardiovascular system. Non-fatal overdoses related to amphetamine use, on the other 
hand, are common.21,32,33 Amphetamine overdoses constitute only a small proportion 
of fatal overdoses, and are mainly associated with co-ingestion of opioids.34 Direct 
amphetamine-related mortality typically occurs as a result of heart attacks, seizures, 
cardiac arrhythmias or respiratory failures.33 
7.7. Acute harms 
Stimulants have actions on multiple receptor sites within the central nervous system 
(CNS), with patterns of effects varying between the drugs. Predominantly stimulant 
drugs inhibit monoamine (especially dopamine) reuptake and are associated with a 
sympathomimetic toxidrome. Entactogenic drugs provoke central serotonin release, 
while newer hallucinogens are serotonin receptor agonists and therefore serotonergic 
effects predominate in toxicity.2
Figure 7.1. Numbers of drug-related deaths where stimulants were mentioned in the 
death certificate, England and Wales death registered between 2003 and 2012
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The variations between substances are not only in relation to the severity of effects 
but also their duration. For example, there are reports of symptoms of 2-DPMP toxicity 
still being manifested 5–7 days after ingestion.35
The factors that have an effect on the severity of acute ATS-related harm include the 
following:12
•	dose and frequency of use;
•	route of administration;
•	environmental conditions (including temperature, stressful environment and 
overcrowding, intense physical activity, too much or too little fluid intake);
•	individual variations and characteristics (including age, ethnicity, gender, physio-
logical and physiopathological states, co-ingestion/poly-use, by-products of 
chemical synthesis).
7.7.1. Features of acute toxicity
Chapters 8–10 give detailed information on the features of acute toxicity of the 
selected drugs. Overall, ATS increase heart rate, blood pressure and breathing 
rates, constrict blood vessels, dilate pupils and release glucose and lipids into the 
bloodstream.11 The toxity, neurotoxicity and cardiotoxicity of amphetamines has 
been well documented, as has its impact on mental health.21
The acute toxic effects of amphetamine-type substances as summarised by TOXBASE® 
are presented in Box 7.1.* 
There is a risk that the use of amphetamine induces strokes and heart attacks because 
it raises blood pressure and constricts blood vessels. People at risk of heart disease 
or strokes are more likely to experience such complications.12,36 Hyperthermia is one 
* References here and below to TOXBASE® relate to the website http://www.toxbase.org. Note that 
registration is required for full access to this site, and registration is available only to UK clinicians. The 
information was taken from the site in March 2014, during the preparation of this chapter, and further 
evidence may have incorporated since that time. 
Box 7.1. The acute toxic effects of amphetamine-type substances
Tremor
Sweating
Dilated pupils
Agitation
Confusion
Headache
Anxiety
Vomiting
Abdominal pain
Seizures
Hallucinations or delusions
Chest pain
Palpitations
Dyspnoea
Systemic hypotension
Hypertension
Narrow-complex tachycardias 
Ventricular tachycardia
Ventricular fibrillation
Hyperpyrexia
Metabolic acidosis
Serotonin syndrome
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of the most life-threatening acute physiological consequences of ATS intoxication, 
with case reports suggesting that its incidence and severity varies between drugs, 
with those most implicated being methamphetamine, MDMA, MDEA and PMA.12,37,38 
Hyperthermia associated with these drugs appears to be responsible for fatal com-
plications, including rhabdomyolysis, acute renal failure, disseminated intravascular 
coagulation, multiple organ failure and acidosis.12,36,39,40 Hepatocellular injury caused 
by ATS is well established, although not yet completely understood;12 it may arise 
from both acute and chronic use of amphetamine.12,36
7.7.2. Serotonin syndrome
Serotonin syndrome is a clinical condition that occurs as a result of a drug-induced 
increases in intrasynaptic serotonin levels, primarily resulting in activation of 
serotonin 2A receptors in the central nervous system.41 It is argued by some that the 
term ‘serotonin toxicity’ is preferable to ‘serotonin syndrome’, especially in relation to 
more severe cases, because it describes the serotonin excess more accurately.41,42 In 
this document, the term ‘serotonin syndrome’ and ‘serotonin toxicity’ are used inter-
changeably.
Serotonin syndrome is a potentially life-threatening adverse reaction to the use of 
particular drugs (illicit or prescribed ) or the interaction between drugs. A number of 
ATS used for recreational purposes are associated with serotonin syndrome, including 
(but not limited to) MDMA, MDPV, PMA and mephedrone, as well as methamphetamine 
and cocaine. There is also a dose–effect relationship; high doses or repeated doses of 
MDMA, for example, intensify serotonin release.43 In addition, the simultaneous use of 
multiple serotonergic substances (e.g. ecstasy and methamphetamine) increases the 
risk of serotonin syndrome.44
Drugs used therapeutically are also associated with serotonin syndrome (Box 7.2).45–55 
It has been reported that the syndrome occurs in approximately 14–16% of individuals 
who have overdosed on SSRIs,56 but a single therapeutic dose of SSRI has also been 
associated with it.46 The use of illicit substances with therapeutic drugs increases 
the risks of serotonin toxicity. There is evidence that some users deliberately use 
MAOIs to enhance the effect of psychoactive substances and/or help during the 
Box 7.2. Therapeutic drugs used that are associated with serotonin syndrome
Monoamine oxidase inhibitors (MAOIs)
Tricyclic antidepressants
Selective serotonin reuptake inhibitors 
(SSRIs; also called serotonin-specific re uptake 
inhibitors)
Opiate analgesics
Tramadol
Over-the-counter cough medicines
Antibiotics
Weight-reduction agents
Antiemetics
Antimigraine agents
Herbal products
Psychoactive drugs used for recreational 
purposes
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recovery period. For example, in an Australian study of ecstasy users, 1 in 25 reported 
deliberately combining ecstasy and moclobemide.57,58
Three critical features have been described as critical in understanding the disorder: 
•	serotonin syndrome is a predictable consequence of excess serotonergic agonism 
of CNS receptors and peripheral serotonergic receptors; 
•	excess serotonin produces a spectrum of clinical findings; 
•	the clinical manifestations range from the barely perceptible to lethal. Signs of 
excess serotonin range in mild cases from tremor and diarrhoea to neuromuscular 
rigidity and hyperthermia in life-threatening cases.59 
Serotonin syndrome has three classic features of:
•	mental state changes, 
•	autonomic hyperactivity 
•	neuromuscular abnormalities
Not all patients with the syndrome manifest signs and symptoms of all three 
features.59 In a study of 2222 consecutive cases of self-poisoning with serotonergic 
drugs, the clinical findings that had a statistically significant association with 
serotonin syndrome were primarily neuromuscular (including hyperreflexia, inducible 
clonus, myoclonus, ocular clonus, spontaneous clonus, peripheral hypertonicity and 
shivering), as well as autonomic derangement (including tachycardia on admission, 
hyperpyrexia, mydriasis, diaphoresis and diarrhoea) and mental health/psychiatric 
symptoms (agitation and delirium).60 There is also evidence that, in severe cases, 
stroke, myocardial infarction, severe hyponatraemia, rhabdomyolysis, disseminated 
intravascular coagulation (DIC) and renal failure may occur. Hepatocellular damage 
has also been reported, on TOXBASE® and elsewhere.41
The clinical symptoms are on a spectrum of severity, from mild to life-threatening 
(Table 7.1).59
Table 7.1. Clinical symptoms of the serotonin syndrome: severity spectrum 
Mild Patients can be aferbile. Tachycardia possible, shivering, diaphoresis, mydriasis
Moderate Tachycardia, hypertension, hyperthermia (40oC is common), mydriasis, hyperactive 
bowel sounds, diaphoresis, hyperreflexia and clonus (considerably greater in lower 
extremities than upper); patient may exhibit horizontal ocular clonus; mild agitation 
or hypervigilance, slightly pressured speech; repetitive rotation of the head with the 
neck held in moderate extension
Severe Severe hypertension and tachycardia that might deteriorate abruptly into frank 
shock. Patient may have agitated delirium, muscle rigidity and hypertonicity and 
increase in muscle tone (considerably greater in lower extremities than upper). 
Muscle hyperactivity may produce a core temperature of more 41.1oC in some cases. 
Metabolic acidosis, rhabdomyolysis, elevated levels of serum aminotransferase and 
creatinine, seizures, renal failure, disseminated intravascular coagulopathy.
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There is a dose–effect relationship, with more severe cases involving a combination 
of serotonergic drugs, rather than a single one. The simultaneous use of multiple 
stimulants increases the risk of serotonin toxicity and problems relating to sympatho-
mimetic over-stimulation, such as dehydration and hyperthermia,61 and cardiovascular 
problems,62, as well as increasing the chances of neurotoxicity.63 The risk is not only 
increased when two serotonergic psychoactive substances are co-ingested, but also 
when one psychoactive substance is ingested with a range of serotonin-releasing 
illicit drugs as well as medications (Box 7.2).45–55
Monoamine oxidase inhibitors (MAOIs) are strongly associated with serotonin 
syndrome or toxicity, especially when these are used in combination with a number of 
other drugs, including methylenedioxypyrovalerone MPDV47,64–66 mephedrone, methyl-
enedioxypyrovalerone (MDPV),67,68 butylone, methylone68 and phenethylamines 
(2C-I).69 The potentially life-threatening interaction may have serious implications for 
people on antidepressants who also use these recreational substances.70
Serotonin toxicity generally presents abruptly and can progress quickly, sometimes 
within minutes,71 especially when a combination of serotonergic drugs has been 
used.41 It has been suggested that patients with serotonin toxicity will develop clinical 
manifestations within 6 hours.41 Where a combination of drugs has been used, signs 
and symptoms will start when the second drug reaches effective blood levels, usually 
after one or two doses.41
7.8. Management of the acute harms 
associated with use of ATS 
7.8.1. Identification and assessment of acute toxicity
Chapters 8–10 provide detailed information on the identification and diagnosis of 
acute toxicity specific to each drug discussed.
Overall for ATS, clear airway management and adequate ventilation in case of un-
consciousness is recommended. In case of cardiac arrest, TOXBASE® recommends 
cardiopulmonary resuscitation (CPR), which should be continued for at least 1 hour 
and stopped only after discussion with a senior clinician. Prolonged resuscitation for 
For up-to-date guidance on the management of ATS acute toxicity, it is recommended that 
information be sought from the National Poisons Information Service (NPIS), specifically the 
NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/A-Products/Amphetamine-related-Drugs-of-
Abuse/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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cardiac arrest is recommended following poisoning, as recovery with good neurological 
outcome may occur. This should be the case for all overdoses of recreational drugs, 
particularly as most patients are young and fit.
The benefits of gastric decontamination are uncertain, but TOXBASE® recommends 
oral activated charcoal if any amount of an ATS has been ingested within 1 hour, 
provided the airway can be protected. It also recommends that asymptomatic 
patients are observed for at least 4 hours, or 8 hours for patients who have ingested 
sustained-release preparations.
7.8.2. Management of serotonin syndrome
It has been suggested that people with serotonin syndrome related to the use of 
psychoactive substances such as ecstasy usually present to hospitals with advanced 
symptoms because some of the early, mild signs of the syndrome are often perceived 
as normal drug effects.47,70
There are no laboratory tests to confirm the diagnosis. Serotonin syndrome is difficult 
to diagnose for a number of reasons, which include the variability in clinical manifes-
tations, lack of awareness of the syndrome and limitations of the diagnostic criteria, 
which in turn may contribute to the lack of recognition.41 It has been argued that when 
assessing a patient with serotonin syndrome, the key elements of the history include 
the quantity and type of drugs ingested and the evolution and rate of progression of 
symptoms.72 Boyer et al. suggest that clinicians should consider serotonin syndrome 
for patients who present with tremor, clonus or akathisia with no additional extra-
pyramidal signs, after consideration of the patient history and physical examination.59
A formalised diagnostic approach to serotonin syndrome is the ‘Hunter Serotonin 
Toxicity Criteria: decision rules’,73 based on the presence or absence of seven clinical 
features (Figure 7.2). Of all the clinical features, clonus was considered the most 
important sign (spontaneous, inducible and ocular).
IF (spontaneous clonus = yes) 
THEN serotonin toxicity = YES
ELSE IF (inducible clonus =yes) 
AND [(agitation =yes) OR (diaphoresis = yes)] 
THEN serotonin toxicity = YES
ELSE IF (ocular clonus = yes) 
AND [(agitation = yes) OR (diaphoresis = yes)] 
THEN serotonin toxicity = YES
ELSE IF (tremor = yes) AND (hyperreflexia = yes) 
THEN serotonin toxicity = YES
ELSE IF (hypertonic = yes) AND (temperature >38˚C) 
AND [(ocular clonus = yes) OR (inducible clonus =yes)] 
THEN serotonin toxicity = YES
Figure 7.2. Hunter Serotonin Toxicity Criteria: decision rules (in the presence of a 
serotonergic agent)
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Most cases of serotonin syndrome are mild and may be treated by withdrawal of 
the offending agent and supportive care. Most mild cases will resolve spontaneously 
within 24 hours. Patients with moderate or severe cases of serotonin syndrome require 
hospitalis ation. Although many cases will resolve within 24 hours after cessation of the 
drugs involved and initiation of treatment, clinical symptoms may persist for longer in 
cases involving serotonergic drugs with long duration of action, active metabolites or 
long half-lives.59 If serotonin syndrome is recognised and complications are managed 
appropriately, the prognosis is favourable.74
Benzodiazepines are the standard treatment for the agitation and tremor. It has been 
suggested that, 5-HT2A antagonists (cyproheptadine and chlorpromazine) could be 
used in more severe cases,41 as they have been successfully used to treat serotonin 
syndrome following overdose. However, there are no controlled trials to support this, 
and there is a risk of convulsions as serotonin toxicity lowers the seizure threshold. 
The agitation, autonomic instability and hyperthermia need to be controlled.59,75 In 
moderate cases of serotonin syndrome, patients may have cardiorespiratory abnor-
malities and pyrexia, which should be treated aggressively.41 Death of patients with 
serotonin syndrome is normally due to hyperpyrexia-induced multi-organ failure and 
it is therefore essential to rapidly lower the patient’s temperature if it exceeds 39°C. 
(TOXBASE® recommends ice-baths and internal cooling devices, wherever available). 
Critically ill patients may require neuromuscular paralysis, sedation and intubation.74
Life-threatening serotonin syndrome may occur in 50% of cases of combined 
ingestion of an MAOI and an SSRI recreational drug, such as ecstasy. Rapid deteriora-
tion generally occurs and it has been recommended that patients be transferred to 
intensive care; toxicology investigations are also strongly recommended.41 The long 
half-life of some MAOIs (e.g. phenelezine, tranylcypromine) means that users could 
still be susceptible to interactions with ATS such as ecstasy up to 2 weeks after they 
have stopped using the drug.76,77
For up-to-date guidance on the management of serotonin syndrome, it is recommended that 
information be sought from the National Poisons Information Service (NPIS), specifically the 
NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/S-Products/Serotonin-syndrome/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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7.9. Harms associated with chronic use of ATS
7.9.1. Dependence and withdrawal
The WHO has estimated that 11% of ATS users become dependent and may require 
specialist interventions. However, even occasional users may experience physical, 
social or psychological harms and may progress to more harmful or dependent drug 
use.78
Dopamine dysfunction has been reported as the main neurobiological mechanism 
in amphetamine dependence.11 Amphetamines in general have low protein binding, 
which gives high bioavailability and supports their easy diffusion from the plasma to 
the extravascular compartment.14 It has been reported that people dependent on 
amphetamines may have a larger volume of distribution and longer plasma elimination 
half-life relative to drug-naïve individuals (6 versus 4 l/kg). This is probably due to 
tissue sequestration as a result of the development of pharmacokinetic tolerance 
to the drug.12,14 Dependence on ATS is characterised by increased tolerance and 
withdrawal symptoms on cessation, which include sleep and appetite disturbances, 
fatigue, depression, irritability, craving, depression, anxiety and agitation. It is also 
characterised by the inability to reduce drug use despite significant negative social, 
health and psychological problems associated with use.
Amphetamine withdrawal is extremely common, with 87.6% of the 647 participants 
with amphetamine dependence of one study reporting six or more signs of 
amphetamine withdrawal listed in DSM.79 There are variations in the level of intensity 
Table 7.2. Three phases of ATS withdrawal
Phase78 Time since last stimulant use Common signs and symptoms
‘Crash’ Typically commences 12–24 
hours after last amphetamine 
use and subsides by 2–4 days
Exhaustion, fatigue, agitation and irritability, 
depression, muscle ache akathisia
Sleep disturbances (typically increased sleep, 
although insomnia or restless sleep may occur)
‘Withdrawal’ Typically commences 2–4 days 
after last use, peaks in severity 
over 7–10 days and then 
subsides over 2–4 weeks
Strong cravings
Fluctuating mood and energy levels, alternating 
between irritability, restlessness, anxiety and 
agitation
Fatigue, lack of energy
May mimic narcolepsy
‘Extinction’ Weeks to months
(requires integration between
withdrawal and post-with-
drawal
services)
Gradual resumption of normal mood with 
episodic fluctuations in mood and energy levels, 
alternating between irritability, restlessness, 
anxiety, agitation, fatigue, lack of energy
Episodic cravings
Disturbed sleep
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of withdrawal from the various ATS, as discussed in Chapters 8–10. For amphetamine 
withdrawal80 (amphetamine, dextroamphetamine and methamphetamine), when 
heavy chronic users discontinue their use abruptly, many will report time-limited 
withdrawal symptoms that commence up to 24 hours after their last dose and can 
last for three weeks or more. These can be sufficiently severe to result in relapse to 
drug use. 
Phases of withdrawal include the initial ‘crash’, which resolves within approximately 
a week.81,82 Severe symptoms include increased sleep (but of poor quality), increased 
appetite and a cluster of depression-related symptoms. Phase 2 is a sub-acute 
protracted set of withdrawal symptoms which are not well defined but include 
continued sleep disturbances and increased appetite.81,82 Some symptoms may 
continue for weeks or months.
The WHO Technical Brief 2 on ATS78 outlines three phases of ATS withdrawal. These 
are set out in Table 7.2.
7.9.2. Physical and psychiatric/psychological harms 
from chronic use
It is clear that amphetamine has a cardiotoxic effect and has been associated 
with chronic cardiac pathology. The risks of coronary artery disease are probably 
compounded by the chronic effect of amphetamines (including methamphetamine) 
in the heart tissue, as well as the effects of amphetamine intoxication, and this may be 
a cause of premature mortality, although other factors – such as tobacco and alcohol 
use – are often additional factors.83 Hepatocellular damage may also occur from the 
chronic use of amphetamine.12,36
Amphetamine dependence has been associated with depression, anxiety, psychotic 
disorders,84 attention deficit hyperactivity disorder (ADHD)85 and antisocial personality 
disorder.86 It has also been associated with sexual risk behaviour and increased risk of 
HIV32 and a tendency to suicide.87
A minority of people who use amphetamines will develop a psychotic episode that 
requires care from emergency departments or psychiatric units.88 A Cochrane review 
of treatment for amphetamine psychosis noted that it is difficult to determine in 
any robust way the prevalence of amphetamine-induced psychosis at local or global 
levels. The epidemiology of the disorder indicates that patients with the symptoms of 
psychosis due to amphetamine present to emergency departments and psychiatric 
units at low rates compared with the census of all patients; it also reports that 
significant psychotic symptoms are common to users with more extensive and severe 
patterns of amphetamine use.88 
Common symptoms of amphetamine-induced psychosis include paranoid and/or 
persecutory delusions, as well as auditory and visual hallucinations, with extreme 
agitation. However, even among those who use amphetamine frequently, psychotic 
symptoms are more likely to be sub-clinical and not to require highly intensive inter-
ventions. The development of psychosis and sub-clinical symptoms is related to the 
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cumulative quantity of amphetamine ingestion, or the individual’s lifetime history of 
amphetamine use.88
There are similarities in clinical presentation between amphetamine-induced 
psychosis and schizophrenia, but the psychotic symptoms may be due solely to the 
heavy use of amphetamine, or heavy use of amphetamines may underlie a vulnerabil-
ity to schizophrenia.88 There are some indications that the two disorders may be linked 
genetically, with a study suggesting that relatives of the users of methamphetamine 
with a lifetime history of amphetamine psychosis are five times more likely to have 
schizophrenia than methamphetamine users without such a history.89
7.10. Management of harms 
associated with chronic use
7.10.1. Identification and assessment of ATS use and dependence90
The diagnosis of amphetamine use and dependence is based on criteria listed in 
the International Classification of Diseases (ICD-10). Amphetamine dependence is 
diagnosed if three or more of the following have been experienced or exhibited at 
some time during the previous 12 months:
•	a strong desire or sense of compulsion to take stimulants;
•	difficulties in controlling stimulant-taking behaviour in terms of its onset, 
termination or levels of use;
•	a physiological withdrawal state when stimulant use has ceased or been reduced;
•	evidence of tolerance, such that increased doses of stimulants are required in order 
to achieve the effects originally produced by lower doses;
•	progressive neglect of alternative pleasures or interests because of stimulant use;
•	persisting with stimulant use despite clear evidence of overtly harmful con-
sequences.90
Daily use of amphetamine is considered to be the most harmful pattern; it often has 
adverse outcomes for the health and psychosocial functioning of the user. However, 
the use of amphetamines on a weekly basis or more has been associated with adverse 
effects, and injecting and smoking are associated with higher risk. Typically, the 
threshold signalling a high risk of developing dependence starts after 6–12 months 
of weekly use, although there are reports of users experiencing problems even after 
relatively low levels of exposure.21
7.10.2. Stepped care for ATS users
The WHO Technical Brief on ATS90 recommends that services for ATS users are 
provided at a series of levels, as set out in Table 7.3. 
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Table 7.3. Stepped care for ATS users
Type of user suited to 
intervention
Activities/interventions
Step 1 Occasional ATS users 
believed to be at 
relatively low risk
Personal care activities: Self/family care in reducing/
stopping drug use. Self-help groups, informal commu-
nity-based care
Information about the risks of drug use, brief 
counselling, peer outreach and education, drop-in 
centres, skills and vocational training, rehabilitation and 
reintegration services
Step 2 ‘Problem’ ATS users Drug services in primary health-care settings: 
assessment, brief counselling, harm reduction 
information, needle and syringe programmes, referral 
to specialist services if required, assistance with basic 
symptomatic detoxification and withdrawal. Referral 
back to the community for support, rehabilitation and 
reintegration services or referral to expert care
Step 3 Heavy/dependent ATS 
users
Specialised drug dependence clinical care: Assessment 
of dependence, pharmacologically assisted withdrawal, 
harm reduction, needle and syringe programmes, 
outpatient and/or inpatient or residential treatment 
and specialised counselling, referral to rehabilitation and 
reintegration services, and back to the community for 
support
Activities 
to be 
undertaken 
at every 
step
All users Case management and counselling are important at 
every stage – though the exact technique and intensity 
will depend on the profile of the ATS user
Also important is the provision of opportunities for ATS 
users to undergo vocational training and assistance to 
gain employment, as well as improve family relations, 
deal with legal problems and assist in the development 
of new recreational activities and social networks in the 
community
7.10.3. Psychosocial and pharmacological support 
for the management of dependence
At the time of writing, psychosocial interventions remain the best treatment option 
for the management of amphetamine dependence.11
7.10.3.1. Psychosocial interventions
For details on psychosocial interventions see Chapter 2. 
Data are available on psychosocial interventions specific to stimulants and/or ATS. 
A Cochrane review of the psychosocial interventions for cocaine and psychostimu-
lant amphetamine-related disorders, reported little significant behavioural changes, 
with reductions in rates of consumption after an intervention. In addition, current 
evidence does not support a single treatment approach that is able to tackle the 
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multi dimensional facets of addiction and to yield better outcomes to resolve the 
chronic relapsing nature of addiction and its consequences.91,92
Nonetheless, a comparison between different types of behavioural interventions 
by the Cochrane review91 showed results in favour of treatment with some form 
of contingency management in respect to reducing treatment drop-outs and 
decreasing use and abstinence.91 The more comprehensive behavioural treatment, in 
which a contingency management program is provided in addition to a community 
reinforcement approach had significantly better results when compared to groups of 
patients receiving drug counselling or behavioural treatment only, without the added 
incentive programme involving vouchers to be exchanged for goods contingent on 
cocaine-negative urine samples.91
The Cochrane Review’s conclusions in terms of implication for practice were that, 
until further studies are available, clinicians may consider contingency management 
techniques as a good treatment approach, provided this can be replicated in a 
particular therapeutic setting. However, desired outcomes will not be achieved if 
the patient’s readiness for treatment and change is not managed and addressed. 
Treatment interventions need to be adequate to the particular stage of recovery a 
patient is in at the time she or he seeks treatment.91
The Cochrane review suggests that currently, the best results for treating psychostim-
ulant dependence are those of behaviour treatment with contingency management, 
in association with community reinforcement and workplace behaviour interventions, 
but these have limitations. Reductions in the amount or frequency of use is a benefit, 
but short-term reduction is of little lasting value. A patient must make effective 
changes in his/her life including sustained abstinence and the ability to work and 
maintain successful relationships with others. The nature and amount of treatment 
must be based on the range of problems a given patient faces. The review therefore 
conclude from the best available evidence, clinicians should take into account the fact 
that the best treatment has to match the patient’s needs.91
The WHO Technical Brief 278 suggests that crisis interventions may be needed in 
some instances for psychiatric symptoms, such as persecutory delusions or perceptual 
disturbances. It also recommends brief interventions, targeting ATS users to engage 
them in a discussion about their substance use and steer the discussion to encourage 
a person to decide if they want to change their behaviour. Brief interventions on their 
own have been shown to be successful at promoting behaviour change and can often 
be used as the first stage of more intensive treatment if needed. Information and 
counselling may also be needed, and a variety of approaches have been used from 
client-centred to open-ended counselling. 78
Gender differences have been described by a few studies. Some have argued that 
there is some evidence of sexual dimorphism in response to stimulants, with some 
preliminary evidence that suggests a potential biological mechanism involving brain-
derived neurotrophic factor that might contribute to these differences and that 
additional research is needed.93 Clinical and pre-clinical studies have for example 
found that women amphetamine users reported higher frequency of amphetamine 
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use than men.93–95 A human laboratory study suggested that women self-administer 
more frequently but a lower dose of amphetamine than men.96 It can be argued that 
although more research is needed before any conclusions are made clinicians may 
want to consider gender-specific issues as an important element in the management 
of amphetamines. 
7.10.3.2. Pharmacological interventions
Pharmacological interventions specific to each drug will be discussed in detail in 
all relevant chapters. Most of the research was carried out on treatment for meth-
amphetamine use and a recent Cochrane review of the efficacy of psychostimulant 
drugs for amphetamine abuse or dependence has concluded that it does not support 
the use of psychostimulant medications at the tested doses, as a replacement for 
amphetamines. The review also added that these conclusions may change in the future, 
as the number of included studies and participants were limited and information on 
outcomes were missing.11
There are some recommendation for symptomatic treatment of withdrawal. The 
WHO Technical Brief 2 on ATS recommends that treatment for severe insomnia be 
provided with light sedatives and hydration is maintained. Clinicians should be aware 
that depressive symptoms of varying severity may occur during or after withdrawal 
and there may be risk of suicide.78
7.10.4. Management of amphetamine psychosis
The resolution of symptoms among those who experience amphetamine-induced 
psychosis usually occurs with abstinence, although it may be incomplete, thus 
increasing risks of relapse.97 Symptoms usually resolve with medication, which is as 
for schizophrenia,98 including antipsychotics and benzodiazepines.88
A Cochrane review88 of the pharmacological treatment for amphetamine psychosis 
identified only one study that met criteria for inclusion. This randomised controlled 
trial with 58 participants showed that antipsychotic medication reduced symptoms 
of amphetamine psychosis effectively, with the newer-generation medication 
olanzapine showing significantly greater safety and tolerability than the more 
commonly used haloperidol controls, measured by the frequency and severity of 
extrapyramidal symptoms.99 However, the review also added that although antipsy-
chotic medications have shown their efficacy in providing short-term relief when a 
heavy user of amphetamines experiences psychosis, there is no evidence regarding 
the long-term use of these medications for preventing relapse into psychosis.88
Because of the similarities in the clinical presentations of amphetamine psychosis 
and schizophrenia, it has been suggested that distinguishing between them is 
often determined by the quick resolution of symptoms in amphetamine psychosis, 
which is not a likely outcome of schizophrenia.88,100 It has also been argued that the 
management, treatment and response to acute amphetamine psychosis are much 
like those for schizophrenia and antipsychotics produce similar results.88,101
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7.10.5. Aftercare and support
See Chapter 2 on psychosocial interventions.
7.11. Public health and safety 
and harm reduction
The WHO Technical Brief on ATS suggests that clinicians should advise users of ATS 
(including methamphetamine) to reduce harms by taking into account the following:78
•	ATS can stimulate excessive physical activity, leading to overheating. Users should 
therefore ensure they drink enough fluids, while taking care not to drink too much 
(not more than one pint in one hour when dancing) as this can cause hyponatraemia 
( an electrolyte disturbance in which the sodium ion concentration in the plasma is 
lower than normal).
•	Users should not combine ATS with other drugs, including alcohol. The simultaneous 
use of more than one drug can cause serotonin syndrome, which can be severe. 
•	Users should think about safer sex. Methamphetamine in particular can increase 
sexual desire and the ability to have sex for longer periods. Users should always 
protect themselves by using condoms.
•	Straws used for snorting should not be shared, as they carry the risk of transmission 
of blood-borne viruses.
•	Where ATS are injected, users should never share equipment. They should also 
rotate sites to avoid vein damage.
•	Users should avoid taking ATS too many days in a row, to avoid dependence and to 
give their bodies a rest.
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Chapter 8
Methamphetamine
Drug group: stimulant
The use of methamphetamine in the UK continues to be relatively uncommon, with 
its use limited to specific populations and contexts, most particularly men who have 
sex with men (MSM). However, a discussion of methamphetamine harms and their 
management is included in this guidance document because of both the level of harms 
relating to the use of this substance and the lack of experience in the management 
of its harms in the UK.
Methamphetamine hydrochloride is stable and volatises easily so can be smoked, 
unlike amphetamine sulphate.
8.1. Street names
Street names at the time of publication include Crystal Meth, Tina, Christine, Ice, 
Glass, Crank, Yaba and Crazy Medicine. Other street names may be used locally.
8.2. Legal status
Methamphetamine and 4-methylamphetamine are Class A drugs under the Misuse of 
Drugs Act 1971.
8.3. Quality of the research evidence
There is a much larger and more robust body of evidence on methamphetamine harms 
and treatment than for other club drugs. This includes a number of well conducted 
randomised controlled trials (RCTs) and Cochrane reviews, especially in relation to 
dependence. 
However, most of the research evidence on methamphetamine comes from the 
US, Australia and South East Asia. UK and European research is much more limited, 
reflecting the currently low rates of use across most of Europe. Some of the findings 
of international studies may be less relevant in a UK context, especially those relating 
to epidemiology and trends.
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8.4. Brief overview of pharmacology
Methamphetamine is an N,α-dimethylphenethylamine and a member of the 
phenethylamine family. It is a synthetic stimulant and a derivative of amphetamine.1 
Methamphetamine is a potent psychomotor stimulant with strong physiological 
effects on the peripheral and central nervous systems, resulting in physical and 
psychological effects.2 It is typically described as a more potent stimulant than non-
methylated amphetamines. It is highly lipophilic, and in comparison with amphetamine 
at similar doses crosses the blood–brain barrier more easily, is more potent and has 
a more pronounced and a longer-lasting stimulant effect.3 Methamphetamine has 
short-term and long-term effects that are similar to those produced by cocaine, but 
they last longer and can be more severe.4 
The action of methamphetamine and other amphetamines have been well 
described.2,5,6,7 Methamphetamine increases the activity of the noradrenergic and 
dopamine neurotransmitter systems. It increases the release and blocks the reuptake 
of dopamine. It has an active metabolite, amphetamine, and two inactive metabolites, 
p-OH-amphetamine and noradrenaline. It is oxidised and metabolised in the liver 
through enzymatic degradation primarily involving cytochrome P450-2D6. Approxi-
mately 10% of Caucasians are deficient in this enzyme, and a study has suggested 
that this makes them particularly sensitive to the effects of methamphetamine, as 
they lack the ability to metabolise and excrete the drug efficiently.8
Chronic methamphetamine alters brain function. Brain imaging studies have shown 
changes in the activity of the dopamine system that are associated with reduced 
motor skills and impaired verbal learning.9 Imaging studies of methamphetamine-
dependent individuals have found structural abnormalities: severe grey-matter 
deficits in the cingulate, limbic and paralimbic cortices, smaller hippocompal volumes, 
significant white-matter hypertrophy, medial temporal lobe damage and striatal 
enlargement.10,11 
Studies have also shown severe structural and functional changes in areas of the brain 
associated with emotion and memory,11,12 as well as neurochemical and metabolite 
changes in the ventral striatum.13,14 Prolonged use has been reported to lead to down-
regulation of dopamine D2 receptors and uptake sites.
15 A state of hypo dopaminergic 
activity has been reported.16,17
The psychiatric consequences of methamphetamine use are theorised to be 
secondary to its mechanisms of action: methamphetamine enters the synaptic 
neurons via monoamine transporters and, once in the neurons, displaces the 
monoamines from vesicular and intracellular locations, pushing the monoamines into 
the extraneuronal spaces. Long-term use is associated with alterations in the levels of 
monoamines implicated with stimulant use, which include noradrenaline, serotonin 
and dopamine.18,19 
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8.5. Clinical and other legitimate 
uses of methamphetamine
Methamphetamine has been used in the treatment of narcolepsy and attention deficit 
hyperactivity disorder (ADHD). There is also some research on other therapeutic uses 
of methamphetamine. A rat study looked at whether low-dose methamphetamine 
could prevent neuronal loss and improve functional behaviour after severe traumatic 
brain injury (TBI). It found that low doses elicited a robust neuro-protective response, 
resulting in significant improvements in behavioural and cognitive function.20
8.6. Prevalence and patterns of use
Methamphetamine is one of the most widely misused drugs in the world, with over 35 
million users estimated. However, at a European level, the use of methamphetamine 
has historically been low, with some exceptions, notably in the Czech Republic and, 
more recently, Norway and Slovakia. However, there are some indications that meth-
amphetamine is increasing in availability and data from some European countries 
suggest that it may be replacing amphetamine.21,22
In the UK, methamphetamine use is still limited, and amphetamine sulphate 
continues to be much more available and widely used. Data from the Crime Survey 
for England and Wales (CSEW) on the use of methamphetamine have been collected 
since 2008/09 and show the following, with no statistically significant changes over 
the years. Use of methamphetamine in the last year was reported by 0.1% of adults 
(16–59 years) in all six annual surveys, with no significant differences between young 
adults and all 16–59-year-olds in the proportion of people reporting its use.23
Other UK data also suggest its limited use. A retrospective study on the number of 
enquiries to the poison centres of two large inner-city hospitals from 2000 to the 
end of 2006, as well as the National Poisons Information Centre 2005/06, reported 
that there was no evidence of increasing use of methamphetamine or that acute 
methamphetamine poisoning was a significant clinical problem in comparison with 
other established, drugs such as MDMA.24 
The prevalence of methamphetamine use is higher among some sub-groups (e.g. 
‘clubbers’), although there rates still remain lower than for other club drugs. Among 
the UK sample from the Global Drug Survey in 2012 3.8% of respondents reported 
ever trying methamphetamine, with 0.8% reporting use in the last 12 months and 
0.2% in the last month. The percentage of methamphetamine users among those 
described as ‘regular clubbers’ was higher, with 1% reporting use in the last 12 
months.25
There is some evidence that methamphetamine use is more common among MSM 
than it is among the general population and that its use is mainly concentrated in 
this population. This was shown by the 2013/14 CSEW, which analysed responses 
by sexual orientation where this was self-reported (these data have to be treated 
with caution because of the small number of respondents involved). The results are 
presented in Table 8.1.
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Table 8.1. Proportion of 16–59-year-olds reporting methamphetamine use in the 
past year (3-year combined data-sets 2011/12, 2012/13 and 2013/14)23
Heterosexual: 
all
Male 
heterosexual
Female 
heterosexual
Gay or 
bisexual: all
Male gay or 
bisexual
Female lesbian 
or bisexual
0.0% 0.1% 0.0% 0.6% 1.1% 0.0%
Other data from targeted surveys also suggest that in the UK the use of metham-
phetamine may be higher among MSM than the general population. These surveys, 
although not comparable, suggest rates of use that are higher than those reported 
by the CSEW,26–28 with for example a 2007 survey of London MSM estimating use 
of methamphetamine in the past year at 7.8%29 and a survey carried out in 2010 
reporting 8.7%.30 
Studies have also shown differences in the use of methamphetamine within 
populations of MSM. Like other international research, UK studies have reported that 
HIV-positive men are more likely to use methamphetamine than other MSM.30–34 US 
studies have shown that the incidence of HIV among MSM who use methamphet-
amine is more than double that among MSM who do not use methamphetamine.35
There are also differences based on geography, with methamphetamine found in 
metropolitan areas mainly (e.g. London and Manchester). In the UK methampheta-
mine is more widely used by gay men in London than elsewhere in the country.29,30 A 
recent study also showed differences within London, with higher prevalence in areas 
such as Lambeth, Southwark and Lewisham (LSL), which are home to large populations 
of gay and bisexual men, and have a large gay commercial scene and sex-on-premises 
venues. In these locations methamphetamine use in the past four weeks (4.9% of LSL 
respondents) was higher than among gay men elsewhere in London (2.9%) and sub-
stantially higher than elsewhere in England (0.7%).30 Methamphetamine is associated 
with ‘chemsex’, as discussed in greater detail in section 8.10.2.
There is no evidence that the use of methamphetamine is becoming more widespread 
among MSM in the UK, although one report suggested that its use appears to be 
increasing, albeit slowly and certainly not exponentially.30 There is also no evidence 
that its use is becoming more mainstream in the UK, or whether it will ever expand 
to the wider population. Drug-using cultures differ and methamphetamine use may 
not follow the same pathways as in other parts of the world, including the US and 
Australia, where its use has expanded beyond MSM populations. 
US and other studies have shown a change over time in the sociodemographic 
characteristics of methamphetamine users. A study of treatment admissions from 
the California Alcohol and Drug Data System from 1992 to 2002 showed not only a 
five-fold increase of methamphetamine admission, but also a shift towards usage by 
minority ethnic groups and a more vulnerable population in terms of homelessness, 
chronic mental health problems and disability. There was also a substantial increase in 
people reporting a legal supervision status (criminal justice intervention).36 In the UK, 
this vulnerable population is currently typically more associated with crack cocaine 
and opiate use.
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8.7. Routes of ingestion and dosing
The most common form of methamphetamine is a hydrochloride salt, which comes 
as a white or off-white bitter-tasting powder, or as purer crystals that are soluble in 
water. It can also come in tablets, which carry logos similar to those on ecstasy tablets.
Most of the methamphetamine used in the UK is in the crystalline form. It is currently 
mainly smoked but it is also snorted, injected intravenously (known as ‘slamming’ 
among MSM in the UK), used anally (known as ‘booty bumping’) or inserted into the 
urethra. It has been noted that if too much methamphetamine is inserted anally, it 
may not all be completely dissolved and there is a risk of abrasion of condoms resulting 
from friction with this undissolved methamphetamine, which can contribute to the 
condom breaking.37
There is some evidence that smoking methamphetamine has more harmful psycho-
logical effects and a higher addictive potential than snorting or swallowing the drug, 
and that smokers have levels of dependence approaching those seen among meth-
amphetamine injectors.38,39
Methamphetamine is rapidly absorbed after ingestion and its half-life is 8–13 hours.40 
The stimulant effects depend on a number of factors, including route of ingestion 
and dose; they may last between 6 and 12 hours, but longer durations have been 
reported.41 Intravenous injection and smoking have a rapid onset of action. Following 
oral administration, peak concentrations are seen in 2.6–3.6 hours and the mean 
elimination half-life is 10.1 hours (range 6.4–15 hours). Following intravenous use the 
mean half-life is slightly longer (12.2 hours). 
Methamphetamine is expensive in the UK, with a cost of up to £260 per gram, which 
is much above the cost in countries where it is more highly prevalent.42 It is also 
considerably more expensive than other stimulant drugs, including cocaine, at ap-
proximately £50–£100 per gram.
8.8. Desired effects for recreational 
use and unwanted effects
The effects of methamphetamine result from a surge in newly synthesised catechol-
amines and serotonin; these include excitation, well-being, increased alertness, energy 
and confidence, highly focused attention and decreased appetite. Methamphetamine 
use creates feelings of increased confidence, sociability and euphoria.43 In metham-
phetamine-naïve individuals, acute doses can improve cognitive processing. Studies 
show that single low to moderate doses increase arousal and alertness, and improve 
attention and concentration, particularly among those who are sleep-deprived. 
Methamphetamine has an apparent aphrodisiac effect, with increased sexual drive, 
decreased fatigue and loss of sexual inhibition. It can delay ejaculation, assist longer 
intercourse and decrease humoral secretions.44,45 Paradoxically, there is evidence that 
long-term use is associated with decreased sexual functioning in some men.46 
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Higher dose of methamphetamine can cause dysphoria, restlessness and anxiety, 
and are associated with tremors and dyskinesia. In binge use of methamphetamine, 
the euphoric effects decrease over time, while dysphoria and compulsive behaviour 
increase. Bingeing has also been reported to induce sleeplessness, hallucinations and 
paranoia.47 
The negative psychological effects of methamphetamine use may include anxiety, 
restlessness, insomnia, grandiosity, paranoia, psychosis, hallucinations (including 
delusional parasitosis), depression, unprovoked aggressive or violent behaviour and 
irritability. Individuals can talk excessively, be agitated, aggressive and restless, and 
may be observed performing repetitive meaningless tasks.8
Unwanted effects of methamphetamines have been reported to be common. A 
US study of 350 individuals found that the majority reported problems associated 
with methamphetamine use, which included weight loss (84%), sleeplessness (78%), 
financial problems (73%), paranoia (67%), legal problems (63%), hallucinations (61%), 
work problems (60%), violent behaviour (57%), dental problems (55%), skin problems 
(36%) and high blood pressure (24%).48 In the UK Gay Men’s Sex Survey 2007, 40.4% 
of men who had used methamphetamine in the past year reported concerns about 
this drug.26
The ‘come-down’ from methamphetamine is one of the most common unwanted 
effects reported by users.49 Users may feel irritable, restless, anxious, depressed and 
lethargic, and there are reports of the use of benzodiazepines or heroin to soften the 
come-down. It has been reported in New Zealand that it is often sold in a package 
with GHB/GBL to help with its come-down effects.50 Anecdotal evidence from the UK 
suggests that the two substances are sometimes used together.
8.9. Mortality
A study of cohorts of individuals in California hospitalised from 1990 to 2005 with 
a diagnosis of disorders relating to methamphetamine, cocaine, alcohol, opiates and 
cannabis and followed up for 16 years (74,139 individuals and 4122 deaths) found 
that hospitalised methamphetamine users had a higher mortality risk than the users 
of all substances, except for opiates. The standardised mortality rate for metham-
phetamine found by the study was 4.67, which is similar to rates found by studies in 
inpatient or treatment settings in the Czech Republic,51 Denmark52 and Taiwan,53 but 
slightly larger than those reported by a community-based sample of amphetamine 
users in Sweden.54
Deaths associated with methamphetamine have been attributed to homicide, suicide, 
motor vehicle accidents, manufacturing, distribution and sales of the drug as well 
as its direct toxic effects.55 Biologically based causes include stroke and cerebral 
haemorrhage, cardiovascular collapse, pulmonary oedema, myocardial infarction, 
hyperpyrexia and renal failure.56,57
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8.10. Acute harms
8.10.1. Acute toxicity
The features of acute toxicity are summarised in Box 8.1. The relevant literature is 
discussed in section 8.11.
8.10.1.1. Cardiovascular and respiratory harms
The acute (and chronic) use of methamphetamine can severely affect the cardio-
vascular system.8 It causes an acceleration of heart and lung action through 
vasoconstriction and bronchodilation, while muscle activity is primed via transient 
For up-to-date guidance on the management of methamphetamine acute toxicity, it is 
recommended that information be sought from the National Poisons Information Service 
(NPIS), specifically the NPIS 24-hour telephone service and the poisons information database 
TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/M-Products/Methamphetamine/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
Box 8.1. Feature of acute methamphetamine toxicity
Cardiovascular and respiratory 
Narrow-complex tachycardias (common)
Chest pain
Palpitations
Systemic hypotension or hypertension 
Ventricular tachycardia or ventricular fibrillation.
Dyspnoea 
Gastrointestinal and urological 
Abdominal pain
Vomiting
Metabolic acidosis
Neurological, psychiatric and central nervous system
Tremor
Sweating
Dilated pupils
Agitation
Confusion
Headache
Anxiety
Seizures
Hallucinations or delusions
Hyperpyrexia (may be severe)
Serotonin syndrome (especially if more than one stimulant drug has been used) (serotonin 
syndrome is discussed in depth in section 7.7.2).
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hyperglycaemia and dilation of blood vessels in skeletal muscles.58 Some non- essential 
physiological activity is inhibited (e.g. stomach and intestinal function); levels of stress 
hormones – including cortisol and adrenocorticotropic hormone – are increased by 
200% in humans following ingestion59 and remain elevated for hours.2 Tachycardia 
and hypertension are common features of methamphetamine toxicity.4
Chest pain is a common complaint associated with methamphetamine use,60 with one 
study reporting that they account for 38% of emergency department visits and 28% 
of admissions among patients using methamphetamine.61 It has also been suggested 
that although in some patients chest pain is due to methamphetamine-induced 
hypertension, tachycardia or anxiety, acute coronary syndrome (ACS) is common 
among methamphetamine users. One study recommended that patients with chest 
pain in the context of methamphetamine use should be evaluated for ACS.62 The 
prevalence of ACS was found to be 25% in a small series of patients presenting to an 
emergency department with chest pain after methamphetamine use.63 
Methamphetamine users have significantly higher rates of coronary artery disease 
than the general population.64 Even those with normal coronary arteries are at risk of 
methamphetamine-induced myocardial infarction, because of coronary spasm, which 
may be refractory to intracoronary vasodilator therapy.65 The putative mechanisms 
of myocardial infarction in the context of methamphetamine use include accelerated 
atherosclerosis, rupture of pre-existing atherosclerotic plaques, hypercoaguability 
and epicardial coronary artery spasm.65,66 Acute myocardial infarction following 
methamphetamine use can be severe and can result in cardiogenic shock and death.67
There is an association between methamphetamine use and cardiomyopathy, with 
different levels of problems reported by studies in areas where the prevalence of 
methamphetamine use is high. A study in Hawaii (where methamphetamine use is 
high) reported that methamphetamine use accounts for 40% of all admissions of 
patients under the age of 45 years with cardiomyopathy. More than 20% of with 
heart failure were former or current methamphetamine users.68 A US registry 
containing information on more than 11,000 patients with decompensated heart 
failure reported that more than 5% were stimulant users.69 
One case series reported that more than a quarter (27.2%) of methamphetamine-
intoxicated patients had a prolonged corrected QT interval (QTc>440ms), suggesting 
that methamphetamine-induced alterations in cardiac conduction may be partly 
responsible for the drug’s dysrhythmogenic effects.70 
Other conditions related to methamphetamine intoxication include premature 
ventricular contractions, premature supraventricular contractions, accelerated 
atrioventricular conduction, atrioventricular block, intraventricular conduction 
delay, bundle branch block, ventricular tachycardia, ventricular fibrillation, and supra-
ventricular tachycardia.63,70,71 Methamphetamine-induced dysrhythmias may also 
occur because of myocardial ischaemia or infarction.60
Methamphetamine use may also be associated with aortic dissection and carries 
a greater risk for that than cocaine; it may be second only to hypertension in its 
importance as a risk factor for aortic dissection.72 Methamphetamine can cause 
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cerebral stroke, haemorrhage and hypertension.40,73 Like other drugs injected, the 
injection of methamphetamine has been associated with endocarditis.60 Cardiovas-
cular events are often involved in medical complications and death associated with 
methamphetamine.74 The ingestion of large quantities of methamphetamine has 
been associated with cerebrovascular haemorrhage.75,76,77 
The risks associated with the long-term use of methamphetamine are discussed in 
section 8.12. 
8.10.1.2. Hyperthermia
The ingestion of large quantities of methamphetamine has been associated with 
hyperthermia, above 41°C.75–77
8.10.1.3. Rhabdomyolysis
A five-year US study found that 43% of patients who presented to an emergency 
department with rhabdomyolysis were positive for methamphetamine.78
8.10.1.4. Urological 
The ingestion of large quantities of methamphetamine has been associated with 
renal and liver failure.75–77
8.10.2. Methamphetamine use and high-risk sexual behaviours
There are current anecdotal reports in the UK of high-risk behaviours associated with 
methamphetamine among a minority of gay men,79 with this drug most commonly 
associated with what is referred to as ‘chemsex’, or sometimes as ‘party and play’, which 
is used to describe sex between men that occurs under the influence of drugs taken 
immediately before and/or during the sexual session.30 Three patterns of behaviour 
are associated with methamphetamine use: high-risk sex, sexualised injecting and the 
sharing of injecting equipment. 
The use of club drugs in a sexual context has been described.80,81 Methamphetamine 
is one of the drugs most commonly used in a sexual context (chemsex) in the UK79 
and elsewhere. In a US study of 60 MSM, 68% reported using methamphetamine 
during sex more than 50% of the time.82
A relatively large body of evidence shows the heightened sexual risk-taking associated 
with methamphetamine use83–89 and a relationship has been observed between 
increased severity of methamphetamine use and HIV risk.88 Methamphet amine use 
has also been associated with sexually transmitted infections (STI), with studies 
showing that MSM who use methamphetamines, regardless of their HIV status, have 
a greater risk of STIs than those who do not.32,90
There is some evidence that compared with use of other drugs, methamphetamine 
use is a particularly strong predictor of unprotected anal sex among MSM.91,92 It has 
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also been associated with increased rates of STIs,35,93,94 including HIV infection.80,95–103 
Men who use methamphetamine are 1.5–2.9 times more likely to acquire HIV than 
those who do not.87,104–107 There is also an association between methamphetamine 
use and rates of HIV and hepatitis C.108–115 
Studies also suggest that HIV-positive MSM who use methamphetamine are sig-
nificantly more likely than MSM who do not use methamphetamine (regardless of 
their HIV status) to engage in unprotected anal sex,32,116–118 and group sex,119 to have 
multiple sexual partners,29,32,116,120,121 to find sexual partners on the internet,32 to 
have sex with an injecting drug user116 and to be intoxicated during sex.32,116 Among 
HIV-infected MSM men who have a sero-discordant partner (i.e. HIV negative, or status 
unknown), the use of methamphetamine is significantly associated with unprotected 
anal sex.33,122,123 
A number of factors and sub-groups of methamphetamine users have been associated 
with particularly high-risk behaviours for transmission of HIV and STIs. These include 
methamphetamine users who use sildenafil (Viagra)91–93,123,124 or other illicit drugs 
during sex,125,126 those who exchange sex for methamphetamine,127 those who report 
high levels of sexual compulsivity,123,128 those who engage in sexual encounters in 
public spaces34,129 and those who report methamphetamine binges.130
A recent review of outcomes among MSM who use methamphetamines has reported 
a low adherence to medication by HIV-positive MSM who use methamphetamine. 
This, the authors believe, may contribute to the transmission of HIV virus resistant 
to medication which has been seen in newly infected MSM who use methamphet-
amine.89
However, it is important to note that a causal link between methamphetamine use 
and STIs, HIV and other blood-borne viruses (BBV) has not been established. There is 
some evidence that individuals who engage in high-risk sexual activity are more likely 
to use recreational drugs131 and evidence that among MSM recreational drug use in 
general (rather than methamphetamine use specifically) is associated with high-risk 
activity.132,133
The link between methamphetamine use and high-risk sexual activities is not unique 
to MSM, although most of the research has been carried out among MSM and less 
evidence is available for heterosexuals.134 Studies of male and female heterosexual 
populations also suggest that methamphetamine users have a higher frequency of 
sexual activity, have more sexual partners and engage in higher-risk sexual behaviours 
(unprotected vaginal sex and anal sex) than the users of any other drugs.135–139
8.10.3. Injecting risks
There is some anecdotal evidence of injecting methamphetamine among a minority 
of MSM in London (sometimes in combination with mephedrone), taking place at 
sex parties or other social gatherings, where people may share injecting equipment. 
For some people, injecting appears to have become sexualised. This combination of 
factors has been described as ‘a perfect storm for transmission of both HIV and HCV 
[hepatitis C], as well as a catalogue of ensuing mental health problems’.79
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It has been noted that HIV-positive men are more likely to inject psychoactive 
substances (including methamphetamine) than other MSM, with injecting increasingly 
common with older age, peaking among men in their 40s.30 There are some reports 
from methamphetamine users of increased sexual desires with injecting metham-
phetamine, in comparison with other forms of methamphetamine use.140,141
Injecting is a serious public health concern, as well as heightening risks and harms to 
the individual user.142 The evidence on the elevated injecting-related risk behaviours 
among methamphetamine users in comparison with other injectors has been 
ambiguous.84,143–145 Regardless, methamphetamine injecting has been identified 
as a significant risk factor and injectors often present with more complex needs. 
Studies have shown that methamphetamine injectors are more dependent than non- 
injectors,146 are at increased risk of non-fatal overdose,147 are more likely to engage 
in HIV-risk behaviours;143,148–150 and a study has reported a higher prevalence of STIs 
than among non-injecting methamphetamine users.151
Methamphetamine injectors are more likely to have co-morbid psychiatric disorders 
than are non-injecting methamphetamine users.152,153 There is also evidence that meth-
amphetamine injectors may be more likely to attempt suicide than those who smoke 
or snort the drug,153,154 with a seven-year study reporting that people who injected 
methamphetamine had an 80% greater risk of attempting suicide than those who did 
not inject, even after taking into account a wide range of potential confounders. The 
study also showed a dose–response relationship between frequency of injecting meth-
amphetamine and suicidal behaviour. The conclusion was that individuals who inject 
methamphetamine should be considered at high risk of suicide among populations of 
methamphetamine users, as well as the broader injecting population.155
8.10.4. Acute harms of poly-drug use and drug interactions 
The high level of poly-drug use among methamphetamine users has been well 
established.156 Cross-sectional population surveys suggest that the concurrent use 
of alcohol and cocaine is particularly common.157 This can cause harm as it increases 
blood pressure. Methamphetamine can also mask the effects of alcohol, which may 
increase the risk of alcohol poisoning and accidents due to false feelings of being sober. 
Concurrent use of amphetamine and cannabis can increase psychotic symptoms in 
some users. Methamphetamine used with heroin can lead to respiratory depression 
and can increase the risk of heroin overdose.1 The combination of methamphetamine 
and cocaine has been shown to increase substantially the cardiotoxic effects of both 
drugs.158
The co-ingestion of GHB and methamphetamine might increase the risk of GHB 
overdose, as methamphetamine can mask the signs of acute toxicity. There are also 
risks associated with the use of methamphetamine with other serotonergic substances. 
Informal reports from specialist UK ‘club drug’ clinics and some UK research30 suggest 
that methamphetamine is often used in combination with mephedrone, another 
stimulant, leading to a potential risk of serotonin toxicity (on which, see section 7.7.2). 
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The potential for drug interactions with CYP2D6 inhibitors is high and co- 
administration of these agents may increase the toxicity of methamphetamine. 
Well known CYP2D6 inhibitors include: amiodarone, citalopram, codeine, fluoxetine, 
haloperidol, methadone, paroxetine and valproic acid. Among the antiretrovirals, while 
low-dose ritonavir does not seem to affect CYP2D6 activity,159 the newer booster 
cobicistat is included in the list of CYP2D6 inhibitors.
8.10.5. Acute withdrawal
For withdrawal see section 8.12.2.
8.10.6. Emergency hospital admissions
In countries where rates of methamphetamine use are high, admissions to emergency 
departments (EDs) are reportedly very common. US data demonstrate that regular 
users of methamphetamine have a high rate of presentation to ED61,160,161 and there 
is some evidence that adult methamphetamine users use ED and other hospital 
resources more than the users of other substances.61,162 A Canadian study of homeless 
and street-based youth reported that frequent injecting of methamphetamine was 
associated with increased risk of ED utilisation.155 Studies have shown that 1–2% 
of all ED visits are related to methamphetamine in endemic areas, with psychiatric 
conditions being the most common complaints.154,163–173 
No such data are available for the UK, where the prevalence of methamphetamine 
use is low. However, 0.46% of drug-related presentations to an inner city hospital 
ED between 1 October 2005 and 31 December 2006 were related to self-reported 
methamphetamine use.24
In comparison with other patients presenting to EDs for toxicology-related issues, 
some studies have shown that those presenting with methamphetamine-related 
problems are more agitated, violent and aggressive and more likely to present on 
arrival with tachycardia and hypertension.174,175
In terms of mental health presentations, a study of psychiatric admissions to EDs 
reported that there were no differences in heart rate, admission route or cost of care 
of methamphetamine-related visits and other visits. This, according to the study, 
suggests that methamphetamine users presenting for psychiatric problems are 
clinically similar to non-amphetamine users with psychiatric problems.176
Studies have also shown relatively high levels of methamphetamine-related hospital 
presentations for psychiatric problems. Psychiatric symptoms, including acute 
psychosis, depression and anxiety disorders, have been associated with both acute 
and chronic methamphetamine use.154,163–176
Some studies have also suggested that more amphetamine-related presenta-
tions to EDs were for psychiatric problems than for other problems; 18% of 
 methamphetamine-related ED visits were associated with psychiatric complaints or 
diagnosis, representing the largest patient sub-group visiting EDs with psychiatric 
issues.163,176
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In the US, where rates of methamphetamine use are significantly higher than in 
the UK, a study reported that methamphetamine-related psychiatric visits to EDs 
represented 7.6% of all psychiatric attendances at EDs, a percentage which the 
authors described as ‘disproportionate’. In comparison, 1.8% of all trauma visits 
were methamphetamine-related and 2.1% of presentations with chest pain were 
 methamphetamine-related.176
8.11. Management of acute harms
TOXBASE® recommends that where a patient has impaired consciousness, emergency 
clinicians should ensure clear airways and adequate ventilation. As with other 
amphetamines, in the event of cardiac arrest, resuscitation should be continued for 
at least 1 hour and only stopped after discussion with a senior clinician. Prolonged 
resuscitation for cardiac arrest is recommended following poisoning, as recovery with 
good neurological outcome may occur. 
TOXBASE® also suggests that the benefit of gastric decontamination is uncertain. 
Clinicians should consider oral activated charcoal if methamphetamine has been 
ingested within 1 hour, provided the airway can be protected. Asymptomatic 
patients should be observed for at least 4 hours, or 8 hours for patients who have 
ingested sustained-release preparations. Agitated adults can be sedated with an 
initial dose of oral or intravenous diazepam.
8.12. Harms of chronic use and dependence
8.12.1. Dependence
The risk of dependence with methamphetamine use is high. Tolerance to metham-
phetamine takes place when the drug is taken frequently, leading to users taking 
higher doses or using more frequently or changing the route of administration in 
order to get the desired effect.* There is some emerging evidence that craving to 
methamphetamine cues can be measured in dependent individuals177–179 and that 
cue-elicited methamphetamine craving is a strong predictor of subsequent use.180
There is some evidence that methamphetamine-dependent users show a decrease 
in everyday functioning, disruption in everyday activities and increased errors in 
planning a daily schedule. Methamphetamine dependence has also been linked to 
impairments in the domains of communication, work and recreation.181,182 There is 
also evidence that the chronic use of methamphetamine causes cognitive deficits 
after withdrawal.183–185 Studies have also shown that this may be associated with 
disruptions of the dopaminergic and serotonergic systems.183,186–189 Chronic use of 
methamphetamine causes neurochemical and neuroanatomical changes, which 
includes memory impairment. 
* Section 7.9.1 has discussed ICD-10 criteria for harmful use and dependent use and should be 
referred to when reading the present chapter. It also offers additional information on dependence on 
 amphetamine-type substances.
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Dependence results in deficits in memory and in decision-making and verbal 
reasoning.22 There is limited evidence that this functional deficit continues several 
months after abstinence.182,190 One study has reported deteriorating cognitive 
performance during the first three months of abstinence from methamphetamine, 
with abstinent patients or abstinent patients with a recent lapse scoring worse on 
neuropsychological testing than patients with on-going methamphetamine use. This 
reflects the difficulties in attention, understanding and memory often encountered 
in methamphetamine patients in treatment settings.184 Although it needs to be 
substantiated by larger studies, Henry et al. suggest that this may have important 
implications for treatment interventions, as individuals with poor functional ability 
may have difficulty responding to cognitive-behavioural therapy (CBT) and the 
cognitive enhancement techniques commonly used in the treatment of metham-
phetamine misuse.190
8.12.2. Withdrawal
Methamphetamine is associated with a clear withdrawal syndrome. A time-limited 
withdrawal syndrome may occur within 24 hours of the last dose when heavy chronic 
users of methamphetamine cease to use the drug abruptly. The withdrawal syndrome 
is common and severe enough to cause relapse outside a contained environment.191 
Chapter 7 (the overview of amphetamine-type substances) has discussed in greater 
detail the phases of amphetamine withdrawal and should be read in conjunction 
with this present one. Phases of withdrawal symptoms have also been identified with 
methamphetamine users. For example, a study of 21 inpatients suggested that meth-
amphetamine withdrawal has two phases: an acute phase lasting 7–10 days, in which 
overall symptom severity declines in a linear pattern from a high initial peak; and a 
sub-acute phase lasting at least a further 2 weeks, with some studies reporting much 
longer periods.192 Withdrawal from methamphetamine has been described as more 
characterised by psychological and psychiatric symptoms than physical symptoms.56 
Table 8.2. The two phases of methamphetamine withdrawal.
Acute withdrawal symptoms Longer-term withdrawal symptoms 
(can last up to 12 months)
Severe dysphoria Anhedonia
Irritability Impaired social functioning
Melancholia Intense craving
Anxiety Hyper-arousal
Hypersomnia and marked fatigue, Vegetative symptoms
Intense craving Anxiety-related symptoms
Paranoia Severe dysphoria
Intensity of post-binge dysphoria can lead to suicide ideation 
and attempts have also been linked to withdrawal56,197 (for 
more information on the withdrawal syndrome see Chapter 7)
Mood volatility
Akathisia/restless legs Irritability
Sleep pattern disruption
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Table 8.2 outlines the two phases of methamphetamine withdrawal, according to the 
reported symptoms.48,56,76,153,193–197 
Greater severity of withdrawal symptoms in methamphetamine-dependent individuals 
has been reported among those who are older, who have been using methamphet-
amine longer and who have more severe methamphetamine use disorder.192,197
8.12.3. Physiological, psychological and psychiatric 
effects of long-term use and dependence
Chronic use has been associated with malnourishment.198
8.12.3.1. Cardiovascular effects
Long-term use of methamphetamine can result in severe cardiovascular complica-
tions related to chronic hypertension and cardiovascular disease, such as angina, 
arrhythmias, valvular disease, haemorrhagic/ischaemic strokes and a high incidence 
of myocardial infarction.67,68,76,199–203
8.12.3.2. Neurological effects
The chronic CNS hyperstimulation can lead to frequent headaches, tremors, 
athetoid movements and seizures.8 There is evidence that users of amphetamine-
type substances, including methamphetamine, may have an above-normal risk 
of developing Parkinson’s disease (PD) because of enduring damage to the brain’s 
dopamine neurons. This was shown by a retrospective population-based cohort 
study of inpatient hospital episodes and death records from 1990 through to 2005 
in California. Patients at least 30 years of age were followed for up to 16 years. The 
study found that methamphetamine users had a 76% increased risk of developing 
Parkinson’s disease in comparison with the matched population proxy control group. 
The authors noted that this finding may be limited to high-dose, chronic metham-
phetamine users and only when they reach middle and older age, when they have 
suffered age-related loss of dopamine neurons.204
8.12.3.3. Pulmonary and respiratory harms
The smoking of methamphetamine can cause respiratory symptoms and disorders 
such as pulmonary oedema, bronchitis, pulmonary hypertension, haemoptysis and 
granuloma.8 Methamphetamine is associated with pulmonary arterial hypertension 
(PAH),205 although its precise role remains unclear.60
8.12.3.4. Blood-borne infections, and haematological, 
gastrointestinal and urological effects
Methamphetamine has been reported to cause acute liver injury, with hepatic necrosis 
and centrilobular degeneration, even in the absence of hepatitis.206 Mesenteric 
infarction,207 segmental ischaemic colitis, vasculitis or vasospasm with spontaneous 
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resolution have been reported.208 Severe acute necrotic haemorrhagic pancreatitis 
has been reported in cases of sudden death of chronic methamphetamine users.60
Because of the increased likelihood of high-risk sexual behaviours discussed in section 
8.10.2, methamphetamine users are more likely to be diagnosed with a sexually 
transmitted infection than non-users.135,138 Methamphetamine users are also at 
greater risk of viral hepatitis, especially where the drug is injected, but even among 
methamphetamine smokers and insufflators, hepatitis C is more common than it is in 
the general population.209–211
8.12.3.5. Oral/dental health
Methamphetamine use is associated with ‘meth mouth’, which is a constellation of 
symptoms, but it has been suggested that lifestyle factors, rather than the drug, may 
also be at play,212 including poor personal hygiene and malnutrition.213 Symptoms 
includes severe tooth decay and loss of teeth, advanced tooth wear, tooth fracture, and 
oral soft-tissue inflammation and breakdown.214,215 A study of 301 adults dependent 
on methamphetamine found that 41.3% had oral or dental disease. They also had sig-
nificantly more missing teeth than controls. The injecting of methamphetamine was 
significantly more likely to be associated with missing teeth than smoking the drug.212
8.12.3.6. Dermatological 
Methamphetamine users may suffer from skin lesions resulting from compulsive 
scratching (due to formication – a sense of having ants under the skin). These lesions 
can result in bacterial cellulitis and, in some cases, bacteraemia and sepsis. In a case 
series of methamphetamine users presenting to an emergency department, skin 
infection accounted for 6% of the initial presentations and 54% of subsequent 
admissions to hospital.61
8.12.3.7. Pott puffy tumour
There is a case report of Pott puffy tumour (PPT) associated with the intranasal use 
of methamphetamine. This is an anterior extension of a frontal sinus infection that 
results in frontal bone osteomyelitis and subperiosteal abscess.216
8.12.3.8. Ophthalmological harms 
Acute unilateral vision loss has been reported following a single dose of intranasal 
methamphetamine use and is believed to be due to ischaemic optic neuropathy 
secondary to methamphetamine-induced vasospasm and methamphetamine-asso-
ciated vasculitis.217,218
8.12.3.9. Psychological and psychiatric effects
The frequent and prolonged use of methamphetamine has a number of adverse 
effects. There are direct physiological effects, but the cognitive and behavioural 
changes associated with its use may be secondary to neurotoxicity.219 
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There is a well established association between methamphetamine use and mental 
health problems.76,220 Studies have found elevated rates of mood disorders, anxiety 
disorders and antisocial personality even after treatment.221 Depressive disorders and 
symptoms are frequently associated with methamphetamine use.170,172,173,222–225 The 
high prevalence of substance misuse among people with bipolar disorders or major 
depressive disorders has been established for a number of years.226 It is also well 
established that substance misuse can exacerbate mental health problems.227 There 
is some evidence that serious psychiatric disorders may emerge or worsen as a result 
of methamphetamine use,48,56,153,228,229 including increased risk of suicide.230 
The state of catechlolamine and serotonin depletion after several days of metham-
phetamine use can manifest itself as exhaustion, depression, lethargy and anhedonia. 
Psychological symptoms include persistent anxiety, paranoia, insomnia, auditory hallu-
cinations, delusion, psychotic or violent behaviour and suicidal or homicidal thinking,8 
although violent behaviour is not an inevitable outcome of even heavy long-term 
use.231 Some of the symptoms can resemble those of paranoid schizophrenia.22
Methamphetamine-induced psychotic disorder has been associated with the chronic, 
high-dose and continuous use of methamphetamine.232 Symptoms may include 
paranoid delusions, persecutory delusions and other delusions, and auditory, visual 
and tactile hallucinations. The disorder is often associated with mood disturbances.233 
While sustained and high doses of methamphetamine can cause symptoms that 
resemble those of psychosis, relatively few studies have observed this in people using 
only methamphetamine who have no history of mental illness.2 Nonetheless, a US 
study of 43 methamphetamine-dependent users and 42 cocaine-dependent users 
reported psychotic symptoms in at least 60% of both groups.167 An Australian study 
of 27 treatment-seeking methamphetamine users with no prior diagnosis of schizo-
phrenia, or other psychotic disorder, found that 18% had what was referred to by the 
authors as ‘clinically significant’ psychotic symptoms.39
Symptoms usually remit after acute intoxication but some individuals may develop 
psychosis weeks or months after stopping methamphetamine,233,234 and may prove to 
be refractory to antipsychotic medication.235
Stress can precipitate spontaneous psychosis in former methamphetamine users 
who are abstinent.236 
Much of the literature on persistent methamphetamine psychosis comes from Japan, 
where methamphetamine has been illicitly used for over 50 years, which suggests 
that persistent methamphetamine psychosis is not uncommon.235 Japanese studies 
also reported that psychotic symptoms may recur where there is new exposure to the 
drug.235,237–241 Japanese research has also reported discouraging results with standard 
antipsychotic drugs, as many patients remain clinically psychotic after many months 
of treatment.234,242 
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8.12.3.10. Cognitive effects
Neuroimaging in chronic users has shown significant neural damage in patients 
and evidence of cognitive impairment, but it is not established whether the link is 
causal.40,243
8.12.4. Co-morbidities of methampheta-
mine use disorders and HIV
Methamphetamine has been shown to interfere with the efficacy of HIV medication 
and treatment.244. Its use has been linked to non-adherence to medication regimens245 
and there is a suggestion that it may be associated with increased viral loads, even 
among those taking antiretroviral medication.246
Both methamphetamine use and HIV may be associated with impaired cognitive 
function, and in combination may result in greater impairment than each condition 
alone.244 There is evidence that hepatitis C increases these cognitive deficits.247
8.13. Management of harms of chronic and 
dependent use of methamphetamine
8.13.1. Identification and assessment of dependence
The identification and assessment of chronic use of methamphetamine and ensuing 
harms are similar to those for ATS in general (see Chapter 7), but with particular 
vigilance to the issues pertaining to MSM, who are currently the group in the UK who 
mostly use methamphetamine.
8.13.2. Psychosocial interventions for dependence
Studies have shown that some people dependent on drugs may achieve abstinence 
without the need for treatment.248 
At present, the most effective treatments for methamphetamine addiction are 
psychosocial interventions and behavioural therapies. Historically, treatment for 
stimulant dependence has relied on cognitive-behavioural therapy (CBT), with efforts 
to integrate contingency management (CM) (for more information see Chapter 7).
Overall, the evidence suggests that psychosocial interventions, such as CBT and CM, 
are moderately effective in achieving methamphetamine abstinence.249 A Cochrane 
review of psychosocial interventions for cocaine and psychostimulant amphetamine 
disorders reported that comparisons between different types of behavioural inter-
ventions showed results in favour of treatments with some form of contingency 
management with respect to both reducing drop-outs and lowering use. However, 
the review also reports there are few significant behavioural changes even after 
reductions in drug consumption following an intervention. The authors conclude that 
there are no data supporting a single-treatment approach that is able to tackle the 
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multidimensional facets of addiction and to resolve the chronic, relapsing nature of 
addiction, with all its correlates and consequences.250
A number of US studies have reported the effectiveness of CM within specific research 
and drug treatment settings,251 as well as outside those settings.252 CM in combination 
with other interventions, such as CBT, has proved to be modestly effective at reducing 
methamphetamine dependence.252–255 CM was also shown to have superior efficacy to 
CBT during drug treatment.251,256 
Similarly, there is some evidence that behavioural-based treatment for metham-
phetamine misuse can be effective in reducing HIV infections, in terms not only of 
injecting behaviours but also of unsafe sexual practices.102 Studies have shown the 
effectiveness of CM with methamphetamine users in changing other risk behaviours. 
For example, a pilot study of 35 MSM (not in drug treatment) who were given post-
exposure prophylaxis (PEP) and CM showed that this may be useful as a combination 
HIV prevention strategy.257 
Although psychosocial and behavioural interventions have been the most effective 
treatment for methamphetamine use, some argue that their role is still in question. 
CM, in particular, has shown benefit but a key limitation o includes its failure to address 
adequately mental health needs or develop relapse prevention plans for after the 
intervention.89 There is also some evidence that CM is not likely to have a sustained 
and large effect on methamphetamine use.258 One randomised controlled trial of CM 
to reduce methamphetamine use and sexual risk studied 217 non-treatment-seekers 
over 12 weeks and found that CM was potentially associated with an increase in 
methamphetamine use and decreases in sexual risk, but these were not statistically 
significant.258
As relapse rates are high,259 there have been calls for more work in improving metham-
phetamine treatment. Further research into cognitive-behavioural and behavioural 
treatments for methamphetamine users is required, with a focus on increasing the 
duration of the effect of intervention and improving its effectiveness among patients 
with more complex presentations.260
8.13.2.1. Implementation of CM 
Some studies have looked in greater detail at the impact of CM and at variations in 
CM models used and which specific factors were most effective in producing positive 
treatment outcomes. Roll et al. found that there were significant differences in terms 
of a CM schedule’s ability to initiate and maintain abstinence. The schedule based on 
an escalating programme of reinforcement with a reset contingency (developed by 
Higgings261) showed the best results for a successful treatment episode.262
Ling Murtaugh et al. found, in their study of 162 MSM methamphetamine-dependent 
users, that it was the act of voucher redemption, rather than the receipt or size of 
payment, that affected subsequent abstinence from methamphetamine. Participants 
who delayed spending the vouchers, and those who saved the vouchers, had worse 
outcomes once they did finally redeem them. The authors recommend that frequent 
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purchases in incentive-based programmes should be promoted to improve abstinence 
outcomes.263
8.13.3. Pharmacological interventions for meth-
amphetamine dependence and withdrawal
The need to develop safe and effective medication for methamphetamine dependence 
continues to be a global strategic aim. According to the US National Institute on Drug 
Abuse (NIDA), one approach currently tried is to target the activity of glial cells with a 
drug called AV411 (ibudilast). This has been shown to inhibit methamphetamine self-
administration in rats; it is now being studied in clinical trials to establish its safety 
and effectiveness in humans. Other approaches currently under study use the body’s 
immune system to neutralise the drug in the bloodstream before it reaches the brain. 
These approaches involve injecting a user with (anti)methamphetamine antibodies 
or with vaccines that stimulate the body to produce its own antibodies.264 A clinical 
study is currently being conducted to establish the safety of an anti-methamphet-
amine monoclonal antibody, known as mAb7F9, in human methamphetamine users.264
As well as new compounds, a number of medications approved for other conditions 
have been tested for their efficacy and safety in treating methamphetamine 
dependence. These have included serotonergic agonists, dopaminergic agonists, 
monoamine agonists and mixed monoamine agonists/antagonists.57,82,265–280 
For the moment, however, psychosocial therapies continue to be the cornerstone 
of treatment, with drug therapy regarded as an adjunct rather than a replacement 
for psychosocial approaches.8 There is currently no approved pharmacotherapy for 
methamphetamine dependence259 and no specific medication to counteract the 
effects of methamphetamine, or prolong abstinence. 
A recent Cochrane review281 of the efficacy and safety of psychostimulant medications 
for amphetamine dependence (dexamphetamine, bupropion, methylphenidate and 
modafinil), in addition to psychosocial interventions, reported that no significant 
differences were found between psychostimulants and placebo for any of the studied 
outcomes. Overall retention in studies was low (50.4%). Psychostimulants did not 
reduce amphetamine use, or amphetamine craving, and did not increase sustained 
abstinence. The proportion of dropouts due to adverse events was similar for psycho-
stimulants and placebo. The review concluded that the evidence does not support 
the prescribing of psychostimulants (at the tested doses) as replacement therapy, 
although further research may change this conclusion.281
A small double-blind placebo-controlled study on the use of N-acetyl cysteine plus 
naltrexone found no significant difference with placebo on treatment outcomes.276
Other trials conducted with methamphetamine users have tested selegeline, 
ondansetron, paroxetine,267 fluoxetine282,283 and sertraline,253,269 usually accompanied 
by a psychosocial structured therapy. A placebo-controlled trial studying the selective 
serotonin reuptake inhibitor sertraline, for the treatment of methamphetamine use 
showed that subjects receiving sertraline did not show improvements in depressive 
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symptoms or craving compared with those who did not receive it.269 It has been 
argued that, overall, results suggest that sertraline, and possibly all selective serotonin 
reuptake inhibitors, are ineffective and may even be contraindicated for metham-
phetamine dependence.269
A number of small studies have suggested that there may be a potential for the 
use of mirtazapine (a noradrenergic and specific serotonergic antidepressant).8,82,284 
Mirtazapine (in addition to counselling) was shown to reduce use among active meth-
amphetamine users.82 It was also shown to lessen the symptoms of methamphetamine 
withdrawal (including the subjective symptoms) over 10 days of abstinence, with 
reductions in agitation, anxiety, fatigue, irritability, paranoid ideation, anhedonia, vivid 
dreams and suicide ideation. It also increased the amount of sleep.277 
The impact of mirtazapine, in addition to counselling, on sexual behaviours that 
were shown by one study is noteworthy. A 12-week double-blind trial of mirtazapine 
among 60 MSM found that most sexual risk behaviours decreased significantly in the 
mirtazapine arm of the study in comparison with the placebo arm, even though both 
arms received HIV risk-reduction counselling at baseline. The study also found that 
the reduction in sexual risks was associated with a reduction in negative test results 
for amphetamine use, perhaps suggesting a possible causal pathway between the 
two outcomes.82
Not all studies of mirtazapine have shown its effectiveness in the management of 
methamphetamine dependence.278 One study which focused on patients with acute 
withdrawal symptoms showed that it does not facilitate retention or recruitment in 
outpatient methamphetamine withdrawal treatment.278
The use of anticonvulsants has also been investigated. A randomised controlled trial 
of 140 methamphetamine-dependent adults prescribed topiramate (at doses of up to 
200 mg/day) suggested that this medication does not promote abstinence. However, 
there is some indication that it may reduce amounts ingested and can reduce relapse 
rates among those already abstinent.265
Similarly, a trial randomly assigning people to an active medication regimen – 
comprising flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg 
to day 40) and hydroxyzine (50 mg to day 10) – or placebo showed that the regimen 
was no more effective than placebo in reducing methamphetamine use, retaining 
patients in treatment or reducing craving.285 These results were different from those 
of another study using the same protocol that found fewer positive urine tests for 
methamphetamine throughout the trial and decreased cravings.275 Differences may 
be due to study conditions and different demographic characteristics of participants 
in a private medical setting.285
A double-blind study of 60 subjects with bipolar or major depressive disorder and 
methamphetamine dependence randomised them to placebo or citicolin, an over-
the-counter nutritional supplement (2000 mg/day), for 12 weeks. A significant 
between-group difference in depressive symptoms was observed. The study also 
showed significantly higher completion rates among those on citicolin than those on 
placebo.227
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8.13.4. Treatment effectiveness, impact, retention and completion
Some studies have shown that, when methamphetamine users seek treatment, 
there is a substantial likelihood of treatment drop-out and relapse,36 although the 
treatment outcomes for methamphetamine users are not necessarily different from 
those of the users other drugs.286,287 There is, though, a lack of treatment provision.288
Treatment for methamphetamine use/dependence can have a positive impact on 
other high-risk behaviours. A study on CM and CBT for MSM found that those who 
reported the greatest decrease in methamphetamine use also reported the greatest 
and quickest reduction in depressive symptoms and high-risk sexual behaviour.289 
The authors suggest that lowering methamphetamine use can have an effect on 
depression and sexual behaviour and that some users who respond well to treatment 
may show improvements in these co-occurring problems, without the need for more 
intensive targeted interventions.289 
Similar findings were reported by other studies.82 There is some evidence that inter-
ventions to reduce or eliminate methamphetamine use for MSM in drug treatment 
settings also produce reductions in high-risk sexual behaviours and resultant HIV 
transmission. Drug treatment may be an important part of an HIV/STI prevention 
strategy for MSM.251 One study of methamphetamine users found that longer 
treatment retention and greater rates of treatment completion were significantly 
related to greater reductions in risky sexual and injecting behaviours and were 
associated with reductions in HIV risk three years after treatment.290
There is a growing body of evidence on the factors that help predict methamphet-
amine treatment success, and most particularly failure, including retention in 
treatment and treatment completion.36 There is consistent evidence that poorer 
outcomes are associated with: 
•	greater frequency of use prior to treatment;36,270,291–294
•	more extensive history of previous treatment;292,293,295
•	lower educational attainment,36,292 although conflicting evidence on this has been 
reported.291,294 
Other factors have also been associated with success or failure, but the evidence is 
either limited or inconsistent. These include greater craving for methamphetamine,180 
legal coercion of treatment,36 residential versus outpatient treatment,292 shorter 
treatment duration,295 disability,36 selling methamphetamine295 and intravenous 
use.36,293 Race, gender and ethnicity have also been associated with treatment success 
or failure, but the findings have differed between the studies. 
Similar factors were identified as affecting health-related quality of life (HRQOL) 
for those completing treatment. A study of the HRQOL trajectories of 723 people 
dependent on methamphetamine, resulting from treatment completion and continued 
care over one year, found greater improvements in mental health. It described ‘fairly 
static’ trajectories in physical health status, in comparison with those who did not 
complete treatment or who continued to use services. The study showed differential 
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patterns of health improvement. Factors identified as negatively affecting HRQOL 
included unemployment, lifetime trauma, suicide history, interpersonal conflict, 
continued use of methamphetamine, poly-drug use and medical and psychiatric 
impairment.296 The study also found that higher education was associated with a 
poorer health outcome, a finding that is not supported by the literature. The authors 
speculated that this might be because drug use among highly educated subjects can 
lead to a lower perceived health status, with the subjects not being able to maintain 
previous health standards and not able to fulfil goals they had set before drug use. 
The study also showed poorer health outcomes for women on methamphetamine.296
The frequency of use at entry to treatment and early treatment responsiveness have 
been identified as predictors of treatment success. One study of 60 individuals looked 
at whether cognitive performance can predict success in treating methamphetamine 
dependence, and considered whether cognitive performance is more or less predictive 
of treatment success than the established factors, such as frequency of use.297 
The study found that, although a few neurocognitive and psychiatric variables 
were associated with treatment outcome, the frequency of methamphetamine use 
at the study outset was a much stronger predictor of outcomes. Participants who 
had two or fewer urine tests positive for methamphetamine during the first two 
weeks were much more likely to complete treatment and achieve abstinence in the 
majority of the treatment weeks,297 a finding that was consistent with several other 
studies.36,270,291–293,298
The authors suggest that it is possible that this finding was partially due to study 
design. Nonetheless, the study did show that patterns of methamphetamine use 
during the initial stages of treatment were able to predict the outcomes in terms of 
continued use and treatment attendance. A few cognitive measures were related to 
treatment outcome, but these did not allow for prediction after adjustment for meth-
amphetamine use at the beginning of the study. The authors concluded that clinicians 
who want to identify patients at risk of treatment failure should use multiple urine 
tests. They also suggest that it is more plausible to predict treatment failure than 
treatment success.297
Similarly, a study of bupropion found that early treatment responsiveness may be 
important for positive outcomes, a finding consistent with smoking cessation273 and 
with some research in cocaine treatment.273,274 Data analysis showed that the inability 
of users to provide at least three methamphetamine-free samples in the first two 
weeks of treatment was associated with a likelihood of treatment failure exceeding 
90%. The authors suggest that clinicians prescribing bupropion can predict treatment 
failures confidently within two weeks when they carry out drug testing three times 
a week, with weekly testing yielding acceptable predictive power within three weeks. 
The ability to predict treatment failure was substantially more precise than the 
prediction of treatment success, which the authors attributed partially to the overall 
treatment failure rates. The absence of an early response predicts treatment failure 
better than the presence of an early good response predicts treatment success. The 
authors therefore suggest that this prediction of treatment failure is relevant to 
clinicians, as it signals the need to change treatment modality and intensity.272
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8.13.5. Access to treatment
People dependent on methamphetamine may not access treatment services for 
many years and there is often a delay between first use, first recognising a problem 
with methamphetamine, and first treatment assessment. Different studies have 
shown a range for average length of time for the first treatment. An Australian study 
found that methamphetamine users can wait an average of five years from first 
experiencing problems to seeking treatment.299 US studies have reported an average 
of eight300 and nine years.48
There are many reasons why this may be the case. A US study reported a common 
belief among methamphetamine users that it is a ‘functional drug’, which may 
encourage frequent and prolonged daily use.48,301 Similarly, Kenny et al. reported 
common reasons for not seeking methamphetamine treatment: users did not believe 
that they were dependent (despite meeting DSM-IV criteria for dependence); they 
did not feel that regular use of methamphetamine warranted formal treatment; they 
discounted their dependence; and they recognised their dependence but were not 
ready to do anything about it.302 
There is also some non-UK evidence that treatment services may not be, or be 
perceived to be, accessible to methamphetamine users. An Australian study303,304 
suggested that the reasons for the under-representation of methamphetamine users 
in the treatment system include poor orientation of services for this group, lack of 
information about treatment options and little confidence in the effectiveness of 
programmes.
Barriers to treatment are not only constructed by service users but also by clinical 
staff. A study has also looked into barriers to methamphetamine treatment from the 
perspective of treatment providers, who saw barriers as extensive and wide-ranging. 
They included the particular personality characteristics of methamphetamine users, 
complexities associated with mental health co-morbidity, waiting periods resulting in 
loss to treatment, the binge nature of methamphetamine use, lack of pharmacologi-
cal options and negative attitudes of staff towards this patient group.305 
Improved understanding of the ways methamphetamine users access other treatment 
services could be used to facilitate effective referral pathways. Studies have looked 
at the factors, and user characteristics, that make individuals more likely to seek 
support.306,307 GPs have been identified as a likely common starting point for patients 
seeking referral, for all drug-related problems.308 
Quinn et al.’s study suggests that service utilisation for other problems, such as 
mental health or other drug problems, increases the likelihood of accessing treatment 
for methamphetamine use.307 They suggest that contact with other services may 
increase the opportunity for treatment of methamphetamine misuse and break 
down barriers to professional support, such as ignorance of the services available 
and stigma associated with service utilisation.309 People who use services for other 
issues are more receptive to seeking treatment for methamphetamine misuse.307 
The authors also note that these findings suggest a need to facilitate professional 
support pathways for treating methamphetamine users who engage in harmful use 
patterns.307
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The availability of appropriate and relevant services has been identified as enhancing 
service uptake. Australian studies have suggested that methamphetamine injectors 
are more likely than those who smoke or snort the drug to seek and receive treatment 
from specialist services.307,310,311 It has been suggested that there is greater availability 
of services for people who inject and fewer barriers to treatment (such as needle 
exchanges). 
In comparison with other substances such as opiates, it may be important to make 
the treatment settings specific to methamphetamine users, to accommodate the 
different nature of methamphetamine dependence and withdrawals. Although this 
may be beyond the means of many drug treatment systems and services, services 
can undertake some small changes that could have a large impact on user perception, 
such as allocating some time each day for methamphetamine clients or allocating 
specific staff or rooms with specific methamphetamine resources.302
The cultural competence of services has also been identified as enhancing treatment 
uptake. A study of behavioural psychological interventions on depression, sexual risk 
behaviour and methamphetamine use among 162 MSM found that a gay-specific CBT 
intervention reported the greatest reduction in all three outcomes.289
Treatment readiness may also be key to accessing support for methamphetamine 
problems. Quinn et al. found that two key factors were associated with seeking help 
for methamphetamine problems: seeking help from family or peers in the year before 
entry into the study; and adoption of personal methods for the reduction or cessation 
of methamphetamine use.307 It has been suggested that targeted interventions to 
identify and access individuals when they first experience readiness to change could 
be important. Motivational interviewing and stepped care could be beneficial. 
One study found that only a small number of methamphetamine-using participants 
had reported access to more intensive drug treatment services (i.e. residential de-
toxification and/or rehabilitation), maybe suggesting a preference for low- rather 
than high-threshold treatment services,307,312 or that many individuals feel that they 
are able to address harmful and/or dependent use without the need for intensive 
professional intervention.248
8.13.6. Aftercare and support
See section 7.10.5.
8.14. Harm reduction 
The implications of driving under the influence of methamphetamine has been 
discussed.313
Harm reduction is covered in Chapter 7. 
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Chapter 9
Mephedrone and other synthetic 
cathinones
Drug group: stimulants 
Mephedrone (4-methylmethcathinone) is the most commonly used synthetic 
cathinone in the UK and is therefore the focus of this chapter. There are approxi-
mately 30 synthetic cathinones and those used for recreational purposes include 
methylenedioxypyrovalerone (MDPV), butylone, ethcathinone, ethylone, 3- and 
4-fluoromethcathinone, methedrone, methylone, pyrovalerone, 3-MeOMC; 3-MMC; 
4-BMC; 4-MEC; 4-MeO-a-PVP; 4-MeO-PBP; 4-MeO-PV9; 4-MPD; 4F-PV8; 4FPV9; 
4F-PVP; a-PBT; a-PHP; a-PVT; dibutylone; DL-4662; ethylone; MDPPP; MOPPP; NEB; 
pentedrone; PV-8.By 2012 more than 30 synthetic cathinones had been notified in 
the European Union as potential drugs of misuse.1 During 2013, seven more synthetic 
cathinones were notified by the member states for the first time through the EU Early 
Warning System.2
Synthetic cathinones are beta-keto phenethylamines. Typically, they have an amphet-
amine-type analogue, which means that they are structurally related to amphetamine, 
methamphetamine and MDMA. Other synthetic cathinones recently identified on the 
drug market are analogues of pyrovalerone (3,4-methylenedioxypyrovalerone and 
naphyrone).3 
9.1. Street names 
Street names for mephedrone at the time of publication include: Bubble(s), Miaow, 
Meow Meow, 4-MMC, Mcat, Sub-coca, Toot, Top Cat, Meph, M1, Drone, Spice E, Charge, 
Rush, Ronzio, Fiskrens, MMC Hammer, Bounce; Moonshine, Neo drones, Plant feeder, 
Roxy, SC spirit, White magic, Mad-dog, Bubbleluv, and Challenge (which ketamine is 
also known as). Other local names may also exist.
The term ‘bath salts’ is mainly used in the US to refer to a number of synthetic 
cathinones and will appear in the American literature.
9.2. Legal status
Mephedrone and other cathinone derivatives are Class B Schedule 2 drugs under the 
Misuse of Drugs Act 1971 (except the antidepressant buproprion and those already 
controlled under the Act, including cathinone itself, which is Class C).
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9.3. Quality of the research evidence
Currently, the bulk of the UK and European literature on the harm associated with 
the use of synthetic cathinones and the management of those harms focuses on 
mephedrone, and to some extent MDPV, reflecting their higher prevalence of use 
relative to other synthetic cathinones. The international evidence on the management 
of the acute and chronic harms related to the use of mephedrone and other synthetic 
cathinones is limited. There are a few case reports and series and a small number of 
prospective observational studies, retrospective series and analyses of patient records, 
user surveys and qualitative studies. Not all studies have analytical confirmation of 
cathinone use, reducing the ability to draw robust conclusions and make recommen-
dations.
US studies generally refer to the whole group of so-called ‘bath salts’ and tend to 
include findings relating to methylenedioxypyrovalerone (MDPV) in particular, as 
well as mephedrone and other synthetic cathinones. Some do not specify what 
compounds are involved in the ‘bath salts’ discussed and were therefore not included 
in this review.
9.4. Brief summary of pharmacology
The natural analogue to synthetic cathinones is the active compound in the leaves 
of the khat plant (Catha edulis), which have been chewed for centuries in parts of 
Africa and the Arabian Peninsula for their stimulant properties.4 Mephedrone was 
first synthesised in 1929 and has been widely available on mainland Europe since 
2007, and in the UK since 2009. 
Like amphetamines, cathinones act as central nervous system stimulants, although 
they are generally less potent than amphetamine. Synthetic cathinones are amphet-
amine-like behavioural stimulants which have similar effects to amphetamine on 
monoamine reuptake, including serotonin, dopamine and noradrenaline.5 They also 
have a similarly strong sympathomimetic effect.
Synthetic cathinones exert their stimulant effects through increasing synaptic concen-
tration of dopamine, serotonin and noradrenaline. They are able to inhibit monoamine 
uptake transporters producing a decreased clearance of the neurotransmitters from 
the synapse. They may cause release of biogenic amines from intracellular stores.6 
Synthetic cathinones are generally less able than amphetamines to cross the blood–
brain barrier because the beta-keto group causes an increase in polarity.7 
Mephedrone is produced by replacement of the 4-position aromatic hydrogen of 
cathinone with a methyl group, and carries a similar molecular structure to many 
common street drugs, including amphetamine and MDMA.8
Mephedrone and methylone were consistently found to act as potent inhibitors of 
the uptake of all three monoamines. Mephedrone and methylone are approximately 
equipotent inhibitors of all three monoamine transporters, with potencies comparable 
to that of MDMA.9 
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The ability of mephedrone to cause subjective effects resembling those of MDMA 
is likely to have contributed to its relatively widespread use. However, its ability to 
cause dopamine release may be problematic, inasmuch as in comparison with MDMA, 
mephedrone may have a greater liability to misuse, resembling that of dopamine-
releasing agents, such as methamphetamine.10
Following oral administration, maximum mephedrone concentrations are achieved 
after 0.5–1 hour. Its absolute bioavailability is low (10%) and it is moderately protein 
bound (21.59 ± 3.67%). Animal and human studies showed that mephedrone is 
metabolised by different phase I reactions (i.e. demetylation, oxidation, etc.). These 
may be undertaken by different CYP450 isoenzymes (e.g. CYP2D6 and CYP3A4). Phase 
II reactions (i.e. glucuronidation) are also involved in mephedrone’s metabolism.11–13
9.5. Clinical uses of mephedrone 
and synthetic cathinones
Currently, bupropion is the only cathinone derivative that carries a medical indication 
in the US and Europe. It is used for the treatment of depression and as a smoking-
cessation aid.14 It has been specifically exempted from the legislation that has made 
many cathinones Class B Schedule 2 in the Misuse of Drugs Act 1971, because of its 
clinical utility and it having no propensity to misuse. 
9.6. Prevalence and patterns of use
The rapid increase in the use of mephedrone in 2009 in the UK was noted by a 
number of studies.15,16 There are suggestions that in the UK and Holland, this was 
associated with the poor quality of cocaine and ecstasy at the time. Its popularity was 
also enhanced by its relative low cost, easy availability due to its ‘legal’ status before 
2010 and its desired effects.14,15,17
There is a mixed picture of its availability and prevalence of use in the UK after the 
ban.18 Some studies have suggested the control of the drug in 2010 did not stop the 
spread of its use,19,20 while have others suggested it did.21 There are indications that 
its use is in now decline, although it remains one of the most prevalent club drugs, (or 
novel psychoactive substances (NPS), used and reductions in use cannot necessarily 
be attributed to legal control. 
Nonetheless, data from the Crime Survey for England and Wales (CSEW; formerly 
the British Crime Survey)22 suggest that mephedrone use (at all in the previous year) 
among 16–59–year-olds fell from 1.4% in 2010/11 to 0.6% in 2013/4, although it 
remained the joint fifth most commonly used drug among adults. A reduction was 
also noted in the 16–24-year age group, from 3.3% in 2010/11 to 1.9% in 2013/4.
As with other club drugs, the use of mephedrone is associated with lifestyle. The 
CSEW 2013/14 reported that the use of mephedrone (in the previous year) was 
around 20 times higher among those who had visited a nightclub four or more times 
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in the past month (5.8%) than among those who had not visited a nightclub in the 
past month (0.3%). 
UK data from the self-selected respondents of the 2012 Global Drug Survey reported 
42.7% lifetime use and 19.5% in the last year. Prevalence of use among regular clubbers 
(in the last year) was reported as 30%. Yet, even among this group there is some 
evidence of a reduction in its use since its peak. Indeed, the 2012 Global Drug Survey23 
also suggested a decline in its popularity. Similarly, in an analysis of pooled urine from 
12 portable urinals in central London, mephedrone was only present in 6 urinals; in 
contrast, cocaine, cannabis and MDMA were present in 11 and amphetamine was 
present in 10.24 The UK National Poisons Information Service (NIPS) also reported a 
reduction of activity relating to mephedrone in its annual reports since 2010/11.25,26 
However, the decline of mephedrone use may not be universal and differences may exist 
based on sexuality and geography. Two surveys in a gay-friendly nightclub suggested 
that its use had in fact increased substantially. A study conducted in 2010 among 
people attending gay-friendly nightclubs in south London reported that mephedrone 
was the drug most commonly used, with 27% reporting using it or planning to use 
it on the night.16 A follow-up study one year after the control of the drug suggested 
that mephedrone remained the most popular drug in this setting and that its use had 
increased substantially in 2011, with 41% of respondents reporting they had used it 
or were planning to use it on the night. The most commonly reported favourite drug 
by respondents was mephedrone (20.4%).27 Similarly, in 2013 the Welsh government 
reported an increase in the use of NPS and most particularly mephedrone in the past 
two years, as well as a rise in mephedrone-related referrals.28
Among most mephedrone users, the drug is often taken as part of a wider repertoire 
of substances. The CSEW 2012 survey suggested that 25% of mephedrone users 
were simultaneous poly-users. Studies of people who frequented the night-time 
economy in London and Lancashire found that mephedrone had been added to the 
existing drug repertoire. It did not act as a gateway to other drug use for those with 
no pre-existing drug use and mephedrone did not lead to a wholesale displacement of 
other drugs.15,29 Other evidence suggests that poly-substance use is common among 
mephedrone users, with other substances ingested including alcohol, cannabis, 
cocaine, ecstasy and ketamine.30 Alcohol and cannabis are reported in one survey 
as the most commonly co-ingested substances.31,32 There is also anecdotal evidence 
from clinical practice that mephedrone is used in combination with methampheta-
mine by men who have sex with men (MSM) in particular.
There is evidence that some users co-ingest more than one substance not only to 
enhance the desired effects but also to attempt to reduce the harmful effects. Popular 
combinations reported are mephedrone or MDPV in combination with the following 
drugs:30,31,33–39
•	alcohol, propranolol or another beta-blocker to offset tachycardia;
•	cannabis, diazepam or alprazolam for anxiety and overstimulation;
•	famotidine, omeprazole or domperidone for stomach pain;
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•	other psychostimulants such as cocaine, amphetamine, modafinil, trifluoromethyl-
phenylpiperazine, benzylpiperazine, butylone, methylone or pentylone to enhance 
stimulant and entactogenic effects;
•	opiates, such as morphine or tramadol, to create ‘speedball’-like effects; 
•	GHB/GBL to enhance sexual stimulation; 
•	ketamine or zopiclone to enhance visual hallucinations.
There is limited evidence that synthetic stimulants, especially cathinones, are replacing 
opioids in countries reporting heroin shortages. The motive for the transition from 
injecting heroin to cathinones is unclear, but may be linked to easy availability and 
perceived high quality of the new drugs.2 There have been reports of mephedrone 
injecting from Romania, Slovenia and Ireland,40 as well as the Channel Islands.
There have been reports of some mephedrone injecting in opiate-using people in the 
UK, but the evidence is mainly anecdotal.41 A 2012 Druglink survey carried out among 
police forces, drug agencies and drug user groups mentioned the growing cohort 
of people injecting mephedrone, although this evidence is again mainly anecdotal. 
The report suggests that some of these injectors were heroin and crack users known 
to drug services, as well as new injectors who had made the transition from oral or 
intranasal use of mephedrone.42 However, harder evidence is not yet available to 
substantiate these claims. A more systematic study was carried out in Ireland through 
the analysis of urine collected from attendees of a methadone maintenance clinic, 
which found that 14% were positive for mephedrone and 3% for methylone.43
Little has been published on patterns of mephedrone injecting in the UK. There are 
anecdotal reports of an increase in the injecting of mephedrone (sometimes together 
with methamphetamine) among some MSM in London at sex parties or chill-outs, 
where many people share equipment without sterilising it.44 One qualitative Irish study 
of 11 attendees of low-threshold harm-reduction services reported that compulsive 
re-injecting with excessive binge use over long periods was common, despite the fact 
that respondents were aware of the risks of injecting and of safer injecting practices. 
In this small cohort, 7 of the 11 were homeless, and injecting in public spaces and 
groin injecting were common. Mephedrone was not the first drug injected and its use 
appears to be an extension to other drugs also injected.38
9.7. Routes of ingestion, dosing 
and frequency of dosing
Before its control in the UK in 2010, mephedrone was sold mainly through internet 
websites, ‘head shops’ and local street-level drug dealers. Although it is still available 
for sale on the internet through sites not based in the UK, there is some evidence 
that since its classification there has been a shift towards the purchase of the drug 
from street dealers. Users are paying a higher price than before control, for what is 
perceived to be a lower-quality product.16,19
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Mephedrone is typically sold as a white or off-white crystalline powder, with a 
light yellow hue.45 Some users have reported its distinctive unpleasant smell37 and 
some that their body sweat had developed a ‘chemical smell’ as a result of its use. 
Mephedrone powder is often sold in small plastic bags (typically 1 g doses), but there 
are reports of its sale as tablets pressed from the powder or as capsules containing 
the powder. At the time of writing, the cost of 1 g of mephedrone was approximately 
£20,46 but with local and regional variations in price. 
Mephedrone is water soluble. It is typically either snorted or swallowed (usually 
wrapped in a cigarette paper – a process known as ‘bombing’) or added to a drink 
(sometimes referred to as ‘whizzy water’). It is also used by ‘dabbing’ (rubbing on 
the gum), rectally, by smoking, or by injection (intramuscular and intravenous).15,32,41 
Users have also reported multiple concomitant routes of use.31,4–49
A cross-sectional anonymous online survey of mephedrone users (recruited as part of 
a larger study exploring patterns of drug use among those associated with the dance 
music scene) was carried out in 2010. It suggested that the most common route of 
use was intranasally (65.9%), with women significantly more likely than men to use 
the drug through snorting (76.2% and 67.2% respectively).48 Snorting is often carried 
out through the ‘keying’ method, whereby a user will dip a key in the powder and 
snort the powder off the key (it is estimated that five to eight keys would represent a 
1 g dose).14 There are suggestions that the insufflation of mephedrone is associated 
with significant nasal irritation, which has led some users to switch to oral ingestion.50 
Intranasal use may be associated with greater liability to misuse than oral use.48,51 A 
survey carried out among 947 UK mephedrone users, contacted before the control 
of the substance in 2010, reported that the amount of drug used in a typical session 
was significantly larger for those snorting (mean 0.97 g, SD 0.91) than for those using 
it orally (mean 0.74 g, SD 0.64). Those who snorted the drug reported significantly 
more days of use per month (mean 4.85, SD 5.11) than those who used it orally (mean 
3.21 days, SD 3.01). Those who snorted the drug were significantly more likely to 
use it more frequently, with 59.2% having used it at least monthly over the last 12 
months.48
The onset of the desired effects of mephedrone is linked to the route of administra-
tion, being within a few minutes through nasal insufflation or intravenous injection 
and 15–45 minutes following oral ingestion. The onset of the effects following oral 
use can be delayed in the presence of food.52 Rectal administration has been described 
by users as having a faster onset and the effects require lower doses.37
The duration of the effects are also linked to mode of use. The effect last up to 2–3 
hours following nasal or oral use, albeit with a shorter duration where ingested 
through nasal insufflation, but only 15–30 minutes following intravenous use. Some 
users combine routes of use in a single session, for instance first snorting it and then 
using it orally in order to achieve both a fast effect and a longer-lasting effect.52
The relatively short duration of effects of mephedrone is associated with repeated 
dosing during a single session.52 Regardless of the route of ingestion the majority 
of mephedrone users will repeatedly re-dose within a single session to maintain the 
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desired effect (sometimes referred to as ‘fiending’), leading to ‘bingeing’.53 An animal 
study has reported vigorous mephedrone self-administration behaviour in rats, 
eliciting response levels that appear to match, or even exceed, those seen with other 
drugs of misuse.54
Typically, users ingest mephedrone in staggered doses, between 0.5 g and 1 g per 
session. Although a UK survey of clubbers found that approximately a quarter of 
mephedrone users took more than 1 g in a typical session,48 other studies reported 
oral doses of 1–2 g55 or even higher.14 The same survey respondents reported that the 
average duration of a single session was 10.4 hours and that there was a correlation 
between total amount used and the duration of a session.48 
9.8. Desired and undesired 
effects for recreational use
The reported desired effects of mephedrone include its stimulant and sympathomi-
metic effects, similar to those of MDMA (ecstasy) and cocaine.15,37,48,52,56,57 Reasons for 
its appeal include the fact that it is non-potent and short-acting. Mephedrone is used 
for both its mood-enhancing properties and its role as a psychomotor stimulant in 
social situations.48 Users report stimulant-related subjective effects such as euphoria, 
increased concentration, the urge to move, talkativeness, reduced appetite and 
wakefulness. Desired effects also include stimulation, enhanced appreciation of 
music, mood elevation, reduced hostility, improved mental function and increased 
energy.15,19,30,48 At higher doses, perceptual distortions or hallucinations and the 
empathogenic properties of mephedrone have been reported.15,19,48
There is some evidence that some users ingest stimulant and hallucinogenic drugs 
in general to increase sexual thoughts, intensify sexual desire, enhance sensuality, 
improve sexual functioning and prolong sexual performance. A dose–response 
relationship between mephedrone and heightened sex drive has been reported.48,58 
Users have reported heightened sensuality, disinhibition, prolonged performance for 
males, the ability to reach climax for females and sexual behaviours which they would 
not engage in while sober.58–63 However, the effects of mephedrone also depend on 
combinations and types of drugs used, dosage, length of time used, sexual roles, 
normative risk, settings and the individual’s experiences and expectation.60,64
Surveys suggest that approximately 20–56% of users of mephedrone have experienced 
adverse effects31,65 and these are similar to those reported for amphetamine, meth-
amphetamine and MDMA.66 There is evidence that the most of severe unwanted 
effects may be associated with high doses and/or prolonged use.52 
However, there are important individual variations and similar doses may have sig-
nificantly different effects and consequences in different individuals.67 It has been 
suggested that it is impossible to determine what a ‘safe’ dose is, as negative effects 
may present with any dosage taken.68
The most common unwanted effects of mephedrone reported by users are summarised 
in Box 9.1.17,37,43,48,52,57,65
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A survey of 900 clubbers using mephedrone suggested that the frequency of specific 
unwanted effects (predetermined by the study) as follows: excessive sweating 
(67.2%), headaches (50.7%), palpitations (43.4%), nausea (37%) and cold blue finger 
and toes (15.3%).48 Similarly, in a Scottish student survey more than half (56%) of 
those who had used mephedrone reported having at least one unwanted effect, at 
the following frequency: bruxism (teeth grinding) (28.3%), paranoia (24.9%), sore 
nasal passages (24.4%), hot flushes (23.4%), sore mouth/throat (22.9%), nose bleeds 
(22.4%), suppressed appetite (21.5%), blurred vision (21.0%), palpitations (20.5%), 
insomnia (19.5%), hallucinations (18.0%), nausea/vomiting (17.1%) and blue/cold 
extremities (14.6%).65 Other unwanted effects include difficulties with urination, poor 
concentration and aggression.
9.9. Mortality
A study of data from the National Programme on Substance Misuse Deaths (NPSAD)* 
showed that most deaths occurred when more than one substance was ingested, and 
especially when alcohol was one of these.69 Nonetheless, in a small number of cases 
in the UK, death was directly related to mephedrone on its own, which confirms the 
concerns regarding the acute toxicity potential of the drug itself.69
In the same study, Schifanno et al. found that factors associated with mephedrone-
associated death were young age (mean age 29 years), male and with previous history 
of substance misuse. They also noted the excess number of mephedrone-associated 
* To be recorded in the NPSAD database as a drug-related death, at least one of the following criteria 
must be met: presence of one or more psychoactive substances directly implicated in death; history of 
dependence or misuse of drugs; and presence of controlled drugs at post-mortem examination.
Box 9.1. Some common unwanted effects of mephedrone,  
as reported by users17,37,43,48,52,57,65
Jaw clenching
Reduced appetite
Nasal irritation and nose bleeds
Nausea and vomiting
Discolouration of extremities and joints
Insomnia and/or nightmares
‘Head rush’
Inability to concentrate and/or to focus visually
Memory problems
Altered conscious levels
Anxiety
Agitation
Hallucinations and delusions
Headaches
Tremors and convulsions
Raised body temperature
Chest pains
Elevated heart rate
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deaths between Saturdays and Tuesdays, linked to the more frequent ingestion of the 
drug at weekends.69 A cause of concern resulting from UK observation was self-harm, 
especially hanging, which was identified as the mechanism of death in almost 30% of 
inquests, and bizarre risk behaviour in a further 6 cases (9.7%). This led the authors 
to question whether mephedrone, either in its own or used with other substances, 
may have an acute potential to cause or exacerbate psychosis and/or depression, thus 
facilitating bizarre behaviour or self-harm.69
9.10. Acute harms
9.10.1. Acute toxicity
Case reports and case series relating to hospital presentations with acute mephedrone 
toxicity41,49,32,70,71,72 describe sympathomimetic clinical features49 and clinical effects 
consistent with stimulant intoxication.72 Triangulation of data from a number of 
sources present a picture of mephedrone acute toxicity (Box 9.2) that is consistent 
with that seen with the use of other sympathomimetic recreational drugs, such as 
amphetamine, cocaine and MDMA.73
Box 9.2. Features of acute mephedrone toxicity
Cardiovascular
Hypertension, tachycardia, chest pain, palpitation, diaphoresis, hot flushes, shortness of breath, 
palpitations, cardiac arrest, peripheral vasoconstriction
Cognitive
Confusion, improved concentration, alertness, amnesia,
cravings, empathy/feelings of closeness, dysphoria
Dermatological
Unusual sweat odour, rash
ENT
Sore nasal passages, mouth/throat pain, epistaxis
Gastrointestinal
Nausea/vomiting, anorexia, dry mouth, abdominal pain, sore mouth/throat
Metabolic
Elevated creatinine, metabolic acidosis
Neurological psychiatric/ psychological 
Anxiety, panic, depression, irritability, lack of motivation, anhedonia, sexual arousal, sociability, 
euphoria, insomnia, bruxism, headache, dizziness/light-headedness, tinnitus, seizures, 
nystagmus, mydriasis, blurred vision, numbness, blue/cold extremities, fever, paraesthesias, 
visual and auditory hallucinations, paranoid delusions, intensification of sensory experiences, 
reduced consciousness, agitation, aggression, short-term psychosis, short-term mania
Musculoskeletal
Increase in muscle tone, trismus
Respiratory
Dyspnoea
Serotonin syndrome
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Cardiac, psychiatric and neurological symptoms are the most common reported 
effects that require medical care.74 Serotonin syndrome may occur, especially when 
the user has been exposed to two or more drugs that increase the effects of serotonin, 
either as an acute overdose or taken regularly. There are reports of serious cardio-
vascular and neurological effects and some reports of hallucination, chest pains and 
convulsions. 
Reports of other effects of mephedrone toxicity include the following:
•	emerging evidence that when intoxicated, mephedrone use can impair working 
memory acutely;53
•	hyponatraemia;41,71,75 
•	a case of mephedrone-induced euvolaemic hypoosmotic hyponatraemia with en-
cephalopathy and raised intracranial pressure;71
•	a case report of posterior reversible encephalopathy syndrome (PRES);76
•	a case report of myocarditis;70
•	a case report of catatonia;77
•	a case report of spontaneous subcutaneous emphysema associated with 
mephedrone use, which did not require airway support;78 
•	a case report of methaemogloninaemia, a serious complication caused by a number 
of oxidising drugs;79
•	a case report of serotonin syndrome, with the patient becoming hyperthermic;80 
•	a case report of MDPV-induced serotonin syndrome;81
•	a case report of severe refractory left ventricular failure.83
In addition, one case report highlighted the potential danger of mephedrone to 
people with diabetes. A patient with type 1 diabetes developed ketoacidosis following 
self-reported mephedrone use. Cathinone compounds may directly increase the 
risk of diabetic ketoacidosis by stimulating the central nervous system. They may 
also indirectly impair an individual’s ability to manage diabetes through changes in 
cognitive function and behaviour.82 
It is not possible to quantify accurately how common these presentations are. A 
US case series of 35 patients presenting at an emergency department with toxicity 
relating to synthetic cathinones reported that:
•	91% had neurological symptoms;
•	77% had cardiovascular symptoms;
•	49% had psychological symptoms.72
In the UK, a report of a case series of 72 patients with self-reported acute mephedrone 
toxocity45 indicated that the most common symptoms on presentation to hospital, 
or before, were: agitation (38.9%); tachycardia (36.1); palpitations (25.0%); vomiting 
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(13.9%); clinically significant hypertension (13.9%); chest pain (12.5%); severe 
tachycardia (8.3%); headaches (7.2%); self-limiting pre-hospital seizures (6.9%).
Because users cannot be certain of the actual content of the preparation they are 
taking, or its purity, exposure can be variable.84,85 A number of adulterants have 
been reported and include, but are not limited to, caffeine, paracetemol, cocaine, 
amphetamine and ketamine.86
9.10.2. Harms from high-risk injecting and sexual behaviour
There is some evidence that mephedrone hydrochloride (the common form in the 
UK) is sometimes injected. The limited research describing this practice strongly 
suggests its potential for unpleasant side-effects. Intravenous users of mephedrone 
report paracitosis (leading to scratching and gouging of the skin of the face, necks 
and arms in particular), paranoia, suicidal ideation and severe insomnia, especially 
after prolonged use.52
In a small qualitative Irish study, participants reported unwanted effects which 
included intense paranoia, violent behaviour and aggression, and the emergence of 
Parkinson-type symptoms, in the form of spasm, ‘wobbling’ and permanent numbness 
in the extremities. Injectors also report intense burning sensations at injection sites, 
limb abscesses, and vein clotting, damage and recession. These result from drug 
toxicity, crystallisation of the drug when diluted and syringe flushing practices. They 
also report multi-drug and serial drug injecting. Heroin is used in an attempt to 
manage the intense ‘rush’ and avoid an unpleasant come-down from mephedrone.38
As with other club drugs, mephedrone use has been linked to high-risk sexual 
behaviours among heterosexual men and MSM.30,63 There is some anecdotal evidence 
of mephedrone injecting among MSM in London (referred to as ‘slamming’), sometimes 
in combination with methamphetamine and injecting behaviours that put users at 
high risk of HIV and hepatitis.44
9.10.3. Acute withdrawal
For withdrawal see section 9.12.2.
9.10.4. Poly-drug use and drug interaction
The co-ingestion of other substances alongside mephedrone appears to increase harm. 
The reports of most mephedrone-associated deaths in the UKindicate poly-drug use.69 
Alcohol in particular may potentiate the effects of mephedrone.87,88. A two-patient 
case study found that large quantities of alcohol ingested with mephedrone may 
lead to serious cardiac arrhythmias.89 The co-ingestion of two stimulants is likely to 
increase mephedrone toxicity, as well as its potential harm,34 including the risk of 
serotonin syndrome or toxicity (see section 7.7.2). 
An animal study found that mephedrone enhances the neurotoxicity of metham-
phetamine, amphetamine and MDMA, substances that are commonly used alongside 
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mephedrone.90 There is also one reported death resulting from a combination of GHB 
and mephedrone, albeit with no analytical confirmation of the substances used.91
As CYP2D6 and CYP3A4 may be involved in mephedrone metabolism, inhibitors 
of these metabolic enzymes could increase the systemic exposure to mephedrone 
and lead to increased toxicity. Among the antiretrovirals, these would be ritonavir 
(a CYP3A4 inhibitor at low boosting doses) and cobicistat (a CYP3A4 and CYP2D6 
inhibitor). The role of ritonavir’s inducing effect on glucuronidation and its impact on 
mephedrone exposure remains unclear.
9.11. Management of acute harms
9.11.1. Identification and assessment of mephedrone toxicity
There are currently no rapid urine or serum tests for the confirmation of the ingestion 
of mephedrone (or of other drugs often co-ingested). It is recommended that 
diagnosis is made on clinical assessment, with other causes of presentation excluded 
and recognition of the associated clinical toxidrome. 
Data from the National Poisons Information Service show that in the UK in 2012–13, 
the section on mephedrone was more frequently accessed on TOXBASE® than the 
sections on other drugs of misuse, and mephedrone similarly ranked seventh in 
telephone enquiries, although reductions in numbers of the latter were noted over 
the course of three years.26 In 2012–13, 76 phone enquiries about mephedrone were 
made (-2.6% from the previous year) and the TOXBASE® mephedrone webpages were 
accessed 8432 times (an increase of 36.1% from previous year).92
It is not possible to determine accurately the numbers of presentations to hospital 
associated with mephedrone toxicity or indeed admissions resulting from the use 
of any recreational drug, not least because presentations with acute toxicity are 
assigned a wide variety of primary codes, which are likely to relate to symptoms 
rather than cause.93. In addition, toxicological screening is not usually carried out for 
patients presenting to emergency departments because the results are typically not 
available in time to inform the patient’s management. Mephedrone is also often used 
as part of a wider repertoire of drugs ingested and thus effects may be due to other 
substances.52
Two UK case series of presentations to an emergency department (ED) for acute 
mephedrone toxicity provide some insight into numbers. A study carried out in the 
ED of Aberdeen Royal Infirmary from 1 December 2009 to April 2010 (before the 
mephedrone ban in the UK) reported 89 cases in total; self-reports suggested that 33% 
had ingested mephedrone only, 30% mephedrone and alcohol, and 35% co-ingestion 
of other substances.94 A study looking at the impact of the control of mephedrone 
on presentations to an inner-London ED reported 58 cases in the year before control 
and 55 in the year after control, showing that presentations for mephedrone-related 
harms continued after the classification of the drug.21,32,52
It is suggested that clinicians should consider methedrone upon presentation with 
psychosis.
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9.11.2. Management of acute toxicity
No randomised controlled trials or other large robust studies have looked at the 
management of acute mephedrone intoxication, but there is consistency from case 
series and reports that treatment should consist of symptom-directed supportive 
care. It has been argued that, given the similarities with cocaine and amphetamine, 
management strategies similar to those recommended for intoxication with those 
drugs might be useful.74
Symptom-directed supportive care for acute stimulant intoxication may include the 
management of agitation, convulsions, metabolic acidosis, hypertension, hypotension 
and rhabdomyolysis. The management of serotonin syndrome may also be indicated. 
TOXBASE® suggests the observation of asymptomatic patients for at least 4 hours, 
or 8 hours for patients who have ingested sustained-release preparations. It also 
suggests that agitated adults be sedated with an initial dose of oral or intravenous 
diazepam (0.1–0.3 mg/kg body weight). Larger doses may be required.
Other than benzodiazepines, some case studies have reported the use of propofol, 
haloperidol and other antipsychotics,34,95 although it is also argued that anti-
psychotics should be used cautiously with synthetic cathinone intoxication, as they 
increase seizure activity.96 One report described lorazepam as effective for agitation 
and various sympathomimetic features of mephedrone use.49 In another case report, 
a treatment regimen of as-needed doses of quetiapine and lorazepam for paranoid 
ideation, agitation and anxiety was found to be clinically useful.
9.11.3. Treatment outcome
People who present to hospitals generally make a good recovery. The majority (84.7%) 
of the 72 patients presenting to hospital with acute toxicity described in one case 
series45 were discharged either directly from the emergency department or from a 
short-stay observation ward; the other 15.3% were admitted to hospital, with 11.1% 
admitted for observation/management on a general internal medicine ward, and 
4.2% required admission to intensive care. Overall, 13.9% required benzodiazepines 
(oral or intravenous) for ongoing agitation at, or after, presentation to the hospital. All 
but one patient were discharged, with no long-term sequelae at the time of discharge, 
For up-to-date guidance on the management of mephedrone acute toxicity, it is recommended 
that information be sought from the National Poisons Information Service (NPIS), specifically 
the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/M-Products/Mephedrone/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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and the length of stay following presentation ranged from 0.3 to 30 hours (a mean of 
6.7 hours, SD 7.3 hours).45
9.11.4. Management of acute withdrawal
See section 9.12.2.
9.12. Harms associated with chronic use
9.12.1. Dependence
There is emerging evidence that mephedrone has a dependence potential. It has 
been argued that the ability of mephedrone to cause striatal dopamine release may 
be problematic inasmuch as, in comparison with MDMA, mephedrone may have an 
enhanced liability to misuse, more resembling that of dopamine-releasing agents such 
as methamphetamine.10 One animal study suggests that the dopaminergic effects of 
mephedrone may contribute to its addictive potential.97 
A report from the Advisory Council on the Misuse of Drugs (ACMD) on cathinones 
suggests that, because of its similarity to amphetamine, they carry a similar risk of 
dependency, with chronic use leading to dependence and a cycle of bingeing and 
periods of recovery associated with depression.14 There is one published case report 
of dependence on mephedrone based on ICD-10 criteria98 where dependence led to 
psychotic symptoms. Other studies have also shown the potential for dependence. In 
one study of 100 mephedrone users, 30% met three or more of the DSM-IV criteria 
for stimulant dependence, with evidence of a strong compulsion to use the drug.30 
In a Scottish school survey, 17.6% of those who had used mephedrone reported 
‘addiction/dependency’ symptoms relating to their use of mephedrone.65 Similarly, 
a survey of 797 UK clubbers who had used mephedrone reported that it was ‘as or 
more addictive’ than cocaine.48 In another survey, 50% of 1500 mephedrone users 
considered it to be addictive.31 
There is increasing evidence that mephedrone causes a strong and repeated 
compulsion to use,17,65 that tolerance to mephedrone develops quickly and that 
users tend to consume higher doses more frequently. Subjective reports of craving 
suggest that mephedrone may have a greater potential for repetitive and compulsive 
use than MDMA,17,31,65 although these observations are made on the basis of self-
reports. Emerging evidence on the subjective effects of mephedrone suggests that its 
ingestion is associated with ‘wanting more’17,30,53 and this was shown to be elevated 
significantly when users were sober but anticipated use in the near future.53
9.12.2. Withdrawal
There are a few reports of craving for mephedrone15,37,65 and of withdrawal. There 
are users’ reports that the development of cravings for mephedrone may be linked 
to increased frequency of use.48 A survey of users also suggested that those who 
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ingested the drug through nasal insufflation were more likely than those who used it 
orally to rate it as more addictive than cocaine,48 possibly reflecting the more rapid 
onset and shorter duration of desired effects of mephedrone when it is used nasally. 
Craving for mephedrone has been described as stronger than for ecstasy.17 
A study of 100 users by Winstock et al. suggested that the most frequent effects 
related to withdrawal after a session of mephedrone use were tiredness, insomnia, 
nasal congestion and impaired concentration. Other withdrawal symptoms include 
depression, anxiety, increased appetite, irritability, unusual sweat odours and urge or 
craving to use.30
Mephedrone was described by a frequent and heavy user in a case report as providing 
a more intense initial euphoria and a more severe withdrawal syndrome than MDPV.99 
In this case report, the user, who also reported a history of opiate and methamphet-
amine use, reported mephedrone withdrawal as the most unpleasant drug withdrawal 
he had experienced. He reported that discontinuation of mephedrone resulted in 
agitation and dysphoria within a few hours, which was more severe than that of 
cocaine or methamphetamine, and which was accompanied by an increase in muscle 
tone, the alleviation of which required constant movement.99 He reported that only 
methamphetamine gave some degree of relief to the withdrawal.99
9.12.3. Other harms: risk of systemic and viral infections
Like other club drugs, the impact of mephedrone on sexual behaviour can affect the 
transmission of blood-borne viruses and sexually transmitted infections.63 Moreover, 
mephedrone is associated with compulsive and frequent injecting, making its users at 
particular risk of the acquisition and transmission of blood-borne viruses. To this are 
added the risks specifically linked to the injection of mephedrone, which can include 
limb abscesses and vein clotting, damage and recession. This places injectors at risk of 
septicaemia, endocarditis, deep-vein thrombosis and other complications.
9.13. Management of harms related 
to chronic use and dependence
9.13.1. Clinical management of chronic use and dependence
See Chapter 7 on the identification and assessment of dependence on ATS in general 
(section 7.10.1), which apply to mephedrone, as does the guidance on psychosocial 
and pharmacological support and intervention (section 7.10.3).
9.13.2. Management of withdrawal
There are no pharmacological regimes for the management of withdrawal, although 
those with psychological dependency may require medical treatment for their 
symptoms on discontinuation. Ongoing psychological support may be required, 
including for the prevention of relapse.52
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There have been no randomised controlled trials for treatment of either acute 
intoxication or withdrawal. Reports suggest supportive treatment with low to 
moderate doses of benzodiazepines for agitation and paranoia. A treatment regime of 
olanzapine98 was described in a case report of dependence on mephedrone (diagnosis 
based on ICD-10 criteria) and where dependence had led to psychotic symptoms. 
Another case report described a patient put on antidepressants for residual 
symptoms of depressed mood, anhedonia and hopelessness present in all his periods 
of abstinence.99 A further case report described a pharmacological intervention for 
MPDV withdrawal involving risperodone, which was effective for symptoms of disor-
ganisation, delusions and hallucinations.100
9.13.3. Presentation to specialist drug treatment services
In England, there was an 82% increase in mephedrone presentations between 
2011/12 and 2013/14, from 900 in to 1,641.101
In Northern Ireland, 150 people presented for treatment of mephedrone misuse from 
1 April 2011 to 31 March 2012 (118 males and 32 females; 19 were under 18 years, 69 
were aged 18–25 years and 62 were over 25 years; 37 had had previous experience of 
drug treatment and 113 had not).102
9.13.4. Aftercare and support
See section 7.10.5.
9.14. Public health and harm reduction
Winstock et al. recommend as harm reduction:51
•	avoiding using regularly to avoid developing tolerance;
•	not using with stimulants or large amounts of alcohol and/or other depressants;
•	not injecting;
•	avoiding dehydration; 
•	avoiding overheating.
See also the general comments in Chapter 7.
9.14.1. Public safety: driving
An analysis of 376 cases of alleged driving under the influence of drugs found 6 
cases of driving under the influence of mephedrone. Mephedrone can affect driving 
inasmuch as it can produce poor concentration, hallucinations and psychosis.103
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Chapter 10
Ecstasy (MDMA, 3,4-methylene-
dioxymethamphetamine) and drugs 
with similar effects 
Drug group: stimulant
This chapter uses the term ‘ecstasy’ to refer to illicit drug products that contain MDMA 
(3,4-methylenedioxy-N-methylamphetamine) as their only, or primary, psychoactive 
component. Despite some changes in the prevalence of its use, MDMA has been a 
popular drug for many decades in the UK. 
MDMA is structurally similar to both amphetamine-type stimulants and to mesca-
line-type hallucinogens, but is pharmacologically different from other substance 
classes.1 In addition of their stimulant and hallucinogenic effects, MDMA and similar 
substances share properties that are sometimes referred to as ‘entactogenic’2,3 or 
empathogenic.4,5 This has been defined as combining a psychostimulant effect with 
highly unusual changes in consciousness, leading to euphoria and an intense love of 
self and others.5 MDMA presents a good example of the difficulties in drawing clear 
distinctions between empathogens and stimulants, as it combines both properties.6
This chapter also addresses issues pertaining to the consumption of MDMA-like novel 
psychoactive substances (NPS),6 which include other substituted amphetamines (see 
Table 10.1). Some cathinones and benzofurans also mimic the effects of MDMA (see 
Chapter 9), although there are subtle differences in their psychic effects.6
Users of ‘ecstasy’ may use the term strictly to mean MDMA, or generically to mean 
any substance with a similar effect. Users may deliberately acquire and consume one 
of the named entactogens listed in Table 10.1, or may consume them unknowingly7,8 
in products they obtain as ‘ecstasy’. 
There are significant variations in the compounds found in products sold on the 
market as ‘ecstasy’. Studies have shown variations in the purity of MDMA over time 
and location, and variations in the compounds found in tablets sold as ecstasy,8–12 Over 
the years, the latter have included non-MDMA products such as MDA, benzofuran, 
methylone,13 piperazines such as BZP14 and, more recently, PMA and PMMA. 
There are also significant variations in the potency of tablets, even among those sold 
as the same product or ‘brand’ and containing MDMA as the main active ingredient. In 
a study carried out from November 2013 to July 2014, 24 separate groups of tablets 
sold as ‘ecstasy’ in the Glasgow area were analysed to quantify their MDMA content, 
to determine the common dose and to identify any other drugs in the tablets. There 
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was a 5.7-fold difference in the lowest to the highest concentration found. Variations 
were even found between tablets that carried the same logo and looked identical.15
A small number of samples analysed by a Welsh drug testing service demonstrate 
that methylone and MDA have been recently sold in the UK as ‘ecstasy’ or under their 
own names.* Only two samples were tested by this service that were presented as 
MDAI and contained MDAI; a further 6 samples presented as MDAI contained other 
drugs, in line with evidence of the misrepresentation of MDAI purchased online.16 Four 
samples presented as other drugs contained MDAI. Benzofuran derivatives, such as 
5- and 6-APB, were certainly available for purchase and in use since around 2011, but 
their use was not widely reported in surveys.17. Whether they remain in use following 
the 2014 ban, or whether they are replaced by vendors with other entactogen NPS, 
remains to be seen. 
* This paragraph refers to the Welsh Emerging Drugs and Indentification of Novel Substances 
(WEDINOS), whose website (http://www.wedinos.org) was searched in September 2014 using the 
keyword search ‘methylone’, ‘MDA’ and ‘MDAI’.
Table 10.1. Entactogens MDMA and MDMA-like novel psychoactive substances:
Chemical name Street names (these 
come and go, and other 
names may be used 
locally)
Substituted methylenedioxyphenethylamines18
3,4-methylenedioxy-N-methylamphetamine MDMA Ecstasy, E, Molly, Mandy, 
MD, 
3,4-methylenedioxy-N-ethylamphetamine MDEA, MDE Eve
1,3-benzodioxolyl-N-methylbutanamine 
(N-methyl-1,3-benzodioxolylbutanamine)
MBDB19 Eden, Methyl-J
3,4-methylenedioxyamphetamine MDA Tenamphetamine, love 
drug,8 Sass
Other substituted amphetamines2
4-methylthioamphetamine 4-MTA19 Flatliners20
para-methoxyamphetamine 
4-methoxyamphetamine
PMA, 4-MA (note 
that another drug, 
4-methylamphet amine, 
shares this name)
Dr Death,  
Death
para-methoxy-N-methylamphetamine 
4-methoxy-N-methylamphetamine 
PMMA, 4-MMA Dr Death 
Death
Table 10.2. Other substances used for their entactogenic properties
Chemical name Street name
3,4-methylenedioxy-N-methylcathinone
bk-3,4-methylenedioxymethamphetamine 
bk-MDMA
(MDMC, methylone)
Methylone MDMC, 
bk-MDMA, or ‘Molly’
β-keto-N-methylbenzodioxolylbutanamine
B1
bk-MBDB 
(beta-ketone-MBDB)
Butylone
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A number of other substances are also used for their entactogenic properties, 
including some cathinones (particularly those which are also beta-keto analogues of 
methylenedioxyphenethylamines21). They are listed in Table 10.2 
Some benzofurans derivatives, indanylalkylamine derivatives and aminoindane 
derivatives are also used recreationally for similar effects. They are addressed briefly 
at the end of this chapter.
10.1. Street names
Street names used at the time of publication include the ones listed in Tables 10.1 
and 10.2. Other street names may be used locally.
10.1.1. Tablets, pills and capsules
The term ‘ecstasy’ (often shortened to ‘E’, ‘XTC’ etc.) is most often used for pressed 
tablets or capsules (‘pills’, ‘beans’, ‘Es’, ‘bickies’ ‘bangers’ etc.) containing a dose of 
MDMA. Users may also refer to such products by the variable ‘branding’ colour, shape, 
imprinted logo with which manufacturers make them distinguishable (e.g. ‘White 
Doves’, ‘Yellow Superman’, ‘Apples’, ‘Pink Hexagons’).
10.1.2. Crystals and powders
Ecstasy powders and crystals are often referred to by users as ‘MDMA’ or ‘pure MDMA’ 
as opposed to the tablet form, which is referred to as ‘ecstasy’.
Specific names include Mandy, MD, Mad Dog and Molly (the term currently used in 
US pop culture, so more likely to be adopted by a younger generation of users). A 
dose wrapped in tissue or cigarette paper for swallowing may be called a ‘bomb’ or 
‘parachute’.
10.2. Legal status
MDMA is a Class A drug under the Misuse of Drugs Act 1971. Other entactogens 
are controlled across the classes (Table 10.3). New entactogenic substances that fall 
outside legal control may emerge. 
Table 10.3. Legal status of entactogens (as of February 2015)
Classification under Misuse of Drugs Act 1971 Drug
Class A MDMA, MDEA, MDA, MBDB, 4-MTA, PMA, PMMA
Class B bk-MDMA (methylone), bk-MBDB (butylone), 
5-APB, 6-APB, 5-APDB, 6-APDB, 5-MAPB, 6-MAPB, 
5-EAPB, 5-APDI22
Class C MDAI (Isle of Man)
Uncontrolled (‘legal highs’) MDAI (excluding Isle of Man), 5-IAI 
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10.3. Quality of research evidence
Although much more is known about MDMA than other club drugs, the evidence 
is limited on its acute and chronic harms, and on the management of those harms 
particular. Much of the clinical evidence is derived from individual case reports and 
case series and a small number of prospective observational studies, retrospective 
audits and analysis of patient records.
A number of reviews of the evidence have been carried out,23–25 but there is still no 
consensus on some of the harms among leading ecstasy researchers.26,27 For example, 
Parrott emphasises the accumulation of literature detailing the harms of the drug, 
particularly chronic neurotoxic effects.24,25 However, his conclusions have been 
contested.26 A recent review by Cole takes a more critical approach to the evidence 
base, emphasising the lack of certainty about many of the harms putatively attributed 
to ecstasy. He suggests that the number of clinical presentations relating to ecstasy is 
far smaller than would be expected, given the high prevalence of its use.27
As with other NPS and club drugs, the reliability of case reports is inconsistent. Many 
lack toxicological confirmation. Some authors have suggested that such case studies 
fail to convince that ecstasy use is, on balance, the most plausible explanation for the 
clinical observations.28,29 However, despite these limitations, these sources have built 
up a consistent picture of common patterns of acute ecstasy toxicity.
The evidence relating to specific NPS analogues of MDMA, used for entactogenic 
effects, is much more limited, consisting of a small amount of animal and in vitro 
research on their pharmacology and some case studies of acute toxicity. However, 
reports of their effects and toxicity generally fall within the range described in the 
larger literature on ecstasy,18 and on amphetamine-type stimulants (ATS), so useful 
inferences can be made from the existing literature.
10.4. Brief summary of pharmacology 
MDMA and other ecstasy-type drugs have phenethylamine-derived molecular 
structures, and can be thought of, pharmacologically, as atypical ATS. MDMA has 
multiple actions at different targets: it is a releaser and reuptake inhibitor of the 
monoamines serotonin, dopamine and noradrenaline.30,31 It also has an MAOI effect 
and acts directly as an agonist at receptors, including the 5HT2A receptor, the 
serotonin receptor responsible for psychedelic effects.30 Its action on the noradrena-
line transporter appears to explain much of the euphoric psychostimulant effect,32 
with the powerful serotonergic action being chiefly responsible for its pharmacologi-
cal divergence from typical psychostimulants.33,34
However, among the stimulant and psychedelic drugs, the risk–effect profiles of 
ecstasy-like drugs are unique, and comparison with drug classes with divergent 
properties can misguide as much as inform, so they have been increasingly seen as 
neither classical hallucinogens nor classical stimulants.2
In addition to its stimulant effects (such as increased energy, euphoria) and cardio-
vascular effects common to ATS and cocaine, MDMA- produces characteristic alterations 
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of mood and perception, particularly increased empathy, feelings of emotional 
well-being, sociability and sensuality.2,35 This has led to MDMA being described as 
intermediate between (or combining some properties of) stimulants and psychedelic 
hallucinogens.2 
This family of drugs with shared MDMA-like emotional and behavioural effects are 
known as ‘entactogens’,1,36 although this word has not gained universal use. The 
word ‘empathogen’ has also been used to describe drugs sharing the psychoactive 
properties of MDMA.4 These drugs have been described as capable of inducing 
a reversible controlled alteration of consciousness in humans characterised by 
emotional relaxation, feelings of happiness and empathy with other persons2 that 
has been called the ‘entactogenic syndrome’.37 MDMA induces altered states of con-
sciousness characterised by increase empathy with others38 and an ‘open mind’ state, 
characterised by heightened self-acceptance and openness for communication, and a 
decrease of fear responses, without psychedelic-like effects.2 Other typical entactogen 
effects, including subjective ‘relaxation’,39 ‘peacefulness’,36 ‘closeness to others’40 and 
‘empathy’,40 may diverge from the effects expected from ATS.
There is uncertainty regarding the pharmacology specific to the ‘entactogenic’ effects 
of MDMA and related drugs. In addition to the direct serotonergic effects on mood, 
the serotonin transporter (SERT), upon which MDMA and its analogues act, appears 
to mediate the release of the neuropeptide hormones oxytocin and prolactin.41 The 
action of MDMA on SERT are hypothesised to contribute to its pro-social, entactogenic 
effects.
Doses or serum concentrations of MDMA and related drugs are often not closely 
associated with the level of acute harm observed, and lifetime dosage may not be 
closely associated with the degree of chronic harm either. One suggested explanation 
is that genetic polymorphisms affecting the hepatic metabolism of MDMA play a 
mediating role in toxicity.34 The metabolism of MDMA (via steps which include phar-
macologically active and toxic metabolites) is affected by the pattern of dosing,42 
with the metabolism of subsequent doses being inhibited by the limited availability 
of the cytochrome P450 (CYP2D6) enzyme.30,43
Paramethoxyamphetamine (PMA) and paramethoxymethamphetamine (PMMA) are 
potent noradrenaline and serotonin transporter inhibitors and releasers of these 
monoamines. They are associated with higher morbidity and mortality, particularly 
attributable to hyperthermia.44,45 They have a potential for causing greater serotonin 
toxicity. PMA, PMMA and 4-MTA are often characterised by severe hyperthermia, 
probably resulting from severe serotonin toxicity arising from the combined effects 
of marked serotonin release and strong monoamine oxidase inhibition.46–51 Their 
hyperthermic properties are stronger than those of MDMA.52 In combination with 
MDMA and other serotonergic drugs, this risk is multiplied further.53 
MDMA is rapidly absorbed. It typically takes 20–60 minutes to take effect, reaching 
peak effects between 60 and 90 minutes, and lasting up to 5 hours.54 The half-life of 
a typical dose of 100 mg is around 8–9 hours.30 While actively partying on ecstasy, 
saliva levels of cortisol can rise to more than eight times baseline levels.55
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The onset of the effects of similar substances varies. User reports suggest the effects 
of MDAI are felt within 10–12 minutes of oral consumption. The duration of its effects 
has also been reported by users as varying considerably between individuals, with 
effects peaking after 30–45 minutes, to up to 3 hours,56 a variability that has been 
attributed partially to products containing substances other than MDAI.57
The onset of the effects of PMA is significantly later. This has caused concern, especially 
when users take it thinking it is MDMA. Users may take another dose, thinking that 
the first one has had no effect. There is, therefore, the risk of overdose, including fatal 
overdose.
10.5. Clinical uses
MDMA is a Schedule 1 drug with no well supported and no licensed clinical uses. 
However, prior to being classified and scheduled, MDMA was used to facilitate psycho-
therapy.58 
In recent years, some research into its psychotherapeutic use has continued, despite 
the legal barriers to this, and MDMA has now reached phase II clinical trials as an 
adjunct to psychotherapy for treatment-resistant post-traumatic stress disorder 
(PTSD). The first small-scale pilots have demonstrated good preliminary results with 
minimal adverse effects, but larger trials are needed.59
MDMA is hypothesised to support and enhance psychotherapy by increasing the 
subject’s access to emotionally upsetting material, modulating the associated level 
of arousal and strengthening the therapeutic alliance.60 MDMA is known to have 
major effects on serotonergic neurotransmission, but a downstream consequence of 
its effects on serotonin is the release of oxytocin and vasopressin, which may have 
relevance to producing trust and may reduce the threat response of being asked 
to revisit traumatic memories.61. Brain imaging studies show reduced amygdala 
activity after MDMA administration, plus changes in the response to angry and happy 
facial expressions.4 Nonetheless, marked differences of view are apparent among 
experts,26,62 with other scientists believing that the evidence of MDMA’s toxicity is 
already sufficient to conclude that ‘there are no safe clinical applications for MDMA’.63 
10.6. Prevalence and patterns of use
The recreational use of ecstasy has well established in the UK for a number of decades. 
Prevalence has varied over time but data from the Crime Survey for England and 
Wales (CSEW)64 shows that in 2013/14 it was the third most prevalent illicit drug 
after cannabis and cocaine, with 1.6% of adults aged 16–59 and 3.9% of young adults 
(16–24) having used it in the last year. While this represents one of the highest rates 
of use in Europe, last-year use in England and Wales had fallen overall from a high of 
2.1% in 2001/12 (6.8% among 16–24s).64 
Much less is know about the use of other MDMA-like NPS. Prevalence estimates of the 
use of PMA/PMMA are unavailable, but an Australian study reported that a majority 
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of patients presenting with severe symptoms following the use of what had been 
sold as ‘ecstasy’ had in fact consumed PMA.47 Deliberate use of PMA and PMMA is 
negligible to non-existent.47 
The ‘reliability’ of ecsasy, determined by users in terms of the substance sold containing 
a significant quantity of MDMA as the primary active compound, has been variable,65 
and may be linked to changing patterns of use over the years. Between 2012/13 
and 2013/14 there was a significant rise in use of ecstasy again,64 although not to 
2001/12 levels. This is possibly linked to the apparent increase in ecstasy products 
containing ‘reliably’ large amounts of MDMA,66 which appears once again to be the 
norm in the UK,66 following a dip in quality around 2008/09. It has been argued that 
this dip may have helped drive the emergence of mephedrone as a club drug.67 In 
the most recent available data, the average seized tablet contained around 100 mg 
of MDMA;66 such tablets correspond to user preferences, having the optimal ratio of 
desired to unwanted effects.68
In the early years of ecstasy’s emergence as a recreational drug, it was strongly 
associated with underground raves, ‘acid house’ and associated dance subcultures. As 
use has become more widespread, settings of use and types of users have diversified.69 
Clubs, parties and festivals remain the key locations for use, accompanying music and 
dancing. 
Ecstasy has been reported as the favourite drug of surveyed club-goers, and the drug 
has been described as central to the culture of the British club scene.70 Data from 
2013/14 suggest that ecstasy use in the last year was around 15 times higher among 
those who had visited a nightclub at least four times in the past month (11.9%) 
compared with those who had not visited a nightclub in the past month (0.8%).64 
Those frequenting certain clubbing environments, differentiated for example by 
dance music genres, may show even higher rates of use. A majority may have a history 
of recent ecstasy use,71,72 and use ‘ever’ can be almost ubiquitous, as high as 96% of 
respondents of a 1999 survey of readers of Mixmag, a clubbing culture magazine.73.
Although the use of ecstasy is linked to the use of the night-time economy, use 
in other settings, such as homes, is not unusual.74,75 The number of deaths among 
drug-dependent solitary users may suggest that non-clubbing users could be over-
represented among the clinical population.23
The CSEW finds that students were twice as likely to use ecstasy than people in 
employment (who are more likely to use cocaine than students).64 Over the three 
years of data to 2013/14, people who self-identify as gay or bisexual were far more 
likely to be last-year users of ecstasy (5%) than heterosexual people (1.3%), although 
this is likely simply to reflect the higher overall prevalence of all drug use in this group. 
Asian/Asian British people (0.1%) and Black/Black British people (0.3%) were less 
represented among users of ecstasy than White people (1.6%) or people of mixed 
ethnicity (2.3%).64 As with other drugs, men were more likely to have used ecstasy 
than women (2.3% versus 0.9% respectively in 2013/14). Ecstasy is used by people 
across the socioeconomic spectrum.64
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Most people who try ecstasy will not escalate to regular or sustained use.24 A Dutch 
study recruited ecstasy-naïve subjects who said they were probably going to try the 
drug. Of the 64 who did so in the next one to two years, more than half consumed 
only one tablet or less.76 Ecstasy is typically used occasionally.24 CSEW data show that 
86% of last-year ecstasy users took it less frequently than monthly, 10% monthly, and 
4% more regularly than monthly.64 
While CSEW data show only a minority (4%) of last-year users use ecstasy more than 
once a month,64 using ecstasy on many or most weekends is not uncommon among 
users sampled at clubs and raves.77 Use of ecstasy several times a week, or even 
daily,78 has been recorded, although this is exceptional and very likely to be linked to 
comorbidities.78–80 One case has been reported of a poly-drug user who self-reported 
the consumption of 40,000 ecstasy tablets between the ages of 21 and 30, before 
ceasing use following several collapses.81 Bingeing for up to 48 hours and using up to 
25 tablets has been reported,24 but there is a lack of recent evidence, and the number 
of tablets is an imprecise guide to the total dose taken. 
The tendency is for tolerance to the positive effects of ecstasy to build up with use,82 
leading to diminishing returns from consumption. This may be protective against 
sustained heavy use or addiction.24 It has been suggested that regular users often 
follow a trajectory of discovering and strongly liking MDMA, using it most weekends, 
sometimes with escalating dosages, for a year or two, suffering increasing adverse 
effects with decreasing enjoyment (‘losing the magic’) and then reducing or ceasing 
use spontaneously.83 This pattern of decline has been described as almost unique 
among recreational drugs.83
A minority of ecstasy users will develop problems and will access drug treatment 
services, especially when no other problem drugs were also involved. Between 2006/07 
and 2011, adults over the age of 18 years in England and Wales receiving treatment 
for drug use, which included problematic ecstasy use, use fell from 2138 to 1018.66,84 
In 2013/14, only 201 people (less than 0.1%) cited it as their main problem drug; but 
964 people presented to treatment and cited ecstasy as one of their problem drugs.85 
Ecstasy users are highly likely to be poly-drug users.86,87 The CSEW does not record 
poly-drug use annually; 2012 data88 show that ecstasy was commonly taken simul-
taneously with alcohol almost all of the time (95%) and with other illicit substances 
about half of the time (49%). When used simultaneously with other illicit drugs, the 
most common co-intoxicant was cannabis (64%), followed by cocaine (44%) and 
amphetamines (18%).88 Poly-use was shown elsewhere. In a large Australian sample 
of regular ecstasy users, 62% said they usually consumed more than five ‘standard 
drinks’ (equivalent to more than 6 UK alcohol units) when they took ecstasy.89
Ecstasy users have higher levels of consumption of alcohol, cigarettes and cannabis 
than non-ecstasy users, but while they may combine ecstasy with alcohol and other 
drugs, ecstasy intoxication itself may not increase the likelihood of using other drugs 
at times where ecstasy is not used.90
However, among ecstasy users, heavy and frequent users are significantly more likely 
to use other stimulants and psychedelics at higher intensities than lighter ecstasy 
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users.86 Studies suggest that the heavier an individual’s ecstasy use, the heavier and 
more varied their poly-drug use will be.86 This could reflect the fact that people with 
higher levels of use may also be more likely to use other drugs with stimulant and hal-
lucinogenic properties. Scholey et al. suggest that this may represent a greater need 
(on the part of people with high levels of use) to boost drug effects as they become 
tolerant to the effects of MDMA.86
10.7. Forms, routes of ingestions 
and frequency of dosing
Ecstasy is available in a number of forms, mainly as powder/crystals or as pills, tablets 
and capsules. Currently in the UK, powder and crystals are most commonly used. 
In the Global Drug Survey 2014 UK sample, MDMA powder/crystals were twice as 
commonly used as tablets.91 It is unclear whether this current dominance of crystals 
and powders is a universal or reflects the preference for these as a ‘premium’ product70 
among the Global Drug Survey sample – the crystals in particular are reputed among 
users to be a purer and more reliable product than tablets.70 That form first became 
widespread against the backdrop of unreliable or low-dose tablets sold in 2009 
and after. However, as of 2012, the average dose in seized tablets was much higher 
(102 mg) than in the ‘poor quality’ ecstasy sold in preceding years.66 However, powder 
and crystals are no longer necessarily less adulterated or misrepresented than tablets. 
Indeed, a small but significant proportion of ‘MDMA’ crystals currently analysed are 
in fact methylone.92
Ecstasy is typically taken orally,18 including in its powder/crystal form, which can 
be ‘bombed’ (wrapped in a cigarette paper or tissue and swallowed).24 Some users 
consume ecstasy by licking a finger and dipping it into powder93 or through ‘dabbing’ 
on gums.
 When not consumed orally, it may be insufflated,91 which is particularly common 
among experienced users.69 User forums94 report that the insufflation of ecstasy is 
painful and gives a shorter high, but with a rapid onset. According to the Global Drug 
Survey, oral ingestion remains the preferred method of administering MDMA, with 
only 15% of users snorting it.91 Insufflation may be used as an alternative to oral use,18 
or sometimes as an additional route of administration for a boost, following oral 
ingestion.95 Rectal18 (‘plugging’ or ‘booty bumping’) and injecting are uncommon.24,80 
The latter has been described as ‘too intense to enjoy’, leading to reversion to oral 
use.96 Other entactogens, such as 5-APB and 6-APB,97, are also most often used orally.
The reported MDMA content of a single ecstasy tablet or capsule of powder has varied 
from no MDMA content at all to doses as high as 245 mg or 270 mg.98,99 The higher 
doses are likely to cause toxicity, being well above the dose that seems associated with 
the best ratio of wanted to unwanted effects (about 100 mg).68,100 Similarly, in a case 
of a fatality linked to consumption of two capsules thought to be ‘ecstasy’, a further 
single capsule from the batch was found to contain 422 mg bk-MDMA (methylone) 
and 53 mg bk-MBDB (butylone), far higher than typical reported doses.7
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As mentioned in section 10.1, even tablets of the same ‘brand’, can vary between 
batches, or can be easily mimicked in an uncontrolled market. Tablets of the same 
appearance may not deliver a consistent dose, or even contain the same psychoactive 
substance. In 1999, identical-looking ‘Dove’ tablets were shown to range in dose from 
19 mg to 140 mg of MDMA.100 More recently, when two ‘Yellow Rockstar’ tablets from 
Glasgow were analysed, one contained 82 mg of MDMA, lower than doses administered 
to healthy humans in a recent research study,101 and the other contained PMA and 
PMMA, along with caffeine.15
Doses consumed by the ‘bombing’ method (powder, typically wrapped in cigarette 
paper and swallowed) may be higher than average tablet doses.24 There was an 
apparent increase in 2013 of the number of ecstasy users who accessed emergency 
treatment, according to reports to the Global Drug Survey. Users linked this to the 
current dominance of high-purity MDMA powder over pills, with Winstock suggesting 
that users may lack awareness of how to dose with powder.91
A naturalistic study of Australian users found that doses consumed in a session usually 
fell in the 50–150 mg range, but rose as high as 280 mg. Users took 0.5–5 tablets and 
these varied in dose from 0 mg to 245 mg.98 American adolescent users in one study 
rarely took more than one pill per session.102 Evidence from a web survey suggests 
that the dose users choose is linked to their level of experience. None of the 109 
novice users (<10 lifetime uses) reported taking more than one or two tablets in one 
session, but 38% of 37 experienced users (>100 lifetime doses) described doing this.86 
When asked what their record highest ever intake was, heavy users in one sample had 
taken an average highest ever dose of 10.9 tablets,103 but this may say more about 
variability in tablet quality,27 as the same heavy user sample took 3.7 tablets during 
an average session.103
In audits of emergency department presentations in Switzerland and London, 15.4% 
and 20% of patients respectively had taken more than two tablets.104 In a small 
American sample, three-quarters of users took just one dose in a session, usually 
between 8pm and 2am on a Friday or Saturday night. A minority took a further dose, 
usually within the first 2 hours, suggesting the additional dose constitutes a top-up if 
the initial effects are not satisfactory, rather than a typical stimulant dosing pattern 
of extending the high and avoiding the come-down.90
10.8. Desired effects for recreational use
The unique combination of desired effects elicited by ecstasy has been roughly 
summarised as the ‘3 Es’ – energy, euphoria and empathy.105 MDMA’s continued 
presence as the key ingredient in ecstasy pills has been ascribed to its singular 
properties, combining unique desired effects with relatively low adverse effects at 
optimal doses.68 MDMA topped a novel ‘net pleasure index’ among a large self-se-
lected sample (22,000 people). In this index, subjective ratings of adverse effects were 
subtracted from ratings of desired effects to give a mean score that could be used to 
rank a range of drugs.106 MDMA was also considered the best value drug overall by its 
users.106
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Questionnaire evidence from people currently on ecstasy in a naturalistic party setting 
allowed ter Bogt and Engels to identify a hierarchy of motives for taking ecstasy.77 
Energy and euphoria were the leading motivations for a majority of users (as captured 
by users endorsing statements like ‘dance all night’ and ‘feel absolutely great’). These 
were followed by sociability and flirtatiousness (e.g. ‘flirting easier’), sexiness (e.g. ‘sex 
better’) and coping (e.g. ‘forget my problems’); conformity (e.g. ‘be cool’) was the 
least important motivating factor.77 When they contain MDMA, ‘ecstasy’ tablets are 
a relatively reliable producer of subjective pleasure.68 Commonly reported positive 
effects, such as ‘calmness’, however, contrast sharply with paradoxical adverse effects 
that clinicians may encounter, such as agitation and anxiety.35
Pure MDMA usually elicits highly ‘liked’ effects, even in the research environment. 
However, in keeping with its intermediate position between typical stimulants (where 
positive mood change occurs reliably) and psychedelic hallucinogens (where setting 
powerfully mediates mood changes), positive effects may fail to appear in a context 
that is particularly unconducive to them (as observed in a research setting which was 
poor in social stimulation).107
Increased sensual awareness, love, feeling of connection, desire, sexual intensity and 
satisfaction are also reported,77 but paradoxically this may be coupled with erectile 
dysfunction in men and delayed orgasm in both sexes.108,109 It has been hypothesised 
that this is due to release of prolactin and oxytocin, such that ecstasy mimics the 
emotionally close but sexually impaired features of the post-orgasmic refractory 
period.110 Female heterosexual ecstasy users, interviewed in one study, did not 
generally think that ecstasy increases the likelihood of high-risk sexual activities, 
although noted that they sometimes chose to engage in behaviours such as anal sex 
while intoxicated which they otherwise may not have engaged in.109 Roger et al.’s 
systematic review, which includes a meta-analysis, shows that ecstasy use is linked to 
small to moderate increases in sexual risk.23 However, ecstasy is not one of the drugs 
most linked to ‘chemsex’ and associated risks.111
Ecstasy was found in one case to give temporary dramatic relief from the symptoms 
of Parkinson’s disease;112 this discovery, corroborated in animal studies, has led to 
drug development.113 
Although not widespread, it has been reported that some individuals may use 
ecstasy in an attempt to self-medicate, for example to manage current stresses and 
lifetime traumas,114 including PTSD symptoms.80 In the US, there appears to be some 
‘underground’ use of ecstasy for therapeutic purposes.115 
Some NPS have been reported to produce similar subjective effects to those reported 
by MDMA users,13,116 especially an ‘entactogenic syndrome’,2 but evidence from studies 
in humans is limited. In combination with animal research, some anecdotal evidence 
supports the existence of subtle18 to significant differences, with some entactogens 
producing the empathogenic effects and serenity associated with ecstasy but with 
less of the stimulant and euphoriant effect.117
Whereas many NPS are selected by users because they wish to experience a new 
drug, this is not necessarily the case with PMMA and PMA, as these are typically not 
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taken deliberately as such. For example, none of the 22 people seen with PMA toxicity 
in an Australian emergency department reported deliberately taking the drug; rather, 
they had all intended to take ecstasy.47 
In fact, there is no evidence that PMA and PMMA have any prominent desired 
effects,68,118 although their serotonergic pharmacology suggests that they could 
have ‘entactogenic’ effects. A study linking the pharmacological content of a tablet 
consumed and its subjective effects on users reported that desired effects were 
nearly absent with tablets containing MDMA adulterated with PMMA (odds ratio of 
0.05 relative to desired effects from MDMA-only tablets).68
10.9. Unwanted effects
The use of MDMA is associated with a number of unwanted effects. For example, a 
study reported that typical side-effects as experienced by more than half of a sample 
of users included jaw clenching (trismus, ‘gurning’), dry mouth, tachycardia and 
sweating, with a minority having experienced urinary retention, dizziness, nausea and 
vomiting, and decreased libido.119
It has been argued that common side-effects, such as nystagmus, trismus, mild 
confusion and feeling hot, are the low end of a spectrum of serotonergic overactivity 
that has at the higher end serotonin syndrome and death.120 Other adverse reactions 
include feeling cold and shivering.120
Unwanted effects could be associated with MDMA and/or adulterants and other 
compounds found in tablets sold as ecstasy. In one study, adverse drug effects were 
reported by 16% of 924 users who had handed in ‘ecstasy’ for testing by the Dutch 
recreational drug testing service, DIMS.68 The testing revealed that where adulterated 
or counterfeited ‘ecstasy’ had been handed in, a much greater proportion of users had 
complained of adverse effects. Products containing MDMA alone (at widely varying 
doses) were reported to have been associated with adverse effects 8% of the time 
and desired effects 74% of the time. Adverse effects reported from tablets containing 
MDMA included nausea (most common), headache, hallucinations, dizziness, ‘allergic 
reactions’ (note, however, that this term may not have been used by users in its 
medical sense) and, more rarely, palpitations, hyperthermic seizures, agitation and 
abdominal cramps.68
In addition to unwanted acute side-effects, MDMA may have long-lasting effects. 
Users have described ‘mid-week blues’ appearing three to five days after the use 
of ecstasy. These ‘blues’ appear to increase in intensity and incidence120 as users 
persist with the drug.119 Novice users may suffer fatigue, depressed mood and 
decreased appetite in the days after use. The majority of experienced users have 
experienced additional symptoms, such as nightmares and difficulty with memory 
and concentration.119 The subacute effects are associated with depleted serotonin, 
so the worsening effects in experienced users,83 especially when not associated with 
higher doses,119 may indicate chronic serotonergic dysfunction, with heightening 
sensitivity to depletion.121 Depressed mood following use is not universally found 
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after administration of MDMA and other entactogens in a therapeutic or research 
setting, and a positive mood change may even occur, as seen in a study with MDEA,3 
suggesting that the combined effect of the drug and environmental and behavioural 
stressors in typical use is important.122
One study of Dutch ‘ravers’, including 103 women, suggested that females may suffer 
a greater incidence of adverse effects, such as nausea, headache, dizziness and feeling 
faint.77
PMA and PMMA seem to have pronounced unwanted effects. The Dutch testing 
service found that tablets containing MDMA adulterated with PMMA had caused 
adverse effects in the majority of users (56% vs. 8% for MDMA-only tablets).68 There 
is limited evidence on the detail, but self-experimentation by Shulgin and Shulgin 
et al. found that PMA (called 4-MA in their book) produced a sudden robust rise in 
blood pressure at 60 mg, and a feeling of ‘druggedness’ rather than a ‘high’ at 70 
mg.123 PMMA was not liked either, as it produced tachycardia, eye-muscle twitch and 
compulsive yawning, and no enjoyable subjective effects.124 The relative lack of desired 
ecstasy-like effects combined with a slow onset is thought to lead to users believing 
they have taken weaker ecstasy, taking more and suffering greater toxicity.118
10.10. Mortality
In England and Wales, MDMA or ecstasy was mentioned on the death certificate in 
43 cases in 2013,125 representing a steep year-on-year rise from a recent low of 8 in 
2010, but a fall from a peak of 58 in 2005. There have been concerns about the recent 
availability of some ‘super-strength’ formulations, with reports of MDMA content 
2–2.5 times higher than the ‘standard’ dose.126
PMA and PMMA have been associated with a significant number of deaths. Compared 
with MDMA, they appear to have a high potential to cause life-threatening toxicity.47
The emergence of PMA47 and PMMA44 on the ecstasy market internationally dates as 
far back as 1973, when PMA appeared in Canada, leading to fatalities.127 In the UK, the 
number of PMA-associated deaths was 1 in 2011 but then 20 in 2012. In 2013, PMA 
or PMMA was mentioned on 29 death certificates in total, on 14 as the sole drug and 
on 2 with alcohol.125 PMA-related deaths in the UK at first seemed to be concentrated 
in Scotland, but more recently clusters have also been reported in Suffolk and eastern 
England more generally.128 
Deaths in England and Wales related to other NPS are not listed separately, but several 
fatalities associated with substances with entactogenic effects (e.g. MDAI,56 5-APB 
and 6-APB17) have been reported from the UK and internationally in recent years. 
10.11. Acute harms
A minority of users of ecstasy will present to hospitals from ‘raves’129 or nightclubs.130 
In a retrospective review of patients from nightclubs attending a hospital emergency 
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department between 1997 and 1998, ecstasy was the second most common drug 
cause of presentation, after alcohol.131
There is no clear fatal blood concentration level of MDMA. One study showed that 
the levels recorded at autopsy in 13 deaths by ecstasy toxicity alone overlapped 
considerably with MDMA levels recorded from 24 cases where the drug was detected 
post-mortem but trauma was the cause of death.132
There are difficulties in disaggregating the harmful effects specific to MDMA toxicity 
from the confounding effects of analogues, co-intoxicants and environmental and 
individual factors.133 It is not yet clear how much of the overall ecstasy-related harm 
is attributable to the toxicity of MDMA in isolation.23
As with other club drugs, mixed intoxications (from deliberate poly-drug use, alcohol 
or from ecstasy adulteration) are typical in general use and in presentations to acute 
clinical settings.130 Poly-drug use appears to be associated with life-threatening 
outcomes at lower blood concentrations, as shown by a study which reported a mean 
post-mortem MDMA blood concentration of 2.90 mg/l in 22 ecstasy poly-drug deaths, 
whereas it was 8.43 mg/l in 13 cases where only MDMA was found.130
There is evidence that some adverse side-effects may be gender-specific. A study 
reported that women experienced more intense psychological effects, while men 
showed a greater increase in physiological measures, particularly systolic blood 
pressure. Although body weight may play a part, it also appears that there are 
pharmaco kinetic and/or pharmacodynamic differences between genders.134 Adverse 
effects may be dose-dependent as well as gender-specific. In the analysis of clinical 
studies by Lietchi et al., increasing dose was correlated with greater self-reporting of 
hallucinogen-like perceptual effects, in women in particular, and with greater reported 
dysphoric states in women alone. However, increasing dose was not associated with 
increases in measures of desired effects.134 
10.11.1. Features of acute ecstasy toxicity
Table 10.4 provides information on acute MDMA toxicity. In addition, MDMA (as well 
as NPS such as PMA and PMMA) causes severe serotonin syndrome and sympatho-
mimetic effects. Death can follow sudden collapse and cardiac arrest, or can result 
from disseminated intravascular coagulation, protracted seizures and multiple organ 
failure. Many of these result from extreme hyperthermia.
When acute toxicity has occurred following the use of other NPS, patterns of harms 
are similar to the broad spectrum of acute harm associated with MDMA and are 
described below.18,47,135 However, the severity of symptoms may tend towards the 
higher or lower end of the spectrum seen with MDMA. 
PMA and PMMA are particularly associated with severe and life-threatening symptoms, 
such as seizures and coma.23,45 A study from Norway, for example, reported 12 fatalities 
and 22 recoveries from a series PMMA intoxications.44
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Table 10.4. Features of acute ecstasy toxicity
Reported effects associated with ‘ecstasy’ or MDMA Other NPS with similar reported effects
CNS, neurobehavioural and psychiatric
Dilated pupils, mydriasis136 Common104,130 bk-MDMA (methylone),  
bk-MBDB (butylone),7 5-APB, 6-APB97 
Feeling unwell/weak/dizzy Common104
Restlessness Common74 MDEA,3 PMA/PMMA137
Nystagmus bk-MDMA (methylone),13 4-MTA,20 PMA/
PMMA45
Euphoria bk-MDMA (methylone),  
bk-MBDB (butylone)7
Anxiety136 5-APB, 6-APB,138 MDEA3
Panic104 MDEA3
Agitation136 Common74,104,129 6-APB,139 MDEA140
Disorientation/confusion136 Common74,104 Bk-MDMA (methylone),13 4-MTA20
Psychosis136 6-APB,139 MDEA3
Paranoid ideation, delusions136 6-APB,139 MDEA3
Delirium PMA/PMMA141
Sleepiness PMA/PMMA141
Collapse, loss of consciousness Common74,104 PMA/PMMA44,137
Self-injury 6-APB139
Convulsions, seizures136 Common129 bk-MDMA (methylone), bk-MBDB 
(butylone),7 4-MTA,49 PMA/PMMA137,141 
Amnesia (one case without analytic confirmation142) 4-MTA20
Hallucinations136 4-MTA,48 MDEA,3,140 PMA/PMMA45
Coma74 bk-MDMA (methylone), bk-MBDB 
(mutylone),7 PMA/PMMA141
Trism, bruxism,143 increase in jaw/facial tension Bk-MDMA (methylone),13 MDEA,3 PMA/
PMMA45
Thirst104 4-MTA20
Headache136 Common74,104
Brian oedema74
Cardiovascular effects
Tachycardia Very common104,129,130,144 5-APB, 6-APB,97,138 bk-MDMA (methylone), 
bk-MBDB (butylone),7 MDEA,3 PMA/PMMA45
Hyperthermia Common74,104 bk-MDMA (methylone), bk-MBDB 
(butylone),7 4-MTA,20,49 MDEA,140 PMA/
PMMA44,45 
QT prolongation145,146 5-APB, 6-APB138
Palpitations104 5-APB, 6-APB,97 MDEA3
Hypertension Common74,104) bk-MDMA (methylone), bk-MBDB 
(butylone),7 5-APB, 6-APB,97,138 PMA/
PMMA45
Disseminated intravascular coagulation (DIC)104 bk-MDMA (methylone), bk-MBDB 
(butylone),7 MDEA,135,140 PMA/PMMA137
Arrhythmias147 (atrial fibrillation148) MDEA3
Myocardial infarction149
Cyanosis secondary to methaemoglobinaemia, one 
report150
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Gastrointestinal effects
Nausea, vomiting104 bk-MDMA (methylone),13 4-MTA,20,49 
MDEA,3 PMA/PMMA137
Stomach cramps 4-MTA49
Dry mouth MDEA3
Respiratory effects
Tachypnoea130 bk-MDMA (methylone), bk-MBDB 
(butylone),7 MDEA ‘hyperventilation’3
Pneumomediastenum, causing subcutaneous 
crepitation,151 emphysema with neck/chest 
swelling152,153 (3 reports)
Shortness of breath, dyspnoea, breathing 
difficulty104,151,153 
4-MTA,49 MDEA140
Chest pain104,151 
Respiratory failure, acute respiratory distress MDEA,3 PMA/PMMA44
Musculoskeletal effects
Rhabdomyolysis74 bk-MDMA (methylone),13 MDEA,140 PMA/
PMMA137
Hyperreflexia bk-MDMA (methylone), bk-MBDB 
(butylone)7
Shivering105, 130 bk-MDMA (methylone), bk-MBDB 
(butylone),7 5-APB, 6-APB,97 4-MTA,20,48
Shaking Common74 4-MTA48,49 
Tremor104,136 bk-MDMA (methylone), bk-MBDB 
(butylone),7 5-APB, 6-APB97
Muscle spasms MDEA,140 PMA/PMMA45
Myoclonus104 bk-MDMA (methylone), bk-MBDB 
(butylone)7
Increased muscle tone, muscle rigidity Bk-MDMA (methylone), bk-MBDB 
(butylone),7 PMA/PMMA45
Inability to stand 4-MTA,49 MDEA140
Collapse 4-MTA49
Hyperactivity (‘hrashing around’) PMA,127,154 4-MTA155
Other effects
Metabolic acidosis bk-MDMA (,ethylone)156
Sweating, diaphoresis, bk-MDMA (methylone), bk-MBDB 
(butylone),7 5-APB, 6-APB,97 4-MTA,20,48,49 
MDEA140
Fever 5-APB, 6-APB97
Foaming at the mouth 4-MTA,49 MDEA140
Acute kidney injury/ acute kidney failure157
Data from the National Poisons Information Service (NIPS) provides some 
information about harms in the UK. In 2012/13, among telephone enquiries relating 
to psychoactive illicit drugs, those about MDMA were the second highest in number 
(131), after cocaine, and in terms of the number of times the NIPS’s TOXBASE® website 
was accessed (4778), it came third, after cocaine and mephedrone.158
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The majority of presentations are managed in hospital emergency departments; they 
are mild or moderate in severity and self-limiting.23,130 In a recent Australian study, the 
median duration of stay in the emergency department was 3 hours.75
Studies from accident and emergency units show that the most common presenta-
tions after consuming ecstasy include collapse and/or loss of consciousness, as well as 
‘feeling ‘unwell’, ‘strange’, ‘weak’ or ‘dizzy’; nausea, vomiting and palpitations are also 
common.23,130 Most of those presenting have come from a club, rave or party; among 
a series of presentations to a London emergency department, 67% had co-used other 
substances.104,130 Similar and higher rates of co-intoxication were found in more recent 
reviews internationally, with alcohol, amphetamines and cocaine being common co-
intoxicants.23,104
Severe acute harm following use of ecstasy usually falls into the categories described 
below,105,159 although the clinical picture is often complicated by concomitant drug 
use,104 and a single case may have symptoms from more than one category:
•	hyperthermia/hyperpyrexia and secondary manifestations;
•	serotonin syndrome (a cause of hyperthermia105);
•	dilutional hyponatraemia and hyponatraemic encephalopathy. Hyponatraemia is 
particularly a cause of ecstasy fatalities in women;129 
•	acute psychiatric presentations, including symptoms of anxiety, panic or psychosis;
•	other isolated physiological syndromes, including cardiac events, liver failure and 
pneumomediastenum.
It has been suggested that hypoglycaemia, hyperkalaemia160 and QRS elongation47 
may be features specific to PMA poisoning. However, all these signs have a been 
observed occasionally in cases of severe ecstasy toxicity not linked to PMA.161–163 
10.11.2. Hyperpyrexia/hyperthermia and consequences
Ecstasy use can promote the development of hyperthermia in two principal ways:105 
by adding to heat load and by reducing heat dissipation. It promotes a hyper metabolic 
state pharmacologically,162 and behaviourally, often leading to muscular exertion 
through hours of dancing.104 Moreover, hot, overcrowded dance floors are a typical 
setting for its use.164,165 Heat dissipation can be impaired by peripheral vasoconstriction, 
at least in rats,166 or by dehydration. Many ecstasy-using dancers who suffer adverse 
effects display typical symptoms of heat illness, such as feeling unwell and collapsing 
in an exhausted state.104,130,165 Some will move to a ‘chill-out’ room to recover at the 
dance venue, or be treated on site. Some will present to hospital, mostly with self-
limiting symptoms, requiring minimal intervention beyond correcting dehydration 
and allowing rest. However, more severe symptoms have been reported.130
The overheating associated with ecstasy use can produce harms across a spectrum 
of severity; a minority of patients present with a severe hyperpyrexia that will not 
resolve spontaneously with rest in a cooler environment. This has been attributed 
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to an idiosyncratic drug reaction causing a pharmacologically mediated central and 
peripheral thermogenesis.23,167
Hyperpyrexia associated with MDMA can appear across a broad dosage range.23 A 
vicious cycle of positive feedback from agitation, clonus and seizures can all contribute 
to heat generation. The hyperpyrexia and serotonin syndrome seen in association 
with MDMA and related serotonergic drugs are clinically distinct from malignant 
hyperthermia and neuroleptic malignant syndrome.105,168,169
Hyperpyrexia is one of the predominant life-threatening adverse reactions to ecstasy 
and is the underlying cause of many acute ecstasy-related deaths. It is also a cause 
of severe chronic harm resulting from secondary complications such as liver failure 
and brain damage.23,167 Compartment syndrome has been reported as a complication 
at least twice,170 and was in one further case associated with ecstasy injection in the 
absence of hyperpyrexia.171 
There may be considerable overlap between serotonin syndrome and this form of 
acute ecstasy-related toxicity. Serotonin syndrome can be a trigger for uncontrolled 
hyperpyrexia, but hyperpyrexia can also occur without serotonin syndrome.105 Acute 
kidney injury occurs as a consequence of the myoglobinurea seen with rhabdo-
myolysis, but may be compounded by a number of factors, which include a direct 
toxic effect of the drug in the kidney and volume depletion from dehydration.157
10.11.3. Serotonin syndrome/serotonin toxicity
MDMA is a powerful releaser of serotonin and as such is linked to serotonin syndrome. 
Further information on the features and management of serotonin toxicity can be 
found in Chapter 7. 
Ecstasy can be a cause of serotonin syndrome alone, or in combination with other 
factors that increase serotonin to toxic levels, including many recreational and 
pharmaceutical drugs,172 such as MAOIs, SSRIs, tricyclics, tramadol and linezolid (see 
TOXBASE®). In one Australian study, some ecstasy users reported deliberately taking 
these and other pharmaceuticals to magnify the effects of MDMA.173
The risks of serotonin syndrome associated with MDMA are boosted by several 
classes of serotonergic drug.53,174 A recent fatality was associated with 6-APB and 
mirtazapine.22 Some NPS entactogens inhibit monoamine oxidase. 
PMA/PMMA poses a particular threat of severe serotonin toxicity.44 It has been 
suggested that it may simultaneously promote serotonin toxicity in several ways – by 
causing serotonin release, inhibiting reuptake and inhibiting CYP2D6 metabolism.45 
Symptoms commonly seen in reports of severe PMA and PMMA toxicity are consistent 
with serotonin syndrome and hyperthermia. Serotonergic and sympathomimetic 
features may include bruxism, agitation, confusion, convulsions, rhabdomyolysis, 
coagulopathy, organ failure, coma and death.47,160,175 One case series of eight fatal 
PMMA intoxications showed different presentations depending on dose; those with 
lower blood concentrations of the drug had delirious hypertalkativity and convulsions, 
but higher blood concentrations were associated with drowsiness and coma,141 
symptoms consistent with severe serotonin syndrome.
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10.11.4. Dilutional hyponatraemia and 
hyponatraemic encephalopathy
Ecstasy has been described as causing a ‘perfect storm’ of effects that can precipitate 
dilutional hyponatraemia. Women make up more than 85% of symptomatic cases 
in the literature, despite more males being users of MDMA.129,157,176 MDMA has the 
potential to directly affect water balance via a syndrome of inappropriate anti-diuretic 
hormone (SIADH) secretion, at least in women.176
The drug and the typical contexts of use promote exertion and sweating (resulting 
in loss of sodium). Hyponataemia can occur when these effects are combined with 
the consumption of excessive quantities of low-electrolyte fluids such as beer and 
water.143 The psychoactive effects of ecstasy may encourage this, perhaps promoting 
obsessional repetitive behaviour, and masking awareness of emerging symptoms of 
hyponatraemia, such as confusion.23,177 Furthermore, mistaken, or misunderstood, 
harm-reduction information has allegedly led to excessive drinking of water to avoid 
dehydration and heatstroke.177
Mild, asymptomatic hyponatraemia has recently been shown to be a common effect 
of ecstasy use in a typical electronic dance music context. Women are more vulnerable 
than men, as they are more likely to have lower serum sodium levels before MDMA 
use. They are more likely to become mildly hyponatraemic while using, more likely 
to develop symptomatic hyponatraemic encephalopathy, and more likely to die as 
a result.23 Fatalities are almost exclusively in women under 21, although men have 
suffered hyponatraemia so the possibility of male cases should not be ignored.23
In contrast to other acute syndromes caused by ecstasy, dilutional hyponatraemia 
often follows a uniform course, with symptoms mostly resulting from the progression 
of cerebral swelling. Initial headache, vomiting and disturbed mental state are followed 
by seizures, drowsiness, disorientation and muteness, progressing to coma, hypoxia 
and death, often due to tentorial herniation.23 Patients may already be comatosed 
upon admission to hospital.178
Relatively low doses, including single tablets, are not unusual in cases of hypo-
natraemia.23 Also, the excess water intake required to cause symptomatic 
hyponatraemia, in the context of ecstasy intoxication, is not extreme; 1700 ml and 
1200 ml have been cited in case reports;157,178 3500 ml was drunk in a case related 
to bk-MDMA (methylone) and ethcathinone.13 Genetic variation in the function of 
alleles coding for the CYP2D6 enzyme and the COMT enzyme may predispose some 
individuals to ecstasy-induced hyponatraemia. 
10.11.5. Acute psychiatric presentations 
Anxiety and panic are common presentations among users seeking medical help.23 
Ecstasy is an ATS, and is widely used, yet evidence linking it to psychosis is limited to 
a relatively small number of case reports and case series.23 Collectively, these suggest 
that ecstasy does occasionally act as a stressor that precipitates acute psychosis, but 
at a much lower rate than amphetamine, its molecular relative.136
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Psychotic symptoms can result from poly-drug use involving ecstasy or, on occasion, 
from ecstasy alone, particularly in vulnerable individuals.23,136 No single characteristic 
pattern emerges from the evidence base; putative cases include previously healthy 
people experiencing sudden onset of psychosis after taking a single pill,179 as well 
as chronic poly-drug users with complex vulnerabilities taking up to four tablets of 
ecstasy daily before admission with acute symptoms.79 As with psychosis linked to 
other drugs, the prognosis varies from rapid resolution within hours (perhaps in 
those with a low intrinsic propensity to psychosis) to months or years as an inpatient 
(perhaps in those with a high vulnerability).23,180
The evidence base includes several cases where there is no toxicological evidence of 
ecstasy consumption29,179 and, in most cases, deliberate or unintended co-intoxication 
with other drugs linked to psychosis cannot be excluded as a factor.79 It remains 
unclear whether the tendency for ATS to precipitate psychosis is more a direct phar-
macological action or toxicity, or more an indirect product of severe psychological 
stress, such as that caused by sleep deprivation and bingeing behaviour.180,181 In 
either case, ecstasy is an exception among ATS, with lesser effects on dopamine and 
use typically confined to weekends, rather than multi-day binges, as may occur with 
methamphetamine and cocaine. Two cases of ecstasy-induced psychosis occurred in 
individuals who were ‘spiked’ with the drug without their knowledge and consent.23,181 
This may indicate a substantial influence of psychological ‘set’ in determining the 
response to intoxication. A case control study in a subacute population of males 
undergoing treatment for their first-episode psychosis found that those who had a 
recent history of ecstasy use showed significantly different symptoms from those 
who had not used ecstasy, including shorter hospitalisation, less bluntening of affect 
but increased hostility.182
10.11.6 Suicidal ideation and suicide
Ecstasy users have an increased risk of suicide attempts,183 but it is uncertain how 
much of this association is causal, how much may relate to acute use and how 
much to chronic effects. Recent ecstasy use has been linked to suicidal thoughts 
and behaviour, in some case reports in the context of acute psychosis as described 
above, or subacutely, possibly triggered by the ecstasy ‘come-down’ (for example one 
case followed a three-day session of injecting ecstasy).23 Ecstasy overdose has been 
employed as a mechanism of suicide or suicide attempt,184,185,186 as has bk-MDMA 
(butylone).187
10.11.7. Acute and subacute cardiac events
Ecstasy alone, and in mixed intoxication, has been associated with acute cardiac events, 
including myocardial ischaemia and infarction.23,188 It can also unmask underlying 
cardiac dysfunction. Myocardial infarction probably results from coronary artery 
spasms, similar to those observed in cocaine users. A series of three cases of acute 
coronary syndrome and ST elevation myocardial infarction (STEMI) demonstrates 
that, as with cocaine-induced heart problems, they may emerge long after plasma 
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drug concentrations have peaked.188 Hyperkalaemia could also contribute to 
cardiac arrhythmias. There is a single case report of severe dilated cardiomyopathy 
accompanying hepatic damage.189
Cardiac arrests occasionally occur without being precipitated by hyperpyrexia or 
serotonin syndrome.104 When patients present with chest pain and other symptoms, 
concomitant use of other drugs should be considered, especially cocaine, which is well 
known for provoking cardiac dysfunction.23
10.11.8. Pulmonary harms: pneumothorax, pneumomediastenum
One study has reported that ecstasy has been associated (through uncertain 
mechanisms) with at least 23 cases of pneumomediastenum,152 and a smaller number 
of pneumothorax cases are also reported in the systematic review by Rogers et al.23 
Patients usually present with pain of the chest and neck and shortness of breath, 
but subcutaneous emphysema and resultant swelling may also be apparent.152 
Sometimes presentations may be delayed, days after consumption. It is hypothesised 
that the muscle tension caused by ecstasy, combined with exertion from dancing, 
jumping or sex,153,190 could lead to air pressure against a closed glottis, similar to the 
Valsalva manoeuvre, raising alveolar pressures and causing ruptures.152 This can result 
in air being forced out into spaces in the mediastinum.191 One case with an alternative 
mechanism featured a tear in the oesophagus, allowing air into the mediastinum.105
10.11.9. Intracranial haemorrhage 
Ecstasy use has been associated with intracranial haemorrhage, even in the apparent 
absence of co-intoxicants.23,192 Pre-existing aneurysms, or arteriovenous malforma-
tions, may rupture as a result of the acute surge in blood pressure caused by ecstasy, 
similar to the mechanisms seen with cocaine.      
10.11.10. Liver failure
Ecstasy may cause liver failure in two ways. According to a review of the evidence, 
one group develop acute liver failure secondary to a severe hyperthermic reaction 
to ecstasy. The other group appear to suffer, isolated hepatotoxicity without any 
hyperthermia. This is generally a subacute effect which may emerge over the days 
following use, in contrast to the rapid onset of organ failure in the hyperthermic 
patients.23 Despite its rarity, this constitutes one of the more common causes of 
liver failure in this young age group. Patients may present in a critical condition, 
with hepatic encephalopathy, and some will require transplantation.193 It has been 
suggested that ecstasy may cause a greater amount of ‘silent’ liver damage than is 
recognised.23
10.11.11. Diabetic ketoacidosis
A small number of case reports demonstrate that people with diabetes can suffer 
ketoacidosis and associated symptoms following ecstasy use combined with 
exertion.194,195
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10.11.12. Poly-drug use and drug interactions
As discussed above, MDMA is commonly used with other psychoactive drugs and this 
can increase harm. For example, cocaine co-ingested with ecstasy seems to increase 
the risk of severe anxiety. In an audit of 52 acute ecstasy-related admissions, 13 with 
co-use of cocaine, 4 of the 7 patients who suffered panic reactions were among the 13 
cocaine users.104 When MDMA is co-ingested with stimulants in general, the potential 
for toxicity is likely to be raised.196 Co-intoxication with caffeine increases the risk of 
hyperpyrexia in rats.197 PMMA and PMA produce greater toxicity in combination with 
stimulants.45
Poly-drug use commonly confuses the clinical picture of ecstasy intoxication, and 
can lead to paradoxical features that are not those expected from intoxication with 
ecstasy alone. In a Swiss emergency department audit, hypothermia was, paradoxi-
cally, one of the most commonly recorded features, and brachycardia, coma, pupil 
constriction and hypotension were also noted.104 These were associated with the 
co-use of substances, including GHB and opiates.23 Consuming alcohol with ecstasy is 
associated with a higher rate of l harm. Concomitant alcohol use was implicated in 75% 
of cases of ecstasy-related presentations in an Australian emergency department.75
In terms of drug interactions, MDMA and related drugs are substrates and inhibitors 
of CYP2D6, so combining them with other drugs or pharmaceuticals which compete 
for, inhibit or block CYP2D6 may cause greater unwanted effects or toxicity. For 
example, people taking the antiretroviral drug ritonavir are likely to be at particular 
danger from ecstasy toxicity.198 Similar reactions may be possible with any drug 
sharing ritonavir’s capacity to compete with MDMA as a substrate of CYP2D6 and 
inhibit the enzyme. Other drugs linked to apparent cases of adverse interactions 
include dextromethorphan (DXM), fluoxetine, paroxetine and moclobemide.18,43 Drugs 
which could theoretically cause similar problems include haloperidol, thioridazine and 
quinidine.18 CYP3A4 is also involved in the metabolism of MDMA and its derivatives, 
and co-ingestion of ritonavir has been linked with several cases of toxicity.18 There 
may be risks associated with many other substances which affect CYP3A4.18,199 
Importantly, MDMA is metabolised by CYP2D6 and inhibitors of this metabolic pathway 
may therefore increase its level and consequently toxicity. Among the antiretrovirals, 
the new booster cobicistat (used to optimise concentrations of the integrase inhibitor 
elvitegravir or of the protease inhibitors atazanavir and darunavir) has been reported 
to be a CYP2D6 inhbitor.200,201 While ritonavir at low doses (as administered to boost 
HIV protease inhbitors) is not a CYP2D6 inhibitor but is a strong CYP3A4 inhbitor, 
its role may be important if CYP2D6 metabolisers use CYP3A4 as a compensative 
metabolic pathway of MDMA, as the latter would be inhibited and lead to increase 
concentrations of MDMA and toxicity. This would add to the already discussed wide 
inter-individual variability in responses to MDMA.
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10.12. Clinical management of acute toxicity
Admissions following ecstasy use often occur at peak times and therefore put pressure 
on resources.75 PMA and PMMA may account for many cases of severe ‘ecstasy’ toxicity 
encountered in an emergency department.44,47 
In an Australian emergency department, 14% of people presenting to hospital after 
ecstasy consumption required admission.75 The most common interventions required 
are clinical monitoring, observation and reassurance, and symptomatic treatment, 
including fluids.104 The average duration of hospital stay reported by the Australian 
study was three hours.75 TOXBASE® recommends observation of asymptomatic 
patients for at least four hours.
Dehydration should be addressed. Following ecstasy-related presentation to a 
hospital emergency department, intravenous fluids were administered to 31% of 
patients in a UK study,130 and to 71% of cases in a Swiss study,104 but it is important to 
note that symptoms following ecstasy use range from severe dehydration to severe 
hyponatraemia; the latter patients require fluid restriction, so it is dangerous to give 
hypotonic fluids or normal saline to patients prior to proper assessment.143,157
There is no evidence to support gastric decontamination with activated charcoal, but 
it may be appropriate for cases of presentation within 1 hour of ingestion. Gastric 
lavage was used in a case with a positive outcome following an attempted suicide 
with 30 tablets.184 
10.12.1. Hyperpyrexia and hyperthermia
Patients presenting with body temperatures above 39oC need aggressive cooling 
measures, such as icebaths or internal cooling, and benzodiazepine sedation. It has 
been suggested that dantrolene may be considered when hyperthermia persists. 
However, this has been contested by some. No clinical trials have been conducted but 
a review has reported better survival rates for patients with temperatures above 40o C 
who received dantrolene, with minimal adverse effects.202 However, a 2011 evaluation 
of options in MDMA-induced hyperthermia recommended against the use dantrolene 
and antipyretics.203
For up-to-date guidance on the management of ecstasy/MDMA acute toxicity, it is recommended 
that information be sought from the National Poisons Information Service (NPIS), specifically 
the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/M-Products/MDMA2/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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10.12.2. Acute psychiatric presentations 
The most of the common features observed in acute patients can be at least partially 
attributable to anxiety, agitation and panic (e.g. dizziness, palpitations, hyperthermia, 
hypertension). Some features (e.g. tachycardia) act as internal stimuli to anxiety and 
panic attacks through positive feedback. TOXBASE® notes that controlling agitation 
with benzodiazepines may relieve hypertension.
Many cases are resolved in a preclinical setting, or upon reassurance during the initial 
assessment. Agitation, anxiety and panic can be managed as they would be in the 
absence of a drug trigger, but cardiac monitoring is a higher priority.130 Reassuring 
patients that they are not likely to be in physical danger may be sufficient, but benzo-
diazepines are the first-line pharmacological treatment. One study reported that they 
were administered to a quarter of all patients presenting following ecstasy use at a 
Swiss emergency department.104,105 Some suggest that haloperidol is contraindicated 
as a second-line option, because of possible dangerous interactions with MDMA and 
related drugs.18 
10.13. Harms associated with chronic use
While the association between ecstasy consumption and several types of acute harm 
is relatively clear, current understanding of the chronic harm caused by ecstasy use is 
limited, due to incomplete and disputed evidence.
Chronic use of ecstasy has been linked to serotonergic neurological damage and 
dysfunction, which some researchers have suggested may be responsible for a broad 
range of neuropsychiatric symptoms and cognitive impairments. A meta-analysis 
shows these to be predominantly small, subclinical effects.23 Significant trends 
indicating impairment are typically not identified in samples of ecstasy users who 
have taken the drug on fewer than 50 occasions.204 
Other harmful chronic consequences that have been attributed to use of ecstasy 
include cardiovascular damage, particularly serotonergic valvular heart disease. 
Evidence of long-term effects of NPS use is not available, and so the potential for 
each of these to cause harm remains unknown. Chronic use of an NPS product (called 
‘Pink Panthers’) containing MDAI and 2-AI (the latter of which appears to be more 
amphetamine-like than MDMA-like) has been linked to one case of cyanosis caused by 
methemoglobinaemia. Such effects may also result from chronic use of the many NPS 
products containing benzocaine as a cutting agent.205
10.13.1. Neurotoxicity
Differences in the serotonergic function of ecstasy users, compared with controls, 
have been observed in neuroimaging studies.206–211 Observed differences in markers 
of serotonergic function have been interpreted as indicating the degeneration and 
loss of serotonergic neurons and their terminals, i.e. ‘neurotoxicity’.209 Correlations 
have been demonstrated between presumed markers of toxicity seen in users and 
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functional deficits in memory.212,213 This supports the hypothesis that serotonergic 
neurotoxicity is the cause of the cognitive deficits and worsened neuropsychiatric 
status of ecstasy users.25
The idea that MDMA is neurotoxic in typical human users is supported by some animal 
research,206 but some experts do not consider the evidence to be conclusive.27,214 Some 
have argued that the observations in such studies may be consistent with changes and 
loss of serotonergic markers, without loss of the neurons themselves (i.e. serotonergic 
dysfunction occurs but this may or may not amount to ‘neurotoxicity’).215,216 Other 
authors highlight limitations in the predominantly retrospective and non-randomised 
studies supposedly indicative of ‘neurotoxicity’, claiming that current evidence is 
insufficient to exclude non-causal explanations,214 such as pre-existing lower levels 
of serotonergic markers in the brains of ecstasy users.27,217 While poly-drug use in 
virtually all ecstasy users has been cited as a confounding factor, recent investigations 
comparing ecstasy users with LSD users218 and other poly-drug users219 add weight to 
the evidence for ecstasy-specific neurotoxicity.
High lifetime intake may not necessarily be required for neurotoxicity to occur. One 
prospective study found evidence indicative of some brain changes in new users with 
an average lifetime intake of only six tablets. These changes did not, though, include 
losses in serotonin transporter density, which is the marker of toxicity most commonly 
observed. The authors concluded that it is possible that MDMA is neurotoxic even in 
small quantities.76
Studies have found evidence consistent with some recovery220 and adaptation of the 
altered serotonin system,211 but, conversely, other results indicate the persistence of 
serotonergic dysfunction following cessation of ecstasy use.207
The degree of any lasting dysfunction or neurotoxicity caused by MDMA is thought to 
be a function of the bioenergetic stress undergone during acute intoxication.221 This 
theory has led to the hypothesis that there are mediating factors for the bioenergetic 
stress experienced, and thus the vulnerability or resilience an individual may have to 
neurotoxicity, beyond the MDMA dose per session and frequency of use. These factors 
include: ambient temperature and level of exertion (increases of each may promote 
neurotoxicity), poly-drug use (with stimulants likely to promote neurotoxicity222,223) 
and others ranging from users’ genetics and nutritional status to how well rested 
they are.224 
A recent study suggests that people’s age when they first used ecstasy may be strongly 
linked to brain changes brought about by ecstasy, with those first exposed while their 
brains were still developing showing greater apparent deficits. The authors suggest 
that these age-related differences may reflect differences in the maturation stage of 
the 5-HT projection fields at the time of first exposure and enhanced outgrowth of 
the 5-HT system due to 5-HT’s neurotrophic effects.225
Some entactogenic NPS, for example 4-MTA,49 have been referred to in the literature 
as ‘non-neurotoxic’ analogues of MDMA,226,227 and some were developed for this 
purpose.228 However, these assessments were based on pre-clinical evidence, and 
evidence from long-term human use is not available to confirm that these drugs do 
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not cause serotonergic neurotoxicity. Animal and in vitro evidence suggests that 
among MDMA-like drugs, some are likely to be more neurotoxic (e.g. MDA) and some 
less neurotoxic (e.g. MDEA) than MDMA.18
10.13.2. Cognitive deficits
A number of studies have compared the performance of community samples of 
ecstasy users (current or past) against that of matched controls on many standard 
tests of cognitive performance. Weaker performance in certain domains has been 
identified in the ecstasy users, with the greatest and most consistent effects seen on 
aspects of memory and recall,23 such as verbal memory213 and visual paired associate 
learning.229 
One explanation for the poorer performance of the ecstasy users is typically considered 
to be serotonergic neurotoxicity associated with the drug (see above). However, 
there is no consensus on this,26 with many findings open to alternative, non-causal, 
interpretations, such as confounding cannabis use, or tendencies towards impulsivity 
and boredom leading to both ecstasy use and poorer performance on tests.230
The weaker performance of ecstasy users remains within ‘normal’ limits, according 
to some,230 and deficits appear to be specific to certain domains rather than general, 
with one meta-analysis finding general intelligence unaffected and no impairments 
seen in simple cognitive functions like basic attention and reaction times.23
Deficits in verbal memory have been identified, whereas deficits in executive 
function and visual memory have been identified in some studies but not others.230 
The performance of users typically overlaps substantially with the performance of 
controls, and uncertainty and controversy remain over the clinical significance and 
real-world impact of the apparent deficits identified in these samples.25,27
A relatively high intensity of use may be necessary to produce significant deficits. In 
one study, which excluded anyone with significant poly-drug or alcohol use from the 
ecstasy-user sample, and which used controls who also shared the ‘rave’ lifestyle, no 
marked deficits were found. The authors argued that the confounding influences of 
poly-drug use and lifestyle may lead to overestimation of the harm associated with 
ecstasy.231 However, in response it has been argued that this study was nonetheless 
consistent with the serotonergic neurotoxicity of ecstasy causing cognitive deficits, 
since it was not highly powered enough (with fewer than 50 users) to show subtle 
deficits associated with an average lifetime history of use.204
10.13.3. Psychiatric symptoms and harms 
Community samples of current or past ecstasy users have been compared with 
matched controls on measures of psychiatric and psychological health. A study 
has shown poorer results among ecstasy users on several of these indices.232 
MDMA acutely increases cortisol levels, especially when the bioenergetic stress is 
magnified by behaviour and environment, but recent studies have also associated 
ecstasy use with more chronic increases in cortisol and related dysfunction of the 
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hypothalamic–pituitary–adrenal axis. This is in turn has been linked in chronic users to 
symptoms of distress, anxiety, aggression233 and impaired coping.234,235
A meta-analysis in 2005 of 25 studies found a small but significant link between ecstasy 
use and depressive symptoms. However, the authors noted several methodological 
limitations and showed that publication bias may have occurred. They concluded 
that any effect of ecstasy on depression is unlikely to be clinically significant.236 More 
recently, in a sample of 3880 disadvantaged Canadian adolescents, those who self-re-
ported ecstasy use were more likely to have elevated depression symptoms one year 
later (odds ratio 1.5) and those who used MDMA with methamphetamine had even 
higher rates (odd ratio 1.9).237 However, studies have shown that circumstances such 
as a deprived home environment can provide a partial or even complete explanation 
for the higher incidence of depressive symptoms in ecstasy users.238,239
A US study using a national sample reported that suicide risk appears to be elevated 
among adolescent users of ecstasy, almost twice that of users of other illicit drugs 
and nine times the risk among non-users.183
A number of factors may be associated with long-term harms. A study by Soar et 
al. found that the 57 people who reported their ecstasy use as having caused them 
problems (such as increased depression, somatisation and anxiety) did not differ from 
those who reported no harm in the duration of their use of ecstasy. However, those 
who reported problems also reported higher doses, in a pattern the authors call 
‘binge consumption’, without further defining this.240 
Concomitant use of other drugs is a confounding factor133 that may explain much of 
the apparent heightened prevalence of various markers of psychopathology, such as 
depression and anxiety experiences.241 Cannabis use, for example, has been found to 
mediate this relationship.242 Early onset of cannabis use,239 and tobacco use, have been 
shown to correlate with greater anxiety among ecstasy users, where neither lifetime 
nor recent ecstasy use did.239 However, in one sample of 30 users, the users were not 
more likely than controls to report pre-existing depression or anxiety symptoms.243
The come-down period after ecstasy use is characterised by low mood and serotonin 
depletion, and it is possible that, for people vulnerable to depressive symptoms, this 
could exacerbate symptoms or cause suicidality.23
In an experimental set-up, 12 male ecstasy users performed a laboratory task involving 
monetary rewards. They were more ‘aggressive’ and ‘irritable’ than controls towards 
fictional co-players. It is not possible to exclude personality factors that pre-existed 
ecstasy use, and it is uncertain how this ‘aggression’ would translate to real-world 
face-to-face interactions.233
In addition to this evidence of poorer mental health in samples of ecstasy users, 
mostly relating to subtle, subclinical differences, there is evidence from case reports 
of more profound psychiatric disturbances and disorders in individual users. One 
paper detailed two case studies of severe obsessive-compulsive disorder developing 
in chronic heavy users of ecstasy, leading, in one case, to depression with psychotic 
features, and, in the other, to psychosis.244 The former patient (a 16-year-old female 
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who took four or five tablets per week for a year) was judged to have vulnerabilities 
to mental disorder, but the second patient did not (a 23-year-old male who took one 
or two tablets a week for more than two years). Both cases resolved with treatment. 
The authors conclude that causation cannot be determined, but is suggested by the 
case histories.
10.13.4. Dependence and withdrawal
While ecstasy is generally considered to have some potential for dependence,3 use 
is often self-limiting and focused around weekend activities.3 Reasons suggested for 
the low dependence potential include the relatively long period of recovery after one 
dose.24
It has been argued that although the physiological basis of MDMA dependence is 
relatively weak in comparison with some other drugs, other factors related to the 
behavioural and psychological aspects of reward and dependence may have a 
relatively greater contribution to dependence for ecstasy than for other drugs.245
Users may fulfil dependence criteria,246–251 develop problematic chronic use 
patterns, have concerns about their use and seek treatment.245 Several studies have 
demonstrated some features of dependence among ecstasy users, such as worrying 
about use, thinking use was out of control and finding it difficult abstain.245,247 
A number of studies have shown that approximately one in five users have been found 
to be potentially dependent,73,249,252,253 although studies which carried out detailed 
investigation of withdrawal symptoms have shown higher rates, as much as 43% in a 
US study of adolescents and young adults,248,250 and as high as 64% in a study using 
DSM-IV criteria for amphetamines dependence.253
Some studies have suggested that how ecstasy is used, rather than how often, may 
be of key importance in ecstasy dependence, with ‘binge’ use and higher doses being 
associated with dependence.247 Users who ‘binge’, who use ecstasy more frequently, 
and who experience more social and physical harm are more likely to become 
dependent users.96
Ecstasy ‘craving’ does not tend to follow the pattern typical with other drugs, as a 
symptom of dependence, but instead resembles anticipation of an enjoyed activity, 
typically being low during the week, but rising in the hours before weekend use.90
A withdrawal syndrome with ecstasy has been reported. However, it has been argued 
that the wide between-study variations in the incidence of withdrawal symptoms 
indicate the need for improved distinction between the short- and the long-term 
effects of MDMA in standardised assessment tools, despite recent advances. As with 
other stimulants, the period following acute use is marked by a number of phases: an 
initial dysphoric ‘crash’, followed, in chronic users, by an extended ‘withdrawal’ phase, 
marked by anhedonia and anergia.254 It has been argued that the application by some 
studies of withdrawal criteria related to the ecstasy come-down may have led to 
inflation of estimates of rates of potential dependence and withdrawal.255 While ‘true’ 
withdrawal symptoms lead to users taking more of the drug to relieve them, adverse 
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effects following an episode of ecstasy use have been seen as one reason why heavy 
users sometimes spontaneously quit ecstasy.83
Some animal studies have shown that chronic use can lead to ecstasy acting 
increasingly like an addictive stimulant. If chronic use of MDMA causes significant 
serotonergic damage but little or no dopaminergic damage (as supported by brain 
imaging212), then the dopaminergic effects may become more prominent than the 
serotonergic ones, similar to amphetamines with greater addictive potential.256 This 
is partially supported by user experiences; many report ‘losing the magic’83 of the 
serotonergic effects with overuse and, outside the academic literature, users of drugs 
fora note how, after overuse, MDMA feels more typically amphetamine-like.257
Ecstasy dependence presents unique features.247 In an online survey promoted to 
users of a dance-music website, ecstasy users were more likely than users of cocaine, 
ketamine or mephedrone to endorse three or more DSM-IV criteria, yet reported 
less harm, more pleasure and less desire to seek help than users of these other club 
drugs.246
Ecstasy is rarely reported as an individual’s principal problem drug,247 with 201 people 
presenting to drug treatment services in England (fewer than 0.1%) in 2013/14 
citing ecstasy as the main problem drug they used.84 Although ecstasy is rarely a 
primary problematic drug, users of ecstasy are more likely than other drug users to 
have experienced substance use disorders in the past year involving drugs other than 
ecstasy.258 This was the case for 7 out of 10 ecstasy users in an American population 
sample.258
10.13.5. Sleep problems
A history of ecstasy use has been linked to poorer sleep in some studies but other 
studies have found no differences.23,259,260 Dysfunctional sleep processes may be 
involved in the memory deficits associated with ecstasy use.261
10.13.6. Vascular problems 
The typical surge in blood pressure that ecstasy causes may, over time, damage the 
blood vessels, in particular the walls of aneurysms and arteriovenous malformations.23 
This could lead to haemorrhage.262 Therefore, patients with aneurysms, or any other 
history of vascular disorders, should be strongly advised of the risks from any drug 
with a hypertensive effect.
10.13.7. Heart disease 
A link between heavy, chronic MDMA use and valvular heart disease has been proposed, 
due directly to its serotonergic effects.263,264 Activation of the 5-HT2B receptor in heart 
valves by (now obsolete) serotonergic pharmaceuticals such as fenfluramine and 
ergotamine have been demonstrated to cause cell proliferation, fibrotic thickening 
and valve dysfunction.265 There is some limited evidence that ecstasy may be capable 
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of causing such reactions in chronic, heavy users. A blinded study using echocardiog-
raphy to identify abnormalities reported that MDMA may lead to mild to moderate 
valvular heart disease and valvular strands.264
A 33-year-old male smoker with an exceptionally high level of lifetime ecstasy use 
(several pills per week since the age of 17)266 reported shortness of breath and chest 
pain. He had severe mitral valve disease, with fibrotic thickening of the leaflets and 
resulting severe regurgitation, necessitating a valve replacement. It was suggested 
that the lack of reports of similar cases may be explained by the typically short ‘ecstasy 
career’ of most users, and the potential reversibility of the valve damage.263
In addition to valvular heart disease, chronic ecstasy use has been linked to cardiomyo-
pathy more generally,263 although the evidence remains inconclusive. A retrospective 
analysis of autopsy records shows that the hearts of people who had MDMA in their 
bodies at post-mortem were more likely to have enlarged hearts, consistent with 
myocardial hypertrophy, as seen in users of cocaine and methamphetamine. However, 
this study did not appear to be controlled in a way that could exclude the confounding 
factor of poly-drug use.267 A single case study of dilated cardiomyopathy associated 
with ecstasy has been reported.189
10.14. Management of chronic harms
10.14.1. Treatments for harmful use and dependence 
As with other ATS, the treatment of harmful ecstasy use is primarily psychosocial. No 
specific guidelines for psychosocial intervention have been described and validated for 
chronic ecstasy users, but for general guidance on treatment options see Chapter 2.
In most cases, chronic ecstasy users will be poly-drug users, and existing interventions 
would be unlikely to focus on ecstasy in isolation. For example, an intervention in the 
form of 45–60 minutes of structured motivational discussion was trialled in young 
stimulant users, most of whom had recently used ecstasy and cocaine, and most of 
whom were also regular users of cannabis and alcohol.268 This discussion included 
exploration of the individual’s pattern of use, ‘good’ and ‘bad’ effects of use, plans 
for behaviour change, likely outcomes of this and, for users with no immediate plans 
to change behaviour, reflection on what future scenarios would lead to a change 
(boundary setting).268 In this study, the majority (59%) of participants did report 
making efforts to reduce or cease their stimulant use following the intervention, but 
41% of the control group did as well. Average number of days with ecstasy use in the 
previous 90 days fell from around 18 at baseline to around 8 at 6-month follow-up, 
and average dose fell from more than 2 tablets per session to around 1.5, with no 
significant difference seen between intervention and control groups.268 Both the 
intervention and the control groups participated in baseline self-assessment and 
read health information, so the authors speculate that while there was no additional 
benefit from the intervention, contact with personnel and actions that focus attention 
on substance use may be enough to change behaviour.268 
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Similar results were found in a trial aiming to reduce ecstasy use among Australian 
university students. A 50% reduction in use and a 20% reduction in reported severity 
of harm were recorded 24 weeks after ‘motivational enhancement therapy’, but the 
same changes followed the control condition, a 15-minute information session.269 
Another brief intervention for regular users did not produce significant reductions 
in quantity or frequency of use compared with the control condition (assessment 
only), but did significantly reduce reported symptoms of dependence, and a greater 
proportion (16%) achieved abstinence, although the study was underpowered to 
show whether this was statistically significant.270
It has been noted that ecstasy users may not always accurately assess the harm 
that their drug use may be causing. The degree of apparent subclinical cognitive 
impairment in users appears to correlate not with the users’ own assessments of how 
problematic their use is, but with the cumulative dose.271
However, most ecstasy users are aware that there are risks associated with the drug, 
and will have reflected upon, contextualised and rationalised that risk.272,273 Reducing 
risk of harm by encouraging ecstasy users to cease use (especially early in their 
career268) may be difficult because acute harm may be perceived as rare, and chronic 
harm too subtle to motivate behavioural change.274
Consequently, it has been suggested that the best approach to reducing the risk 
of harm may be to encourage users to minimise their intake as much as possible.274 
This can be attempted by exploring users’ experiences of the common unpleasant 
side-effects during and following use, and the disruption to other areas of life.274 
This approach may be supported by sharing the evidence that lighter users tend to 
maintain the positive effects from ecstasy, without the negative effects increasing 
much over time, whereas heavy users tend to find that the positive effects reduce 
sharply and unpleasant effects rise over time, to the point where they outweigh the 
enjoyment.83 Furthermore, typical user ratings of the positive effects from MDMA, as 
a function of dose, peak at around 100 mg (matching the content of a single average 
pill, as of 2012). Doses higher than one average pill, or equivalent, are more likely to 
decrease the positive effects, with adverse effects rising steeply above 120 mg.66,68
10.14.2. Treatment of depression in the context of MDMA use
It is recommended that clinicians prescribing antidepressants ask about recreational 
drug use and discuss the risk of drug interactions with those who use MDMA.53 
One study has reported that citalopram strongly reduces the desired effects of MDMA, 
and other SSRIs would be likely to act similarly.275 Despite this reduction in enjoyment, 
it is possible that SSRIs or SNRIs could increase the risks of MDMA toxicity.53,172 In rats, 
some effects of MDMA, including hyperthermia, are not diminished by citalopram, 
suggesting that if human users attempt to compensate for diminished enjoyment 
with higher doses, the risk of acute harm could be increased.276 Furthermore, the 
pharmacological effects of these drugs involve multiple actions on serotonin release 
and reuptake, and this complexity may allow for unexpected interactions, including 
serotonin syndrome.
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MAOIs are strictly contraindicated in those who are unlikely to be able to abstain 
from ecstasy, because the combination has a high risk of causing serotonin syndrome.
10.15. Public health and harm reduction
Taking precautions and limiting dose were not found to be associated with 
experiencing a lower rate of adverse effects in a sample of 159 ecstasy poly-drug 
users, although most of this sample did not associate their use with adverse effects.277
Ecstasy users sometimes believe that MDMA itself is virtually risk-free when it is 
‘clean’,278 i.e. that adulteration is responsible for most or all of the adverse effects, 
minor and severe. It may be beneficial to tell patients that while adulteration certainly 
does contribute to the risks, pure MDMA can cause harm and death,278 especially in 
high doses and in environments that contribute to overheating and overexertion.99
The principles for the reduction of the harms of ecstasy are similar to those for the 
reduction of ATS harms in general. In addition:
•	Ecstasy users should be made aware that not all ecstasy pills contain the same 
dose, and that some tablets sold as ecstasy may contain other drugs, like PMA, 
which can be stronger, take longer to take effect and have higher risks.
•	Users should be advised to start with a small dose (half or quarter of a tablet) to 
test a tablet to make sure there are no bad effects. They should be made aware 
that taking more than one pill at once might not increase the effect, but can make 
a come-down worse and increase the risk.
•	Users should be advised take regular breaks from dancing and be sensitive to the 
possibility of exhaustion or overheating. 
•	Users should be advised to stay hydrated, but not to over-drink. It is best to take 
regular small sips of water and to drink no more than one pint per hour if dancing 
in a hot environment and half a pint if not dancing.
•	Users should be advised to avoid mixing ecstasy with alcohol and other drugs, as 
this increases the risks. 
•	Users should be aware that serotonin syndrome is dangerous and that they should 
watch out for anyone who looks red hot and rigid and call 999 immediately. A 
person on antidepressants who also takes ecstasy pills will be at greater risk of 
serotonin syndrome.
10.16. Benzofurans
Other substances used for their ‘emphathogenic’, and well as their stimulant effects, 
include benzofurans, principally 6-(2-aminopropyl)benzofuran (6-APB) and 5-(2-
aminopropyl)benzofuran (5-APB), but also the other substances listed in Table 10.5. 
Benzodifurans include a group also known as the ‘fly’ drugs (for example, bromo-dragon 
fly, 2C-B-fly). They are hallucinogens and are discussed in Chapter 12.
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In 2013, temporary legislation was passed relating to a number of benzofurans, in-
danylalkylamines and some ‘NBOMe’ compounds. Then in 2014, benzofurans were 
classified as Class B drugs under the 1971 Misuse of Drugs Act. 
Benzofurans are ring-substituted amphetamine derivatives. Similar compounds 
have also appeared on the market in recent years, including 5- and 6-APB and their 
N-methyl derivatives. It was found that when these two materials were subjected to 
standard analytical techniques, it was not possible to distinguish between them. It is 
therefore very unlikely that those selling these drugs will know which form they are 
selling.22
Benzofurans were initially sold as ‘legal highs’, initially sometimes as ‘legal ecstasy’. 
They were also sold as psychoactive substances in their own right, as ‘Benzofury’. 
A study of internet sites showed that when mephedrone became controlled, the 
vendors aggressively promoted the sale Benzofury, as well as other new compounds 
(e.g. NRG-1 and NRG-2).280 It has been reported that after the temporary drug order 
on these two substances, some websites no longer offered them, but described 
the ethyl analogue 5-EAPB (1-(benzofuran-5-yl)-N-ethylpropan-2-amine) as a legal 
alternative to 5- or 6-APB.22
The term Benzofury was originally applied to 6-APB; however, the name was later 
used interchangeably for 5-APB and 6-APB, as differentiation of the two isomers even 
in laboratory analysis is difficult. 
10.16.1. Pharmacology
Understanding of benzorurans remains limited. Both 5- and 6-APB are phenethyl-
amine-type materials and are related to methylenedioxyphenethylamines, such 
Table 10.5.  Benzofuran derivatives17
Chemical name Street names or product brands 
(other names may be used locally)
5-(2-aminopropyl)benzofuran 5-APB19 Benzofury
6-(2-aminopropyl)benzofuran 6-APB19 Benzofury
5-(2-aminopropyl)-2,3-dihydrobenzofuran 5-APDB Benzofury
6-(2-aminopropyl)-2,3-dihydrobenzofuran 6-APDB Benzofury
1-(benzofuran-5-yl)-N-methylpropan-2-amine 5-MAPB Benzofury
1-(benzofuran-6-yl)-N-methylpropan-2-amine 6-MAPB Benzofury
1-(benzofuran-5-yl)-N-ethylpropan-2-amine 5-EAPB Benzofury
Indanylalkylamine derivative19
5-(2-aminopropyl)-2,3-dihydro-1H-indene 5-APDI
IAP19
Aminoindane derivatives279
5,6-methylenedioxy-2-aminoindane MDAI Sparkle, Mindy56
5-iodo-2-aminoindan 5-IAI116
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as MDMA and MDA.22 They are potent inhibitors of the reuptake of noradrenaline, 
dopamine and serotonin with a potency on monoamine transporters similar to that of 
MDMA.281 An animal study has shown that 5-APB and 6-APB are potent full agonists 
at 5-HT2B receptors.
282 
10.16.2. Patterns of use, modes of ingestion
It is not possible to determine the prevalence of use of benzofurans in the UK, but 
there was confirmation of its use in 2012, through analyses of pooled urine from 
London and north-west England.283,284 There are also police reports of the use of 5- and 
6-APB across north Scotland, with anecdotal evidence that they are more prevalent 
in remote areas. Their use in open prisons was reported by Avon and Somerset police. 
The 2013 reportfrom the Advisory Council on the Misuse of Drugs (ACMD) refers to 
anecdotal evidence that they were one of the most popular products sold in ‘legal 
high’ shops.22 However, there was no evidence of significant use from the 2013 Global 
Drug Survey (only 3.2% of UK respondents reported use at some point in their lives 
and 2.4% use in the past year). Enquiries to the NPIS about benzofuran compounds 
are also infrequent.97
Similarly, in a personal communication from Professor F. Measham to the ACMD, she 
suggests that the prevalence of 5- and 6-APB use is very low in surveys conducted in 
night clubs and festivals.22
As with other substances, benzofurans are used as part of a wider drug repertoire. 
Information about 5 and 6-APB toxicity collected by the NPIS (prior to the ban) 
found that co-used substances (9 cases) included aMT (alpha-methyltryptamine, a 
tryptamine), etizolam (a thienodiazepine currently not controlled nor licensed as a 
medicine in the UK), 5-iodo-2-aminoindane (5,IAI) and 5,6-methylenedioxy-2-ami-
noindane (MDAI) ( phenythelamines; aminoindane derivatives97).
Benzofurans are typically sold as a white powder, or in the form of pellets.285 The 
ACMD review reports that in 2013 it was claimed by sellers on the web that pellets 
contained a 120 mg dose (sold at approximately £10 a pellet, with reductions for 
multiple purchases), while powder was sold for approximately £35 per gram.22
There are reports from police seizures from around the UK, as well as from the Serious 
Organised Crime Agency (SOCA) in 2011 and 2012, that many of the ‘Benzofury’ 
products did not in fact contain benzofurans, but rather piperazines, cathinone 
derivatives, benzocaine, D2PM or caffeine.22
10.16.3. Desired effects
Users report that the effects of 5-APB and 6-APB are comparable to those of MDMA 
but more intense.286 and that they have mood-enhancing, emphathogenic and 
stimulant effects; they suggest that 5-APB is stronger than 6-APB.22
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10.16.4. Clinical uses
A patent application has been made for benzofuran compounds and their use as 
antidepressants and anxiolytics The compounds inhibit serotonin reuptake, exhibit 
serotonin agonistic and antagonistic properties and are claimed to be suitable as 
antidepressants, anxiolytics, antipsychotics, neuroleptics and/or antihypertonics.287
10.16.5. Mortality
Analysis of data collected by NPSAD from 1977 to 2012 showed that there were 10 
cases in 2011 and 2012 in which ‘Benzofury’ was identified at post-mortem, with the 
drug directly implicated in eight of these deaths. In nine cases, other drugs were also 
detected at post-mortem.288
10.16.6. Acute harms
Very little information has been published on the acute harms of benzofuran. 
It is suggested that such compounds produce clinical features similar to those of 
amphetamine, MDMA and mephedrone. Acute toxicity is characterised by serotonergic 
and sympathomimetic toxidrome, with nausea, agitation, anxiety, dizziness and 
hyperthermia.289
Adverse effects include nausea, sympathomimetic stimulation and agitation.286 
Stimulant features of acute intoxication with benzofurans are most common, 
followed by mental health disturbances.97 A study of NPIS patient-specific telephone 
enquiries and user sessions for TOXBASE® from March 2009 to August 2013 was 
conducted, focusing on (2-aminopropyl)-2,3-dihydrobenzofurans. These data were 
compared with those of mephedrone collected over the same period. Ingestion 
of benzofuran was associated with similar toxic effects to those of amphetamines 
and cathinones. However, mental health disturbances and stimulant features were 
reported more frequently following reported ingestion of benzofuran compounds 
than after ingestion of mephedrone. However, there are limitations to these findings, 
resulting from a number of factors, including lack of analytical confirmation.97
Comparing the 57 patients who reported ingesting benzofuran compounds alone with 
315 patients ingesting mephedrone alone, benzofurans were more often associated 
with stimulant features, including tachycardia, hypertension, mydriasis, palpitation, 
fever, increased sweating and tremor (72% v. 38%) and mental health disturbances 
(58% v. 38%). Other features reported after benzofuran compound ingestion included 
gastrointestinal symptoms (16%), reduced level of consciousness (9%), chest pain 
(7%) and creatinine kinase elevation (5%).97
One case report describes agitation and paranoia, but as a number of other drugs 
were ingested it is possible that another substance – or all – contributed to acute 
psychosis.139
It has been argued that the serotonin agonism of benzofuran raises the possibility 
that chronic use of this compound could be associated with valvular heart disease 
similar to that caused by fenfluramine and ergoline derivatives.290,291
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10.16.7. Management of acute harms
A case with severe psychotic symptoms after use of 6-APB was successfully managed 
with benzodiazepines alone.139
10.16.8. Harm reduction
The harm reduction advise given for ATS and for MDMA is applicable here.
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Chapter 11
Pipradrols and pipradrol derivatives
Pipradrols and pipradrol derivatives are a group of amphetamine-type substances 
(ATS) structurally related to methamphetamines. In recent years, 2-DPMP (desoxy-
pipradrol, also known as 2-diphenylmethylpiperadine) and D2PM (diphenylprolinol) 
have appeared on the recreational drug market, initially as so-called legal highs. 
2-DPMP was first sold as ‘Ivory Wave’, but there is some evidence that D2PM has since 
replaced 2-DPMP in Ivory Wave products. Brand names for these substances also 
included ‘Head Candy’ and it was also sold as a ‘research chemical’. As with other ‘legal 
highs’, brand names can be misleading in identifying drug content and associated 
harms. Ivory Wave is a good example, inasmuch as it was shown have contained 
methylene dioxypyrovalerone (MDPV) and lidocaine,1 in addition to 2-DPMP and 
D2PM.2
2-DPMP and related compounds D2PM and diphenylmethylpyrrolidine are Class B 
under the Misuse of Drugs Act.
11.1. Brief summary of pharmacology
Desoxypipradrol (2-DPMP) is a long-acting noradrenaline–dopamine reuptake 
inhibitor originally developed as a treatment for narcolepsy and attention deficit 
hyper activity disorder (ADHD). 2-DPMP is thought to increase the release of dopamine 
and decrease dopamine reuptake, similar to the effects of cocaine.3 There is some 
evidence that 2-DPMP is more potent than cocaine in stimulating dopamine release 
and in inhibiting its reuptake.4 It is also comparable to amphetamine and metham-
phetamine in its potential to cause acute toxicity. 2-DPMP has particularly long-lasting 
effects and a longhalf-life.2 The substance is capable of inducing agitation, which may 
last for several days after a single dose.4
D2PM is a pyrrolidine analogue and 2-DPMP is a desoxy analogue of pipradrol. It has 
been argued that, based on published evidence, that the binding and activity of D2PM 
at the dopamine reuptake transporter are similar to those of cocaine, although it 
appears that D2PM has less biological activity.3 D2PM also has long-lasting effects, 
albeit shorter than those of 2-DPMP.
11.2. Patterns of use and routes of ingestion 
Pipradols are typically part of a drug-using repertoire and their use has been reported 
among a minority of users. For example, in a survey of individuals attending gay-friendly 
nightclubs in south-east London (July 2011), 0.6% of 315 individuals reported that 
they had used a pipradrol: 1.0% had used within the last year and 0.6% had used or 
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were planning to use a pipradrol on the night of the survey.5 Pipradrols were also 
detected in an analysis of anonymous pooled urine samples from stand-alone urinals.6
It is important to note that people who use 2DPM and D2PM do not necessarily know 
that they have consumed this drug. In a case series of five patients who presented 
to an emergency department (ED) in London, none of them knew that they had 
consumed it. They were sold it instead of the substance they had intended to buy.7
2-DPMP is sold as a hydrochloride salt or in free-base form. It is described by retail 
websites ‘as a white crystal powder with not much smell’ or ‘a white coloured fine 
powder’, with a purity of up to 99.9%.2
Oral ingestion is the most common route of administration of 2-DPM (‘bombed’ 
wrapped in a cigarette paper) or dissolved in water. However, the drug can also be 
insufflated, used rectally, smoked and intravenously injected.2 Based on analysis of 
online fora, Corkery et al. reported that doses range from 1 mg to 10 mg according to 
mode of use, typical oral doses being 1–2 mg, but the optimum dose being thought 
of as 5–10 mg. The authors also reported that there is no information on whether the 
effects of 2-DPMP are dose-dependent or dependent on the mode of ingestion.2 The 
elimination half-life is 16–20 hours. 
The oral and insufflation of D2PM have been reported. The typical human active dose 
of D2PM is 2–5 mg, but reports on online drug user fora suggest that rectal doses 
range from 10 mg to 30 mg and oral doses from 35 mg to 50 mg.2
An analysis of user reports suggested that 2-DPMP effects are felt within 60 minutes 
of oral use, and may last up to 24 hours (or even 48 hours). The psychoactive effects of 
D2PM are similar to those of 2-DPMP but appear to occur 15 minutes after ingestion 
and may last up to 10 hours.2
Nasal irritation and epistaxis may occur after nasal insufflation. Analysis of user 
reports suggest that prolonged use of D2PM can cause craving and increased need 
to re-dose.2
11.3. Desired effects
Analysis of user reports of the desired psychoactive effects of 2-DPMP include 
prolonged euphoria, increased energy and alertness, sociability, and loquacity.2 Other 
stimulant effects reported include sweating and bruxism.3 The desired psychoactive 
effects of D2PM are, similar to those of 2-DPMP, but as mentioned earlier, occur 
sooner and last for less time.2
11.4. Mortality
2-DPMP has been detected in three fatalities in the UK,2 its role in these deaths has 
not yet been established. There have been no reports of deaths directly attributed to 
either D2PM or 2-DPMP. 
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11.5. Acute harms
Information on the acute toxicity related to both D2PM and 2-DPMP is very limited. 
Reports suggest the development of sympathomimetic features similar to those seen 
with other recreational drugs and other amphetamines in particular, such as MDMA. 
They also suggest that these compounds may be associated with significant neuro-
psychiatric symptoms, which can be prolonged in nature, in which respect they are 
different to other sympathomimetic compounds.3
The limited experience of the UK National Poisons Information Service (NPIS) suggests 
that their acute clinical effects include tachycardia, palpitations, convulsions, raised 
levels of creatine kinase, acute renal failure and chest pain (sometimes with ECG ab-
normalities). There is also a reported risk of serotonin toxicity.8 D2PM and 2-DPMP are 
related predominantly to neuropsychiatric symptoms.4
There is emerging evidence that they have sympathomimetic properties similar to 
cocaine.3 The initial pattern of acute toxicity is similar to that of other sympatho-
mimetic drugs, with users describing a ‘rush’.7 Prolonged and clinically significant 
neuropsychiatric symptoms have been reported following the use of the D2PM.3,7 A 
high risk of central nervous and cardiovascular system toxicity has been suggested.9 
One case report of a presentation to a London emergency department associated 
with the use of D2PM (in addition to glaucine) described an individual who presented 
with acute onset of agitation and chest pain. The authors suggested that the D2PM 
was likely responsible for the ischaemic chest pain, as the acute toxicity of glaucine is 
more hallucinogenic in nature.10
There are two reports of acute harms associated with 2-DPMP (products sold as ‘Ivory 
Wave’ and ‘Whack’) from Scotland and Ireland,1,11 although both studies lack robust 
analytical confirmation or have none at all (‘Whack’ also contained fluorotropa-
cocaine). 
An analysis of 37 consecutive patients attending the Royal Infirmary of Edinburgh 
emergency department in July and August 2010 with self-reported Ivory Wave use 
was carried out. Over a similar time frame, enquiries regarding Ivory Wave ’ to the NPIS, 
by telephone and via the internet-based TOXBASE®, were analysed. Analysis of both 
sets of data showed a toxidrome which lasted several days, and included tachycardia 
(65%), tachypnoea (76%), dystonia (18%), rhabdomyolysis (96%), leucocytosis (57%), 
agitation (62%), hallucinations (50%), insomnia (32%) and paranoia (21%).1
The use of D2PM and 2-DPMP is related to neuropsychiatric symptoms. There were 
49 enquiries to the Irish National Poisons Information Centre relating to ‘Whack’; 
these commonly described cardiovascular effects, including hypertension in 10 cases, 
and tachycardia. Neuropsychiatric effects were also reported, including agitation and 
psychosis, and these persisted for up to five days. However, this study was limited 
by the fact that fluorotropacocaine was also found in Whack and that there was no 
analysis of biological samples.11 
Similarly, 96% had neuropsychiatric features in a case series of acute intoxication 
related to Ivory Wave. Cases presented up to a week after use, with tachycardia, 
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dystonia, rhabdomyolysis, agitation, hallucinations and paranoia. A similar Ivory Wave 
product contained 2-DPMP in another study, but that was limited by the fact that in 
the majority of cases biological samples were not analysed.1
A case series with analytical confirmation of D2PM in five individuals who presented 
to a London emergency department described patients showing the neuropsychiat-
ric symptoms of agitation, anxiety and insomnia, lasting for 24–96 hours following 
the use of the D2PM.7
11.6. Chronic use
No information is available on the long-term effects of desoxypipradrol or of D2PM. 
Analysis of user reports suggest that, as with desoxypipradrol, prolonged use of D2PM 
leads to craving and a need to re-dose.2
11.7. Management of acute harms
The limited evidence on the acute toxic effects of 2-DPMP and D2PM suggests that 
the management of their harms is similar to the management of the harms from 
other stimulants and ATS.
Because of the particularly long-lasting effects of these drugs, the authors of a case 
series said that an important part of the management of presentations for acute 
intoxication was the reassurance of individuals that the prolonged neuropsychiatric 
symptoms will resolve.7
11. 8. Harm reduction
For more information on the reduction of the harms of ATS, see Chapter x, bearing 
in mind the fact that 2-DPMP and D-2PM are potent amphetamine-type stimulants. 
2-DPMP in particular is a long-acting drug, capable of causing severe agitation, which 
can last for several days after a single dose
For up-to-date guidance on the management of pipradrol acute toxicity, it is recommended 
that information be sought from the National Poisons Information Service (NPIS), specifically 
the NPIS 24-hour telephone service and the poisons information database TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/2-Products/2-DPMP/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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Chapter 12
Hallucinogenic drugs
Drug group: Hallucinogen 
Hallucinogens are drugs that distort the way a user perceives time, motion, colour, 
sounds and self. The varied perceptual distortions caused by such drugs do not strictly 
correspond to clinical definitions of ‘hallucinations’ (perceptions in the absence of 
external stimuli that are experienced as if they were real, as seen in psychoses and 
delirium).1,2 Therefore, alternative terms, such as ‘illusions’ and ‘pseudo-hallucinations’ 
and ‘perceptual distortions’ have also been employed.3 
Some authors have suggested that the term ‘psychedelic’ should replace terms like 
‘classical hallucinogen’ to describe drugs such as LSD and psilocybin,4 but it has also 
been argued that this term carries disadvantages because of its cultural connotations 
of a style of music and art associated with Western counter-culture in the 1960s. 
Other terms used include ‘psychomimetic’, a term previously used to emphasise 
effects that resemble the symptoms of psychosis, and the term ‘entheogen’, which 
emphasises the mystical-type experiences the drugs are said to promote. However, 
these terms have also been criticised, as they highlight only a single aspect of a much 
broader range of hallucinogenic effects.5
This chapter will use the term ‘hallucinogen’ to refer only to the serotonergic hal-
lucinogens: drugs with a mechanism of action mediated primarily by agonism of 
the 5HT2A serotonin receptor. LSD (N,N-diethyl-D-lysergamide) and psilocybin are 
the prototypical and most prevalent drugs of this class. In recent years, a number of 
hallucinogen novel psychoactive substances (NPS) have also been made available on 
the illicit market and as so-called ‘legal highs’ that act on 5-HT2A serotonin receptors.
Two substances which have some ‘hallucinogenic’ properties but are not serotonergic 
hallucinogenic will also be considered briefly in this chapter:
•	Salvia divinorum. This is considered here because it has been described as 
‘ psychedelic-like’6 and its use is widespread.
•	Psychoactive mushrooms in the Amanita genus. These are considered here because 
they can be hallucinogenic and may be conflated by users or clinicians with the 
truly psychedelic ‘magic’ mushrooms of the Psilocybe genus.
There are a number of other substances and drug groups which can produce some 
hallucinogenic effects but cannot be classified as ‘serotonergic ’. These include drugs 
discussed elsewhere in this document: cannabis and other cannabinoid receptor 
agonists (Chapter 13), MDMA and other similar drugs (Chapter 10) and dissociative 
anaesthetics such as ketamine or PCP, which function as NMDA glutamate receptor 
antagonists (Chapter 4).7
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Table 12.1. Hallucinogenic drugs used for recreational purposes
Chemical name Abbreviation 
as used in this 
text.
Street products and names (these change 
over time; other names may be used locally)
Lysergamides
(6aR,9R)-N,N-diethyl-7-methyl-
4,6,6a,7,8,9-hexahydroindolo-[4,3-
fg]quinoline-9-carboxamide
(N,N-diethyl-D-lysergamide)
LSD ‘Acid’, ‘A tab’, ‘Blotter’ (LSD on blotting paper 
squares, ~1 cm2), ‘Geltabs’, ‘Windowpane’ (LSD 
in gelatine squares/pieces), ‘Microdots’ (very 
small pills)8
(8β)-9,10-didehydro-6-methyl-
ergoline-8-carboxamide
LSA (ergine) ‘Morning Glory seeds’ and ‘Hawaiian Baby 
Wood rose seeds’ (seeds containing LSA and 
other alkaloids)
(6aR,9R)-4-acetyl-N,N-
diethyl-7-methyl-4,6,6a,7,8,9-
hexahydroindolo[4,3-fg]
quinoline-9-carboxamide9 
(1-acetyl-N,N-diethyllysergamide)
ALD-529
(6aR,9R)-N,N-diethyl-7-ethyl-
4,6,6a,7,8,9-hexahydroindolo-[4,3-
fg]quinoline-9-carboxamide
(6-ethyl-6-nor-lysergic acid 
diethylamide)
ETH-LAD9
(8β)-N,N-Diethyl-6-propyl-9,10-
didehydroergoline-8-carboxamide
(6-propyl- 6-nor- Lysergic acid 
diethylamide)
PRO-LAD9
6-allyl-6-nor-lysergic acid 
diethylamide
AL-LAD9
(8β)-8-{[(2S,4S)-2,4-
Dimethylazetidin-1-yl]
carbonyl}-6-methyl-9,10-
didehydroergoline (lysergic acid 
2,4-dimethylazetidide)
LSZ9
Tryptamines
O-phosphoryl-4-hydroxy-N,N-
dimethyltryptamine
4-hydroxy-N,N-dimethyl-
tryptamine
Psilocybin
Psilocin
‘Magic mushrooms’, ‘Mushies’ or ‘Shrooms’ 
contain psilocybin and related tryptamines
‘Liberty caps’ or ‘Libs’ are the most common 
wild UK species of magic mushroom, 
Psilocybe semilanceata. Also occurring in the 
UK are Panaeolus cinctulus and ‘Wavy caps’, 
Psilocybe cyanescens
’Cubes’ or ’Boomers’ are the most commonly 
home-cultivated species, Psilocybe cubensis
‘Truffles’ or ’Philosopher’s stones’ are 
cultivated nodular growths (technically 
‘sclerotia’) from other Psilocybe species. They 
are sold online 
N,N-dimethyltryptamine DMT ‘Dimitri’ and ‘Spice’ are terms sometimes 
used for the white, yellow or brown DMT 
crystals or powder, often used for smoking 
(technically vapourising). This should not be 
confused with ‘spice’ also commonly used 
for synthetic cannabinoids. ‘Ayahuasca’ and 
‘Yagé’ are decoctions that include a DMT-con-
taining plant and another plant containing a 
monoamine oxidase inhibitor, which allows 
DMT to be orally bioavailable
alpha-methyltryptamine αMT ‘AMT’ 9
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N,N-diallyl-5-methoxytryptamine  5-MeO-DALT 
N,N-diisopropyltryptamine DiPT ‘Foxy’
5-methoxy-N,N-diisopropyl-
tryptamine
5-MeO-DiPT ‘Foxy Methoxy’
12-methoxyibogamine Ibogaine ‘Iboga’ (Tabernanthe iboga) is the shrub that 
contains ibogaine and other iboga alkaloids
Phenethylamines
3,4,5-trimethoxyphenethylamine Mescaline ‘Hallucinogenic cacti’ contain psychoactive 
alkaloids, principally mescaline. ‘Peyote’, ‘San 
Pedro’ and ‘Peruvian Torch’ are the common 
names for the three predominant species
2C Series, and their derivatives 2C-B has 
various close 
analogues; 
bk-2C-B, and 
25B-NBOMe
The same 
selection of 
analogues 
may exist for 
the rest of 
the 2C series, 
e.g. 2C-E, 2C-I, 
2C-T-7
‘Bees’ are tablets or capsules containing 2C-B. 
‘Nexus’ is also 2C-B
‘Tripstasy’ was 2C-T-7, but could be used for 
any drug combining hallucinogenic effects 
with MDMA-like effects
‘N-Bomb’ drugs are the NBOMe analogues 
series, so 25I-NBOMe may also be called 
‘NBOMe 2C-I’ and so on.
Hallucinogenic 
amphetamines,DOx series and 
their derivatives
DOM, DOI, 
DOB, TMA-2
‘STP’ (for ‘serenity, tranquillity and peace’) 
was the original name for pills of DOM
Tetrahydrodifranyl compounds10 2C-B-FLY, 
bromo-
dragonfly
They are called ‘FLY’ because their molecular 
structure resembles the insect11
Table 12.2. Drugs considered in this chapter that are not true hallucinogens
Drug Plant Street names
Salvia divinorum Salvia Salvia is the term used in the literature, 
on product labelling and by users. 
It is the genus name to which the 
psychoactive belongs, other ‘Salvias’ are 
not psychoactive. This species contains 
the diterpenoid Salvinorin A, which 
is responsible for the effects. ‘Sally D’, 
‘SkaMaríaPastora’, ‘Seer’s Sage’ are other 
names that may be used 
Psychoactive 
Amanita 
mushrooms
Amanita muscaria
Amanita 
pantherina
Fly agaric (Amanita muscaria) 
Panther cap (Amanita pantherina) 
contains the psychoactive muscimol 
(5-(aminomethyl)-isoxazol-3-ol) and 
its prodrug, ibotenic acid
May be described and sold as so-called 
legal ‘magic mushrooms’, but should 
not be confused with the truly halluci-
nogenic psilocybin-containing ‘magic 
mushrooms’
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12.1. Street names 
Hallucinogenic drugs can be roughly divided into tryptamines, phenethylamines and 
lysergamides (LSD-like structures).7 Table 12.1 lists some of the hallucinogenic drugs 
that were available on the market for recreational use at the time of writing and/or 
that have been associated with harm; several of the substances listed will be rarely 
used. 
The drugs listed in Table 12.2 are not true hallucinogens, but are nonetheless 
considered in this chapter.
12.2. Legal status
The most prevalent hallucinogenic drugs, LSD and magic mushrooms, are Class A 
controlled drugs in the UK under the Misuse of Drugs Act 1971 (MDA 1971). Some 
novel psychoactive hallucinogens have also been controlled as Class A drugs Schedule 
1. These include the NBOMe series and others not explicitly named in the Misuse 
of Drugs Act 1971, but are controlled as close analogues of banned drugs in the 
tryptamine or phenethylamine family, and generic clauses in the MDA 1971 exist to 
cover most simple derivatives.9 The compounds captured by the extended definition 
of tryptamines include the substances commonly known as AMT and 5-MeO-DALT. 
Also Class A drugs are the LSD-related compounds commonly known as ALD-52, 
AL-LAD, ETH-LAD, PRO-LAD and LSZ.
The legal status of unrefined natural products containing hallucinogenic drugs, such 
as dried pieces of mescaline-containing cacti and material from DMT-containing 
plants, is ambiguous, or could be seen as de facto legal12 until they are prepared for use 
as drugs. The exception is Psilocybe mushrooms, fresh or dried, or any other fungus 
material containing psilocin and its esters (e.g. psilocybin), possession of which has 
been specifically controlled since 2005.
Some hallucinogens were uncontrolled at the time of writing. Legislation was, 
however, expected to be announced that would bring many currently used ‘legal’ novel 
psychoactive hallucinogens under the generic definitions of the MDA 1971, making 
them Class A Drugs.13 On 10 June 2014 the Advisory Council on the Misuse of Drugs 
recommended that some of these drugs be scheduled as Class A drugs by updating 
the blanket ban clause on tryptamines. This would include both the tryptamine 
5-MeO-DALT13 and αMT,13 which currently do not fall under the tryptamine clause.. 
Similarly, soon due to be banned are bk-2C-B, a legal derivative of the phenethylamine 
2C-B.ALD-52, and the lysergamides ETH-LAD, PRO-LAD, AL-LAD and LSZ.13
At the time of writing, the hallucinogenic-like Salvia is not controlled and is available as 
a ‘legal high’ online14 and in ‘head-shops’. Fly agaric (Amanita muscaria) and Amanita 
pantherina grow in the UK and since they do not contain psilocybin they are currently 
uncontrolled. Dried Amanita muscaria caps are sold as ‘legal highs’ online14 and in 
‘head-shops’. 
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12.3. Quality of research evidence
The international evidence on the clinical management of the harms related to the 
use of hallucinogens remains limited. The bulk of it focuses on LSD and psilocybin, 
although research on the clinical management of harms of even these substances is 
limited. 
Very little has been published about other hallucinogenic drugs, with evidence limited 
to case reports and series of patients with acute toxicity. 
12.4. Brief summary of pharmacology 
As stated above, structurally, most hallucinogens can be roughly divided into 
tryptamines, phenethylamines and lysergamides (LSD-like structures).2,7 LSD and 
other lysergamides share a complex molecular structure with both tryptamine 
and phenethylamine backbones. However, lysergamide structures are sufficiently 
elaborated from these skeletons for them to be more usefully considered a distinct 
class of hallucinogenic.2 Some hallucinogenic NPS, such as the ‘Fly’ series, are less 
easy to classify, because they are fairly distant structural analogues of their pheneth-
ylamine parent compound.11
The common denominator in the pharmacology of true hallucinogenic drugs is 
agonism or partial agonism of 5-HT2 serotonin receptors,
2 particularly 5-HT2A and/or 
other 5-HT2 receptors.
15 This activity is of central importance to their characteristic 
hallucinogenic effects.15 Hallucinogenic drugs interact with an array of other sites 
too, contributing to the psychopharmacological and behavioural effects.15–17 A recent 
study looking at the hallucinogenic drug DMT, a tryptamine, suggests that it may be 
an endogenous ligand for the sigma-1 receptor in humans. This suggests the need to 
look beyond the serotonin system for a complete understanding of the pharmacology 
of tryptamines.18
The naturally occurring tryptamine ibogaine is an example of a hallucinogen with 
pharmacological effects beyond the 5-HT2A receptor. In comparison with other hal-
lucinogens, ibogaine interacts strongly the NMDA receptor, σ–receptors, μ-opioid 
receptors, and muscarinic receptors.16 It also causes serotonin and dopamine reuptake 
inhibition at their transporters (SERT and DAT).19 Ibogaine’s tendency to cause a 
‘rough trip’ with strong physical side-effects has been described.20 It has also been 
shown to block the hERG potassium channel, which may be associated with the life-
threatening QT interval elongation observed in several cases of ibogaine toxicity.21 
The psychoactive Amanita species (A. muscaria and A. pantherina) contain muscimol 
and ibotenic acid. Muscimol is a potent GABAA receptor agonist with depressant, 
hypnotic and dissociative effects.22 Ibotenic acid is a pro-drug for muscimol, but may 
also cause psychoactive effects in its own right as an NDMA glutamate receptor 
agonist.23 It has been argued that the relative proportions of these pharmacologi-
cally distinct substances present in Amanita mushrooms could explain the sharply 
contrasting pharmacological effects reported, with descriptions ranging from 
alcohol-like to hallucinatory.24 Amanita muscaria contains more excitatory ibotenic 
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acid and less depressant muscimol than Amanita pantherina, which has led some to 
refer to two subtypes of syndromes resulting acute Amanita toxicity.25 It has been 
reported that some users deliberately modify the pharmacology through preparatory 
methods that decarboxylate the ibotenic acid into muscimol.26
Understanding of hallucinogen drugs is still very limited. It is assumed that qualitative 
differences in the subjective phenomenology of the drugs may relate to their 
individual affinity profiles.16 In a recent study, psilocybin, the prototypical hallucino-
genic tryptamine, has been shown to reduce apparent activity in hub regions, and 
to uncouple synchronised activity in the posterior cingulate cortex and the medial 
prefrontal cortex.27 This suppression of orderly and regulated patterns of activity 
between different brain areas has been interpreted as allowing for the relatively un-
constrained patterns of cognition, with abnormal integration of sensory information, 
that seem to characterise the ‘psychedelic state’.27 More research is needed.
The structure–activity relationships of hallucinogens are complex, and differ between 
the various drugs. This means that hallucinogen NPS appearing on the market may 
be structurally similar to other NPS, or to other well known hallucinogenic drugs, but 
may have different levels of potency, effects, duration of effects and risks. 
For example, the phenethylamines 2C-B and bk-2C-B28 differ only by the addition of 
a ketone group, but some reports suggest that the latter drug has a significantly 
longer duration of effect.29 The duration of the effects of 5-methoxy-N,N-diisopro-
pyltryptamine (5-MeO-DiPT, foxy methoxy) is seven times greater than that for 
N,N-diisopropyltryptamine (DiPT or ‘Foxy’).30 Bromo-dragonfly is a distant derivative 
from the core phenethylamine structure, with a potency similar to that of LSD, but 
has a far longer duration of effect (1–3 days) and apparently has greater toxicity.11 In 
terms of acute toxicity, within the 2C family, 2-CB has not been associated with any 
fatalities, whereas there are reports from the US of deaths in which 2C-T-7 has been 
implicated.31
Some hallucinogens have strong stimulant effects. For example, αMT is a tryptamine, 
with a methyl group in the alpha position, just like an amphetamine, and has marked 
stimulant effects, seen in clinical observations.32 On the other hand, some phenethyl-
amines, which are amphetamine-type substances, are also hallucinogenic drugs. 
These include ring-substituted substances, such as the ‘2C series’ and the ‘D series’ 
(e.g. DOI, DOC), and benzodifurans (e.g. bromo-dragonfly, 2C-B-Fly). Similarly, the 
phenethylamines DOB(2,5-dimethoxy-4-bromoamphetamine) and MEM are highly 
selective for 5-HT2 receptors.
16 
12.5. Clinical uses
There are currently no hallucinogenic drugs that are licensed for clinical use, and 
many of the compounds, including LSD and psilocybin, are restricted as Schedule 1 
substances. 
Some research on the clinical use of hallucinogens was carried out in the 1950s, 
1960s and 1970s. A recent meta-analysis of early randomised controlled trials of 
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LSD for alcoholism showed that a single application of LSD in a variety of treatment 
modalities reduced alcohol intake or maintained abstinence at rates which compare 
favourably to mainstream treatment with naltrexone and acamprosate.33 Ibogaine, a 
natural hallucinogen from the iboga shrub, has been used as a controversial addiction 
treatment to facilitate withdrawal from opiates and other drugs.34 One evaluation 
began into this clinical use, but a death during the small study may have brought an 
end to clinical research.35
Some clinical research involving the administration of classical hallucinogens 
is currently taking place again.36–39 This includes small pilot studies looking at the 
utility of LSD40 and psilocybin41 for treating anxiety associated with life-threatening 
diseases. Psilocybin has also been trialled in nine people with obsessive-compulsive 
disorder, all of whom experienced improvement in symptoms, mostly short-lived, but 
with one experiencing full, lasting remission.42 Another trial has been approved for 
testing psilocybin in treatment-resistant depression, and is due to begin.43 
12.6. Prevalence and patterns of use
LSD and magic mushrooms have been firmly established and widely available in the 
UK for a number of decades. At a population level, the last-year use LSD and magic 
mushrooms in the UK and Europe in general is relatively low, as shown in Table 12.3. 
Use has fallen since comparable records began in 1996, but has been stable for the 
past 10 years.
The Crime Survey for England and Wales (CSEW) shows that general ‘hallucinogen’ 
use in the past year and LSD use in past year were significantly higher in 2013/14 
than they were in 2012/13.44 The use of magic mushrooms, though, did not change 
significantly during that period. Lifetime use of hallucinogens is comparable to the 
lifetime use of ecstasy or cocaine in adults (aged 16–59 years) (9.1%, 9.3% and 
9.5% respectively). Among 16–24-year-olds, lifetime use was lower, at 5.1%, and less 
common than the use of drugs such as ecstasy, cocaine and amphetamines.
The Global Drug Survey (GDS) shows higher levels of use than those reported in the 
CSEW, reflecting the greater experience of the GDS respondents with illicit substances 
and a possible sample bias. In the 2014 Global Drugs Survey, UK respondents reported: 
last-year LSD use of 12.2% (lifetime use 39.6%) and magic mushrooms last-year use 
of 13.7% (lifetime use 53.1%).45
Much less is known about the prevalence of use of hallucinogenic NPS, especially at 
a population level, as these data are not collected by the CSEW or the Scottish Crime 
and Justice Survey. Some information is provided by the Global Drug Survey 2014 
for use in the last 12 months; in the UK, 7.7% of respondents had used 2CB.46 No 
information at all is available on the use of other NPS, although there is clear evidence 
that they are available on the market. For example, Avon and Somerset police reported 
in March 2014 that αMT was on sale at most ‘legal high’ shops.9
Hallucinogenic drugs tend to be used relatively infrequently. Among respondents to 
the CSEW who had used hallucinogens in the last year, few had taken them more than 
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once a month. In fact, hallucinogens were the least likely kind of substance to be used 
frequently.44
Hallucinogenic drugs are typically used by people who also use other drugs. As with 
other drugs, the CSEW 2013/14 reported higher prevalence rates of use of these 
drugs among those who also used other illicit drugs. Among users, 4% had used magic 
mushrooms and 4% had used LSD in the last year. 
Users of hallucinogens are typically young and use a wide repertoire of other drugs. 
The higher levels of use by ‘clubbers’, in comparison to non-clubbers, has been reported 
by the CSEW (2013/14), where use of hallucinogens was highest among those who 
had visited a club four or more time in the past month. Similar findings were produced 
in the Global Drug Survey 2012 (Figure 12.1).46 
Table 12.3. Figures from the 2013/2014 Crime Survey for England and Wales (CSEW) 
on the use of LSD in the last year and other hallicunogens 
Age group Percentage reporting use in last year
16–59-year-olds reporting LSD use 0.3% in 2013/14, a statistically significant increase from 0.2 
in 2012/13. Use had been relatively stable over the previous 
decade.
16–24-year-olds reporting LSD use 0.9% in 2013/14, showing no significant difference from use 
in 2012/13
16–59-year-olds reporting magic 
mushroom use
0.4% in 2013/14, showing no significant difference from use 
in 2012/13. Use had fallen significantly over the previous 
decade, from 0.8 in 2003/04 
16–24-year-olds reporting magic 
mushroom use
0.8% in 2013/14, showing no significant difference from use 
in 2012/13. Use had fallen significantly over the previous 
decade, from 2.7 in 2003/04
16–59-year-olds reporting Salvia use 0.5% in 2013/14, significantly up from 0.3 in 2012/13
16–24-year-olds reporting Salvia use 1.8% in 2013/140, not significantly different from 2012/13
Figure 12.1. Drug use by frequency of visits to ‘clubs’ (Global Drug Survey 2012)
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Other than ‘clubbers’, there is anecdotal evidence from users and online discussion 
groups, that a particular type of drug user, sometimes referred to as ‘psychonauts’, 
may be more likely to use hallucinogens, more likely to use them more frequently and 
more likely to experiment with a wider range of drugs, perhaps especially NPS.
12.7. Routes of ingestion and 
frequency of dosing
There are very marked differences between the various hallucinogenic drugs in terms 
of potency, and type, onset and duration of effects. 
12.7.1. Potency
The potency of a hallucinogenic substance appears to be broadly, but not entirely, 
a function of its affinity to the 5-HT2Areceptor.
2,15 Substances with lower affinity for 
the receptor, and lower potency, include mescaline2 (typical oral dose approximately 
0.25 g). LSD has a high affinity, and is the most commonly used potent hallucinogenic 
substance (a typical dose may be 75–150 µg47). 
In recent years, very potent new hallucinogenic substances have emerged on the 
recreational market, such as the NBOMe series and bromo-dragonfly.48 The latter, for 
example, has been described by users (on drug user websites) as ‘just too powerful’, due 
to its duration as well as potency.11 This may have contributed to the fact that some 
new drugs, such as bromo-dragonfly, appeared on the market but then disappeared 
quickly.11 Salvinorin A products and commercially available salvia leaf preparations 
prepared for smoking can also be very potent.
12.7.2. Onset of effects and duration
There are significant differences between substances in the speed of onset of effects 
after ingestion, ranging from a few moments to hours. For example, DMT has an 
almost immediate effect, while the effects of LSD appear approximately 60 minutes 
after oral ingestion. Users’ reports suggest that maximal effects following ingestion 
of bromo-dragonfly may not be reached for up to 6 hours after ingestion,49 posing a 
risk that users re-dose because of mistaken belief that the first dose has had no effect.
Similarly, the duration of action of hallucinogenic drugs ranges between minutes and 
days, depending on the substance used. The hallucinogenic-like salvia and vaporised 
DMT are examples of very short-acting drugs with rapid onset. DMT’s effects appear 
in under a minute and may peak within 5 minutes, with minimal adverse after-effects 
(come-down).50 Hallucinogens of intermediate duration include 2C-B,51 with effects 
lasting 2–3 hours. LSD and mescaline are longer-acting hallucinogenics and a duration 
of 8–12 hours is expected.52 Very long-acting hallucinogens include DOM and others 
in the DOx series, ibogaine, 2C-P and bromo-dragonfly, the effects of which have been 
reported to last a day or longer, and in some cases can lead to exhaustion.11,52,53
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The purity and quantity of the active compounds in a single tablet or’ tab’ and the 
reliability of hallucinogenic drugs (in terms of being the drug users think they are 
buying) varies between product and batches, contributing risk to dose estimation. 
As with other drugs, users will not know the strength of the tablet they are taking, 
or may not be ingesting the substance they intended to use, or think they are taking. 
Hallucinogenic NPS have, on some occasions, been sold as LSD.54 For example, three 
samples purchased as LSD and tested by the WEDINOS scheme in Wales in 2014 
were revealed to contain the phenethylamine derivatives 25I-NBOMe, 25C-NBOMe 
and DOB.*
Some drugs can be more ‘reliable’ than others at particular times and in different 
locations. For example, in a Spanish study, 99% of samples purporting to be 2C-B 
actually contained 2C-B (average for the four-year study period), a high reliability 
compared with 66.8% for MDMA, 86.3% for amphetamines, 87.4% for cocaine, 92.2% 
for ketamine.51 Similarly, there are differences between different batches for the 
same product; for example, bromo-dragonfly appears to come in batches of different 
potency.11
Changes in the drugs’ strength and potency over time have also been documented. 
LSD ‘tabs’ in 2003 contained significantly less LSD on average than in the early years 
of use, in the 1960s and 1970s; doses of above 100 µg/tab were then typical, but, by 
2003, 30-40 µg/tab was more usual.55
12.7.3. Modes of ingestion
Hallucinogens are typically ingested orally, or sublingually/buccally, often through 
small blotter paper portions or ‘tabs’, which are held in the mouth to allow absorption 
through the oral mucosa. 
Other routes of administration are used by a minority, including insufflation, smoking, 
rectally and injection. For example, among 59 enquiries about AMT to the UK National 
Poisons Information Service, 55 were about oral ingestions, and 4 insufflations.32 
The route of administration for 25I-NBOMe is typically sublingual and buccal, but 
nasal (insufflation and absorption of liquid solutions), oral, injection (intravenous 
and intramuscular), rectal and smoking have also been reported.56,57 Salvia extracts 
are exceptions, as they are usually smoked; DMT, too, can be ‘smoked’ (technically, 
‘vaporised’ is the appropriate term).
As with other drugs, the route of administration of hallucinogens may have an impact 
on effects, their onset and duration. User reports suggest, for example, that the effects 
of 25I-NBOMe last 6–8 hours when the drug is taken sublingually or buccally, but only 
4–6 hours when it is insufflated.
* Wedinos (2014) Keyword search; LSD. See Sample 000030322, Sample 000030324, Sample W002197. 
Retrieved July 17, 2014, from WEDINOS; Welsh Emerging Drugs and Identification of Novel 
Psychoactive Substances: http://www.wedinos.org/db/samples/search.
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12.7.4. Frequency of use
Overall, bingeing is not reported with hallucinogenic drugs, partly because once the 
effects begin to fade, subsequent doses usually do not produce further psychoactive 
effects (tachyphylaxis)2 (see section 12.13.1 on dependence).
12.7.5. Poly-drug use 
Hallucinogens are sometimes combined with other drugs, in poly-drug repertoires, 
particularly with stimulant drugs.58 In a Spanish study of 52 users of 2C-B, 83% 
reported that they had taken it simultaneously with other drugs, with most commonly 
with MDMA (69%), alcohol (43%) or cannabis (40%).51 Reported combinations 
with bromo-dragonfly include: alcohol; prescribed drugs such as alprazolam; illicit 
substances such cannabis, cocaine, amphetamine or LSD; and legal highs, including 
salvia and kratom.11,59
Some combinations have their own user names; for instance, LSD or magic mushrooms 
taken with ecstasy are called candyflipping and hippyflipping respectively.60 It has even 
been suggested that the popularity of these combinations may have contributed to a 
resurgence of LSD use, following the increasing popularity and use of MDMA.61 
12.8. Desired effects of recreational use
Hallucinogens are a diverse group of drugs that alter and distort perception, producing 
sensory distortions, most notably visual, and also modify thought and mood.62 DiPT is 
atypical because (at least according to anecdotal reports) it produces predominately 
auditory perceptual changes.20 
Desired effects include euphoria, mild stimulation, enhanced appreciation of music 
and lights, visually appealing distortions, intensification of sensual or sexual feelings, 
altered sense of time and place, and a sense of shared and heightened significance 
of the situation. In the 2014 Net Pleasure Index of the Global Drugs Survey, in which 
22,000 people in different parts of the world ranked drugs in terms of pleasure and 
pain, users placed LSD and magic mushrooms as the second and third most pleasurable 
drugs, following MDMA.63
Reports from users and the work of researchers, such as the Shulgins, strongly suggest 
that each drug has distinct characteristics, and that there are qualitative differences 
between the different drugs, with variability in multiple sensory and emotional 
dimensions.20,53 The chemical and pharmacological properties of the various groups 
of hallucinogens will partially determine differences in effects; for example, some 
hallucinogen NPS also have pronounced stimulant effects.
The substances also differ in how pronounced the characteristic visual distortions are. 
This may be linked to the context in which they are used. For example, 2C-B has been 
described as inducing ‘perceptual enhancement’ and euphoria, but these are milder 
than those of classical hallucinogens such as LSD and the drug lacks the potent hallu-
cinogenic effects of LSD.64 This has contributed to its association with ‘clubbing’. 2C-B 
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has proved popular as a dance drug, and has sometimes appeared in tablets sold as 
ecstasy.65 In the Spanish study of 52 users of 2C-B, 60% reported that typical settings 
of 2C-B use were recreational environments (clubs, parties raves), followed by home 
use with friends (54%), at home with partner (37%) or in the countryside (20%).51
Other seek more potent experiences. Self-described ‘psychonauts’ use a wide range 
of hallucinogens and may experiment with newly emerging psychoactive substances, 
potent substances and with drug combinations. The emphasis of use is on seeking 
novelty and extremes of experience and sometimes a spiritual experience. Users may 
push boundaries in terms of potency of the substance and dose. The internet plays an 
important role in providing a platform for sharing experience and information.
However, as with other substances, the effects of hallucinogens are dose-dependent. 
For example, at lower doses 2CB is described by users on discussion fora as an energetic 
experience similar to that produced by ecstasy. At higher doses the experience is 
more similar to that of LSD. In addition, and even when the same substance is used 
at similar doses, any two experiences by the same individual user may be strikingly 
dissimilar qualitatively.66 Unlike most other drugs, the effects of hallucinogens are 
highly variable, producing different effects in different people at different times. 
Non-pharmacological variables such as expectations, personality, environment and 
emotional state appear to have a much greater influence on the effects of halluci-
nogens than with other drugs.67 Compared with the more predictable and replicable 
effects of stimulants and depressants, the desired and actual effects of hallucinogenic 
drugs are highly context-dependent and user-specific.17,66
Hallucinogenic drugs have also had ‘entheogenic’ or religious or spiritual uses in many 
cultures and over many centuries. Emphasis is on ritual, producing introspective and 
meditative states, and access to mystical experiences. 
There is also evidence that some hallucinogenic drugs are used for self-medication. LSD 
and psilocybin are both reportedly used by some sufferers of cluster headaches,68 and 
are anecdotally effective in aborting clusters and also reducing headache frequency 
in the long term.69 A non-hallucinogenic analogue of LSD has been tested on a small 
number of people with apparent success, although the trial was neither blinded nor 
randomised.70
12.9. Unwanted effects
The hallucinogenic experience, even when positive, is often experienced as emotionally 
and physically draining.71 Unwanted psychological effects are common to many hallu-
cinogens and include what is referred to as a ‘bad trip’, characterised by anxiety, fear/
panic, dysphoria and/or paranoia. Distressing effects can be sensory (e.g. frightening 
perceptions), somatic (e.g. distressing awareness of physiological processes), personal 
(e.g. troubling thoughts or feelings) or even metaphysical (e.g. feelings about evil 
forces).5,72,73,74,75 In very rare cases, this may escalate to dangerous behaviour; for 
example, fear and paranoid delusions may lead to erratic behaviour and potential 
aggression against self and others.5,74 This is discussed further below.
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Even when a user is not experiencing a ‘bad trip’, unwanted effects can include 
confusion, disorientation, anxiety and unwanted thoughts, emotions and memories.76 
Other unwanted physical effects can include nausea, diarrhoea or non-specific 
gastric discomfort,66 heaviness or tingling, feelings of heat and cold, trembling 
and weakness.20,53,76 They also include dizziness, weakness, tremors, drowsiness, 
paraesthesia, blurred vision, dilated pupils and increased tendon reflexes.5 Sub-acute 
effects may include headache, which for psilocybin has been shown by an experimental 
study to be dose-dependent.77 Hallucinogens can also moderately increase pulse rate 
and systolic and diastolic blood pressure.5 However, it has been noted that physical 
effects vary and are ‘unimpressive even at doses yielding powerful psychological 
effects’.5
Salvia has been described as frequently dysphoric.78 However, among a self-selecting 
sample who predominantly reported positive effects, the most common adverse 
effects were that the drug experience was unexpected or excessively intense.79
12.10. Mortality
UK deaths directly attributed to acute toxicity linked to the use of the most prevalent 
drugs (LSD and magic mushrooms) are uncommon, but some have reported.74,80 There 
are also several reports of suicides during or following LSD intoxication, although 
studies have not necessarily imply causality.74,81 There are also reports of fatalities 
following ingestion of ibogaine, or products containing mixed iboga alkaloids.34
Hallucinogenic NPS have also been associated with a small number of recent deaths. In 
the UK, αMT is the drug most frequently linked to reported tryptamine-related deaths, 
with three deaths in 2013 and four deaths in 2012.9 5-MeO-DALT was mentioned in 
the coroner’s report on one death in 2010 (hit by a lorry, while under the influence of 
the drug82) and one in 2012. DOC was the cause of one death in 2011.83 
All hallucinogen drugs have been implicated with accidents secondary to intoxication, 
such as traffic accidents and falls.84
12.11. Acute harms
It is common to see psychological effects of hallucinogens without marked physi-
ological symptoms, especially from the use of LSD and magic mushrooms, which are 
of low intrinsic toxicity, unless a very large dose is ingested.85 LSD has a safety ratio 
(the ratio of the typical effective dose to the lethal dose) of around 1:1000, making 
accidental overdoses rare.86
However, some hallucinogenic NPS, such as bromo-dragonfly and other ‘Fly’ drugs, the 
DOx family, the NBOMe series and AMT have much narrower therapeutic ratios and 
a very different safety ratio, and so carry greater risk of acute toxicity and death.54,87
Among hallucinogenic NPS, the patterns of systemic toxicity varies across the 
drug class and type. Some hallucinogens will have a potential to cause toxicity with 
stimulant features (e.g. αMT88); others drugs may more typically evoke symptoms of 
serotonin syndrome (e.g 5-MeO-DiPT30). 
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Box 12.1. Reported features of acute toxicity include are listed in
CNS, neurobehavioural and psychiatric 
Dilated pupils, mydriasis (common, psilocybin89)
Sensory distortions, visual, auditory illusions, synaesthesia8,90
Tactile hallucinations, e.g. formication91
Affect lability
Euphoria92
Dysphoria74
Acute panic8
Paranoia, ideas of reference8,90
Depersonalisation8,90,93
Anxiety8,90
Disorientation94
Dissociation94
Agitation30,33
Aggression, combativeness30
Delirium
Depression, suicidal ideation, attempted suicide95
Psychosis, delusions, hallucinations96,97
Seizures32
Confusion33,98
Ataxia8,90
‘Bizarre behaviour’ 33
Lightheadedness8,93
Headaches8
Paraethesias,94 abnormal sensations of heat and cold, chills8
Restlessness, excitement30,98
Cardiovascular 
Tachycardia8,30
Hypertension8
Musculoskeletal 
Myalgias8
Twitching93
Muscle tension and jaw clenching30
Shaking88
Respiratory 
Tachypnoea30,93
Metabolic 
Metabolic acidosis30
Gastrointestinal/urological
Gastrointestinal symptoms may be more common after consumption of unrefined products 
containing hallucinogens such as Ayahuasca,66 mushrooms and cacti, in comparison with 
refined chemical substances such as LSD
Nausea, vomiting33,94 (psilocybin common)89
Diarrhoea66,94
Rhabdomyolysis30
Renal
Acute kidney injury/acute kidney failure8
Other symptoms
Hyperthermia8,30
Pyrexia94
Hypoglycaemia
Flushing93
Sweating88
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12.11.1. Features of toxicity
Reported features of acute toxicity are listed in Box 12.1.
12.11.2. Psychological and psychiatric effects
These are the most common cause of hospital presentations related to hallucino-
gens8,99 and are sometimes referred to by users as a ‘bad trip’.8 Adverse psychological 
reactions can occur at typical doses, and may feature feelings of loss of control, 
disturbing perceptions and attacks of anxiety, agitation and panic, which can be 
severe.62 A patient’s mental state may switch rapidly between severe anxiety and 
relative normality and back again.100 
A typical distressing hallucinogenic experience is distinct from delirious or dissociative 
states. On typical recreational doses, it is usual for people to maintain insight into 
the cause of their experiences, but the dread of permanent madness or of death is 
not unusual.101 Hallucinogenic drugs may provoke distressing thoughts and reflection 
on personal problems and past experiences and traumas.5 They can profoundly 
exaggerate existing or underlying negative moods.99 Some studies have identified the 
factors that may have contributed to the onset of paranoid delusions and psychosis, 
which include depressed emotional state at the time of taking the drug and doing so 
among strangers.97 
12.11.2.1. Psychosis 
As mentioned above, the term ‘psychosis’ has been used in the literature to describe 
typical hallucinogenic intoxications.102
A study using data from the large representative sample of the US National Survey 
on Drug Use and Health found that the use of hallucinogenic drugs appears not to be 
causally linked to the de novo development of chronic disorders of mental health such 
as schizophrenia or depression.103 
Hallucinogens are rarely a cause of substance-induced psychosis, where the drug 
triggers a psychotic episode that may persist hours, days or even weeks after the 
acute intoxication should have run its course.104 Nonetheless, psychotic symptoms in 
the context of LSD use have been reported, as well as in the context of hallucinogenic 
NPS, for example 2C-T-4.105 It has been suggested that salvia106 can trigger psychosis 
in people with existing psychotic illnesses or predispositions,17 although there are 
also reports of the appearance of psychosis de novo.107 There are a few case reports 
of psilocybin mushrooms causing an exacerbation of psychosis.108 Similarly, it was also 
reported that there was greater psychotic response to LSD in persons with a genetic 
predisposition to schizophrenia.109 
Overall, the evidence suggests that individuals who suffer from prolonged hallucino-
gen-induced psychosis may have pre-morbid mental illness. It is not known whether 
the onset of psychosis in these individuals represents a psychotic reaction that would 
not have occurred in the absence of use of hallucinogens, or whether it represents an 
earlier onset of psychosis that would have occurred anyway.5,74 
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Psychoses, apparently triggered by hallucinogens, have been reported in a small 
number of cases associated with violence and homicide. However, these have also 
been reported in subjects with pre-existing psychiatric conditions.97,107 
12.11.2.2. Excited delirium 
LSD has been involved in a small number of fatalities attributed to ‘excited delirium’, 
more commonly associated with cocaine.110 Excited delirium has also been associated 
with 5-MeO-DALT 111 and αMT.88 It has been argued that, in some instances, fatalities 
attributed to excited delirium may reflect underlying serotonergic and/or sympatho-
mimetic toxicity.112
Excited delirium is often associated with the use of force and restraint, including cases 
where hallucinogens were implicated; the mechanism of death can be positional 
asphyxia or sudden cardiac arrest.110,113
12.11.3. Trauma and self-injury 
Intoxication with hallucinogenic drugs can lead to accidental injury, and deaths, 
including from traffic accidents, falls or hypothermia.110,114 There are a few case 
reports of self-injury associated with the use of hallucinogenic NPS and a case report 
of a fatality following AMT consumption.88 Unusual self-injurious acts have also been 
recorded following hallucinogen use with or without co-intoxicants.115 These include 
at least two cases of severe ocular self-injury,115 a case of self-castration after LSD 
consumption,116 and two cases of self-inflicted stab wounds following consumption 
of magic mushrooms.117
12.11.4. Physiological adverse effects 
Overdose with LSD is rare, but may cause collapse, coma, vomiting, respiratory arrest 
and hyperthermia. Platelet dysfunction may occur causing mild, generalised bleeding 
tendency and polymorph leukocytosis.75,81 Rhabdomyolysis has been reported.118
Tachycardia, tachypnoea, agitation, hyperpyrexia and hypertension have been 
reported following ingestion of bromo-dragonfly, a drug with a potency similar to LSD, 
but a far longer duration (1–3 days) and apparently greater toxicity.11 The vasocon-
striction that has been observed in cases of bromo-dragonfly toxicity has appeared 
resistant to treatment with ACE inhibitors, nitroprusside, prostacyclin analogues, 
glyceryltrinitrate or calcium channel blockers.48
Sympathomimetic toxicity has been reported after ingestion of several hallucinogenic 
agents, including ayahuasca,119 LSD,120 mescaline121 and 2C-series drugs.112 Severe and 
life-threatening effects have been associated with the ingestion of NBOMes122,123 and 
bromo-dragonfly.11
Hallucinogens, particularly when taken in combination with other serotonergic drugs 
such as MDMA and SSRI antidepressants, may contribute to serotonin syndrome, 
which may be life-threatening (see section 7.7.2). Drugs with the potential to cause 
serotonin toxicity, for example 5-MeO-DiPT, may mimic the toxicity profile of MDMA.30
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Other substances used for recreational purposes can also pose a risk of monoamine 
oxidase inhibition and toxicity. The Ayahuasca and Yage ‘brews’ contain a plant 
source of DMT and also a plant containing natural MAOIs (harmala alkaloids124). This 
combination produces hallucinogenic effects that typically last 4–6 hours,76 whereas 
oral DMT without the MAOI is rapidly metabolised and inactivated, producing no hal-
lucinogenic effects in doses of up to 1 g.94
Ayahuasca and various imitations are now concocted worldwide, using plant materials 
purchased online containing DMT and MAOIs. Plant sources of MAOIs such as Syrian 
rue seeds (Peganum harmala, which contains harmine and harmaline) are also used 
to potentiate the effects of other drugs such as 5-MeO-DMT, sometimes to harmful 
or even fatal125effect.126,127 Furthermore, the plant material may be abandoned 
altogether, by using pharmaceutical MAOIs with DMT.128 
12.12. Clinical management of acute toxicity
The management of acute toxicity resulting from the use of hallucinogens will in 
part depend on the hallucinogenic substance consumed. It has been suggested 
that monitoring and supportive treatment is all that is required for the majority of 
patients,62 including airway management. TOXBASE® recommends that all patients 
be observed for at least four hours after exposure. Asymptomatic patients can then 
be discharged with advice to return if symptoms develop. 
Some products sold as LSD may in fact contain potent hallucinogens with far narrower 
therapeutic ratios,54 such as NBOMes, with a greater potential to cause acute toxicity. 
It has therefore been suggested that emergency room staff monitor patients 
presenting following ingestion of ‘LSD’ with the greater intensity and supportive care 
necessary for the management of NBOMe intoxications.129 
The management of phenethylamine derivatives, such as 2-CB, which acts as a 
serotonin agonist, will need to consider the effects and harms relating to the use of 
amphetamine-type substances as well as the potential risks of serotonin syndrome. 
As with other stimulants, TOXBASE® says that in the event of cardiac arrest, CPR 
should be continued for at least 1 hour and stopped only after discussion with a 
For up-to-date guidance on the management of acute toxicity relating to hallucinogens, it 
is recommended that information be sought from the National Poisons Information Service 
(NPIS), specifically the NPIS 24-hour telephone service and the poisons information database 
TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/L-Products/LSD/
http://www.toxbase.org/Poisons-Index-A-Z/2-Products/2C-B/
http://www.toxbase.org/Poisons-Index-A-Z/2-Products/2C-B-NBOMe/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
Hallucinogenic drugs 297
N
E
P
T
U
N
E
senior clinician. Prolonged resuscitation for cardiac arrest is recommended following 
poisoning, as recovery with good neurological outcome may occur.
12.12.1. Management of adverse psychological 
effects, agitation and drug-induced psychosis
A number of studies have looked at the management of adverse reactions and the 
following have been shown to be beneficial:
•	Attempts to ‘talk the patient down’. Sympathetic8 non-judgemental130 reassurance, 
support and observation were often sufficient.5 Where possible, the patient should 
be placed in a well lit room with minimal disturbance.8,17 Patients may be prone 
to mistrust and paranoid ideation, and early efforts in empathising, expressing 
understanding of their fears and establishing confidence have been shown to be 
beneficial. 8,100 Finding a more peaceful corner or room may prove worthwhile,62 as 
the typical clinical environment (with medical equipment and white coats) has been 
shown to be a predictor of adverse anxious reactions in participants in psychedelic 
research.67
•	Benzodiazepines, particularly diazepam or lorazepam,8,62 have been reported by 
some studies to be first-line choice if pharmacological interventions are needed 
and in cases of agitation.5,17 Doses described in the literature include the following: 
10 mg oral doses of diazepam131 (0.1–0.3 mg/kg body weight). Doses of 15–30 mg 
per hour or as needed have been suggested for cases of ‘bad trips’ that do not 
respond to reassurance in an emergency department setting.5 TOXBASE® (accessed 
17 December 2014) suggests an initial dose of oral or intdravenous diazepam 
(0.1–0.3 mg/kg body weight). Larger doses may be required. 
•	Antipsychotics should be considered as a second line if benzodiazepines do not 
produce adequate sedation.130 
•	In cases of severe agitation or ‘excited delirium’, physical restraint should be avoided, 
as this is associated with sudden cardiovascular collapse.132
•	In cases of drug-induced psychosis, TOXBASE® (accessed 17 December 2014) 
recommends that children over 12 years be sedated with a benzodiazepine (e.g. 
oral or intravenous diazepam, 0.1–0.3 mg/kg body weight), or if that is ineffective, 
an antipsychotic such as haloperidol or olanzapine.
12.13. Harms associated with chronic use
There is no evidence that ‘classical’ hallucinogens such as LSD or psilocybin have 
potential neurotoxic effects, as MDMA does in high doses.5 For example, a brain 
imaging study comparing hallucinogen users with ecstasy users found evidence for 
serotonergic neurotoxicity only among the latter.133 
A study has shown that people of a certain personality type – those who score 
highly in the domain of absorption, characterised by propensity to daydreams and 
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mystical experiences – seem more likely to enjoy and find value in hallucinogenic 
intoxication.134 Those who ingest hallucinogens regularly may be fairly atypical135 
and research from the 1970s suggested that, in some cases, alienation, rejection of 
normative values, emotional disturbances and desire for self-change may pre-date 
the use of hallucinogens, and mediate any relationship between use and higher rates 
of psychopathology.136
12.13.1. Dependence
The use of LSD or other classic hallucinogens does not appear to lead to dependence. 
Typically there is no persistent and compulsive pattern of use17,137 and the use of hal-
lucinogens is not associated with any recognised withdrawal syndrome.38,131,138
Hallucinogens do not appear to show classic patterns of tolerance,138 but, on the 
contrary, are associated with tachyphylaxis.2 This means that sensitivity to the effects 
of LSD and other hallucinogens appears to be strongly attenuated for a period after 
use. It may therefore prove difficult for a user to achieve desired effects from LSD if 
taken two days in a row, or indeed to get a desired effect from other hallucinogens.1,2
DMT consumed by vaporisation (usually called ‘smoking’ by users) appears to be 
an exception to this rule, having both an unusually brief duration of action and a 
proportionately brief duration of tachyphylaxis.139 Anecdotal evidence confirms that 
this enables users to have the desired effects multiple times a day if they want to.140 
According to the authors of one survey, this, added to DMT’s fewer unwanted effects 
and less of a ‘come-down’ than LSD or mushrooms, gives it a higher potential for 
misuse.50 However, the same survey did not find an increased desire to use.50
12.13.2. Hallucinogen persisting perceptual disorder (HPPD)
Hallucinogen persisting perception disorder (HPPD) and ‘flashbacks’ have been 
associated with use of classic hallucinogens in particular, although these concepts 
remain somewhat contested. HPPD as a diagnosis has been embraced by a group 
of people experiencing longer-term symptoms resulting from hallucinogen use. 
Hundreds of individuals discuss online their symptoms, including in dedicated fora.* 
Although knowledge of HPPD remains very limited, this disorder can persist for 
months or years after the use of hallucinogens.141 For some, this long-term change 
to vision and hearing is much less problematic than for others,142,143 for whom it can 
cause substantial morbidity.141
The concept of HPPD was first introduced in DSM-III, based on the work of Abraham 
on habitual LSD users.144 The diagnostic criteria of HPPD as defined by DSM-V (292.89 
F16.983) are as follows:
A Following cessation of use of a hallucinogen, the re-experiencing of one or more 
of the perceptual symptoms that were experienced while intoxicated with the 
hallucinogen (e.g. geometric hallucinations, false perceptions of movement in 
* An example of such a forum is HPPD Online, http://hppdonline.com/ (accessed 18 September 2014).
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the peripheral visual fields, flashes of colours, intensified colours, trails of images 
of moving objects, positive afterimages, halos around objects, macropsia, and 
micropsia).
B The symptoms in Criterion A cause clinically significant distress or impairment in 
social, occupational, or other important areas of functioning.
C The symptoms are not due to a general medical condition (e.g. anatomical lesions 
and infections of the brain, visual epilepsies) and are not better accounted for by 
another mental disorder (e.g. delirium, dementia, schizophrenia) or hypnopompic 
hallucinations.
In contrast, ICD-10 views this disorder within the wider paradigm of a psychotic 
disorder (F1x.5) and specifically considers ‘flashbacks’ (F1x.70) within the context 
of ‘residual and late-onset psychotic disorder’ (F1x.7). ICD-10 also specifies that 
‘flashbacks’ ‘may be distinguished from psychotic disorders partly by their episodic 
nature, frequently of very short duration (seconds or minutes) and by their duplication 
(sometimes exact) of previous drug-related experiences’. The forthcoming ICD-11 
may present a revised definition of this disorder.
In contrast with genuine psychosis, there is no paranoid misinterpretation of the 
perceptions in people who suffer from HPPD.145 Studies on HPPD have recommended 
that other conditions be ruled out before a diagnosis of HPPD is made, including 
post-traumatic stress disorder (PTSD), depersonalisation and derealisation associated 
with severe anxiety and depression, as well as other hallucinogen-induced disorders 
recognised by DSM, such as hallucinogen-induced psychosis and mood or anxiety 
disorders.141
The symptoms of HPPD can include any perceptual disturbances but visual ones tend 
to be more prominent. They may be episodic or nearly continuous and must cause 
significant distress or impairment as specified in DSM-V criterion B above. There 
seems to be no strong correlation between HPPD and frequency of use of halluci-
nogens, with reported instances of HPPD in individuals with minimal exposure to 
hallucinogens.146 Common visual features include geometrical hallucinations, flashes 
or intensification of colour, movements, particularly in the peripheral vision, after-
images, trails and haloes.147
A number of people have challenged the value of the concept of ‘flashbacks’.141 
Indeed, it has been argued that the distinction between ‘flashback’ and HPPD remains 
unclear and requires further investigation. Some have even argued that the concept 
of ‘flashback’ is not a useful diagnostic entity, has been defined in very many different 
ways and is ‘essentially valueless’.141 In the literature, there is sometimes a distinction 
between the two, with ‘flashbacks’ generally used to describe intermittent, infrequent 
experiences, in contrast to the more persistent experiences of HPPD.143 ‘Flashbacks’ 
are generally transient and often pleasant, in contrast to HPPD, which is chronic and 
can be highly debilitating.145 
Transient ‘flashback’ phenomena appear largely absent from the more recent clinical 
literature, in which the chronic visual distortions critical for a diagnosis of HPPD 
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predominate. These are commonly associated with co-morbid psychiatric symptoms, 
particularly anxiety, somatisation, panic and affective disorders.103,141,145
HPPD is both rare and unpredictable.143 Estimates of the proportion of users who 
have experienced flashbacks on one or more occasions after hallucinogen use vary 
widely, from 5% to 50%.148,149 However, many of these studies were conducted before 
the development of the DSM-III diagnostic criteria for HPPD and are therefore 
difficult to interpret.141 More recently, a 2003 review of the literature concluded that 
‘it seems inescapable that at least some individuals who have used LSD, in particular, 
experience persistent perceptual abnormalities reminiscent of acute intoxication, not 
better attributable to another medical or psychiatric condition, and persisting for 
weeks or months after last hallucinogen exposure’.141 Current prevalence estimates 
are unknown, but DSM-V suggests 4.2% (292.89 F16.983).
Despite these findings, the existence of HPPD and flashbacks remains contested. 
Analysis of US data from 2001 to 2004 from the National Survey on Drug Use and 
Health does not support the idea of ‘flashbacks’ (described in extreme cases as 
recurrent psychotic episodes, hallucinations, or panic attacks) or HPPD (described as 
persistent visual phenomena with accompanying anxiety and distress). 103
The exact causes of HPPD are not known. The condition is more often seen in 
individuals with a history of psychological problems but can arise in anyone, even 
after a single exposure.150 HPPD is mainly associated with LSD use, but it has also been 
reported after use of other psychedelic drugs, including mushrooms,151 mescaline141 
and 5-MeO-DIPT.152 Other substances may trigger HPPD, including cannabis,153 alcohol 
and MDMA.154 HPPD or flashbacks have also been reported in people who have taken 
pharmaceutical drugs such as risperidone,155 topimarate,156 trazodone, mirtazapine, 
nefazodone145 and SSRIs157 and it has been suggested recently that hallucinogen use 
is not actually a necessary condition for this multifactorial syndrome.145 
It has, however, been suggested that there may not be a common aetiology to the 
diverse phenomena described as HPPD and ‘flashbacks’ in the literature,141,158 with 
diverse interpretations having been made. It has been suggested that some cases 
may be explained in terms of a heightened awareness of and concern about ordinary 
visual phenomena,141 which is supported by the high rates of anxiety, obsessive-
compulsive disorder, somatisation, hypochondria and paranoia seen in many such 
patients. Visual symptoms like ‘visual snow’, ‘floaters’, palinopsia (after-images) and 
trails are all common in the healthy general population,103,141 or may be symptoms of 
psychosis, seizure disorders, persistent migraine aura without headache, or stroke.143 
Explanatory models for HPPD and its association with hallucinogenic drugs have been 
contested because it has been associated with other substances (e.g. cannabis) and 
because of high co-morbidities with anxiety, attention problems and derealisation 
symptoms among people with HPPD.154 Existing models range from purely incidental 
(i.e. no association between the drug use and symptoms) to ‘an increased vulnerabil-
ity to dissociative phenomena in susceptible individuals’.159
Others attribute a directly causal effect through neurotoxicity caused by the drug 
(e.g. ‘destruction of inhibitory serotonergic interneurons’157). Some have argued 
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that serotonergic neurological damage underlies HPPD, resulting in imbalances of 
excitation and inhibition in brain regions responsible for early visual processing.154 
However, these models based on neurological disorders have also been questioned in 
light of reports of HPPD involving a single use of a typical dose of a psychedelic, while 
many users with a much higher frequency and dose of use do not present with these 
symptoms.141
12.13.2.1. Treatment of HPPD
A survey using a web-based questionnaire reported that although symptoms 
of HPPD were common, only a few found them distressing enough or impairing 
enough to consider treatment, with constant symptoms increasing the likelihood of 
seeking treatment. Even when these symptoms were constant, they were not always 
considered problematic.143
There is no established treatment for HPPD and research is very limited. Some cases of 
HPPD are reported to have improved with the use of sunglasses,144 psychotherapy144 
and behaviour modification.160
Promising treatment outcomes have been reported from a number of pharmaco-
logical interventions, but the multifactorial nature of the disorder, and the prominence 
of co-morbidities, suggest the need for highly individualised treatment, with stress 
reduction, reduction of or abstinence from substance use (including alcohol and 
perhaps caffeine)and treatment of co-morbid disorders.145
Pharmacological interventions for HPPD have been used but many of the studies 
(especially older ones) had methodological limitations. These interventions have 
included several classes of antidepressants, anxiolytics and antipsychotics, a COMT 
inhibitor, naltrexone, levodopa, clonidine, lamotrigine145 and citalopram.161 Over the 
years, there have been reports of treatment using haloperidol,162 diphenylhydan-
toin,163 trifluoperazine,164 barbiturates,144 benzodiazepines,144,165 carbamazepine,166 
sertraline,167 naltrexone,168 clonidine,169,170 and a combination of olanzapine and 
fluoxetine.171 Hermle et al. have suggested that the anti-epileptic lamotrigine may be 
a promising new medication for HPPD.145 There are also reports of worsening of HPPD 
in patients receiving phenothiazines,144 the atypical antipsychotic risperidone172,173 or 
serotonin-selective reuptake inhibitors.174
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Chapter 13
Synthetic cannabinoids 
Drug group: synthetic cannabinoid
Synthetic cannabinoids (SCs), also referred to as synthetic cannabimimetics or 
synthetic cannabinoid receptor agonists, are smokable drugs often used as legal 
alternatives to cannabis. They have a strong effect on the endocannabinoid system.
13.1. Street names
A variety of street names are used for synthetic cannabinoids. The term ‘Spice’, which 
is the brand name of one the most common SC products sold in Europe, is often used 
as a generic term for all synthetic cannabinoids. They are often referred to as ‘K2’ in 
the US, and ‘Kronic’ in Australia and New Zealand.1
A wide range of brands of herbal products containing synthetic cannabinoids have 
been available on the market. They include, but are not limited to, Spice, Black Mamba, 
Annihilation and Amsterdam Gold. New brands continue to emerge. Brand names are 
sometimes reminiscent of street names of strains of cannabis. 
13.2. Legal status
Some SC are Class B Schedule I drugs under the Misuse of Drugs Regulations (2001), 
under a generic definition. The cannabinoids targeted for control under these 
generic definitions are CB1 receptor agonists.2 Products that contain other synthetic 
cannabinoids are currently legal to possess and include AM-694 and the Belarus 
compound.3
13.3. Quality of the research evidence
The research evidence on SCs is limited to case reports and case series, as well as 
retrospective toxicology surveys, human and animal laboratory studies, surveys and 
interviews with SC users. There are no longitudinal studies or randomised controlled 
trials.
13.4. Brief summary of pharmacology 
Synthetic cannabinoids play an important part in the ‘legal high’ market. In Europe, 
it is the largest chemical group monitored by the European Union’s early warning 
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system, with 30 new products reported in 2012 and 29 in 2013.4 Although they first 
appeared in Europe, they are now part of the drugs market in almost all developed 
countries throughout the world.5 
SCs have been developed since the discovery of delta-9-tetrahydrocannabinol (Δ9-THC 
or THC) cannabinoids. They are a large and chemically diverse group of molecules 
with some functional similarity to THC and other phytocannabinoids. Overall, SCs 
produce effects that have similarities to THC, although they are not the same and 
in particular are structurally dissimilar.6,7,8 Both SCs and phytocannabinoids (natural 
cannabis) bind CB1 and CB2 receptors.9 However, SCs have a much higher affinity for 
those receptors than natural cannabinoids and produce a stronger effect.10 Structure–
activity relationship analyses reveal that SC compounds may indeed exhibit higher 
potency. In fact, SCs are full agonists on the endocannabinoid system, while THC is 
only a partial agonist.11
THC has a dibenzofuran structure which is not present in the majority of SCs. 
Furthermore, a number of SCs contain nitrogen atoms in their scaffolds, which are not 
found in phytocannabinoids. While THC is a partial agonist and has psychotomimetic 
properties,12 the second most prevalent cannabinoid in natural-grown cannabis, 
cannabidiol (CBD), seems to possess anxiolytic, antipsychotic and anticraving 
properties.13,14 These effects of CBD on THC in cannabis cannot be found in SCs.15
SCs were initially synthesised for biomedical research purposes,16 by scientists inves-
tigating the mode of action of cannabinoids on signalling pathways in the body or as 
therapeutic agents.4 This includes the analogues to THC (the classical cannabinoid) 
which were were developed by Raphael Mechoulam at the Hebrew University (the 
‘HU’ compounds) in the 1960s and include HU-210, which is structurally similar to 
Δ9-THC, but more potent, and difficult to synthesise. 
The cyclohexylphenols (‘CPs’), referred to as non-classical cannabinoids, were 
developed by Pfizer in the 1970s. In the 1990s, John W. Huffman developed the ‘JWH’ 
series of synthetic cannabinoids which evolved from a computational melding of 
the chemical structural features of Δ9-THC with previously developed aminoalkylin-
doles.17 Other indole-derived cannabinoids detected in products for recreational use 
are those synthesised by Alexandros Makriyannis (the ‘AM’ compounds).7
SCs fall into the major structural groups, based on their chemical structure.5,18 Many of 
the compounds incorporate indole-derived moieties, as components of the structure 
or as substituents.19 Indoles are groups structurally similar to serotonin, and so are 
active on 5-HT receptors, and they are typically identified in indoleamine hallucino-
gens such as dimethyltryptamine.20 From this point of view, it could be argued that 
ingestion of indole SC compounds may be associated with particularly high levels 
of activation of serotonin receptors.21,22 Furthermore, it has been suggested that, at 
high doses, SC compounds may also possess some monoamine oxidase inhibitory 
properties.23 This element may further increase the risk of serotonin syndrome in SC 
misusers (for serotonin syndrome see section 7.7.2).
There are currently 200 cannabinoid receptor agonists. Synthetic cannabinoids fall 
into seven major structural groups: naphthoylindoles (e.g. JWH-018, JWH-073 and 
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JWH-398); naphthylmethylindoles; naphthoylpyrroles; naphthylmethylindenes; 
phenyl acetylindoles (i.e. benzoylindoles, e.g. JWH-250); cyclohexylphenols (e.g. CP 
47,497 and homologues of CP 47,497) and classical cannabinoids (e.g. HU-210). 
Over 80 compounds from 13 different chemical groups had been reported in Europe 
alone by June 2013,24,25 and a number of new scaffolds and substituents to produce 
new drugs have recently emerged on the market.26 
The large structural heterogeneity of the different SC compounds means that some 
are more potent than others. There are differences in terms of metabolism, toxicity 
and duration of effects. Generally speaking, the greater the affinity to the CB1 receptor, 
the higher is the pharmacological activity of the agonist compound.
The JWH series of cannabinoids were the most commonly used in Europe,27,28 
although have have become less available since legal control. Their chemical structure 
is markedly different from THC. In comparison with THC, the JWH class has a much 
greater affinity for and full agonism on cannabinoid receptors.29,30 The CP compounds 
are another commonly used group of cannabinoid receptor agonists and also lack the 
classical cannabinoid structure. CP-47,497, often found in herbal products, is up to 28 
times more potent than THC.31,32 The HU compounds are structurally similar to THC 
but are 100–800 times more potent.33 Benzoylindoles are a fourth group and the 
include AM-694 and RCS-4, which have only more recently been detected in herbal 
blends. Very little is known about this last group.34,35
Synthetic cannabinoid receptor agonists do not give a positive result on routine urine 
screening tests for metabolites of delta-9-tetrahydrocannabinol (THC).36 The forensic 
chemical detection of SCs remains complex,37 not least because of continuously 
emerging compounds and the lack of reference samples in laboratories to identify 
them.
13.5. What are synthetic 
cannabinoid products?
In the pure state, SCs are either solids or oils. Smoking mixtures are usually sold in 
metal-foil sachets, typically containing dried vegetable matter to which one or more 
of the cannabinoids have been added. Sachets usually contain 0.5–3 g of finely ground 
plant material.5 
Most synthetic cannabinoids are produced in China and exported, usually in powder 
form, using wrong declarations, such as ‘polyphosphate’, ‘maleic acid’, ‘fluorescent 
whitening agent’ or ‘ethyl vanillin’.5 Once in Europe, the retail products are assembled 
by lacing inert herbal products with synthetic cannabinoids. Commonly used herbal 
bases for the active chemical ingredients are damiana (Turnera diffusa) and lamiaceae 
herbs, such as Mellissa, Mentha and Thymus. The synthetic chemicals are mixed with 
or sprayed onto the herbs, typically on an industrial scale, often using equipment 
like cement mixers and liquid solvents, such as acetone or methanol, to dissolve the 
powders. They are then dried and packaged for sale.4 
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Many of the ‘herbal mixtures’ are inhomogeneous with respect to the concentration 
of compounds contained. For instance, in one analysis the JWH-018 content ranged 
from 6.8 mg/g to 44.4 mg/g within a single product.38 Furthermore, quite often 
more than one SC is added to the ‘herbal mixture’.39 In Japan, Kikura-Hanajiri et al.40 
detected an average of 2.6 SCs per product. The most detected in one mixture by the 
authors was 10.
Other substances identified in SC products include fatty acids and their esters 
(linoleic acid, palmitic acid), amide fatty acids (oleamide, palmitoylethanolamide), 
plant-derived substances (eugenol, thymol and flavours like acetyl vanillin), pre-
servatives (benzyl benzoate) and additives (alpha-tocopherol).41,42 SC products may 
also contain high quantities of tocopherol (vitamin E), possibly to mask analysis of 
the active cannabinoids.37 They are often contaminated with the beta2-adrenergic 
agonist clenbuterol,43 thus providing a basis for sympathomimetic-like effects 
(tremor, tachycardia, anxiety) often described in intoxicated patients presenting to 
emergency departments.44,45 Although the herbal blend that contains the SCs is most 
likely to be an inert product, the pharmacology and toxicology of the plant material in 
these blends is unclear.46 The herbal material, which is used as a basis for the smoking 
of these mixtures, may contain toxicologically relevant substances, like pesticides.39
Generally, herbal blends or mixtures that contain SCs but not tobacco or cannabis47 
are sold online and in so-called ‘head-shops’. There are current reports of its sale in 
pubs, petrol stations and take-away food shops, especially in the north of England.48 
Like other NPS, SC products have on their label ‘not for human consumption’, and are 
instead advertised as incense or room deodoriser. However, they are usually in the 
form of herbal products for smoking. Pure compounds, not sprayed on inert herbal 
products, are also available for sale on websites, which users can mix with their own 
herbal mixture.2
Herbal products containing SCs first appeared around 2004.46 The first SC detected 
in Europe as a so-called legal high was JWH-018, which was detected in Germany and 
Austria in late 2008.4 It has been noted that the popularity of these drugs increased 
significantly around 2008, as a result of numerous media reports that called them a 
‘legal’ alternative to cannabis.5
SCs provide an example of how regulated psychoactive compounds can be easily 
replaced with equally effective homologues for the purpose of avoiding legal control. 
For instance, in January 2009, Germany banned the production, sale, acquisition 
and possession of the two specific psychoactive synthetic chemicals (CP 47,497-C8 
and JWH-018). Within four weeks of this legal control, samples of ‘Spice’ obtained 
throughout Germany demonstrated replacement of those two recently banned 
compounds with JWH-073, a then unregulated chemical homologue.29,49 A study 
by the Poisons Information Centre in Freiburg, Germany, undertaken between 
September 2008 and February 2011, reported that, after January 2010, when 
JWH-073 and JWH-019 were added to the list of scheduled substances, there was an 
increase in emergency presentations associated with the extremely potent synthetic 
cannabinoids JWH-122 and JWH-210. The authors commented that early cases (i.e. 
patients presenting after taking JWH-018), symptoms were generally mild, but more 
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recent presentations, mainly due to the highly potent agonists JWH-081, JWH-122 
or JWH-210, involved much more severe symptoms.50
Elsewhere too, producers of these products have been quick to adapt to changes in 
legislation by using similar compounds that are yet to be controlled.5 Slight modi-
fications are made to banned compounds and new derivatives continue to emerge 
as older ones are regulated. Chemists have synthesised similar compounds easily by 
the addition of a halogen, alkyl, alkoxy or other substitutes to one of the aromatic 
ring systems, or by making small changes in the length and configuration of the alkyl 
chain, for example.5 
This has led to a rapid increase in the number of SCs in recent years. In 2012, out of 
the 73 new psychoactive substances reported in the EU to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), 30 were SCs.4 
Although the manufacturers of SCs and other so-called legal highs often try to 
circumvent the law by developing compounds slightly different from those banned, 
there is evidence that some of these products contain classified compounds and 
are therefore illegal under UK law.3 Similarly, a recent German study found products 
which contain compounds not banned in Germany, such as AM-2201 and MAM-2201, 
together with banned cannabinoids JWH-018 and JWH-122.51
The strength and purity of SC products vary. One US study looked at the purity of 
JWH-018 and JWH-073 from three online suppliers. Purity was determined using 
high-performance liquid chromatography with ultraviolet detection, and compared 
against validated standards obtained from a traditional research chemical supplier. 
The study found that products bought online were of comparable purity to validated 
standards, even though the products varied from each other in colour, texture and 
odour. There was no evidence of other compounds.52
In terms of the herbal products laced with SCs, analytical tests have shown that 
the cannabinoid constituents and dosage vary greatly between products, batches 
and even within the same package, giving rise to what are known as ‘hot spots’.53 
UK research has shown that there is significant variation in the content of ‘legal 
high’ products bought over the internet.54–57 Conversly, different brands on sale may 
contain the same compound. For example, AM2201 was identified in ‘Black Mamba’, 
‘Annihilation’, ‘Tai High’, ‘Hawaiian Haze’ and ‘Bombay Blue Extreme’.2
It has also been reported that SCs have been found recently in products that look like 
cannabis resin, as well as in samples of herbal cannabis. This may be to strengthen 
the potency of weak cannabis or to reduce the ‘harvest time’ and increase production 
rates by improving the poor potency of immature plants. 
A recent trend has been reported whereby SCs have been detected in mixtures 
containing other psychoactive herbs and plants:58
•	benzodiazepines, such as phenazepam;
•	tryptamines;59,60
•	phenethylamines/NBOMe compounds;61 
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•	cathinones;
•	 opioid analgesics;62 
•	 benzocaine;63
•	diphenidine.4,60,64 
It is therefore not easy to determine the contents of each SC product or to predict its 
pharmacological and toxicological characteristics.65
13.6. Clinical and other legitimate 
uses of synthetic cannabinoids
Synthetic cannabinoids have been developed for the past 40 years as potential phar-
maceutical agents, often for pain management66 or nausea. Those currently used 
include nabilone (Cesamet®), for the treatment of anorexia and for its antiemetic 
properties in cancer patients. Dronabinol (Marinol®) and nabiximol (Sativex®) are 
used in the management of multiple sclerosis and pain.5,37
13.7. Prevalence and patterns of use
The use of SC herbal products in the UK seems to be limited, although over the last few 
years they have gained popularity, especially among adolescents and young adults6–8 
and among prison populations.67 This increase in popularity may be because the 
market is quasi-legal market and the products readily available, as well as affordable 
at about £10/12 per gram.68 
One of the main reasons for the misuse of SCs is the difficulty detecting consumption 
by analysis of biological samples. The non-detectability of these compounds makes 
them attractive for persons undergoing regular drug tests (e.g. patients of forensic 
or withdrawal clinics, people obliged to undergo workplace drug testing, and driving 
licence re-granting candidates, those working in law enforcement, fire fighting, the 
armed forces,69 prisoners or clients on probation, mining workers, and athletes).15
SC products have been reported by the Avon and Somerset police as popular among 
inmates of their open prisons, again to circumvent the drug testing.70 Similar findings 
have been reported in prison and probation services in Sweden.71.
Questions on the use of ‘Spice’ were added to British Crime Survey in 2009 and asked 
for two consecutive years. In 2010/11, 0.2% of adults reported using them in the past 
year, with higher rates among adults aged 16–24 years than among those aged 25–59 
years (0.4% and 0.1% respectively).72 In 2011/12, 0.1% of adults in general reported 
using ‘Spice’.72
Comparisons with other European and US studies are not possible because of 
different methods used, sampling frames and terminology, but findings shed light on 
patterns of SC use. In Europe, a 2010 Spanish survey of 25,000 people aged of 14–18 
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years reported 1.1% lifetime use, 0.8% use in the past 12 months and 0.4% in the last 
month.73 
The use of SCs may be significantly more prevalent in the US. A US study of 852 
university students with an average age of 20.6 years (SD 5.1) reported use ever of 
‘K2’ by 8% of the sample (in comparison with 36% who had used cannabis/marijuana). 
Just over 90% of those had also ever used cannabis. Use of ‘K2’ was significantly 
associated with age, gender, year in college and ever use of tobacco and cannabis. 
Use of SCs was more common among males than females, and more common among 
first-year and second-year students than among those in the third year or above.7,74 
The large US ‘Monitoring the Future’ survey looked at SC use in 2011 for the first 
time (45,400 pupils in 395 secondary schools in 2012). Among 12th-grade school 
students, 11.4% reported using in the past 12 months. Use in 2012, which followed 
its control in March 2011, remained unchanged at 11.3%, making it the second most 
used substance among this group, after natural cannabis. Among pupils in grades 
8 and 10 in 2012, 4.4% and 8.8% respectively had used SCs in the previous year. 
Among the 8th-graders, it was the third most used illicit substance, after cannabis 
and inhalants.75
The ‘Monitoring the Future’ survey carried out in 2013 among a similarly large 
number of young people in three grades reported a substantial drop in the use of SCs 
products, such as ‘K2’ and ‘Spice’, but an increase in the use of natural cannabis. The 
use of synthetic marijuana in the previous year dropped significantly, from 11.3% in 
2012 to 7.9% in 2013 among 12th-graders, from 8.8% to 7.4% among 10th-graders, 
and from 4.4% to 4.0% among 8th-graders. It was noted that the drop in SC use 
among pupils in the 12th grade was highly statistically significant, and the drop for 
the three grades combined was also significant.75
Generally speaking, it has been noted that the use of SC products is more prevalent 
among young people. It is also more prevalent among males than females.1,71,76,77 
Although it is not possible to generalise, surveys have looked at SC users’ social capital, 
with two-thirds of respondents to the Global Drug Survey who reported having used 
SC also reporting currently working (66.6%). Over half reported currently studying 
(53.3%) and only a minority of 8.8% reported neither working nor studying. One-third 
of the sample (36.4%) reported having completed a university degree.1 An Australian 
survey of 316 SC users, recruited from the general population, also reported that 
respondents were mostly employed or studying.78
Poly-drug use is common among SC users; for example, a study of young people in 
treatment for SC use found that those using these drugs were also more likely to use 
a range of other substances.66 Similarly, among non-treatment-seekers, an internet 
survey of 168 users in 13 countries found that lifetime use included: alcohol (92%), 
cannabis (84%), tobacco (66%), hallucinogens (37%), prescription opioids (34%), 
MDMA (29%), benzodiazepines (23%), amphetamines (22%), cocaine (17%), Salvia 
divinorum (17%), heroin (7%), inhalants (7%), dissociative anaesthetics (6%), meth-
amphetamine (3%) and miscellaneous other drugs (mephadrone, dextromethorphan, 
kratom; 12%). Spice was reported as the drug of choice among 21% of respondents, 
and 25% reported no plans for future Spice use.79
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Users of SC have been grouped in three main categories based on previous drug use: 
cannabis smokers; occasional drug users seeking to avoid legal complications; and 
drug-naïve curious experimenters.46
The ‘Monitoring the Future’ survey carried out in 2013 (mentioned above) reported 
that a growing number of adolescents perceived the drug as dangerous in comparison 
to previous years, with fewer seeing natural cannabis as harmful.75 Other studies have 
also shown that natural cannabis is generally preferred to synthetic cannabis, with 
natural cannabis rated as giving greater pleasurable effects.1
Poly-substance use with SCs, especially alcohol and cannabis, has been described in 
case reports and series, online surveys and toxicology retrospective reviews.78,80–84 
Poly-drug use of other novel psychoactive substances together with SCs has been 
described too.85,86
13.8. Routes of ingestion and 
frequency of dosing 
Based on user reports, and on the dosage forms of products, the primary route of 
administration of SCs is inhalation, either by smoking the ‘herbal mixture’ as a joint, 
or by utilising a vaporiser, bong or pipe.39 Both oral consumption and snorting of the 
compounds have also been described.63
There are also reports that SCs can be ingested as an infusion, although this is rare. 
There are no reports of parenteral use so far.5 
The onset of the action of SCs is usually within minutes of smoking, like cannabis, 
because of the instant absorption via the lungs and redistribution into the brain and 
other organs, within minutes of use. There is a delay of absorption following oral 
consumption.5
The length of the effect of SCs varies. It has been reported that, within 10 minutes 
of inhaling a 0.3 g dose, users demonstrate mild to moderate cognitive impairment, 
as well as changes in perception and mood. Effects gradually diminish over 6 hours.31 
Although there are no controlled studies in humans, there are reports that the duration 
of action for JWH-018 is 1–2 hours and for CP 47,497 is 6–8 hours.31 Compared with 
THC, the effect seem to be shorter for JWH-018 and longer for CP-47,497 (and its C8 
homologues, the effects of which last 5–6 hours). 
As many of the SC products are much more potent than THC, it has been postulated 
that the psychoactive dose may be less than 1 mg.71 It is possible that smaller doses 
of many SCs may produce the same effects as larger quantities of natural cannabis.66 
Apart from high potency, some of these substances could have long half-lives, and 
active metabolites,87 potentially leading to a prolonged psychoactive effect.4 It has 
been noted that users mistakenly equate the safety and dosing profile of natural 
cannabis to that of SC herbal products.46
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13.9. Desired and undesired effects 
for recreational SC use
The desired effects of SCs are similar to those of cannabis intoxication:79 relaxation, 
altered consciousness, disinhibition, a state of ‘being energised’ and euphoria.79,80,88 
A number of factors have been identified as contributing to the use of SC, including 
easy access, affordability and the fact that it is not detected by many commonly used 
urine drug tests.6,89,90 An Australian survey of 316 SC users reported reasons for first 
use included curiosity (50%), legality (39%), availability (23%), recreational effects 
(20%), therapeutic effects (9%), non-detection in standard drug screening assays 
(8%) and to aid the reduction or cessation of cannabis use (5%).78
Castellanos et al. suggested that the effects cluster in four areas: cognitive impairment; 
behavioural disturbances; changes in mood; and sensory and perceptual changes.66 
Although they are related to THC (found in natural cannabis), SCs are five times more 
likely to be associated with hallucinations.77
In one internet survey of 168 SC adult users from a number of countries, the majority 
of respondents (87%) reported having a positive experience after the use of Spice, 
although 40% also reported negative or unwanted effects. The quantities of SC 
products consumed did not vary significantly between those who had negative effects 
and those who did not. In addition, 11% reported that multiple use of the same brand 
or SC product results in variable and unpredictable effects.79
A study of 11 adolescents aged 15–19 who had used SCs found that all the subjects 
reported a feeling of euphoria but 9 (82%) also reported negative mood changes, 
4 irritability and 3 anxiety. All 11 respondents reported difficulties with memory, 1 
described auditory perceptual disorders, 5 visual perceptual disorders and 2 described 
paranoid thoughts.80
Reported subjective and physiological effects of SC products can vary greatly.8,91 There 
are some reports of sedation, while other users have reported agitation, sickness, hot 
flushes, burning eyes, mydriasis and xerostomia (dryness in the mouth). The most 
commonly reported unwanted physical effects are nausea and vomiting.31,92 There 
are some reports that the frequency of hallucinations is greater than for cannabis. For 
example, in a survey of 168 SC users by Vandrey et al., 28% reported hallucinations 
following SC use, which the authors describe as greater than what would be expected 
for cannabis consumption.79
Similarly, in the Australian survey of 316 SC users, more than two-thirds (68%) reported 
at least one side-effect during their last session of use, including decreased motor 
coordination (39%), fast or irregular heartbeat (33%), dissociation (22%), dizziness 
(20%), paranoia (18%) and pychosis (4%). Four respondents reported seeking help. 
More side-effects were reported by males, respondents aged 18–25 years, those who 
had used water pipes and those who had concurrently used alcohol.78
One study looked at the effects of inhaled versus ingested SCs and suggested that 
there was more abdominal pain with the ingestion route and more dyspnoea with the 
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inhalation route. Both routes of exposure resulted in similar degrees of neurological 
changes, including agitation, drowsiness and hallucinations.93
Despite indicating that the effects of SCs are similar to those of cannabis, 54% of 
respondents to an internet survey reported that SCs produce subjective effects 
unique and discernible from other licit or illicit drugs.79 Similarly, findings from the 
Global Drug Survey also suggest that, whenproducts are smoked, users are able to 
differentiate between the effects of natural versus synthetic cannabis.1
Although it cannot be assumed that that this can be generalised, respondents to the 
Global Drug Survey reported a strong preference for natural over synthetic cannabis 
(it was preferred by 93% of users), with natural cannabis rated as giving greater 
pleasurable effects while leaving the user able to function better. SCs were given sig-
nificantly higher scores for self-reported hangover effects and other negative effects 
than were given to natural cannabis. The survey also found that natural cannabis was 
used more frequently and more recently than SC. Only a small minority of users seem 
to have fully substituted natural for synthetic cannabis.1
13.10. Mortality
A number of deaths have been related to SC ingestion, either on their own or 
in combination, in analytically confirmed reports.94–102 Three completed suicides 
following a SC intake have been described.94,103,104
13.11. Acute harms
A major health problem arises from that the fact that mixtures are inhomogeneous 
with regard to their active ingredients.39 As a consequence, it is not possible for the 
consumer to estimate the dose at all accurately. Two cigarettes or joints prepared 
from the same mixture could contain significantly different amounts of the drug, and 
this raises the risk of harm.
13.11.1. Acute toxicity
We do not yet know how much the different SC compounds vary in effects and harm. 
Variability may be due to the differences between the particular SC compounds, but 
could also be related to individual susceptibility to the effect of the drug or the dose, 
or it may be multifactorial.105 It has been suggested that the effects of SCs are greater 
in individuals with less previous exposure to cannabis, and especially those who are 
drug naïve.50
Little is known about the metabolism and toxicology of SCs in humans, but the 
consensus is that it cannot be assumed that the risks associated with their use will 
be comparable to those of THC. There are concerns that they may have a greater 
potential to cause harm. Again, the amount and type of SC may vary, within and 
between products,66 and some may contain more than intended.9,41,49 In addition, SCs 
are also full agonists, with significantly higher potency than THC.9
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Data on 1898 exposures to SCs were reported to the US National Poison Data System 
between 1 January 2010 and 1 October 2010 (1353 of which were single-agent 
exposures). Despite concerns that the adverse effects after exposure to SCs are 
significantly more severe than with cannabis, the majority of cases had self-limited 
signs and symptoms, and received only symptomatic treatment. Most symptomatic 
exposures to products marketed as SCs are associated with non-life-threatening 
clinical effects.76
Similarly, a study of telephone enquiries to the Swedish Poisons Information Centre 
graded 145 enquiries relating to SC use; 74% were graded as mild (‘Poisoning Severity 
Score’, PSS, 1) and 26% as moderate poisoning (PSS 2). No severe or lethal cases (PSS 
3 or 4) were registered.106 And a case series of 13 SC smokers presenting to hospital 
emergency departments described the severity of poisoning as ‘moderate’ in 10 cases 
and as ‘minor’ in 3.107 
13.11.2. Features of acute intoxication
At least some SCs could lead to severe or even life-threatening intoxication when 
taken in sufficiently larger doses, particularly so in the case of compounds that act as 
a full agonists at the CB1 receptor, such as HU-210, CP-55,940 or WIN-55,212-2.108,109 
SC toxicity is characterised by the following:47,50,89,110,111,112,113,114
•	cannabis-like effects;
•	psychosis; 
•	sympathomimetic effects, including seizures, tachycardia, hypertension, diaphoresis, 
hyperthermia, agitation and combativeness; 
•	the potential for other effects, including acute damage to the kidneys.
TOXBASE® summarises the features of acute SC toxicity as shown in Box 13.1.
Box 13.1. Summary of features of acute SC toxicity 
Central nervous system
Agitation, tremor, anxiety, confusion, somnolence, syncope, hallucinations, changes in 
perception, acute psychosis, nystagmus, convulsions, coma
Cardiac
Tachycardia, hypertension, chest pain, palpitations, ECG changes
Renal
Acute kidney damage
Muscular
Hypertonia, myoclonus, muscle jerking, myalgia
Other
Cold extremities, dry mouth, dyspnoea, mydriasis, vomiting, hypokalaemia
Loss of eyesight and speech also reported
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13.11.2.1. Cognitive, psychological and psychiatric effects
A number of studies have reported cognitive changes associated with SC use, 
including difficulty in thinking clearly, confusion, sedation and somnolence, disorgani-
sation, thought blocking, or nonsensical speech or alogia, memory changes/problems, 
amnesia, increased focus and internal unrest.45,79,80,90,115–119 Studies have also reported 
a variety of behavioural disturbances, including a change of activity from decreased 
activity to excitability, agitation and restlessness. Aggression has been reported in a 
small number of subjects.45,80,82,90,116,117,120,121 Psychomotor retardation and nightmares 
were reported in one study.81,115
Studies have reported changes in mood and affect. There are reports of subjective 
feelings of euphoric mood associated with intoxication,79,80 but reports of users 
experiencing negative mood changes are more common and typify intoxication 
associated with SCs rather than cannabis use.66 Anxiety was reported most frequently 
across the studies reviewed,36,79,80,81,115,119,120,122,123 followed by irritability.80,116 There are 
also reports of inappropriate or uncontrollable laughter,36,79 anger and sadness,80 with 
an odd/flat affect.81 A few subjects were reported to have suicidal ideation.81,82,124,125 
Other problems associated with SC use include paranoid thoughts, combativeness, 
irritability,80,116,123 thought disorganisation,118,122 anxiety and panic attacks,80,116,123 
depression and suicidal thoughts.82,105,125 Sensory and perceptual changes include 
paranoid thinking,79,80,82,90,118,119,122 delusions81,82,90,117,123 and auditory and visual hallu-
cinations.79,81,90,119–121,126
The use of SCs has been associated with psychosis and psychosis linked to SCs has been 
associated with more agitation than would be expected from cannabis alone.36,44,123,127 
It has also been argued by some that there is a greater risk of psychosis with SCs 
than with cannabis. This is due to a combination of factors which may include the 
absence of cannabidiol (CBD), a naturally occurring product in cannabis which has 
antipsychotic properties.123 The impact of the absence of CBD has been described in 
relation to natural cannabis with low cannabidiol content, such as skunk.128
There are reports of SC-associated acute transient psychosis,50,83,120 as well as 
reports that some individuals may experience psychosis that persists for weeks 
after the acute intoxication.81,122–124 There is some evidence that SCs may precipitate 
psychosis in vulnerable individuals,36,44,50,117,118,123 including those with a history of 
psychosis.81,82,117–120,123,124
There is also some evidence of new-onset psychosis in otherwise healthy people 
with no history of psychosis. This will be discussed in section 13.13, on the harms of 
chronic SC use.
13.11.2.2. Physiological effects
13.11.2.2.1. Cardiovascular
Although they are related to THC found in natural cannabis, SCs have been reported 
to be two or three times more likely to be associated with sympathomimetic effects 
such as tachycardia and hypertension.44,45,129 Case reports and case series have 
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described a range of cardiovascular problems, including bradycardia, chest pain and 
cardiac ischaemia.36,45,126,130 Cases of myocardial infarction have been reported in 
healthy adolescents, although this is of limited clinical application because of the lack 
of analytical confirmation.114 There is one case report of cerebrovascular accident 
(CVA) associated with the use of the synthetic cannabinoid K2.131
13.11.2.2.2. Neurological
Some neurological and neuromuscular effects linked to the use of SCs have also 
been reported and include tremors,115,116,121 numbness,80,115,121 tingling,121 light-
headedness,79,126 and dizziness.79 Also reported are pallor,116,121 tinnitus,79 excessive 
sweating,115 diaphoresis119 and unresponsiveness.44
Out of the 1898 exposures to SCs reported to the US National Poison Data System 
between January 2010 and October 2010, 52 seizures were reported; the majority 
(43) were single episodes, although two patients developed status epilepticus. The 
majority of all 1898 patients had minimal symptoms but the study identified 34 cases 
in which there were life-threatening effects associated with exposure, and more than 
half of these involved seizures.76
Although seizures or convulsions associated with the use of (natural) cannabis seem 
to be unusual, there are some reports associated with SC use. These include a case 
report which describes a patient presenting to hospital with seizures after consuming 
a large quantity of analytically confirmed SC powder and alcohol, and reports of 
generalised convulsions occurring after SC use.132–136 
Other reported adverse effects include hypokalaemia.4
13.11.2.2.3. Renal and gastrointestinal
Gastrointestinal effects of SCs include nausea79,115 and vomiting.79,115,121 Acute kidney 
injury (AKI) associated with SC use has also been described.89,137,138 A case series reports 
on four cases of oliguric AKI, associated with SC use, in previously healthy men.139 
The use of at least one compound, XLR-11, which is (1-(5-fluoropentyl)-1H-indol-3-yl)
(2,2,3,3-tetramethylcyclopropyl)methanone, has been associated with AKI.140
13.11.2.2.4. Other
Xerostomia, hyperglycaemia and hypokalaemia have been described in case 
reports.31,36,45 Nystagmus, conjunctival injection* and mydriasis were reported in a 
small number of cases.31,36 The loss of eyesight and speech has been reported.106
13.11.2.3. Presentations for treatment for acute intoxication
In the UK, although enquiries about SC use to TOXBASE® ranked 17th in terms of 
all substances of misuse, it has been noted that there was a seven-fold increase in 
TOXBASE® in 2012/13 accesses in comparison with the previous year.141
* Conjunctival injection is the forcing of a fluid into the conjuctiva; it is common in cluster headaches, 
making the eye appear swollen and red.
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In the US, the rise in the use of SCs was mirrored by a rise in the incidence of SC-related 
health problems. According to the American Association of Poison Control Centers, 
there was a rise from 53 calls related to use of K2 in 2009, to 2500 in 2010.142 Among 
the 1898 exposures to SCs reported to the US National Poison Data System between 
January and October 2010 the age and gender of patients mirrored those of SC 
users (median age 20 years; 74% were male). The majority of reported exposure were 
acute; 3.25% were chronic, 3% were acute on chronic and 5% unknown. The majority 
of cases reported had self-limited signs and symptoms. Only 7.3% of symptomatic 
exposures were coded by a poison centre specialist as potentially life-threatening. 
The most frequently reported cardiac effects were tachycardia (37.7%), hypertension 
(8.1%), chest pain (4.7%), syncope (2.1%), hypotension (1.3%) and bradycardia (1.3%). 
Reported central nervous system effects included agitation/irritability (23.4%), 
drowsiness/lethargy (13.5%), confusion (12%), hallucinations or delusions (9.4%), 
dizziness (7.3%) and respiratory depression (>1%). As mentioned earlier, seizures were 
reported in 3.8% of cases. Overall, and although the majority of cases had minimal 
symptoms, the study identified 34 cases in which there were life-threatening effects 
associated with exposure; more than half were seizures.76 
A case report of 21 patients presenting to an emergency department between 
November 2011 and October 2012, with analytically confirmed SC use, presents a 
broadly similar picture. The most frequent clinical symptoms were tachycardia (12 
cases), nausea/vomiting (11), somnolence (9) and hyperglycaemia (9). Less frequent 
symptoms were hypokalaemia (4), syncope (4), dyspnoea (3), aggressive behaviour 
(3), amnesia (2), diplopia (2) and seizures (2). Acute psychosis in one individual lasted 
for five days. One patient with diabetes mellitus developed pronounced hyper-
glycaemia.51
A retrospective review of cases presenting to an emergency department during a 
three-month period, with chief complaint of SC use before arrival, reported that 
most such patients can be discharged after a period of observation (an average of 
2.8 hours).105
An Australian study of patients hospitalised in an acute psychiatric ward for problems 
associated with SC use from January to April 2013 found that they represented 13% 
of all admissions on the ward (17 patients with 21 admissions). For four patients, 
this was their first hospitalisation and these patients presented with new psychotic 
symptoms; 9 had a recurrence of a pre-existing disorders. Symptoms included 
psychotic symptoms, affective symptoms, disturbances and/or intense suicidal 
ideation/ behaviour. The mean length of admission was 8.5 days, with significantly 
longer duration for those presenting with psychotic symptoms (13.1 days versus 4.4 
days).143
13.11.3. Acute withdrawal
For withdrawal, see section 3.14.
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13.12. Management of acute harms
13.12.1. Identification and assessment 
SCs cannot be detected by the screening tests for phytocannabinoid delta-9-trans-
tetrahydrocannabinol (THC). Although laboratory techniques have been developed 
to detect some compounds,92,144–146 there are currently no widely available tests. In 
addition, more than one SC can be found within the same mixture or product, and the 
regular appearance of new compounds poses another challenge.15
It has therefore been recommended that clinicians need to rely on clinical skills to 
detect SC use. This includes specifically asking about SC, being aware of the physi-
ological effects, such as conjunctival injection, and having a high index of suspicion in 
the context of unexplained deterioration despite a negative urine screen.122
13.12.2. Clinical management of acute toxicity
Symptoms of SC intoxication may be self-limiting and resolve spontaneously.66,76 Case 
reports suggest that, in emergency departments, hydration and monitoring may be 
enough for patients with mild to moderate intoxication.45,116,118,120,147 Benzo diazepines 
may be of benefit to patients who present with symptoms of anxiety, panic and 
agitation.45,82,90,116 Antipsychotic medication may be indicated for some patients, 
especially those who present with agitation or aggression, when the patient has a 
history of psychotic disorders, and when the psychotic symptoms do not remit spon-
taneously or with supportive care.81,82,123,124
The management of SC toxicity is symptomatic and supportive, as no antidotes 
exist.89 Supportive treatment is dependent on a patient’s specific presentation. Only 
a few specific interventions have been described. Intravenous benzodiazepines have 
been reported for the management of seizures, and monitored observation for cases 
of SC-related psychosis.44
The 2010 nine-month study of the National Poison Data System that reported 1898 
SC exposures found that the majority had self-limited signs and symptoms and 
received only symptomatic treatment. The study also reported that the most common 
intervention for patients with a single-agent exposure was the administration of 
For up-to-date guidance on the management of acute toxicity related to synthetic cannabinoids, 
it is recommended that information be sought from the National Poisons Information Service 
(NPIS), specifically the NPIS 24-hour telephone service and the poisons information database 
TOXBASE®: 
http://www.toxbase.org/Poisons-Index-A-Z/S-Products/Synthetic-Cannabinoid-Receptor-
Agonists/
It is recommended that relevant clinicians and departments are registered to receive these 
facilities.
Non-UK readers should consult their local or national guidelines.
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intravenous fluids (25.3%), followed by benzodiazepine (16%), supplemental oxygen 
(5.8%) and anti-emetics (4.7%). The duration of clinical effect was recorded in 907 
cases. Out of those, clinical effect lasted less than 8 hours in 78.4% of cases, between 
8 and 24 hours in 16.6% and more than 24 hours in 4.9% of cases.76
13.13. Harms associated with chronic use
13.13.1. Dependence
In an internet survey of 168 SC users, a subset of respondents met DMS-IV criteria for 
abuse (37%) and dependence (12%). The most commonly endorsed abuse criterion 
was use (of ‘Spice’) in a hazardous situation (27%). The most commonly reported 
dependence criteria were being unable to cut down or stop SC use (38%), experiencing 
symptoms of tolerance (36%), using for longer periods than originally intended (22%) 
and interference with other activities (18%). Reported withdrawal symptoms following 
cessation of SC use were rare, and more prevalent among frequent users. The most 
commonly reported withdrawal effects were headaches (15%), anxiety/nervousness 
(15%), coughing (15%), insomnia/sleep disturbance (14%), anger/irritability (13%), 
impatience (11%), difficulty concentrating (9%), restlessness (9%), nausea (7%) and 
depression (6%).79
Some reports have described withdrawal symptoms following prolonged use,115,122 
and preliminary reports suggest that the chronic use of SCs may be associated with 
tolerance.66 For example, Zimmerman et al. presented a case report of an individual 
who began inhaling 1 g of SC daily, which, due to tolerance, increased rapidly to 3 g 
daily. 115
SCs may have a higher addictive potential than cannabis, due to the quicker 
development of tolerance.115,148 A case report of an individual using for eight months 
mentions a potential withdrawal syndrome, with drug craving, nocturnal nightmares, 
profuse diaphoresis, nausea, tremor, hypertension and tachycardia.115
13.13.2. Other harms of chronic use
The long-term effects of the use of SCs are unknown. Although no experimental data 
are available, it is expected that these SCs, as lipophilic compounds, have high volumes 
of distribution. It is therefore likely that chronic use of them can lead to accumulation of 
the substances themselves and/or their metabolites in fat-containing compartments 
in the body.5 There is also speculation that some of these products, and particularly 
the aminoalkylindoles carrying a naphthyl moiety, may have carcinogenic potential.149
There may also be gastrointestinal effects. One case report suggests that frequent 
habitual smoking of SCs can cause cannabinoid hyperemesis syndrome, which is 
mediated by cannabinoid receptors.150 Xerostomia31,79 has been reported, as well 
as acidosis.31,36,45 There is one case report of pulmonary infiltrates associated with 
chronic SC use.151
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Psychosis has also been reported among frequent users. One study describes 
new-onset psychosis in otherwise healthy young men. 81 A case series reported on 10 
patients admitted in the context of SC use, none of whom had a history of psychosis. 
All of the patients reported smoking SC on more than one occasion (ranging from 
four uses over a three-week period to daily use for a year and a half). The onset of 
psychotic symptoms varied from after the fourth use to after more than a year of use.
Presentations were characterised by paranoid delusions, ideas of reference and a 
disorganised, confused mental state. It was noted that a distinct, though waxing and 
waning, stuporous appearance was often present for weeks after last SC use. The affect 
of patients was described as generally flat, with most patients reporting significant 
depressive symptoms and 40% describing suicidal ideation. Hospitalisation generally 
lasted 6–10 days. Although psychotic symptoms did remit in most patients, 30% were 
noted to have persistent psychosis at 8-month follow-up.81
Three patients who presented to an emergency department with persistent psychosis, 
which did not resolve within 24–48 hours, required at least two weeks of hospitalis-
ation. Two of the patients were treated with haloperidol and one with risperidone 
and, although the patients demonstrated improvements, none had their symptoms 
resolve completely and medication was prescribed upon discharge.82
13.14. Management of harms 
related to chronic use
13.14.1. Clinical management of dependence and chronic use
The Global Drug Survey, carried out in 2011, investigated demand for treatment by 
2513 SC users, including 980 individuals who had used it in the past 12 months. It 
found that 7% reported that they wanted to use less SC in the coming year and 1.8% 
reported that they would like help to reduce or stop their use of SC. Among those 
who had used SC in the past month, those who reported they would like to use less 
SC were those who were using it on significantly more days (median 6 days in past 
month) than others who also had used it in the past month (median 2 days). Similarly, 
those who reported use in the past month and also reported that they would like help 
to reduce or stop, used on significantly more days (median 27 days in last 30 days) 
than other ‘last month’ users (median 2 days).
13.14.1.1. Psychosocial interventions
See Chapter 2 on psychosocial interventions.
13.14.1.2. Pharmacological interventions
Psychopathological disturbances related to SC misuse may be managed with benzo-
diazepines and antipsychotics, with antidepressants being administered in case of 
concurrent depression.110 If faced with a psychotic disorder associated with chronic SC 
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misuse, it can be argued that the use of second-generation antipsychotics (SGAs) may 
be a rational approach. Indeed, with respect to first-generation antipsychotic, SGAs 
present with lower risk of increase in cravings 152 and a more significant antagonism 
at 5-HT2A receptors.
153 In cases of acute SC intoxication, it has been suggested that 
an to perform an electrocardiogram should be performed, because misusers may 
present with vomiting and associated hypokalaemia.154
13.14.1.3. Aftercare and support
See Chapter 2 on psychosocial interventions.
13.15. Harm reduction and public safety
A study focusing on analytical results and signs of impairment documented by the 
police or the physicians who had taken the blood sample from suspects driving under 
the influence of SC reported that the use of SCs can lead to impairment similar 
to typical performance deficits caused by cannabis use. This includes the centrally 
sedating effects of SCs and impairment of the fine motor skills necessary for keeping 
the vehicle on track.155
A study of drivers found that officers or drug recognition experts (DREs) reported 
that drivers suspected of using SCs were more confused and disoriented, and were 
involved in more motor vehicle crashes than were those suspected of using natural 
cannabis. DREs documented significantly more confusion (6/10) or disorientation 
(5/10) in the ‘Spice’ group versus those in the marijuana group (0/25). A significantly 
larger proportion of marijuana users had tremors (25/25) than those in the ‘Spice’ 
group (8/13).156
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Appendix
Interactions of ‘club drugs’ with 
HIV medication
There are concerns about the effects of drugs used by HIV-positive individuals on 
antiretroviral medications because of issues relating to adherence as well as serious 
drug interactions (Table A1).1,2 Case studies have been published on severe problems 
caused by drug interactions3 and even death.4 Studies have also shown the immuno-
suppressant effect of substances.5–7 Recreational drug use has consistently been 
linked to lower rates of adherence to HIV medication,8,9 with especially low levels 
among poly-drug users.10 There is also some evidence of a dose-response relationship 
between the use of certain drugs and medication adherence which suggests that 
binging or heavy use may have a particularly detrimental effect on medication 
adherence,11 although this needs to be investigated further.
A major concern is the interaction of GHB/GBL with antiviral medications for 
HIV-positive patients.1 Romanelli et al. say that HIV-positive patients who use GHB/
GBL must be warned about the potential dangers of a drug interaction with protease 
inhibitors (especially ritonavir). This is because clearance of GHB is mediated partially 
by systemic oxidation and partially by first-pass metabolism via the CYP450 system. In 
the case report described by Romanelli et al. the inhibition of the CYP450 system by 
ritonavir might explain this patient’s exaggerated response to the GHB. It illustrates 
the potential adverse effects that may be seen when club drugs such as MDMA and 
GHB are co-administered with antiretroviral, particularly protease inhibitors with 
CYP450-inhibitive properties2 and possibly efavirenz.1
It has also been recommended that GHB/GBL be used with caution by HIV-positive 
patients with predisposing seizure disorders or with opportunistic infections that 
may lower seizure threshold (e.g. toxoplasmosis, cryptococcal meningitis) as GHB/
GBL may precipitate seizure-like activity. GHB/GBL use may also cause severe nausea, 
vomiting and gastrointestinal-tract irritation, which will adversely affect absorption 
of antiretroviral medication.2 There are also concerns about compliance with HIV 
medication while intoxicated, especially during prolonged binges.2
The use of ketamine raises general issues of adherence to antiretroviral regimens and 
cardiovascular effects of the drug may be deleterious among patients with underlying 
heart disease or lipid abnormalities. As a substrate of the CYP450 system (specifically 
3A4 and 2B6), ketamine may interact with certain antiretroviral medications, 
particularly protease inhibitors and their boosters (ritonavir and cobicistat) as they are 
characterised by CYP3A4- and CYP2B6-inhibitive properties.2 On the other hand, non-
nucleoside reverse-transcriptase inhibitors ( NNRTIs ) like efavirenz and nevirapine 
are inducers of CYP3A4 and 2B6 and lead to a decrease in ketamic effects. This may 
lead individual to inject ketamine to avoid first-pass metabolism and maintained the 
desired effects.
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